FORM PTO-1390 U. S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE ATTORNEY'S DOCKET NUMBER (REV 10/95) HIIRP 1177 TRANSMITTAL LETTER TO THE UNITED STATES

DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR 09/762006

INTERNATIONAL APPLICATION NO. INTERNATIONAL FILING DATE PRIORITY DATE CLAIMED PCT/EP99/05710 6 August 1999 6 August 1998

TITLE OF INVENTION

NOVEL PHOSPHOLIPIDS WITH UNSATURATED ALKYL AND ACYL CHAINS

APPLICANT(S) FOR DO/EO/US

Hansjörg EIBL and Thomas HOTTKOWITZ

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

- This is the FIRST submission of items concerning a filing under 35 U.S.C. 371.
- 2.

 This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.
- 3. This express request to begin national examination procedures (35 U.S.C. 371(f) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(l).
- 4.
 A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority
- 5. A copy of the International Application as filed (35 U.S.C. 371(c)(2))
 - a.

 is transmitted herewith (required only if not transmitted by the International Bureau.)
 - b. A has been transmitted by the International Bureau.
 - c.

 is not required, as the application was filed in the United States Receiving Office (RO/US).
- 6. A translation of the International Application into English (35 U.S.C. 371(c)(2)).
- 7. Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
 - a.

 are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. □ have been transmitted by the International Bureau.
 - c. \square have not been made; however, the time limit for making such amendments has NOT expired.
 - d. \(\square\) have not been made and will not be made.
- 8.

 A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 9. An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
- 10. a A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). Items 11. to 16. below concern document(s) or information included:
- 11. An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
- 12.
 An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
- 13. A FIRST preliminary amendment.
 - A SECOND or SUBSEQUENT preliminary amendment.
- 14. A substitute specification.
- 15.

 A change of power of attorney and/or address letter.
- 16. Other items or information: (a) International Search Report; (b) PCT/IPEA/409; PCT/IB/306/ PCT/RO/101
- 17. The follow fees are submitted: (a) Check for Filing Fee and (b) Assignment Fee

EXPRESS MAIL NO. EL 759723714 US MAILED FEBRUARY (12001

JC07 Reg'd PCT/PTO n 1 FEB 2001 BASIC NATIONAL FEE (37 CFR 1.492(A)(1) - (5)): Search Report has been prepared by the EPO or JPO \$860.00 International preliminary examination fee paid to USPTO (37 CFR 1.482) No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2)) ... \$710.00 Neither International preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$1000.00 International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4) \$100.00 \$860.00 ENTER APPROPRIATE BASIC FFF AMOUNT = ¢ Surcharge of \$130.00 for furnishing the oath or declaration later than 20 months from the earliest claimed priority date (37 CFR 1.492(e)). CLAIMS NUMBER FILED NUMBER EXTRA RATE Total claims 34 - 20 = 14 x \$18.00 \$252.00 2 Independent - 3 = 0 x \$80.00 \$ MULTIPLE DEPENDENT CLAIM(S) (if applicable) + \$250.00 TOTAL OF ABOVE CALCULATIONS = \$1112.00 Reduction of ½ for filing by small entity, if applicable. Verified Small Entity Statement \$ 556.00 must also be filed (Note 37 CFR 1.9, 1.27, 1.28). \$556.00 SUBTOTAL = Frocessing fee of \$130.00 for furnishing the English translation later than ☐ 20 ☐ 30 thonths from the earliest claimed priority date (37 CFR 1.492(fl)). TOTAL NATIONAL FEE = \$556.00 Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be \$ 40.00 accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property-TOTAL FEES ENCLOSED = \$596.00 Amount to berefunded charged \$ a. A check in the amount of \$596.00 (Filing Fee) and Assignment fee to cover the above fees is enclosed. b. D Please charge my Deposit Account No. 50-0624 in the amount of \$_____ to cover the above fees. A duplicate copy of this sheet is enclosed. c.

The Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment to Deposit Account No. 50-0624 . A duplicate copy of this sheet is enclosed. NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, appetition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status. SEND ALL CORRESPONDENCE TO: James R. Crawford

EXPRESS MAIL NO. EL 759723714 US Mailed FEBRUARY 1, 2001

FULBRIGHT & JAWORSKI L.L.P. 666 Fifth Avenue New York, NY 10103 Customer No. 24972

JC07 Rec'd PCT/PTO n 1 FEB 2001 HUBR 1177

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s)

Eibl, et al.

International

Appln. No.

PCT/EP99/05710

International

Filing Date

August 6, 1999

For

NOVEL PHOSPHOLIPIDS WITH UNSATURATED ALKYL AND

ACYL CHAINS

February 1, 2001

Hon. Commissioner of Patents and Trademarks Washington, D.C. 20231 Box PCT

PRELIMINARY AMENDMENT

SIR:

In advance of prosecution, please amend the above-identified patent application as follows:

IN THE CLAIMS

Cancel claims 31, 36-42 without prejudice.

Claim 10, lines 1-2, delete "any of the preceding claims" and substitute -- claim 1 -- .

Claim 11, line 1, delete "any of claims 1 to 9" and substitute -- claim 1 -- .

Claim 12, lines 1-2, delete "any of the preceding claims" and substitute -- claim 1 -- .

Claim 13, lines 1-2, delete "any of the preceding claims" and substitute -- claim 1 -- .

Claim 14, lines 1-2, delete "any of the preceding claims" and substitute -- claim 1 -- .

Claim 18, line 1, delete "any of claims 1 to 13" and substitute -- claim 1 -- .

1

Claim 20, line 1, delete "or 19".

Claim 21, line 1, delete "or 19".

Claim 22, line 1, delete "or 19".

Claim 23, line 1, delete "any of claims 18 to 22" and substitute - claim 18 - .

Claim 24, line 1, delete "any of claims 18 to 22" and substitute -- claim 18 -- .

Claim 25, line 1, delete "19, 21 or 23".

Claim 26, line 1, delete "19, 21 or 24".

Claim 27, line 1, delete "or 19".

Claim 28, line 1, delete "or 19".

Claim 29, lines 4-5, delete "any of claims 1, 18 to 26" and substitute -- claim 1 -- .

Claim 32, line 1, delete "any of claims 29 to 31" and substitute -- claim 29 -- .

Claim 33, lines 2-3, delete "any of claims 1, 14 to 17 and 27 to 29" and substitute -- claim 1 -- .

2

714713.1

REMARKS

Please enter this amendment prior to examination on the merits.

It is not believed that any fees are due at this time, but any necessary fees may be charged to deposit account no. 50-0624.

Respectfully submitted,

FULBRIGHT & JAWORSKI L.L.P.

James R. Crawford

666 Fifth Avenue New York, New York 10103 (212) 318-3148

25

PCT/EP99/05710

JC07 Rec'd PCT/PTO 0 1 FEB 2001

PHOSPHOLIPIDS WITH UNSATURATED ALKYL AND ACYL CHAINS

Description

- 1 -

5 The invention relates to phospholipid-like compounds of the formula (I) with defined apolar constituents, and to a process for the preparation thereof. The invention additionally relates to the use of the phospholipid-like compounds as liposomes, active ingredients and solubilizers.

Phospholipid-type compounds have many possible uses, for example as liposome constituents for transporting drugs or as gene transport vehicles, as solubilizers for drugs of low solubility in water, and themselves as active ingredients against diseases such as, for example, cancer or leishmaniosis.

Phospholipid-like compounds of this type consist of a polar and an apolar moiety. Glycerophospholipids comprise as essential constituent glycerol which is esterified in the sn-1 and sn-2 positions mainly with fatty acids (apolar moiety). If at least one of the two OH groups on the glycerol structure is etherified with an alcohol, the term used is ether phospholipids. The polarity of the compounds of the invention derives from the negatively charged phosphate group and from the esterified alcohol component, which quaternary, positively charged nitrogen. This group may be present one or more times or else not present at all, resulting in each case in a negative or positive excess charge or else no charge.

The apolar portion is formed by alkyl or acyl chains,

which may be in saturated or unsaturated form. The
possible variations in the synthesis of the apolar
region has to date been limited to the naturally
occurring acyl radicals or alkyl chains. It is possible

by specific modifications of the apolar region to change markedly and control specifically the physical, biochemical and biological properties of the phospholipid compounds.

5

10

15

20

25

30

35

Liposomes as transport vehicles or drug carriers are known. The frequently used phosphatidylcholines such as 1,2-dipalmitoyl-sn-glycero-3-phosphocholine 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC) 1,2-dioleyl-sn-glycero-3-phosphocholine (DOPC) form on sonication with cholesterol in the ratio 60.40 liposomes of the order of 60 nm in size. However, it may often be advantageous to produce liposomes with a larger internal volume, because larger amounts of active ingredients can be transported therewith. However, the problem with this is that to produce liposomes with a diameter of more than 100 nm in size it is necessary to use processing techniques such as, for example, extrusion, which is associated with disadvantages, for example distinct due brittleness of the polycarbonate membrane or blockage of the pores. This makes it difficult in particular to prepare relatively large batches for pharmaceutical purposes. It is possible by extending the alkyl or acyl chains of the apolar moiety to achieve, because of steric factors, an arrangement of the molecules with less curvature on formation of vesicles. The result is the formation of larger liposomes, which can be achieved by ultrasound treatment without extrusion processes. In order to keep the phase transition temperature of phospholipids with extremely long fatty acids (with more than 22 C atoms) in a range which is favorable for liposome formation, fatty acids with a cis double bond located as near the middle as possible are used. Such extremely long-chain fatty acids occur in only small amounts in nature.

15

20

25

30

35

Phospholipid compounds can also be employed directly as active pharmaceutical ingredients. The antineoplastic and immunomodulatory effect of lysolecithins (which have only one instead of two fatty acids on the glycerol) and ether lysolecithins in cell culture experiments has been known for more than 30 years. The basic precondition for antineoplastic activity lysophospholipids and analogs is accumulation in the diseased tissue. Lysophosphatidylcholines are readily metabolized by phospholipases or acryltransferases and are no longer available to the body, whereas ether lysolecithins can be detoxified by oxidative cleavage of the ether linkage or acylation of the sn-2 position. This is why substances which are less good substrates for phospholipid-metabolizing enzymes but still have a lysolecithin-like structure have been synthesized. The first phosphocholine with antitumor activity found was the ether lipid 1-0-octadecyl-2-0-methyl-rac-glycero-3phosphocholine (ET18-OCH3 also known as edelfosine). ET18-OCH3 shows excellent antineoplastic activity in cell-culture experiments but proved to be virtually inactive in complex organisms.

Dispensing with glycerol as basis of the structure results in the metabolically more stable alkylphosphocholines (APC), substances which accumulate in membranes and have a marked effect in cell properties. Alkylphosphocholines do not occur in nature and are phosphocholine esters of long-chain alcohols which, because of their simplified structure, now have substrate properties only for phospholipase D. The best known representative to date of this class substances is hexadecylphosphocholine (HePC), an alkylphosphocholine which was approved as medicine in 1992 under the name Miltex® (active ingredient: miltefosine) and has therefore also been intensively investigated. HePC is employed for the topical treatment of breast and lymphomas with cutaneous cancers metastases.

1.0

30

35

Alkylphosphocholines not only reduce tumors but also activate cytotoxic macrophages and inhibit the invasion by neoplastic cells. healthy tissue investigations have shown that APCs (and especially HePC) are potent active ingredients for controlling leishmaniosis and trypanosomiasis. Direct intravenous HePC solution causes administration of an thrombophlebitis in rats. In clinical studies, HePC shows toxicities in the gastrointestinal tract on oral administration and therefore cannot be administered in effective concentrations. One exception is HePC for controlling leishmaniosis: HePC acts in doses so low that the side effects described above do not occur.

The first intravenously injectable alkylphosphocholine to be found was erucylphosphocholine (ErPC), a phosphocholine with a C₂₂-alkyl chain and cis double bond in the ω -9-position. It has emerged that structural variations in the apolar region of unsaturated and thus intravenously administrable alkylphosphocholines, for example on shifting the double bond to the ω -12 or ω -6 position, lead to improved antitumor activity compared with erucylphosphocholine, the most effective compound to date (see table 2 in example 5).

Phospholipids are also used as solubilizers for drugs of low solubility in water. Once again, these solubilizing properties can be improved by modifying the apolar region.

To date it has been possible to modify specifically only the polar moiety in the synthesis of phospholipids of the abovementioned classes. It has to date been possible to use for the apolar portion only commercially available fatty acids and naturally occurring fatty acids.

Phospholipids occurring in nature and specifically in mammals mainly comprise unbranched fatty acids with 8 to 24 C atoms which, owing to their biosynthesis, have almost exclusively an even number of carbon atoms. Unsaturated fatty acids usually have 1 to 4 double bonds, mainly in the cis configuration. Naturally occurring monounsaturated fatty acids usually have the double bond in the middle, i.e. in palmitoleic acid it is located at the ω -7 position or at the (Z)-9 position in the preferred notation used in the examples herein. The higher fatty acids oleic, eicosenoic, erucic and nervonic acid each have the double bond at the ω -9 position in the carbon chain or, correspondingly, at the (Z)-9, (Z)-11, (Z)-13 and (Z)-15 position in the notation preferred herein.

In polyunsaturated fatty acids, the positions of the unsaturations are such that in each case there is only one $\mathrm{CH_2}$ group between them. This is important for making the autoxidation of the fatty acids possible. However, it would be advantageous, precisely on use of phospholipids as drugs or liposomes, to prevent the autoxidation in order to obtain more stable compounds. This can be achieved only by compounds in which the unsaturations in the alkyl and acyl chains are more than one methylene group apart.

German patent application DE 197 35 776.8 discloses phospholipid-analogous compounds as liposome constituents, active pharmaceutical ingredients or solubilizers, which contain saturated or monounsaturated acyl or alkyl radicals, with the total of the carbon atoms in the acyl and alkyl being between 16 and 44.

35

25

30

It was therefore an object of the present invention to provide compounds which, owing to modifications in the apolar region, have improved properties for the

15

20

25

30

aforementioned applications and, in addition, can be prepared on an industrial scale. It was a further object of the present invention to make it possible, by a novel process, to prepare unsaturated fatty acids in which the double bonds are at positions which do not occur in naturally occurring mono- and diunsaturated fatty acids, or to provide a process which makes it possible to prepare monounsaturated fatty acids which are difficult to obtain, for example nervonic acid, in industrial quantities.

This object is achieved according to the invention by a compound of the general formula (I)

(I) $A - PO_3$ - B in which B is a radical of the general formula (II)

(II)
$$\begin{bmatrix} CH_2 \\ CH_2 \\ R_3 \end{bmatrix}_m^{CH_3} - (CH_2)_x - \begin{bmatrix} CH_2 - \begin{pmatrix} CH \\ OH \end{pmatrix}_y - CH_2 - O \\ CH_2 - CH_2 - O \end{bmatrix}_z$$

in which

n is an integer from 2 to 8;

m is 0, 1 or 2;

x is an integer from 0 to 8;

y is an integer from 1 to 4;

z is an integer from 0 to 5;

R₃ is an alkyl radical having 1 to 3 C atoms, which may be substituted by one or more hydroxyl groups;

and in which A is a radical selected from one of the formulae (III) to (IX):

(V) CH_2-O-R_1 (VI) CH_2-O-R_1 (VII) CH_2-O-R_1 (VII) CH_2-O-R_1 (VII) CH_2-O-R_1 (CH₂)₀ CH_2-O-R_1 (CH₂)₀

- 7 -

(VIII) O (CH₂)_p (CH₂)_qH

in which

g is an integer from 0 to 8;

p, q, r, s, $t \ge 0$;

 $12 \le p + q \le 30$ and $8 \le s + t + r \le 26$;

where R_1 and R_2 are each independently hydrogen, a saturated or unsaturated acyl or alkyl radical or a radical selected from one of the formulae (X), (XI), (XII) and (XIII), and at least one of R_1 and R_2 is a radical selected from one of the formulae (X), (XI), (XII) and (XIII):

$$(X) \qquad (CH_2)_p \qquad (CH_2)_qH$$

$$(XII) \qquad (CH_2)_s \qquad (CH_2)_t \qquad (CH_2)_rH$$

$$(XIII) \qquad CH_2 \qquad (CH_2)_p \qquad (CH_2)_qH$$

$$(XIII) \qquad CH_2 \qquad (CH_2)_s \qquad (CH_2)_t \qquad (CH_$$

C.

The state of the s

5

15

- +--

10

20

25

30

35

where $q \neq 8$ for p+q=14, 16, 18 or 20, if neither of the radicals R_1 and R_2 is a radical of the formula (XI) or (XIII), or if A is a radical of the formula (VIII).

structural elements used in the substances described herein can be varied as desired and tailored to suit the particular use. Particularly preferred monounsaturated acyl and alkyl radicals are those whose double bond is not in a natural position. Compounds in which both the radicals R1 and R2 are naturally occurring monounsaturated acyl or alkyl chains, such as, for example, those having the C=C bond in the ω -9 position, thus do not form part of the invention. The process of the invention makes it possible to choose the position of the double bond(s) without restriction, so that previously inaccessible alkyl/acyl chains can be prepared. As already explained above, the cis double bonds of natural diunsaturated alkyl and acyl chains are in each case separated by only one methylene group. Such compounds are unstable at room temperature in the presence of oxygen and must therefore be stored at low temperatures under nitrogen. The possibility synthesizing (Z)-fatty acids and (Z)-alkenols with the alkyl or acyl chains of the formulae (IX), (XI) and (XIII) having 16 to 34 C atoms allows structural elements in which there are at least 2 methylene groups between the unsaturations to be provided. This results in a considerable stabilization of the fatty acids and alcohols and of the classes of compounds synthesized therefrom. Compounds of the invention can be stored without difficulty at room temperature without inert gas. The term (Z)-fatty acids or -alkenols as used herein encompasses both mono- and diunsaturated chains with one or two cis double bonds.

The advantage of the particularly preferred alkyl and acyl chains with two double bonds is that the physicochemical properties are favorable. Thus, for

30

35

10

example, the diunsaturated fatty acids (Z,Z)-10,19octacosadienoic acid, which is based on a 28 carbon liquid at room temperature, monounsaturated fatty acids of this chain length occur only in the solid state at 20°C, irrespective of the position of the cis double bond. The incorporation of the structures of the invention into phospholipids makes it possible to transfer these properties to the compounds of the invention, which is phase transition inter alia in low temperatures. It is likewise possible, by extending the fatty acid chains, to more than double the vesicle diameter compared with liposomes prepared conventional lecithins, which corresponds to internal volume of ultrasound-prepared liposomes being eight times as large. It is thus possible to transport more than eight times as much active ingredient as is possible with conventional liposomes. In addition, preparations of large unilamellar vesicles (LUVs) in highly viscous solutions, for example sugar solutions, are possible, that is to say in a medium in which it is difficult to prepare liposomes by extrusion processes. The phase transition temperatures of the phospholipids with the extremely long fatty acids of the invention are, because of the cis double bond(s), in a region favorable for liposome preparations.

The compound of the general formula (I) has two variable components A and B, each of which can be modified individually. The compound of the invention of the formula (I) does not comprise a mixture of different molecules of indeterminate composition and chain length; on the contrary it is possible specifically to obtain a desired structure. This means that, if the desired product is an N,N-dimethyl-N-(2-hydroxypropyl-3,1-0,0-dihydroxypropyl)ammonium derivative, with y = 1 and z = 2 in formula (I), the compound is chemically defined and contains scarcely any

contributions from y=1 and z=1 or y=1 and z=3 etc. Preference is given to the use of hydroxypropyl derivatives of a very particular chain length essentially free of other chain lengths.

5

10

30

35

The compound of the formula (I) is, according to the invention, a homogeneous compound of defined structure. The compound is preferably more than 99% homogeneous in relation to the value of z. However, it is also possible to provide the compound with a homogeneity of more than 99.9% in relation to the value of z.

For B in the compound of the formula (I), preference is given to m=1 with n=2 to 8. Particular preference is given to n=2 to 6, and even greater preference to 2 to 4. When z=0, x is preferably an integer from 1 to 3 and is even more preferably 1.

If z=1, y preferably has a value from 1 to 4, and if z=1 to 5, y is preferably 1. In the case where y>1, the radical $-CH_2(CHOH)_y-CH_2-OH$ is preferably derived from sugar alcohols having four hydroxyl groups for y=2, five hydroxyl groups for y=3 and six hydroxyl groups for y=4. Examples of such radicals are mannitol derivatives for y=4, lyxitol derivatives for

y = 3 and threitol derivatives for y = 2.

It is possible and also preferred for x to be 0. In this case, y is 2 to 4 for z = 1. Or, in another preferred embodiment, z = 1 to 5 for y = 1.

It is possible and also preferred for m to be 0, in which case the compound of the formula (I) has a negative excess charge because of the negatively charged PO $^{\circ}_3$ group. For m = 0, x is preferably 0, and y = 1 for z = 1 to 5, or, in a likewise preferred embodiment, y = 2 to 4 for z = 1.

35

The radical R_3 is preferably CH_3 , C_2H_5 or 1,2-dihydroxypropyl.

The groups of the formulae (III) to (VII) are preferably in enantiopure form. However, they may also be racemates.

The compound of the formula (I) is according to the invention a. compound of defined structure.

10 Monounsaturated alkyl chains are preferably more than 97% homogeneous, but may also be provided with homogeneity of more than 99%. Diunsaturated alkyl chains are preferably more than 90% homogeneous, but may also in some cases be provided in purities of 15 > 97%.

The compound preferably comprises phospholipids with mono- or diunsaturated alkyl or acyl chains having 16-14 chain carbon atoms.

The compounds encompassed by the general formula (I) have excellent biological properties and are used as

- liposome constituents for preparing liposomes for targeted accumulation of active ingredients or nucleic acids in target cells (alkyl/acyl chain length preferably 16-32 C atoms)
- active ingredients against oncoses and protozoal
 infections (alkyl/acyl chain length preferably 16-26 C
 atoms) and
 - 3. solubilizers for substances which are difficult to administer intravenously, such as, for example, Taxol (alkyl/acyl chain length preferably 16-30 C atoms).

Conventional liposomes have a residence time in serum of up to 5 hours but, especially on use of liposomes as

10

20

30

35

carriers of active pharmaceutical ingredients, it is desirable for the residence time of liposomes in the bloodstream to be as long as possible, but especially in conjunction with uptake in selected target cells.

has emerged from ultrasound preparations of Ιt liposomes that symmetrical lecithins with (Z)-fatty acids having up to 24 carbon atoms form liposomes when mixed with cholesterol, and the homogeneity of the vesicle population is crucially determined by the position of the double bond. The precondition for a narrow standard deviation of the vesicle size is a particular distance of the double bond from the carboxyl function. There is evidently, by comparison with conventional lecithins, a significant increase in the vesicle diameter, which is 125 nm for (Z)-15-tetra-(nervonic acid). Mixed-chain acid phosphatidylcholines with a saturated acyl chain in the sn-1 position also form vesicles with very long-chain (Z)-fatty acids, and it is to be assumed that there is

interdigitation of the fatty acid chains. The average hydrodynamic liposome diameter on esterification with (Z)-15-triacontenoic acid (30:1 $\Delta^{15})$ is 111 nm (stearic acid in the sn-1 position). A distinct enlargement of vesicles is also obtained by use of extremely long fatty acids in the case of phospholipids having a modified polar region, such as, for example, in the case of phospholipids containing oligoglycerols linked via nitrogen atoms.

When the compound of the invention of general formula (I) is used as liposome constituent, the constituent A is preferably two-chain radical derived from glycerol, of the formulae (III) or (IV). In constituent B, these compounds preferably have an alkylammonium group, i.e. m is preferably equal to 1. The preferred parameters

1.0

15

20

25

30

35

for compounds of the formula (I) used as liposome constituents are:

m = 1, n = 2-6, x = 0, y = 1, z = 1-5 or

m = 1, n = 2-6, x = 0, y = 2-4, z = 1 or

m = 1, n = 2-6, x = 1, z = 0 or

m = 0, x = 0, y = 1, z = 1-5, preferably 2-4 or

m = 0, x = 0, y = 2-4, z = 1.

R₃ is in this case preferably 1,2-dihydroxypropyl, C₂H₅ or even more preferably CH₃. The compound preferably comprises hydroxypropyl derivatives with 1 to 3 hydroxypropyl units, i.e. x = 0 and z = 1 to 3. Since y is preferably 1, these involve 1,3-linked linear oligoglycerol residues which are linked to the nitrogen atom via a 2-hydroxypropyl radical.

These compounds which are suitable as liposome constituents preferably have 2 radicals, that is to say R_1 and R_2 . These may be in each case independently a radical of one of the formulae (X) to (XIII). If R_1 and R_2 are identical, they preferably have a maximum chain length of, in each case, 16 to 26 C atoms. In another preferred embodiment, one of the radicals is longer than 26 C atoms and may preferably have up to 32 C atoms. In this case, a methyl radical is preferably present on the nitrogen, i.e. when $z=0,\,x$ is preferably 1. It is likewise preferred for at least of R_1 and R_2 to be a diunsaturated radical of the invention, and it is even more preferred for both R_1 and R_2 to be a diunsaturated radical of the invention.

One of the radicals R_1 and R_2 may also be a saturated acyl or alkyl radical. In this case, the other radical is a compound of one of the formulae (X) to (XIII), and is preferably a diunsaturated alkyl or acyl chain of the formula (XI) or (XIII).

In another preferred embodiment, the compound of the general formula (I) as liposome constituent may also

15

20

25

30

have a negative excess charge. This is the case when m=0. Preference is given in this connection to glycero-glycerols and phosphatidyl-glycero-glycero-glycerols (in these cases, x=0, y=1 and z=2 to 4). Additionally preferred in this connection are the previously mentioned compounds with y>1, i.e. the radical $CH_2-(-CHOH)_y-CH_2-OH$ is preferably derived from sugar alcohols having 4 hydroxyl groups for y=2, 5 hydroxyl groups for y=3 and 6 hydroxyl groups for y=4. Likewise preferred in this connection are phospho-sn-G1 compounds.

Active ingredients of the invention are preferably compounds of the general formula (I) in which the structural parameter A is a radical of one of the formulae (VIII) or (IX). They are therefore unsaturated alkylphosphocholines.

The advantage of unsaturated chains in the apolar region is that such compounds can be administered intravenously. Active ingredients of the invention have better antitumor activity than erucylphosphochiline, the most effective compound to date. An increased cytostatic effect is obtained, for example, by shifting the cis double bond toward the phosphocholine group. Thus, even with the lowest dose, (Z)-10-docosenyl-1-phosphocholine (42 μ mol/kg/week) shows a tumor reduction to 9% (T/C), whereas erucylphosphocholine with a dose which is more than twice as high (90 μ mol/kg/week) shows a reduction only to 31% (T/C) (see example 5, table 1).

The preferred parameters for compounds of the formula 35 (I) which are suitable as active ingredients are: $m=1,\;n=2\text{--}6,\;\text{more preferably}\;n=2\text{--}4,\;x=1,\;z=0\,.$

Compounds of the general formula (I) are particularly suitable as active pharmaceutical ingredients when they have an alkylammonium radical (i.e. m = 1) with which the distance between ammonium and phosphate is greater than or equal to 2, i.e. n is preferably 2, 3 or 4. In this case, R_3 is preferably a $\rm CH_3$ or $\rm C_2H_5$ group. It is likewise preferred for R_3 to be 1,2-dihydroxypropyl. These compounds are particularly active antitumor agents.

10

15

20

25

3.0

The most preferred compounds are those having an N,N,N-trimethylalkylammonium group, so that preference is given to z=0 and x=1.

It is preferred to dispense with a glycerol basic structure or a similar basic structure according to one of the formulae (III) to (VII) for active ingredients. The structural parameter A is thus preferably a compound of the formulae (VIII) or (IX). These are therefore preferably (Z)-alkenylphosphocholines or (Z,Z)-alkadienylphosphocholines.

If a monounsaturated alkyl radical is present, this preferably has 16 to 23 carbon atoms. This is because it has emerged that compounds with chains having 24 C atoms or more are distinctly less suitable. With a diunsaturated alkyl radical, longer chains are suitable, preferably having about 19 to 26 C atoms. It has emerged that diunsaturated chains with 16 to 18 carbon atoms are inactive. It should be particularly emphasized in this connection that alkadienylphosphocholines with a terminal double bond (i.e. r=0) in formula (IX) have a marked antitumor effect even at very low dosage.

35

Compounds with a glycerol-like constituent also show antitumor activity, i.e. a compound according to one of the formulae (III) to (VII) may also be present on the

30

35

phosphate residue. If in this case 2 radicals R_1 or R_2 are present, however, it is important that one R is a short chain. This short chain is preferably an alkyl radical having 1 to 4 C atoms. The other radical R_1 or R_2 is then preferably a radical of the formula XII or XIII. It is, in particular, a radical of the formula XIII.

Additionally preferred compounds are those in which 10 both radicals R_1 and R_2 are each linked by an ether linkage to the glycerol residue, i.e. they are each independently a group of the formula (XII) or (XIII). Particular preference is also given to a compound where R_1 and R_2 are the same mono- or diunsaturated radical of the invention.

Mention should be made, as another preferred embodiment of the compound of the general formula (I), of compounds which are distinguished by a good solubilizing property. The preferred structural parameters for compounds of the formula (I) suitable as solubilizers are:

m = 1, n = 2-6, \mathbf{x} = 0, \mathbf{y} = 1, \mathbf{z} = 1-3, more preferably \mathbf{z} = 1,

25 m = 1, n = 2-6, x = 0, y = 2-4; z = 1 or m = 1, n = 2-6, x = 1, z = 0.

 \mbox{R}_3 is prferably $\mbox{CH}_3, \mbox{ } \mbox{C}_2\mbox{H}_5$ or 1,2-dihydroxypropyl.

Known compounds of this type encompass, for example, the erucyl (C_{22}) compounds. The compounds of the invention which are therefore preferred are those which have as structural parameter A a group according to one of the formulae (III) to (VII), where one of the radicals R_1 and R_2 is preferably a compound of the formulae (X) or (XI), i.e. one of the radicals R_1 or R_2 is preferably a diunsaturated chain according to the invention. Single-chain compounds are preferred for the

solubilizers, i.e. when A is a group of the formulae

- 17 -(III) or (IV), and one of R_1 and R_2 is -OH or an alkyl having 1 to 4 C atoms.

When A is a radical according to one of the formulae (V) to (VII), i.e. when only one R_1 is present, R_1 is likewise preferably a diunsaturated chain. Solubilizers of the invention are preferably in the form of esters, i.e. chains of the formula (X) or (XI) are preferred. Very particular preference is given in this connection in turn to compounds with one or two diunsaturated 10 alkadienyl radicals. Some compounds of the classes already mentioned previously are also suitable here too. One example are the single-chain glycero-phospho compounds not hydroxylated on the nitrogen, i.e. m = 1, x = 1 and z = 0 in the structural parameter B. 15

Compounds particularly preferred as solubilizers are those having only one long-chain radical such as, for example, compounds based on lysolecithin which have an OH group on a C atom of the glycerol residue. Particularly preferred compounds are therefore those in which the structural parameter A is a radical according to one of the formulae (III) to (VII).

Some compounds with 2 radicals R1 and R2 also display 25 particularly good solvent properties, however. Examples are those compounds in which R1 and R2 are two diunsaturated radicals having 16 to 24 C atoms.

The present invention further relates to a process for 30 preparing unsaturated (Z)-fatty acids or (Z,Z)-fatty acids or (Z)-alkenols or (Z,Z)-alkenols having 16 to 34 carbon atoms, the process of the invention making available diunsaturated (Z,Z)-fatty acids and alkenols which have more than one ${
m CH}_2$ group between the cis double bonds. A lactone which may comprise 13 to 19 C atoms is used as starting material for this process.

15

20

25

30

35

The process comprises the following steps:

- cleavage of the lactone ring with a trimethylsilyl halide to give the corresponding trimethylsilyl halocarboxvlate.
- 2) simultaneous or subsequent alcoholysis of the trimethylsilyl halo-carboxylate to give the corresponding halo-carboxylic ester,
- 3) reaction of the halo-carboxylic ester with 10 triphenylphosphane to give the corresponding phosphonium salt,
 - 4) reaction of the phosphonium salt with an aldehyde using a base and subsequent hydrolysis to give a corresponding (Z)-fatty acid salt,
 - 5) liberation of the (Z)-fatty acid from the (Z)-fatty acid salt, and
 - 6) where appropriate conversion of the (Z)-fatty acid into the corresponding (Z)-alkenol using lithium aluminum hydride.

In step 1) there is preferably use of lactones of the formula (\mbox{XIV})

(XIV)

where a = 10 to 16. The trimethylsilyl halides used to cleave the lactone ring are preferably trimethylsilyl iodide or trimethylsilyl chloride. The alcohol used for the alcoholysis in step 2) is preferably ethanol. The reaction of the phosphonium salt with an aldehyde is based on the procedure for a Wittig reaction in the absence of lithium salts, which is also referred to as a salt-free Wittig reaction. The stereoselectivity of such reactions is generally elicited by sodium- or potassium-containing bases, and therefore preferred

15

20

25

30

35

bases are, for example, NaNH₂, potassium tert-butoxide, NaHMDS or KHMDS. NaHMDS is particularly preferred. The hydrolysis and subsequent liberation and, where appropriate, the conversion of the fatty acids into an alkenol takes place by known processes.

A particularly preferred embodiment of the process of the present invention is the process for preparing nervonic acid ((Z)-15-tetracosenoic acid). This entails using cyclopentadecanolide as starting lactone and pelargonaldehyde as aldehyde in step 4. This process can be used to synthesize nervonic acid, which occurs only in small amounts in nature, even on an industrial scale.

The present invention further relates to liposomes comprising phospholipid-like compounds of the formula (I) as constituents of the liposome shell. These liposomes additionally contain phospholipids and/or alkylphospholipids and, where appropriate, cholesterol, the liposomes containing 1 to 50 mol% of a compound according to the invention of the formula (I) or salt thereof and, together with the phospholipids, the alkylphospholipids and the cholesterol, resulting in 100 mol% of the liposome shell.

The liposomes of the invention have a distinctly increased internal volume. They are thus able to transport a larger amount of active ingredient and/or nucleic acids. Preferred liposomes of the invention additionally comprise an active ingredient and, where appropriate, pharmaceutically acceptable diluents, excipients, carriers and fillers. The liposomes may comprise a nucleic acid in addition to the active ingredient or in place of the active ingredient. It is also possible according to the invention to use as active ingredients the active ingredients of the invention.

The present invention further relates to a pharmaceutical composition which comprises as active constituent a compound of the formula (I) which is suitable as active ingredient. The pharmaceutical composition may moreover additionally comprise pharmacologically acceptable diluents, excipients, carriers and fillers.

The present invention further relates to the use of the 1.0 compounds of the invention as liposome constituents, as pharmacological active ingredients or as solubilizers. It has emerged that some of the compounds of the invention show a particularly good antitumor effect. Compounds of the invention can be employed not only as 15 antitumor active ingredient but also against protozoal infections such as, for example, leishmaniosis or trypanosomiasis. They can likewise be used to promote the solubility of substances of low solubility in water, for example Taxol, so that these substances can 20 also be administered intravenously in conjunction with the solubilizers of the invention.

The active ingredients which can be used are generally all active ingredients which can in fact be introduced 25 by means of liposomes into the plasma. Preferred groups active ingredients are, on the one cytostatics, especially anthracycline antibiotics, such as, for example, doxorubicin, epirubicin or daunomycin, with doxorubicin being particularly preferred. Further 30 preferred cytostatics are idarubicin, alkylphosphocholines in the structural variations described by us, 1-octadecyl-2-methyl-rac-glycero-3-phosphocholine structural analogs derived therefrom, 5-fluorouracil, cis-platinum complexes such as carboplatin and 35 Novantrone, and mitomycins.

Further preferred groups of active ingredients are immunomodulating substances such as, for example, cytokines, and among these in turn interferons and, in particular, a-interferon are particularly preferred, substances with antimycotic activity (for example active and ingredients against amphotericin B) (malaria, protozoal infections trypanosome leishmania infections). Taxol is likewise preferred as active ingredient.

10

15

A further preferred group of active ingredients are ingredients as described in active DE 41 32 345 A1. Miltefosine, edelfosine, ilmofosine and SRI62-834 are preferred. Alkylphosphocholines, also alkvl chains, for example extended erucvlphosphocholine and erucylphosphocholines extended phospho-nitrogen distance, are particularly preferred.

20 Th

The present invention further relates to the use of liposomes of the invention for producing an antitumor composition, where the active ingredient is particularly preferably doxorubicin.

25 The present invention additionally relates to the use of the liposomes of the invention for producing a composition for influencing the proliferation of cells, where the active ingredient is a cytokine, particularly preferably α -interferon.

30

The liposomes of the present invention can thus also be used as transport vehicles and specifically as gene transport vehicles.

35 The process and the compounds of the general formula (I) are illustrated in more detail in the following examples.

15

20

25

3.0

Examples

Example 1: Synthesis of ω -substituted phosphonium salts 1a) Synthesis by monobromination of α , ω -diols

The starting materials used for synthesizing olefinic alcohols are alkanediols, which are monobrominated with 48% strength hydrobromic acid to give ω -bromoalkan-1ols. After acetylation of the remaining hydroxyl group, the compounds are fused with triphenylphosphane to give the triphenylphosphonium bromides substituted in the ω position. The latter are deprotonated with NaHMDS and then converted into olefins with unsubstituted alcohols.

$$HO \longrightarrow GCH_2)_X \longrightarrow GF \longrightarrow GF$$

$$GF \longrightarrow GF$$

Synthesis of [ω (acetoxy)alkyl]triphenylphosphonium bromides by monobromination of α, ω -diols

Monobromination

6-Bromo-1-hexanol

200.8 g (1.70 mol) of 1,6-hexanediol, 600 ml of 48% strength hydrobromic acid and 2 l of toluene were heated under reflux with vigorous stirring for 2 hours. After cooling to room temperature, the phases were separated. The organic phase was washed with 2 × 500 ml of saturated NaHCO₃ solution and 700 ml of water. Removal of the solvent resulted in 301.2 g (1.66 mol, 98%) of 6-bromo-1-hexanol.

 $MW = 181.07 \text{ g/mol } (C_6H_{13}BrO)$

3.0

 R_f (precursor) = 0.19 (diethyl ether) R_f = 0.59 (diethyl ether)

10-Bromo-1-decanol

87.8 g (0.50 mol) of 1,10-decanediol, 165.1 g of 48% 5 strength hydrobromic acid and 2.5 l of high-boiling petroleum ether (b.p. 100-140°C) were heated under reflux with vigorous stirring for 4 hours. A further 80.0 g of 48% strength hydrobromic acid were added, and the mixture was boiled for 5 hours. After cooling to 10 30°C, the phases were separated. The organic phase was washed first with a solution of 100 g of Na₂CO₃ in 500 ml of water and then with 2 \times 500 ml of water. Removal of the solvent was followed by chromatography 700 q of silica gel. The byproduct 1,10-1.5 dibromodecane was eluted with cyclohexane/diethyl ether (20:1). Chromatography with cyclohexane/diethyl ether (2:1) afforded 103.9 g (0.44 mol, 87%) of 10-bromo-1decanol.

- 23 -

20 MW = 237.18 g/mol $(C_{10}H_{21}BrO)$

 $R_{\rm f} = 0.38$ (diisopropyl ether)

 $^{1}\text{H-NMR}$ (300 MHz, CDCl₃): δ = 1.30-1.43 (m, 12H, (CH₂)₆), 1.57 (m, 2H, CH₂CH₂OH), 1.85 (mc, 2H, CH₂CH₂Br), 2.22 (s, D₂O-exchangeable, 1H, OH), 3.41 (t, ^{3}J = 6.9 Hz, 2H,

25 CH_2Br), 3.64 (t, $^3J = 6.7 Hz$, 2H , 2CH_2OH)

Acetylation to give ω -bromoalkyl acetates

Acetylation of the ω -bromoalkan-1-ols is carried out with acetic anhydride in THF with catalysis by DMAP. The esterifications take place rapidly at 30°C, irrespective of the chain length of the compound, and are complete only a few minutes after addition of the reactive anhydride.

35 6-Bromohexyl acetate

20.1 g (0.16 mol) of DMAP were added to 297.4 g (1.64 mol) of 6-bromo-1-hexanol in 1500 ml of THF. A solution of 184.4 g (1.81 mol) of acetic anhydride in

20

2.5

3.0

35

561 (w)

300 ml of THF was added dropwise in such a way that the reaction temperature did not exceed 30°C. After completion of the addition, the mixture was stirred for a further 30 minutes. The reaction mixture was mixed with 500 ml of diisopropyl ether and extracted successively with 700 ml each of water, 2 × saturated NaHCO3 solution and water. After drying over sodium sulfate, the solvent was removed in vacuo. 352.8 g (1.58 mol, 96%) of 6-bromohexyl acetate were obtained.

10 MW = 223.11 g/mol $(C_8H_{15}BrO_2)$

 $R_f = 0.81$ (diethyl ether)

 $^{1}\text{H-NMR} \ (300 \ \text{MHz}, \ \text{CDCl}_{3}): \ \delta = 1.33\text{-}1.53 \ (\text{m}, \ 4\text{H}, \ (\text{CH}_{2})_{2}), \\ 165 \ (\text{mc}, \ 2\text{H}, \ \text{CH}_{2}\text{CH}_{2}\text{O}), \ 1.87 \ (\text{mc}, \ 2\text{H}, \ \text{C}\underline{\text{H}}_{2}\text{CH}_{2}\text{Br}), \ 2.04 \ (\text{s}, \ 3\text{H}, \ \text{OOCCH}_{3}), \ 3.41 \ (\text{t}, \ ^{3}\text{J} = 6.8 \ \text{Hz}, \ 2\text{H}, \ \text{C}\underline{\text{H}}_{2}\text{Br}), \ 4.06 \ (\text{t}, \ ^{3}\text{J} = 6.7 \ \text{Hz}, \ 2\text{H}, \ \text{CH}_{2}\text{O}) \\ \text{IR} \ (\text{film}): \ \nu[\text{cm}^{-1}] = 2937 \ (\text{s}), \ 2859 \ (\text{s}), \ 1736 \ (\text{s}), \ 1460 \ (\text{m}), \ 1365 \ (\text{m}), \ 1240 \ (\text{s}), \ 1044 \ (\text{m}), \ 731 \ (\text{w}), \ 641 \ (\text{w}), \ \end{cases}$

Quaternization to give phosphonium bromides

[10-(Acetoxy) decyl] triphenylphosphonium bromide 117.3 g (0.42 mol) of the appropriate ω -substituted alkyl bromide/iodide and 110.2 g (0.4 mol) of triphenylphosphane were heated at 130°C with stirring (glass stirrer) for 12 hours. The heating was removed and the mixture was allowed to cool to 90°C. 400 ml of THF were slowly added through the reflux condenser to the reaction mixture, which was stirred until a homogeneous phase was formed. It was allowed to cool to room temperature.

Addition of 2 l of diethyl ether was followed by vigorous stirring for 30 minutes. After standing for several days at -20°C, the supernatant solvent was decanted off from the solid phoshonium salt. The product was mixed with 800 ml of toluene and stirred at 60°C for several hours. After phase separation, the phosphonium salt was taken up in 300 ml of

25

dichloromethane. 3 l of diethyl ether were added and the mixture was left at -20°C for several days. After renewed decantation off, the product was dissolved in dichloromethane and transferred into a flask. The phosphonium salt was dried in vacuo at 80°C for 6 hours. 181.6 g (335 mmol, 80%) of [10-(acetoxy)-decyl]triphenylphosphonium bromide were obtained as a yellow, highly viscous oil.

 $MW = 541.51 \text{ g/mol } (C_{30}H_{38}BrO_2P)$

10 R_f = 0.23 (chloroform/methanol, 9:1)

Analysis:	С	H	P
Calculated	66.54	7.07	5.72
Found	66.67	7.06	5.55

15 1b) Synthesis via ω -halo carboxylic acids

Ethyl 11-bromoundecanoate

1000 g of 90% pure 11-bromoundecanoic acid (equivalent to 3.39 mol), 304.0 g (6.60 mol) of ethanol and 20.0 g of p-toluenesulfonic acid were introduced into 400 ml of chloroform in an experimental apparatus with water trap (for entrainers with higher specific gravity than water). The mixture was heated under reflux until water no longer separated out (about 6 hours). After the solution had cooled to room temperature it was washed successively with 1 l of water, 500 ml of saturated NaHCO₃ solution and 1 l of water. The solvent was removed in vacuo. Vacuum distillation (b.p. 131-133°C/1 mbar) resulted in 716.3 g (2.44 mol, 72%) of ethyl 11-bromoundecanoate.

30 $MW = 293.24 \text{ g/mol } (C_{13}H_{25}BrO_2)$

 $R_f = 0.66$ (cyclohexane/diisopropyl ether, 1:1)

Analysis: C H
Calculated 53.25 8.59
Found 53.22 8.57

35 $^{1}\text{H-NMR}$ (300 MHz, CDCl₃): δ = 1.23-1.42 (m, 15H, COOCH₂CH₃, 6 × CH₂), 1.62 (mc, 2H, CH₂CH₂COO), 1.85 (mc, 2H, CH₂CH₂Br), 2.29 (t, ^{3}J = 7.5 Hz, 2H, CH₂COO); 3.41

15

2.5

30

(t, ^{3}J = 6.9 Hz, 2H, $C\underline{H}_{2}Br$), 4.12 (quart, ^{3}J = 7.1 Hz, 2H, COOCH₂CH₃)

IR (film): $v[cm^{-1}] = 2930$ (s), 2854 (s), 1737 (s), 1464 (m), 1372 (m), 1179 (s), 1118 (m), 723 (w), 645 (w), 563 (w)

ω -Iodo-carboxylic esters

Central intermediates in the synthesis of (Z)-15- and (Z)-16-olefins:

10 Lactone cleavage of cyclopentadecanolide and cyclohexadecanolide with trimethylsilyl iodide and subsequent alcoholysis results in the ethyl ω -iodo-carboxylates.

Lactone cleavage

Ethyl 15-iodopentadecanoate

150.3 g (0.63 mol) of cyclopentadecanolide were dissolved in 500 ml of acetonitrile under a nitrogen atmosphere, and 229.0 g (1.53 mol) of sodium iodide were added. 170 ml (1.34 mol) of trimethylsilyl chloride were added dropwise through a septum. The mixture was heated under reflux for 18 hours. 158.5 g (3.44 mol) of ethanol were cautiously added to the boiling reaction mixture, which was heated under reflux for a further 2 hours and then allowed to cool to room temperature. 500 ml of diethyl ether were added and the mixture was extracted three times with 500 ml of 1N sodium hydroxide solution each time. The aqueous phases were back-extracted with 300 ml of diethyl ether, and

the solvent was removed from the combined organic phases in vacuo. The residue was crystallized from methanol twice at -20°C. Drying in vacuo for several days resulted in 202.3 g (0.51 mol, 81%) of ethyl 15-iodopentadecanoate. Although the product was obtained in good purity, it had an intense odor of precursor owing to very small amounts of lactone (perfumed!).

 $MW = 396.35 \text{ g/mol} (C_{17}H_{33}IO_2)$

10 R_e (intermediate) = 0.15 (dichloromethane/diisopropyl ether, 50:1)

 $R_f = 0.73$ (dichloromethane/diisopropyl ether, 50:1)

Analysis: C H
Calculated 51.52 8.39
Found 51.40 8.24

Melting point: 31.4°C

room temperature.

 $^{1}\text{H-NMR} \quad (300 \quad \text{MHz}, \quad \text{CDCl}_{3}): \quad \delta = 1.19\text{-}1.38 \quad (\text{m}, \quad 23\text{H}, \\ \text{COOCH}_{2}\text{CH}_{3}, \quad 10 \quad \times \text{CH}_{2}), \quad 1.61 \quad (\text{mc}, \quad 2\text{H}, \quad \text{CH}_{2}\text{CH}_{2}\text{COO}), \quad 1.82 \quad (\text{mc}, \quad 2\text{H}, \quad \text{CH}_{2}\text{CH}_{2}), \quad 2.29 \quad (\text{t}, \quad ^{3}\text{J} = 7.6 \quad \text{Hz}, \quad 2\text{H}, \quad \text{CH}_{2}\text{COO}), \quad 3.19 \\ (\text{t}, \quad ^{3}\text{J} = 7.0 \quad \text{Hz}, \quad 2\text{H}, \quad \text{CH}_{2}\text{I}), \quad 4.12 \quad (\text{quart}, \quad ^{3}\text{J} = 7.1 \quad \text{Hz}, \\ 2\text{H}, \quad \text{COOCH}_{3}\text{CH}_{3})$

IR (KBr): ν [cm⁻¹] = 2916 (s), 2848 (s), 1735 (s), 1474 (w), 1464 (w), 1294 (w), 1248 (w), 1200 (m), 1166 (m), 720 (w)

25

15

20

Conversion into phosphonium salts

[14-(Ethoxycarbonyl)tetradecyl]triphenylphosphonium iodide

119.0 g (0.30 mol) of the appropriate ω-substituted
30 alkyl bromide/iodide and 78.8 g (0.30 mol) of
triphenylphosphane were heated at 130°C with stirring
(glass stirrer) for 12 hours. The heating was removed
and the mixture was allowed to cool to 90°C. 400 ml of
THF were slowly added through the reflux condenser to
35 the reaction mixture, which was stirred until a
homogeneous phase formed. It was allowed to cool to

15

20

The product was precipitated by adding 2 1 of diethyl ether at 0°C, and the resulting mixture was stirred at 4°C for one day. It was then filtered with suction as quickly as possible through a large glass fiber filter, the residue was dissolved in dichloromethane and transferred into a flask. The solvent was removed in vacuo and then the phosphonium salt was dried in vacuo at 70°C for 7 hours (in a rotary evaporator). 197.5 g (0.30 mol, 100%) of [14-(ethoxycarbonyl)tetradecyl]triphenylohosphonium iodide were obtained.

 $MW = 658.64 \text{ q/mol } (C_{35}H_{48}IO_2P)$


 $R_f = 0.53$ (chloroform/methanol, 9:1)

Analysis:		C	H	P
Calculated		63.83	7.35	4.70
Found		64.00	7.42	4.61
¹ H-NMR (300	MHz, CDCl ₃): <i>S</i> =	1.19-1.28	(m, 25H,
COOCH ₂ CH ₃ , 11	\times CH ₂), 1.6	3 (m, 2H,	CH2CH2COO), 2.28 (t,

COOCH₂CH₃, 11 × CH₂), 1.63 (m, 2H, CH₂CH₂COO), 2.28 (t, 3J = 7.5 Hz, 2H, CH₂COO), 3.66 (m, 2H, CH₂P⁺Ph₃I⁻), 4.12 (quart, 3J = 7.1 Hz, 2H, COOCH₂CH₃), 7.69-7.86 (m, 15H, aromatic-H)

aromatic-n/

Example 2: Synthesis of ω -substituted aldehydes



25

30

Direct epoxide cleavage with periodic acid in aqueous 1,4-dioxane

Ethyl 10,11-epoxyundecanoate

283.7 g (1.2 mol) of 73% pure m-chloroperoxybenzoic acid were added over the course of 1 1/2 hours to 212.4 g (1.0 mol) of ethyl 10-undecenoate in 2 l of

15

2.0

25

dichloromethane, maintaining the temperature below 20°C. After stirring at room temperature for 5 hours (glass stirrer) the reaction mixture was kept at -20°C overnight. The precipitated m-chlorobenzoic acid was filtered off with suction and washed with 500 ml of cold pentane (-20°C). The solvent was removed from the filtrate in vacuo, and the residue was taken up in 1 l of pentane. This solution was cautiously extracted with 2×500 ml of saturated NaHCO3 solution and 500 ml of water. After drying over sodium sulfate, the solvent was removed in vacuo. The epoxide synthesized in this way still contained m-chlorobenzoic acid.

Crude yield: 259.5 g

 $MW = 228.33 \text{ g/mol} (C_{13}H_{24}O_3)$

 $R_f = 0.44$ (dichloromethane/diisopropyl ether 50:1)

29.0 g (130 mmol) of 6-bromohexyl acetate, 31.6 g (332 mmol) of pyridine N-oxide, 26.8 g (319 mmol) of NaHCO3 and 200 ml of toluene were heated under reflux in an inert gas atmosphere for 18 hours. The reaction solution was washed with 400 ml of water, and the aqueous phase was back-extracted with 300 ml of toluene. After the solvent had been distilled out of the combined organic phases in vacuo, the crude product was filtered through a column of 300 g of silica gel (disporpyl ether/cyclohexane, 1:1).

Yield: 12.5 g (79 mmol, 61%)

30 $MW = 158.20 \text{ g/mol } (C_8H_{14}O_3)$

 $R_f = 0.44$ (diisopropyl ether)

Analysis: C H
Calculated 60.74 8.92
Found 60.66 8.92

35 $^{1}\text{H-NMR}$ (300 MHz, CDCl₃): δ = 1.30-1.41 (m, 2H, 4-CH₂), 1.57-1.68 (m, 4H, CH₂CH₂CH₀, CH₂CH₂O), 2.00 (s, 3H, OOCCH₃), 2.42 (dt, $^{3}\text{J}_{2,1}$ = 1.6 Hz, $^{3}\text{J}_{2,3}$ = 7.3 Hz, 2H,

15

20

25

30

 $CH_2CHO)$, 4.02 (t 3J = 6.6 Hz, 2H, CH_2O), 9.73 (t, 3J = 1.6 Hz, 1H, CHO)

IR (film): ν [cm⁻¹] = 2941 (s), 2865 (s), 2724 (m), 1736 (s), 1462 (m), 1389 (m), 1367 (s), 1241 (s), 1048 (s), 634 (m), 607 (m)

Example 3

The (Z)-alkenols and the monounsaturated (Z)-fatty acids are synthesized by stereoselective Wittig reaction of an ω -substituted aldehyde with an unsubstituted phosphonium salt and by reaction of an ω -substituted phosphonium salt with an unsubstituted aldehyde, respectively.

Unsubstituted aldehydes with a purity of more 97% are commercially available chemicals up to a chain length of 12 carbon atoms (dodecanal) and can be employed directly in the Wittig reaction. Longer-chain aldehydes can be obtained from purchasable fatty alcohols by Swern or Kornblum oxidation. Unsubstituted alkyl halides (mainly bromides and chlorides) are used to prepare simple phosphonium bromides, it being possible to purchase alkyl halides in a purity of more than 97%. Reference is made in example 1 and 2 to the synthesis of w-substitued Wittig precursors. The generation of ylide solutions from phosphonium iodides is simpler because the deprotonation starts even at relatively low temperatures, and there is thus no need to heat the reaction mixture. The fatty acids can in some cases be obtained in good purity without chromatographic purification by precipitating their potassium salts.

20

25

30

Nervonic acid synthesis

Unsaturated fatty acids can be converted into the corresponding fatty alcohols using lithium aluminum hydride by processes described in the literature.

(Z)-Stereoselective Wittig reaction of an ω -substituted phosphonium bromide

(Z) -10-Docosen-1-ol

86.7 g (160 mmol) of [10-(acetoxy)decyl]triphenylphosphonium bromide were introduced into 400 ml of dry THF. Under argon atmosphere, 200 ml of sodium an bis(trimethylsilyl)amide (1M in THF) were injected into the reaction solution. Stirring (glass stirrer) at room temperature for 30 minutes was followed by heating under reflux for one hour. The ylide solution was then cooled firstly to 10°C and then to -78°C and, after stirring at this temperature for 30 minutes. 30.0 g (163 mmol) of lauraldehyde in 50 ml of THF were slowly added dropwise. The mixture was stirred for a further 30 minutes and then allowed to warm to room temperature overnight.

Workup

The reaction mixture was mixed with 600 ml of water and 200 ml of diethyl ether, the phases were separated, and the solvent was removed from the organic phase in vacuo. For the hydrolysis, a solution of 25 g of

potassium hydroxide in 10 ml of water/200 ml of methanol was added, and the mixture was stirred at 60°C for 20 minutes. The reaction solution was mixed with 600 ml of water and extracted with 300 ml of diethyl ether. After the organic phase had been washed with 500 ml of saturated NaHCO₃ solution and 500 ml of water, the solvent was distilled off in vacuo. The crude product was purified by column chromatography (cyclohexane/diisopropyl ether: gradual increase in the polarity from 19:1 to 1:1) on 550 g of silica gel. The compound was precipitated from acetone at -20°C. Drying in a desiccator for several days resulted in 26.8 g (82.6 mmol, 52%) of the long-chain fatty alcohol.

 $MW (C_{22}H_{44}O) = 324.59 \text{ g/mol}$

Analysis: C H
Calculated 81.41 13.66
Found 81.56 13.72

25

20

10

15

Stereoselective Witting reaction of an ω -substituted phosphonium iodide

(Z)-15-Tetracosenoic acid (nervonic acid)

197.4 g (300 mmol) of the appropriate phosphonium salt
30 were introduced into 1100 ml of dry THF under an inert
gas atmosphere. After cooling to -78°C, 360 ml of
sodium bis(trimethylsilyl)amide (1M in THF) were slowly
added dropwise to the reaction solution while stirring
(glass stirrer). After stirring at this temperature for
35 30 minutes, a solution of 47.0 g (330 mmol) of
pelargonaldehyde in 50 ml of THF was added dropwise
over a period of 40 minutes; after stirring vigorously

for 30 minutes, the mixture was allowed to warm to room temperature overnight.

Workup

- 50 ml of water were added to the reaction mixture, and then the solvent was removed in vacuo. A solution of 25 g of potassium hydroxide in 10 ml of water/200 ml of methanol was added, and the reaction solution was stirred at 60°C for 20 minutes. Azeotropic drying was then carried out with addition of toluene 10 distillation in vacuo. The residue was heated with 1.5 l of acetone while stirring vigorously at 60°C for 10 minutes. The potassium salt which precipitated during this was filtered off with suction and washed several times with acetone. The product was dissolved 15 off the filter using a solution of 600 ml of THF/150 ml of concentrated hydrochloric acid. The resulting twophase mixture was mixed with 500 ml of diisopropyl ether and the phases were separated. The organic phase was washed three times with 500 ml of water each time 20 and dried over sodium sulfate, and the solvent was distilled off in vacuo.
- The crude product was purified by column chromatography
 on 1100 g of silica gel. The apolar impurity was eluted
 first with cyclohexane/diisopropyl ether (19:1).
 Chromatography with cyclohexane/diisopropyl ether (1:1)
 afforded the product.
- 30 The acid was dissolved in acetone with heating, and crystallized at -20°C. In the dry state, 52.5 g (142 mmol, 48%) of fatty acid were obtained as a white crystalline powder.

 $MW = 366.63 \text{ g/mol} (C_{24}H_{46}O_2)$

35 Analysis: C H
Calculated 78.63 12.65
Found 78.77 12.52
Melting point: 41.1°C (Lit. 42-43°C)

It is also possible to prepare monounsaturated (Z)-alkenols and (Z)-fatty acids by reacting ω -substituted aldehydes with saturated phosphonium salts by the processes described above.

Terminally unsaturated alkadienecarboxylic acids are obtained by (Z)-selective Wittig reaction of a terminally unsaturated aldehyde with an ω -substituted phosphonium salt (for example 10-undecenal).

Example 4

Reaction of α, ω -dibromoalkanes at both ends with triphenylphosphane results in α, ω -bis(triphenylphosphonio)alkane dibromides. After conversion into the bisphosphorane, stereospecific conversion into an olefin takes place under salt-free conditions with a solution of a substituted and an unsubstituted aldehyde. Alkaline hydrolysis of the resulting ester affords, depending on the aldehyde used, (Z,Z)-alkadienols or (Z,Z)-fatty acids.

25 Lithium salt-free crossed Wittig reaction of a bisphosphonium salt with an unsubstituted and with an

20

25

30

35

ω-substituted aldehyde: synthesis of (Z,Z)-10,16docosadien-1-ol

Synthesis of an α, ω -bis(triphenylphosphonio)alkane dibromide

1.6-Bis(triphenylphosphonio)hexane dibromide (62)

122.2 g (0.50 mol) of 1,6-dibromohexane were dissolved together with 341.7 g (1.30 mol) of triphenylphosphane in 1500 ml of DMF. The reaction mixture was heated under reflux with stirring (glass stirrer) for 4 hours. It was allowed to cool to room temperature. The product was filtered off with suction and washed with 2×250 ml of acetone and 200 ml of diethyl ether. Drying in vacuo for several days resulted in 336.5 g 15 (0.44 mol, 88%) of the crystalline bisphoshonium salt. $MW = 768.55 \text{ g/mol } (C_{42}H_{42}Br_2P_2)$

 $R_f = 0.26$ (chloroform/methanol, 9:1)

Analysis:	C	H	P
Calculated	66.64	5.51	8.06
Found	65.77	5.59	7.98

Crossed Wittig reaction

(Z,Z)-10,16-Docosadienoic acid

76.9 g (100 mmol) of 1,6-bis(triphenylphosphonio)hexane dibromide were suspended in 500 ml of THF. 240 ml (240 mmol) of sodium bis(trimethylsilyl)amide (1M in THF) were injected through a septum under an inert gas atmosphere. The ylide solution was stirred at room temperature for 30 minutes and then under reflux for 1 hour. After it had been cooled to -78°C, a solution of 21.5 g (100 mmol) of ethyl 9-formylnonanoate and 10.1 g (101 mmol) of caproaldehyde in 50 ml of THF was added dropwise over the course of 30 minutes. The mixture was stirred for a further 30 minutes and then allowed to warm to room temperature overnight.

50 ml of water were added to the reaction mixture, and then the solvent was removed in vacuo. A solution of

15

2.0

vacuo.

25 g of potassium hydroxide in 10 ml of water/200 ml of methanol were added, and the reaction solution was stirred at 60°C for 20 minutes. It was then dried azeotropically by addition of toluene and distillation in vacuo. The residue was heated with 1.5 l of acetone while stirring vigorously at 60°C for 10 minutes. The potassium salt which precipitated during this was filtered off with suction and washed several times with acetone. The product was dissolved off the filter using a solution of 600 ml of THF/150 ml of concentrated hydrochloric acid. The resulting two-phase mixture was mixed with 500 ml of diisopropyl ether, and the phases were separated. The organic phase was washed three times with 500 ml of water each time and dried over sodium sulfate, and the solvent was distilled off in

The crude product was purified by column chromatography (cyclohexane/diisopropyl ether; gradual increase in the polarity from 4:1 to 1:1) on 400 g of silica gel. 13.0 g (38.6 mmol, 39%) of the diunsaturated fatty acid were obtained.

 $MW = 336.56 \text{ g/mol } (C_{22}H_{40}O_2)$

 $R_f = 0.35$ (cyclohexane/diisopropyl ether, 1:1)

25 Analysis: C H
Calculated 78.51 11.98
Found 78.30 11.92

 $^{1}\text{H-NMR}$ (300 MHz, CDCl₃): δ = 0.89 (t, ^{3}J = 6.8 Hz, 3H, $^{-}\text{CH}_{3}$), 1.30-1.43 (m, 20H, 10 × CH₂), 1.63 (mc, 2H, CH₃COOH), 2.03 (bs, 8H, allyl-H), 2.35 (t,

30 $CH_2CH_2COOH)$, 2.03 (bs, 8H, ally1-H), 2.35 ($^3J = 7.5 \text{ Hz}$, 2H, $CH_2COOH)$, 5.34 (mc, 4H, -CH=CH-cis)

Example 5

Comparison of the known antitumor active ingredient erucylphosphocholine with active ingredients of the invention

5

Comparison of a compound not of the invention (erucylphosphocholine) with two active ingredients of the invention is shown in Table 1.

10

15

Table 1

Alkylphosphocholine	Weekly dose	T/C [%]*
	[µmol/kg]	
Erucylphosphocholine (data	90	31
taken from Kaufmann-Kolle et	180	6
al. 1996)	360	< 0.1
(Z)-10-Docosenyl-1-PC	42	9
	170	0.5
	256	0.2
(Z)-11,21-Docosadienyl-1-PC	42	8
	170	2

Table 1: * Quotient of the median tumor volume in the treated and the control group \times 100. Evaluation after therapy for 5 weeks.

After the lack of activity of a (Z,Z)-alkadienylphosphocholine with methylene-interrupted double bonds and based on the C₁₈ chain had been demonstrated, it was possible to restore the activity of the class of substances by extending the alkadienyl chain and isolating the double bonds more markedly from one another (table 2).

- 38 -

Table 2

Unsaturated alkylphosphocholine	Dose [µmol/kg]	Median tumor volume [cm³]	
arity ipinop		End of	2 weeks
		therapy	later
(Z)-12-Heneicosenyl-	42	3.4	4.5
1-phosphocholine	84	0.3	1.2
T Production	170	0.1	0.1
	256	0.2	0.8
(Z)-10-Docosenyl-1-	42	4.0	4.5
phosphocholine	84	1.2	3.4
(double bond in	170	0.2	0.2
ω-12 position)	256	0.1	0.2
(Z)-16-Docosenyl-1-	42	26.9	
phosphocholine	84	2.5	7.6
(double bond in	170	0.2	0.4
ω-6 position)			
(Z,Z)-6,12-Eicosadi-	42	10	13.9
enyl-1-PC	84	3.2	13.9
	170	0.4	1.9
	256	0	0
(Z)-11,21-Docosa-	42	1.5	2.5
dienyl-1-PC	84	0.9	2.9
1	170	0.4	0.5
(Z,Z)-10,16-Docosa-	42	7.5	11.4
dienyl-1-PC	84	0.6	0.6
•	170	0.5	0.7

Example 6: Exemplary compounds

The Rf values of the exemplary compounds were determined in the system $CHCl_3/CH_3OH/glacial$ acetic acid/ H_2O : 100/60/20/5 (proportions by volume). They are grouped very closely together, specifically as follows:

Rf	Compounds Nos.
0.10-0.15	1454-1496
0.15-0.20	1399 - 1453; 1543 - 1555
0.20-0.25	1320 - 1398; 1523 - 1542; 1752-1812
0.25-0.30	1497 - 1522; 1691 - 1751
0.30-0.35	1083 - 1319; 1556 - 1568; 1630 - 1690
0.35-0.40	1569 - 1629
0.40-0.45	1813 - 1839
0.30-0.40	1 - 1082

Examples of (Z)-alkenylphosphocholines

$$(A = VIII; n = 2; R_3, CH_3; m = 1, x = 1, z = 0)$$

$$A - PO_3 - \left[(CH_2)_n - N_1 \atop R_3 \right]_m - (CH_2)_x - \left[CH_2 - \left(CH_1 \atop OH_1 \right)_y - CH_2 - O \right]_z - H$$

where A is a monounsaturated alkyl chain of the following structure (p, $q \ge 0$; $12 \le p+q \le 30$):

$$A = 0 (CH2)p (CH2)qH$$

formula VIII

16 chain carbon atoms

C₂₁H₄₄NO₄P (405.56)

- 1. (Z)-3-hexadecenyl-1-phosphocholine
- 2. (Z)-4-hexadecenyl-1-phosphocholine
- 3. (Z)-5-hexadecenyl-1-phosphocholine
- 4. (Z)-6-hexadecenyl-1-phosphocholine
- 5. (Z)-8-hexadecenyl-1-phosphocholine
- 6. (Z)-9-hexadecenyl-1-phosphocholine

- 7. (Z)-10-hexadecenyl-1-phosphocholine
- 8. (Z)-11-hexadecenyl-1-phosphocholine
- (Z) -12-hexadecenyl-1-phosphocholine 9.
- 10. (Z)-13-hexadecenyl-1-phosphocholine
- (Z) -14-hexadecenyl-1-phosphocholine 11.
- 12. 15-hexadecenyl-1-phosphocholine

C22H46NO4P (419.59)

- (Z) -3-heptadecenyl-1-phosphocholine 13.
- 14. (Z)-4-heptadecenyl-1-phosphocholine
- 15. (Z)-5-heptadecenvl-1-phosphocholine
- (Z)-6-heptadecenyl-1-phosphocholine 16.
- (Z)-7-heptadecenyl-1-phosphocholine 17.
- (Z)-8-heptadecenyl-1-phosphocholine 18.
- (Z) -9-heptadecenyl-1-phosphocholine 19.
- 20. (Z)-10-heptadecenyl-1-phosphocholine
- (Z)-11-heptadecenvl-1-phosphocholine 21. (Z)-12-heptadecenvl-1-phosphocholine
- 22.
- (Z) -13-heptadecenyl-1-phosphocholine 23.
- (Z)-14-heptadecenyl-1-phosphocholine 25. (Z)-15-heptadecenyl-1-phosphocholine
- 16-heptadecenyl-1-phosphocholine 26.

18 chain carbon atoms

C23H48NO4P (433.61)

24.

- 27. (Z)-3-octadecenvl-1-phosphocholine
- (Z)-4-octadecenyl-1-phosphocholine 28.
- (Z)-5-octadecenyl-1-phosphocholine 29.
- 30. (Z)-6-octadecenyl-1-phosphocholine
- 31. (Z)-7-octadecenyl-1-phosphocholine
- (Z) -8-octadecenyl-1-phosphocholine 32.
- (Z)-10-octadecenvl-1-phosphocholine 33.
- (Z)-11-octadecenvl-1-phosphocholine 34.

- 35. (Z)-12-octadecenyl-1-phosphocholine
- 36. (Z)-13-octadecenyl-1-phosphocholine
- 37. (Z)-14-octadecenyl-1-phosphocholine
- 38. (Z)-15-octadecenyl-1-phosphocholine
- 39. (Z)-16-octadecenyl-1-phosphocholine
- 40. 17-octadecenyl-1-phosphocholine

C24H50NO4P (447.64)

- 41. (Z)-3-nonadecenyl-1-phosphocholine
- 42. (Z)-4-nonadecenyl-1-phosphocholine
- 43. (Z)-5-nonadecenyl-1-phosphocholine
- 44. (Z)-6-nonadecenyl-1-phosphocholine
- 45. (Z)-7-nonadecenyl-1-phosphocholine
- 46. (Z)-8-nonadecenyl-1-phosphocholine
- 47. (Z)-9-nonadecenyl-1-phosphocholine
- 48. (Z)-10-nonadecenyl-1-phosphocholine
- 49. (Z)-11-nonadecenyl-1-phosphocholine
- 50. (Z)-12-nonadecenyl-1-phosphocholine
- 51. (Z)-13-nonadecenyl-1-phosphocholine
- 52. (Z)-14-nonadecenyl-1-phosphocholine
- 53. (Z)-15-nonadecenyl-1-phosphocholine
- 54. (Z)-16-nonadecenyl-1-phosphocholine
- 55. (Z)-17-nonadecenyl-1-phosphocholine
- 56. 18-nonadecenyl-1-phosphocholine

20 chain carbon atoms

C25H52NO4P (461.67)

- 57. (Z)-3-eicosenyl-1-phosphocholine
- 58. (Z)-4-eicosenyl-1-phosphocholine
- 59. (Z)-5-eicosenyl-1-phosphocholine
- 60. (Z)-6-eicosenyl-1-phosphocholine
- 61. (Z)-7-eicosenyl-1-phosphocholine
- 62. (Z) -8-eicosenyl-1-phosphocholine

- 63. (Z)-9-eicosenyl-1-phosphocholine
- 64. (Z)-10-eicosenyl-1-phosphocholine
- 65. (Z)-12-eicosenyl-1-phosphocholine
- 66. (Z)-13-eicosenyl-1-phosphocholine
- 67. (Z)-14-eicosenyl-1-phosphocholine
- 68. (Z)-15-eicosenyl-1-phosphocholine
- 69. (Z)-16-eicosenyl-1-phosphocholine
- 70. (Z)-17-eicosenvl-1-phosphocholine
- 71. (Z)-18-eicosenyl-1-phosphocholine
- 72. 19-eicosenyl-1-phosphocholine

C26H54NO4P (475.69)

77.

- 73. (Z)-3-heneicosenyl-1-phosphocholine
- 74. (Z)-4-heneicosenyl-1-phosphocholine
- 75. (Z) -5-heneicosenyl-1-phosphocholine
- 76. (Z)-6-heneicosenyl-1-phosphocholine
- 78. (Z)-8-heneicosenyl-1-phosphocholine

(Z)-7-heneicosenvl-1-phosphocholine

- 79. (Z)-9-heneicosenyl-1-phosphocholine
- 80. (Z)-10-heneicosenyl-1-phosphocholine
- 81. (Z)-11-heneicosenyl-1-phosphocholine
- 82. (Z)-12-heneicosenyl-1-phosphocholine
- 83. (Z)-13-heneicosenyl-1-phosphocholine
- 84. (Z)-14-heneicosenyl-1-phosphocholine
- 85. (Z)-15-heneicosenyl-1-phosphocholine
- 86. (Z)-16-heneicosenyl-1-phosphocholine
- 87. (Z)-17-heneicosenyl-1-phosphocholine
- 88. (Z)-18-heneicosenyl-1-phosphocholine
- 89. (Z)-19-heneicosenyl-1-phosphocholine
- 90. 20-heneicosenyl-1-phosphocholine

C27H56NO4P (489.72)

(Z) -3-docosenyl-1-phosphocholine 91. 92. (Z)-4-docosenyl-1-phosphocholine 93. (Z)-5-docosenyl-1-phosphocholine 94. (Z)-6-docosenyl-1-phosphocholine (Z)-7-docosenvl-1-phosphocholine 95. (Z)-8-docosenyl-1-phosphocholine 96 97. (Z)-9-docosenyl-1-phosphocholine 98. (Z)-10-docosenyl-1-phosphocholine (Z)-11-docosenvl-1-phosphocholine 99. 100. (Z)-12-docosenvl-1-phosphocholine 101. (Z) -14-docosenyl-1-phosphocholine 102. (Z)-15-docosenyl-1-phosphocholine 103. (Z)-16-docosenyl-1-phosphocholine 104. (Z)-17-docosenyl-1-phosphocholine 105. (Z)-18-docosenvl-1-phosphocholine 106. (Z)-19-docosenyl-1-phosphocholine 107. (Z)-20-docosenvl-1-phosphocholine

108. 21-docosenyl-1-phosphocholine

- 43 ~

23 chain carbon atoms

C28H58NO4P (503.75)

109. (Z)-3-tricosenyl-1-phosphocholine
110. (Z)-4-tricosenyl-1-phosphocholine
111. (Z)-5-tricosenyl-1-phosphocholine
112. (Z)-6-tricosenyl-1-phosphocholine
113. (Z)-7-tricosenyl-1-phosphocholine
114. (Z)-8-tricosenyl-1-phosphocholine
115. (Z)-9-tricosenyl-1-phosphocholine
116. (Z)-10-tricosenyl-1-phosphocholine
117. (Z)-11-tricosenyl-1-phosphocholine
118. (Z)-12-tricosenyl-1-phosphocholine

119. (Z)-13-tricosenyl-1-phosphocholine

- 120. (Z)-14-tricosenyl-1-phosphocholine
- 121. (Z) -15-tricosenyl-1-phosphocholine
- 122. (Z)-16-tricosenyl-1-phosphocholine
- 123. (Z) -17-tricosenyl-1-phosphocholine
- 124. (Z)-18-tricosenyl-1-phosphocholine
- 125. (Z)-19-tricosenyl-1-phosphocholine
- 126. (Z) -20-tricosenyl-1-phosphocholine
- 127. (Z) -21-tricosenyl-1-phosphocholine
- 128. 22-tricosenyl-1-phosphocholine

C29H60NO4P (517.77)


- 129. (Z)-3-tetracosenyl-1-phosphocholine
- 130. (Z)-4-tetracosenyl-1-phosphocholine
- 131. (Z)-5-tetracosenyl-1-phosphocholine
- 132 (Z)-6-tetracosenyl-1-phosphocholine
- 133. (Z)-7-tetracosenyl-1-phosphocholine 134. (Z)-8-tetracosenyl-1-phosphocholine
- 135. (Z)-9-tetracosenyl-1-phosphocholine
- 136. (Z)-10-tetracosenyl-1-phosphocholine
- 137. (Z)-11-tetracosenyl-1-phosphocholine
- 138. (Z)-12-tetracosenyl-1-phosphocholine
- 139. (Z)-13-tetracosenyl-1-phosphocholine
- 140. (Z)-14-tetracosenvl-1-phosphocholine
- 141. (Z) -16-tetracosenyl-1-phosphocholine
- 142. (Z) -17-tetracosenyl-1-phosphocholine
- 143. (Z)-18-tetracosenyl-1-phosphocholine

Examples of (Z)-alkenyl-1-phospho-N,N,N-trimethylpropylammonium compounds

$$(A = VIII; n = 3; R_3, CH_3; m = 1, x = 1; z = 0)$$

$$A - PO_3 - \left[(CH_2)_n - N^+ \atop R_3 \right]_m - (CH_2)_x - \left[CH_2 - \left(\begin{matrix} CH \\ OH \end{matrix} \right)_y - CH_2 - O \right]_z - H_z$$

where A is a monounsaturated alkyl chain of the following structure (p,q \geq 0; 12 \leq p+q \leq 30):



formula VIII

16 chain carbon atoms

C22H46NO4P (419.59)

- 144. (Z)-3-hexadecenyl-1-phospho-N,N,N-trimethylpropylammonium
- 145. (Z)-4-hexadecenyl-1-phospho-N,N,N-trimethylpropylammonium
- 146. (Z)-5-hexadecenyl-1-phospho-N,N,N-trimethylpropylammonium
- 147. (Z)-6-hexadecenyl-1-phospho-N,N,N-trimethylpropylammonium
- 148. (Z)-7-hexadecenyl-1-phospho-N,N,N-trimethylpropyl-ammonium
- 149. (Z)-8-hexadecenyl-1-phospho-N,N,N-trimethylpropylammonium
- 150. (Z)-9-hexadecenyl-1-phospho-N,N,N-trimethylpropylammonium
- 151. (Z)-10-hexadecenyl-1-phospho-N,N,N-trimethylpropylammonium
- 152. (Z)-11-hexadecenyl-1-phospho-N,N,N-trimethyl-propylammonium
- 153. (Z)-12-hexadecenyl-1-phospho-N,N,N-trimethylpropylammonium
- 154. (Z)-13-hexadecenyl-1-phospho-N,N,N-trimethylpropylammonium
- 155. (Z)-14-hexadecenyl-1-phospho-N,N,N-trimethylpropylammonium
- 156. 15-hexadecenyl-1-phospho-N,N,N-trimethylpropylammonium

H fred lines ford wells

13

17 chain carbon atoms

C23H48NO4P (433.61)

- 157. (Z)-3-heptadecenyl-1-phospho-N,N,N-trimethylpropylammonium
- 158. (Z)-4-heptadecenyl-1-phospho-N,N,N-trimethyl-propylammonium
- 159. (Z)-5-heptadecenyl-1-phospho-N,N,N-trimethylpropylammonium
- 160. (Z)-6-heptadecenyl-1-phospho-N,N,N-trimethylpropylammonium
- 161. (Z)-7-heptadecenyl-1-phospho-N,N,N-trimethyl-propylammonium
- 162. (Z)-8-heptadecenyl-1-phospho-N,N,N-trimethylpropylammonium
- 163. (Z)-9-heptadecenyl-1-phospho-N,N,N-trimethylpropylammonium
- 164. (Z)-10-heptadecenyl-1-phospho-N,N,N-trimethyl-propylammonium
- 165. (Z)-11-heptadecenyl-1-phospho-N,N,N-trimethylpropvlammonium
- 166. (Z)-12-heptadecenyl-1-phospho-N,N,N-trimethylpropylammonium
- 167. (Z) -13-heptadecenyl-1-phospho-N,N,N-trimethyl-propylammonium
- 168. (Z)-14-heptadecenyl-1-phospho-N,N,N-trimethylpropylammonium
- 169. (Z)-15-heptadecenyl-1-phospho-N,N,N-trimethylpropylammonium
- 170. 16-heptadecenyl-1-phospho-N,N,N-trimethyl-propylammonium

M. The Print State of the State of

- 47 -

18 chain carbon atoms

C24H50NO4P (447.64)

- 171. (Z)-3-octadecenyl-1-phospho-N,N,N-trimethylpropylammonium
- 172. (Z)-4-octadecenyl-1-phospho-N,N,N-trimethylpropylammonium
- 173. (Z)-5-octadecenyl-1-phospho-N,N,N-trimethyl-propylammonium
- 174. (Z)-6-octadecenyl-1-phospho-N,N,N-trimethylpropylammonium
- 175. (Z)-7-octadecenyl-1-phospho-N,N,N-trimethylpropylammonium
- 176. (Z)-8-octadecenyl-1-phospho-N,N,N-trimethylpropylammonium
- 177. (Z)-10-octadecenyl-1-phospho-N,N,N-trimethyl-propylammonium
- 178. (Z)-11-octadecenyl-1-phospho-N,N,N-trimethyl-propylammonium
- 179. (Z)-12-octadecenyl-1-phospho-N,N,N-trimethyl-propylammonium
- 180. (Z)-13-octadecenyl-1-phospho-N,N,N-trimethylpropylammonium
- 181. (Z)-14-octadecenyl-1-phospho-N,N,N-trimethylpropylammonium
- 182. (Z)-15-octadecenyl-1-phospho-N,N,N-trimethylpropylammonium
- 183. (Z)-16-octadecenyl-1-phospho-N,N,N-trimethylpropylammonium
- 184. 17-octadecenyl-1-phospho-N,N,N-trimethyl-propylammonium

- 48 -

19 chain carbon atoms

C25H52NO4P (461.67)

ammonium

- 185. (Z)-3-nonadecenyl-1-phospho-N,N,N-trimethylpropylammonium
- 186. (Z)-4-nonadecenyl-1-phospho-N,N,N-trimethylpropylammonium
- 187. (Z) -5-nonadecenyl-1-phospho-N,N,N-trimethylpropylammonium
- 188. (Z)-6-nonadecenyl-1-phospho-N,N,N-trimethylpropylammonium
- 189. (Z) -7-nonadecenyl-1-phospho-N,N,N-trimethylpropylammonium
- 190. (Z)-8-nonadecenyl-1-phospho-N,N,N-trimethylpropyl-
- 191. (Z)-9-nonadecenyl-1-phospho-N,N,N-trimethylpropylammonium
- 192. (Z)-10-nonadecenyl-1-phospho-N,N,N-trimethylpropylammonium
- 193. (Z)-11-nonadecenyl-1-phospho-N,N,N-trimethylpropylammonium
- 194. (Z)-12-nonadecenyl-1-phospho-N,N,N-trimethylpropylammonium
- 195. (Z)-13-nonadecenyl-1-phospho-N,N,N-trimethylpropylammonium
- 196. (Z)-14-nonadecenyl-1-phospho-N,N,N-trimethylpropylammonium
- 197. (Z)-15-nonadecenyl-1-phospho-N,N,N-trimethylpropylammonium
- 198. (Z)-16-nonadecenyl-1-phospho-N,N,N-trimethylpropylammonium
- 199. (Z)-17-nonadecenyl-1-phospho-N,N,N-trimethylpropylammonium
- 200. 18-nonadecenyl-1-phospho-N,N,N-trimethylpropylammonium

- 49 -

20 chain carbon atoms

C26H54NO4P (475.69)

- 201. (Z)-3-eicosenyl-1-phospho-N,N,N-trimethylpropylammonium
- 202. (Z) -4-eicosenyl-1-phospho-N,N,N-trimethylpropylammonium
- 203. (Z)-5-eicosenyl-1-phospho-N,N,N-trimethylpropylammonium
- 204. (Z)-6-eicosenyl-1-phospho-N,N,N-trimethylpropylammonium
- 205. (Z)-7-eicosenyl-1-phospho-N,N,N-trimethylpropylammonium
- 206. (Z)-8-eicosenyl-1-phospho-N,N,N-trimethylpropylammonium
- 207. (Z)-9-eicosenyl-1-phospho-N,N,N-trimethylpropylammonium
- 208. (Z)-10-eicosenyl-1-phospho-N,N,N-trimethylpropylammonium
- 209. (Z)-12-eicosenyl-1-phospho-N,N,N-trimethylpropylammonium
- 210. (Z)-13-eicosenyl-1-phospho-N,N,N-trimethylpropylammonium
- 211. (Z)-14-eicosenyl-1-phospho-N,N,N-trimethylpropylammonium
- 212. (Z)-15-eicosenyl-1-phospho-N,N,N-trimethylpropyl-ammonium
- 213. (Z)-16-eicosenyl-1-phospho-N,N,N-trimethylpropylammonium
- 214. (Z)-17-eicosenyl-1-phospho-N,N,N-trimethylpropylammonium
- 215. (Z)-18-eicosenyl-1-phospho-N,N,N-trimethylpropylammonium
- 216. 19-eicosenyl-1-phospho-N,N,N-trimethylpropylammonium

- 50 -

21 chain carbon atoms

C27H56NO4P (489.72)

- 217. (Z)-3-heneicosenyl-1-phospho-N,N,N-trimethylpropylammonium
- 218. (Z)-4-heneicosenyl-1-phospho-N,N,N-trimethylpropylammonium
- 219. (Z)-5-heneicosenyl-1-phospho-N,N,N-trimethylpropylammonium
- 220. (Z)-6-heneicosenyl-1-phospho-N,N,N-trimethylpropylammonium
- 221. (Z)-7-heneicosenyl-1-phospho-N,N,N-trimethylpropylammonium
- 222. (Z)-8-heneicosenyl-1-phospho-N,N,N-trimethylpropylammonium
- 223. (Z)-9-heneicosenyl-1-phospho-N,N,N-trimethylpropylammonium
- 224. (Z)-10-heneicosenyl-1-phospho-N,N,N-trimethylpropylammonium
- 225. (Z)-11-heneicosenyl-1-phospho-N,N,N-trimethylpropylammonium
- 226. (Z)-12-heneicosenyl-1-phospho-N,N,N-trimethyl-propylammonium
- 227. (Z)-13-heneicosenyl-1-phospho-N,N,N-trimethylpropylammonium
- 228. (Z)-14-heneicosenyl-1-phospho-N,N,N-trimethylpropylammonium
- 229. (Z)-15-heneicosenyl-1-phospho-N,N,N-trimethylpropylammonium
- 230. (Z)-16-heneicosenyl-1-phospho-N,N,N-trimethylpropylammonium
- 231. (Z)-17-heneicosenyl-1-phospho-N,N,N-trimethylpropylammonium
- 232. (Z)-18-heneicosenyl-1-phospho-N,N,N-trimethyl-propylammonium
- 233. (Z)-19-heneicosenyl-1-phospho-N,N,N-trimethylpropylammonium

234. 20-heneicosenyl-1-phospho-N,N,N-trimethylpropylammonium

22 chain carbon atoms

C28H58NO4P (503.75)

- 235. (Z)-3-docosenyl-1-phospho-N,N,N-trimethylpropyl-
- 236. (Z)-4-docosenyl-1-phospho-N,N,N-trimethylpropylammonium
- 237. (Z)-5-docosenyl-1-phospho-N,N,N-trimethylpropylammonium
- 238. (Z)-6-docosenyl-1-phospho-N,N,N-trimethylpropylammonium
- 239. (Z)-7-docosenyl-1-phospho-N,N,N-trimethylpropyl-ammonium
- 240. (Z)-8-docosenyl-1-phospho-N,N,N-trimethylpropyl-ammonium
- 241. (Z)-9-docosenyl-1-phospho-N,N,N-trimethylpropyl-ammonium
- 242. (Z) -10-docosenyl-1-phospho-N,N,N-trimethylpropylammonium
- 243. (Z)-11-docosenyl-1-phospho-N,N,N-trimethylpropylammonium
- 244. (Z)-12-docosenyl-1-phospho-N,N,N-trimethylpropyl-ammonium
- 245. (Z)-14-docosenyl-1-phospho-N,N,N-trimethylpropylammonium
- 246. (Z)-15-docosenyl-1-phospho-N,N,N-trimethylpropylammonium
- 247. (Z)-16-docosenyl-1-phospho-N,N,N-trimethylpropylammonium
- 248. (Z) -17-docosenyl-1-phospho-N,N,N-trimethylpropylammonium
- 249. (Z) -18-docosenyl-1-phospho-N,N,N-trimethylpropylammonium

- 250. (Z)-19-docosenyl-1-phospho-N,N,N-trimethylpropylammonium
- 251. (Z)-20-docosenyl-1-phospho-N,N,N-trimethylpropylammonium
- 252. 21-docosenyl-1-phospho-N,N,N-trimethylpropyl-ammonium

C29H60NO4P (517.77)

- 253. (Z)-3-tricosenyl-1-phospho-N,N,N-trimethylpropyl-ammonium
- 254. (Z)-4-tricosenyl-1-phospho-N,N,N-trimethylpropyl-ammonium
- 255. (Z)-5-tricosenyl-1-phospho-N,N,N-trimethylpropylammonium
- 256. (Z)-6-tricosenyl-1-phospho-N,N,N-trimethylpropyl-ammonium
- 257. (Z)-7-tricosenyl-1-phospho-N,N,N-trimethylpropyl-ammonium
- 258. (Z)-8-tricosenyl-1-phospho-N,N,N-trimethylpropyl-ammonium
- 259. (Z)-9-tricosenyl-1-phospho-N,N,N-trimethylpropyl-ammonium
- 260. (Z)-10-tricosenyl-1-phospho-N,N,N-trimethylpropyl-ammonium
- 261. (Z)-11-tricosenyl-1-phospho-N,N,N-trimethylpropylammonium
- 262. (Z)-12-tricosenyl-1-phospho-N,N,N-trimethylpropyl-ammonium
- 263. (Z)-13-tricosenyl-1-phospho-N,N,N-trimethylpropylammonium
- 264. (Z)-14-tricosenyl-1-phospho-N,N,N-trimethylpropyl-ammonium
- 265. (Z)-15-tricosenyl-1-phospho-N,N,N-trimethylpropylammonium

- 266. (Z)-16-tricosenyl-1-phospho-N,N,N-trimethylpropylammonium
- 267. (Z) -17-tricosenyl-1-phospho-N,N,N-trimethylpropylammonjum
- 268. (Z)-18-tricosenyl-1-phospho-N,N,N-trimethylpropyl-
- 269. (Z)-19-tricosenyl-1-phospho-N,N,N-trimethylpropylammonium
- 270. (Z)-20-tricosenyl-1-phospho-N,N,N-trimethylpropylammonium
- 271. (Z)-21-tricosenyl-1-phospho-N,N,N-trimethylpropylammonium
- 272. 22-tricosenyl-1-phospho-N,N,N-trimethylpropylammonium

C30H62NO4P (531.80)

- 273. (Z)-3-tetracosenyl-1-phospho-N,N,N-trimethylpropylammonium
- 274. (Z)-4-tetracosenyl-1-phospho-N,N,N-trimethylpropylammonium
- 275. (Z) -5-tetracosenyl-1-phospho-N,N,N-trimethylpropylammonium
- 276. (Z)-6-tetracosenyl-1-phospho-N,N,N-trimethylpropylammonium
- 277. (Z) -7-tetracosenyl-1-phospho-N,N,N-trimethylpropylammonium
- 278. (Z)-8-tetracosenyl-1-phospho-N,N,N-trimethylpropylammonium
- 279. (Z)-9-tetracosenyl-1-phospho-N,N,N-trimethylpropylammonium
- 280. (Z)-10-tetracosenyl-1-phospho-N,N,N-trimethylpropylammonium
- 281. (Z) -11-tetracosenyl-1-phospho-N,N,N-trimethylpropylammonium

- 282. (Z)-12-tetracosenyl-1-phospho-N,N,N-trimethylpropylammonium
- 283. (Z)-13-tetracosenyl-1-phospho-N,N,N-trimethyl-propylammonium
- 284. (Z)-14-tetracosenyl-1-phospho-N,N,N-trimethylpropylammonium
- 285. (Z)-15-tetracosenyl-1-phospho-N,N,N-trimethylpropylammonium
- 286. (Z)-16-tetracosenyl-1-phospho-N,N,N-trimethylpropylammonium
- 287. (Z)-17-tetracosenyl-1-phospho-N,N,N-trimethylpropylammonium
- 288. (Z)-18-tetracosenyl-1-phospho-N,N,N-trimethylpropylammonium

3. Examples of (Z)-alkenyl-1-phospho-N,N,N-trimethylbutylammonium compounds

 $(A = VIII; n = 4; R_3, CH_3; m = 1, x = 1; z = 0)$

$$A-PO_3 - \left[(CH_2)_n - \stackrel{CH_3}{\stackrel{\bullet}{\mathbb{R}}_3} \right]_m - (CH_2)_{\chi} - \left[CH_2 - \left(\stackrel{CH}{OH} \right)_y - CH_2 - O \right]_z - H$$

where A is a monounsaturated alkyl chain of the following structure (p,q \geq 0; 12 \leq p+q \leq 30):

$$A = O (CH_2)_p (CH_2)_qH$$

formula VIII

16 chain carbon atoms

C23H48NO4P (433.61)

- 289. (Z)-3-hexadecenyl-1-phospho-N,N,N-trimethylbutylammonium
- 290. (Z)-4-hexadecenyl-1-phospho-N,N,N-trimethylbutyl-ammonium

- 291. (Z)-5-hexadecenyl-1-phospho-N,N,N-trimethylbutyl-ammonium
- 292. (Z)-6-hexadecenyl-1-phospho-N,N,N-trimethylbutyl-ammonium
- 293. (Z)-7-hexadecenyl-1-phospho-N,N,N-trimethylbutylammonium
- 294. (Z)-8-hexadecenyl-1-phospho-N,N,N-trimethylbutylammonium
- 295. (Z)-9-hexadecenyl-1-phospho-N,N,N-trimethylbutyl-ammonium
- 296. (Z)-10-hexadecenyl-1-phospho-N,N,N-trimethylbutylammonium
- 297. (Z)-11-hexadecenyl-1-phospho-N,N,N-trimethylbutylammonium
- 298. (Z)-12-hexadecenyl-1-phospho-N,N,N-trimethylbutyl-ammonium
- 299. (Z)-13-hexadecenyl-1-phospho-N,N,N-trimethylbutyl-ammonium
- 300. (Z)-14-hexadecenyl-1-phospho-N,N,N-trimethylbutyl-
- 301. 15-hexadecenyl-1-phospho-N,N,N-trimethylbutylammonium

C24H50NO4P (447.64)

- 302. (Z)-3-heptadecenyl-1-phospho-N,N,N-trimethylbutylammonium
- 303. (Z)-4-heptadecenyl-1-phospho-N,N,N-trimethylbutyl-ammonium
- 304. (Z)-5-heptadecenyl-1-phospho-N,N,N-trimethylbutylammonium
- 305. (Z) -6-heptadecenyl-1-phospho-N,N,N-trimethylbutylammonium
- 306. (Z)-7-heptadecenyl-1-phospho-N,N,N-trimethylbutyl-

- 56 -307. (Z)-8-heptadecenyl-1-phospho-N,N,N-trimethylbutylammonium
- 308. (Z)-9-heptadecenyl-1-phospho-N,N,N-trimethylbutylammonium
- 309. (Z)-10-heptadecenyl-1-phospho-N,N,Ntrimethylbutylammonium
- 310. (Z)-11-heptadecenyl-1-phospho-N,N,Ntrimethylbutylammonium
- 311. (Z)-12-heptadecenyl-1-phospho-N,N,Ntrimethylbutylammonium
- 312. (Z)-13-heptadecenyl-1-phospho-N,N,Ntrimethylbutylammonium
- 313. (Z)-14-heptadecenyl-1-phospho-N,N,Ntrimethylbutylammonium
- 314. (Z)-15-heptadecenyl-1-phospho-N,N,Ntrimethylbutylammonium
- 315. 16-heptadecenyl-1-phospho-N,N,N-trimethylbutylammonium

C25H52NO4P (461.67)

- 316. (Z)-3-octadecenyl-1-phospho-N,N,N-trimethylbutylammonium
- 317. (Z)-4-octadecenyl-1-phospho-N,N,N-trimethylbutylammonium
- 318. (Z)-5-octadecenyl-1-phospho-N,N,N-trimethylbutylammonium
- 319. (Z)-6-octadecenyl-1-phospho-N,N,N-trimethylbutylammonium
- 320. (Z)-7-octadecenyl-1-phospho-N,N,N-trimethylbutylammonium
- 321. (Z)-8-octadecenyl-1-phospho-N,N,N-trimethylbutylammonium
- 322. (Z)-10-octadecenyl-1-phospho-N,N,N-trimethylbutylammonium

- 323. (Z)-11-octadecenyl-1-phospho-N,N,N-trimethylbutylammonium
- 324. (Z)-12-octadecenyl-1-phospho-N,N,N-trimethylbutylammonium
- 325. (Z) -13-octadecenyl-1-phospho-N,N,N-trimethylbutyl-
- 326. (Z)-14-octadecenyl-1-phospho-N,N,N-trimethylbutyl-ammonium
- 327. (Z) -15-octadecenyl-1-phospho-N,N,N-trimethylbutylammonium
- 328. (Z) -16-octadecenyl-1-phospho-N,N,N-trimethylbutyl-
- 329. 17-octadecenyl-1-phospho-N,N,N-trimethylbutyl-ammonium

C26H54NO4P (475.69)

- 330. (Z)-3-nonadecenyl-1-phospho-N,N,N-trimethylbutyl-
- 331. (Z)-4-nonadecenyl-1-phospho-N,N,N-trimethylbutylammonium
- 332. (Z)-5-nonadecenyl-1-phospho-N,N,N-trimethylbutylammonium
- 333. (Z)-6-nonadecenyl-1-phospho-N,N,N-trimethylbutyl-ammonium
- 334. (Z)-7-nonadecenyl-1-phospho-N,N,N-trimethylbutyl-
- 335. (Z) -8-nonadecenyl-1-phospho-N,N,N-trimethylbutylammonium
- 336. (Z)-9-nonadecenyl-1-phospho-N,N,N-trimethylbutylammonium
- 337. (Z)-10-nonadecenyl-1-phospho-N,N,N-trimethylbutylammonium
- 338. (Z)-11-nonadecenyl-1-phospho-N,N,N-trimethylbutyl- ammonium

- 339. (Z) -12-nonadecenyl-1-phospho-N,N,N-trimethylbutyl-ammonium
- 340. (Z) -13-nonadecenyl-1-phospho-N,N,N-trimethylbutyl-
- 341. (Z)-14-nonadecenyl-1-phospho-N,N,N-trimethylbutylammonium
- 342. (Z)-15-nonadecenyl-1-phospho-N,N,N-trimethylbutyl-ammonium
- 343. (Z)-16-nonadecenyl-1-phospho-N,N,N-trimethylbutyl-
- 344. (Z)-17-nonadecenyl-1-phospho-N,N,N-trimethylbutylammonium
- 345. 18-nonadecenyl-1-phospho-N,N,N-trimethylbutylammonium

C₂₇H₅₆NO₄P (489.72)

- 346. (Z)-3-eicosenyl-1-phospho-N,N,N-trimethylbutylammonium
- 347. (Z)-4-eicosenyl-1-phospho-N,N,N-trimethylbutyl-ammonium
- 348. (Z)-5-eicosenyl-1-phospho-N,N,N-trimethylbutyl-
- 349. (Z)-6-eicosenyl-1-phospho-N,N,N-trimethylbutylammonium
- 350. (Z)-7-eicosenyl-1-phospho-N,N,N-trimethylbutyl-ammonium
- 351. (Z)-8-eicosenyl-1-phospho-N,N,N-trimethylbutylammonium
- 352. (Z)-9-eicosenyl-1-phospho-N,N,N-trimethylbutyl-ammonium
- 353. (Z)-10-eicosenyl-1-phospho-N,N,N-trimethylbutylammonium
- 354. (Z)-11-eicosenyl-1-phospho-N,N,N-trimethylbutylammonium

- 355. (Z)-12-eicosenyl-1-phospho-N,N,N-trimethylbutylammonium
- 356. (Z)-13-eicosenyl-1-phospho-N,N,N-trimethylbutylammonium
- 357. (Z)-14-eicosenyl-1-phospho-N,N,N-trimethylbutylammonium
- 358. (Z)-15-eicosenyl-1-phospho-N,N,N-trimethylbutylammonium
- 359. (Z)-16-eicosenyl-1-phospho-N,N,N-trimethylbutylammonium
- 360. (Z)-17-eicosenyl-1-phospho-N,N,N-trimethylbutylammonium
- 361. (Z)-18-eicosenyl-1-phospho-N,N,N-trimethylbutylammonium
- 362. 19-eicosenyl-1-phospho-N,N,N-trimethylbutyl-

C28H58NO4P (503.75)

- 363. (Z)-3-heneicosenyl-1-phospho-N,N,N-trimethylbutylammonium
- 364. (Z)-4-heneicosenyl-1-phospho-N,N,N-trimethylbutylammonium
- 365. (Z) -5-heneicosenyl-1-phospho-N,N,N-trimethylbutylammonium
- 366. (Z)-6-heneicosenyl-1-phospho-N,N,N-trimethylbutylammonium
- 367. (Z)-7-heneicosenyl-1-phospho-N,N,N-trimethylbutylammonium
- 368. (Z)-8-heneicosenyl-1-phospho-N,N,N-trimethylbutyl-ammonium
- 369. (Z)-9-heneicosenyl-1-phospho-N,N,N-trimethylbutylammonium
- 370. (Z)-10-heneicosenyl-1-phospho-N,N,N-trimethylbutylammonium

371. (Z)-11-heneicosenyl-1-phospho-N,N,N-trimethylbutylammonium

- 60 -

- 372. (Z)-12-heneicosenyl-1-phospho-N,N,N-trimethylbutvlammonium
- 373. (Z)-13-heneicosenyl-1-phospho-N,N,N-trimethylbutylammonium
- 374. (Z)-14-heneicosenyl-1-phospho-N,N,N-trimethylbutylammonium
- 375. (Z)-15-heneicosenyl-1-phospho-N,N,N-trimethylbutylammonium
- 376. (Z)-16-heneicosenyl-1-phospho-N,N,N-trimethylbutylammonium
- 377. (Z)-17-heneicosenyl-1-phospho-N,N,N-trimethylbutvlammonium
- 378. (Z)-18-heneicosenyl-1-phospho-N,N,N-trimethylbutylammonium
- 379. (Z)-19-heneicosenyl-1-phospho-N,N,N-trimethylbutvlammonium
- 380. 20-heneicosenyl-1-phospho-N,N,N-trimethylbutylammonium

22 chain carbon atoms

C29H60NO4P (517.77)

- 381. (Z)-3-docosenyl-1-phospho-N,N,N-trimethylbutylammonium
- 382. (Z)-4-docosenyl-1-phospho-N,N,N-trimethylbutylammonium
- 383. (Z)-5-docosenyl-1-phospho-N,N,N-trimethylbutylammonium
- 384. (Z)-6-docosenyl-1-phospho-N,N,N-trimethylbutylammonium
- 385. (Z) -7-docosenyl-1-phospho-N,N,N-trimethylbutylammonium
- 386. (Z)-8-docosenyl-1-phospho-N,N,N-trimethylbutylammonium

- 387. (Z)-9-docosenyl-1-phospho-N,N,N-trimethylbutylammonium
- 388. (Z)-10-docosenyl-1-phospho-N,N,N-trimethylbutylammonium
- 389. (Z)-11-docosenyl-1-phospho-N,N,N-trimethylbutyl-
- 390. (Z)-12-docosenyl-1-phospho-N,N,N-trimethylbutylammonium
- 391. (Z)-14-docosenyl-1-phospho-N,N,N-trimethylbutylammonium
- 392. (Z)-15-docosenyl-1-phospho-N,N,N-trimethylbutylammonium
- 393. (Z)-16-docosenyl-1-phospho-N,N,N-trimethylbutylammonium
- 394. (Z)-17-docosenyl-1-phospho-N,N,N-trimethylbutyl-ammonium
- 395. (Z)-18-docosenyl-1-phospho-N,N,N-trimethylbutylammonium
- 396. (Z)-19-docosenyl-1-phospho-N,N,N-trimethylbutylammonium
- 397. (Z)-20-docosenyl-1-phospho-N,N,N-trimethylbutyl-ammonium
- 398. 21-docosenyl-1-phospho-N,N,N-trimethylbutyl-ammonium

C₃₀H₆₂NO₄P (531.80)

- 399. (Z)-3-tricosenyl-1-phospho-N,N,N-trimethylbutylammonium
- 400. (Z)-4-tricosenyl-1-phospho-N,N,N-trimethylbutyl-ammonium
- 401. (Z)-5-tricosenyl-1-phospho-N,N,N-trimethylbutyl-ammonium
- 402. (Z)-6-tricosenyl-1-phospho-N,N,N-trimethylbutyl-ammonium

- 403. (Z)-7-tricosenyl-1-phospho-N,N,N-trimethylbutylammonium
- 404. (Z)-8-tricosenyl-1-phospho-N,N,N-trimethylbutylammonium
- 405. (Z)-9-tricosenyl-1-phospho-N,N,N-trimethylbutylammonium
- 406. (Z)-10-tricosenyl-1-phospho-N,N,N-trimethylbutyl-ammonium
- 407. (Z)-11-tricosenyl-1-phospho-N,N,N-trimethylbutylammonium
- 408. (Z) -12-tricosenyl-1-phospho-N,N,N-trimethylbutylammonium
- 409. (Z)-13-tricosenyl-1-phospho-N,N,N-trimethylbutyl-ammonium
- 410. (Z)-14-tricosenyl-1-phospho-N,N,N-trimethylbutylammonium
- 411. (Z)-15-tricosenyl-1-phospho-N,N,N-trimethylbutylammonium
- 412. (Z)-16-tricosenyl-1-phospho-N,N,N-trimethylbutylammonium
- 413. (Z)-17-tricosenyl-1-phospho-N,N,N-trimethylbutylammonium
- 414. (Z)-18-tricosenyl-1-phospho-N,N,N-trimethylbutylammonium
- 415. (Z)-19-tricosenyl-1-phospho-N,N,N-trimethylbutylammonium
- 416. (Z)-20-tricosenyl-1-phospho-N,N,N-trimethylbutylammonium
- 417. (Z)-21-tricosenyl-1-phospho-N,N,N-trimethylbutyl-
- 418. 22-tricosenyl-1-phospho-N,N,N-trimethylbutylammonium

C31H64NO4P (545.83)

419. (Z)-3-tetracosenyl-1-phospho-N,N,N-trimethylbutylammonium

- 63 -

- 420. (Z)-4-tetracosenyl-1-phospho-N,N,N-trimethylbutylammonium
- 421. (Z)-5-tetracosenyl-1-phospho-N,N,N-trimethylbutylammonium
- 422. (Z)-6-tetracosenyl-1-phospho-N,N,N-trimethylbutylammonium
- 423. (Z)-7-tetracosenyl-1-phospho-N,N,N-trimethylbutyl-ammonium
- 424. (Z)-8-tetracosenyl-1-phospho-N,N,N-trimethylbutyl-ammonium
- 425. (Z)-9-tetracosenyl-1-phospho-N,N,N-trimethylbutylammonium
- 426. (Z)-10-tetracosenyl-1-phospho-N,N,N-trimethylbutylammonium
- 427. (Z)-11-tetracosenyl-1-phospho-N,N,N-trimethylbutylammonium
- 428. (Z)-12-tetracosenyl-1-phospho-N,N,N-trimethylbutvlammonium
- 429. (Z) -13-tetracosenyl-1-phospho-N,N,N-trimethylbutvlammonium
- 430. (Z)-14-tetracosenyl-1-phospho-N,N,N-trimethylbutylammonium
- 431. (Z)-15-tetracosenyl-1-phospho-N,N,N-trimethylbutylammonium
- 432. (Z)-16-tetracosenyl-1-phospho-N,N,N-trimethylbutylammonium
- 433. (Z)-17-tetracosenyl-1-phospho-N,N,N-trimethylbutylammonium
- 434. (Z)-18-tetracosenyl-1-phospho-N,N,N-trimethylbutylammonium

4. Examples of (Z,Z)-alkadienylphosphocholines

 $(A = IX; n = 2; R_3, CH_3; m = 1, x = 1, z = 0)$

$$A - PO_3 = \left[(CH_2)_n - N^* \atop R_3 \right]_m - (CH_2)_x - \left[CH_2 - \left(\begin{matrix} CH \\ OH \end{matrix} \right)_y - CH_3 - O \right]_z - H$$

where A is a diunsaturated alkyl chain of the following structure (s, t, $r \ge 0$; $8 \le s + t + r \le 26$):

$$A = 0$$
 (CH₂)₅ (CH₂)₇H

formula IX

16 chain carbon atoms

C21H42NO4P (403.54)

435. (Z,Z)-3,7-hexadecadienvl-1-phosphocholine

436. (Z,Z)-4,8-hexadecadienyl-1-phosphocholine

437. (Z,Z)-5,9-hexadecadienyl-1-phosphocholine

438. (Z,Z)-6,10-hexadecadienyl-1-phosphocholine

439. (Z,Z)-7,11-hexadecadienyl-1-phosphocholine

440. (Z,Z)-8,12-hexadecadienyl-1-phosphocholine

441. (Z,Z)-9,13-hexadecadienvl-1-phosphocholine

442. (Z,Z)-3,8-hexadecadienyl-1-phosphocholine

443. (Z,Z)-4,9-hexadecadienyl-1-phosphocholine

444. (Z,Z)-5,10-hexadecadienyl-1-phosphocholine

445. (Z,Z)-6,11-hexadecadienyl-1-phosphocholine

446. (Z,Z)-7,12-hexadecadienyl-1-phosphocholine

447. (Z,Z)-8,13-hexadecadienyl-1-phosphocholine

448. (Z,Z)-3,9-hexadecadienyl-1-phosphocholine

449. (Z,Z)-4,10-hexadecadienyl-1-phosphocholine

450. (Z,Z)-5,11-hexadecadienvl-1-phosphocholine

451. (Z.Z)-6.12-hexadecadienvl-1-phosphocholine

452. (Z,Z)-7,13-hexadecadienyl-1-phosphocholine

- 453. (Z,Z)-3,10-hexadecadienyl-1-phosphocholine
- 454. (Z,Z)-4,11-hexadecadienyl-1-phosphocholine
- 455. (Z, Z) -5, 12-hexadecadienyl-1-phosphocholine
- 456. (Z,Z)-6,13-hexadecadienyl-1-phosphocholine
- 457. (Z,Z)-3,11-hexadecadienyl-1-phosphocholine
- 458. (Z,Z)-4,12-hexadecadienyl-1-phosphocholine
- 459. (Z,Z)-5,13-hexadecadienyl-1-phosphocholine
- 460. (Z,Z)-3,12-hexadecadienyl-1-phosphocholine
- 461. (Z,Z)-4,13-hexadecadienyl-1-phosphocholine
- 462. (Z,Z)-3,13-hexadecadienyl-1-phosphocholine

C22H44NO4P (417.57)

- 463. (Z,Z)-3,7-heptadecadienyl-1-phosphocholine
- 464. (Z,Z)-4,8-heptadecadienyl-1-phosphocholine
- 465. (Z,Z)-5,9-heptadecadienyl-1-phosphocholine
- 466. (Z,Z)-6,10-heptadecadienyl-1-phosphocholine
- 467. (Z,Z)-7,11-heptadecadienyl-1-phosphocholine
- 468. (Z,Z)-8,12-heptadecadienyl-1-phosphocholine 469. (Z,Z)-9,13-heptadecadienyl-1-phosphocholine
- 470. (Z,Z)-10,14-heptadecadienyl-1-phosphocholine
- 471. (Z,Z)-3,8-heptadecadienyl-1-phosphocholine
- 472. (Z, Z) -4, 9-heptadecadienyl-1-phosphocholine
- 473. (Z,Z)-5,10-heptadecadienyl-1-phosphocholine
- 474. (Z,Z)-6,11-heptadecadienyl-1-phosphocholine
- 475. (Z,Z)-7,12-heptadecadienyl-1-phosphocholine
- 476. (Z,Z)-8,13-heptadecadienyl-1-phosphocholine
- 477. (Z, Z) -9,14-heptadecadienyl-1-phosphocholine
- 478. (Z, Z) -3,9-heptadecadienyl-1-phosphocholine
- 479. (Z,Z)-4,10-heptadecadienyl-1-phosphocholine

```
480. (Z,Z)-5,11-heptadecadienyl-1-phosphocholine
481. (Z,Z)-6,12-heptadecadienyl-1-phosphocholine
482. (Z,Z)-7,13-heptadecadienyl-1-phosphocholine
483. (Z,Z)-8,14-heptadecadienyl-1-phosphocholine
484. (Z,Z)-3,10-heptadecadienvl-1-phosphocholine
485. (Z,Z)-4,11-heptadecadienyl-1-phosphocholine
486. (Z,Z)-5,12-heptadecadienyl-1-phosphocholine
487. (Z.Z)-6.13-heptadecadienvl-1-phosphocholine
488. (Z,Z)-7,14-heptadecadienyl-1-phosphocholine
489. (Z,Z)-3,11-heptadecadienyl-1-phosphocholine
490. (Z,Z)-4,12-heptadecadienyl-1-phosphocholine
491. (Z,Z)-5,13-heptadecadienyl-1-phosphocholine
492. (Z,Z)-6,14-heptadecadienyl-1-phosphocholine
493. (Z,Z)-3,12-heptadecadienyl-1-phosphocholine
494. (Z,Z)-4,13-heptadecadienyl-1-phosphocholine
495. (Z,Z)-5,14-heptadecadienyl-1-phosphocholine
496. (Z,Z)-3,13-heptadecadienyl-1-phosphocholine
497. (Z,Z)-4,14-heptadecadienyl-1-phosphocholine
```

```
C23H46NO4P (431.60)
```

499. (Z,Z)-3,7-octadecadienyl-1-phosphocholine 500. (Z,Z)-4,8-octadecadienyl-1-phosphocholine 501. (Z,Z)-5,9-octadecadienyl-1-phosphocholine 502. (Z,Z)-6,10-octadecadienyl-1-phosphocholine 503. (Z,Z)-7,11-octadecadienyl-1-phosphocholine 504. (Z,Z)-8,12-octadecadienyl-1-phosphocholine 505. (Z,Z)-9,13-octadecadienyl-1-phosphocholine 506. (Z,Z)-10,14-octadecadienyl-1-phosphocholine 507. (Z,Z)-11,15-octadecadienyl-1-phosphocholine

498. (Z,Z)-3,14-heptadecadienyl-1-phosphocholine

508. (Z,Z)-3,8-octadecadienyl-1-phosphocholine 509. (Z.Z)-4.9-octadecadienvl-1-phosphocholine 510. (Z,Z)-5,10-octadecadienyl-1-phosphocholine 511. (Z,Z)-6,11-octadecadienyl-1-phosphocholine 512. (Z,Z)-7,12-octadecadienyl-1-phosphocholine 513. (Z,Z)-8,13-octadecadienyl-1-phosphocholine 514. (Z,Z)-9,14-octadecadienyl-1-phosphocholine 515. (Z,Z)-10,15-octadecadienyl-1-phosphocholine 516. (Z,Z)-3,9-octadecadienvl-1-phosphocholine 517. (Z,Z)-4,10-octadecadienvl-1-phosphocholine 518. (Z,Z)-5,11-octadecadienyl-1-phosphocholine 519. (Z.Z)-6.12-octadecadienvl-1-phosphocholine 520. (Z,Z)-7,13-octadecadienyl-1-phosphocholine 521. (Z,Z)-8,14-octadecadienyl-1-phosphocholine 522. (Z,Z)-9,15-octadecadienyl-1-phosphocholine 523. (Z,Z)-3,10-octadecadienyl-1-phosphocholine 524. (Z,Z)-4,11-octadecadienvl-1-phosphocholine 525. (Z,Z)-5,12-octadecadienyl-1-phosphocholine 526. (Z,Z)-6,13-octadecadienyl-1-phosphocholine 527. (Z, Z) -7,14-octadecadienyl-1-phosphocholine 528. (Z,Z)-8,15-octadecadienyl-1-phosphocholine 529. (Z,Z)-3,11-octadecadienyl-1-phosphocholine 530. (Z,Z)-4,12-octadecadienyl-1-phosphocholine 531. (Z,Z)-5,13-octadecadienyl-1-phosphocholine 532. (Z,Z)-6,14-octadecadienyl-1-phosphocholine 533. (Z,Z)-7,15-octadecadienyl-1-phosphocholine 534. (Z,Z)-3,12-octadecadienyl-1-phosphocholine 535. (Z,Z)-4,13-octadecadienyl-1-phosphocholine 536. (Z,Z)-5,14-octadecadienyl-1-phosphocholine 537. (Z,Z)-6,15-octadecadienyl-1-phosphocholine 538. (Z,Z)-3,13-octadecadienyl-1-phosphocholine 539. (Z,Z)-4,14-octadecadienyl-1-phosphocholine

540. (Z,Z)-5,15-octadecadienyl-1-phosphocholine

541. (Z,Z)-3,14-octadecadienyl-1-phosphocholine

542. (Z,Z)-4,15-octadecadienyl-1-phosphocholine

543. (Z,Z)-3,15-octadecadienyl-1-phosphocholine

19 chain carbon atoms

C24H48NO4P (445.62)

```
544. (Z,Z)-3,7-nonadecadienyl-1-phosphocholine
545. (Z,Z)-4,8-nonadecadienyl-1-phosphocholine
```

546. (Z,Z)-5,9-nonadecadienyl-1-phosphocholine

547. (Z,Z)-6,10-nonadecadienyl-1-phosphocholine

548. (Z,Z)-7,11-nonadecadienyl-1-phosphocholine

549. (Z,Z)-8,12-nonadecadienyl-1-phosphocholine

550. (Z,Z)-9,13-nonadecadienyl-1-phosphocholine

551. (Z,Z)-10,14-nonadecadienyl-1-phosphocholine

552. (Z,Z)-11,15-nonadecadienyl-1-phosphocholine

553. (Z,Z)-12,16-nonadecadienyl-1-phosphocholine

554. (Z,Z)-3,8-nonadecadienyl-1-phosphocholine

555. (Z,Z)-4,9-nonadecadienyl-1-phosphocholine

556. (Z,Z)-5,10-nonadecadienyl-1-phosphocholine

557. (Z,Z)-6,11-nonadecadienyl-1-phosphocholine 558. (Z,Z)-7,12-nonadecadienyl-1-phosphocholine

559. (Z,Z)-8,13-nonadecadienyl-1-phosphocholine

560. (Z,Z)-9,14-nonadecadienyl-1-phosphocholine

561. (Z,Z)-10,15-nonadecadienyl-1-phosphocholine

562. (Z,Z)-11,16-nonadecadienyl-1-phosphocholine

563. (Z,Z)-3,9-nonadecadienyl-1-phosphocholine

564. (Z,Z)-4,10-nonadecadienyl-1-phosphocholine

565. (Z,Z)-5,11-nonadecadienyl-1-phosphocholine

566. (Z,Z)-6,12-nonadecadienyl-1-phosphocholine

567. (Z,Z)-7,13-nonadecadienyl-1-phosphocholine

568. (Z,Z)-8,14-nonadecadienyl-1-phosphocholine

- 569. (Z,Z)-9,15-nonadecadienyl-1-phosphocholine 570. (Z,Z)-10,16-nonadecadienyl-1-phosphocholine
- 571. (Z,Z)-3,10-nonadecadienyl-1-phosphocholine
- 572. (Z,Z)-4,11-nonadecadienyl-1-phosphocholine
- 573. (Z,Z)-5,12-nonadecadienyl-1-phosphocholine
- 574. (Z,Z)-6,13-nonadecadienyl-1-phosphocholine
- 575. (Z,Z)-7,14-nonadecadienyl-1-phosphocholine
- 576. (Z,Z)-8,15-nonadecadienyl-1-phosphocholine
- 577. (Z,Z)-9,16-nonadecadienyl-1-phosphocholine
- 578. (Z,Z)-3,11-nonadecadienyl-1-phosphocholine
- 579. (Z,Z)-4,12-nonadecadienyl-1-phosphocholine
- 580. (Z,Z)-5,13-nonadecadienyl-1-phosphocholine
- 581. (Z,Z)-6,14-nonadecadienyl-1-phosphocholine
- 582. (Z,Z)-7,15-nonadecadienyl-1-phosphocholine
- 583. (Z,Z)-8,16-nonadecadienyl-1-phosphocholine
- 584. (Z,Z)-3,12-nonadecadienyl-1-phosphocholine
- 585. (Z,Z)-4,13-nonadecadienyl-1-phosphocholine
- 586. (Z,Z)-5,14-nonadecadienyl-1-phosphocholine 587. (Z,Z)-6,15-nonadecadienyl-1-phosphocholine
- 588. (Z,Z)-7,16-nonadecadienyl-1-phosphocholine
- 589. (Z,Z)-3,13-nonadecadienyl-1-phosphocholine
- 590. (Z,Z)-4,14-nonadecadienyl-1-phosphocholine
- 591. (Z,Z)-5,15-nonadecadienyl-1-phosphocholine
- 592. (Z,Z)-6,16-nonadecadienyl-1-phosphocholine
- 593. (Z,Z)-3,14-nonadecadienyl-1-phosphocholine
- 594.~(Z,Z)-4,15-nonadecadienyl-1-phosphocholine
- 595. (Z,Z)-5,16-nonadecadienyl-1-phosphocholine
- 596. (Z,Z)-3,15-nonadecadienyl-1-phosphocholine
- 597. (Z,Z)-4,16-nonadecadienyl-1-phosphocholine

20 chain carbon atoms

```
C25H50NO4P (459.65)
```

```
598. (Z,Z)-3,7-eicosadienyl-1-phosphocholine
599. (Z,Z)-4,8-eicosadienyl-1-phosphocholine
600. (Z,Z)-5,9-eicosadienyl-1-phosphocholine
601. (Z,Z)-6,10-eicosadienyl-1-phosphocholine
602. (Z,Z)-7,11-eicosadienyl-1-phosphocholine
603. (Z,Z)-8,12-eicosadienyl-1-phosphocholine
604. (Z,Z)-9,13-eicosadienvl-1-phosphocholine
605. (Z,Z)-10,14-eicosadienyl-1-phosphocholine
606. (Z, Z) -11, 15-eicosadienyl-1-phosphocholine
607. (Z,Z)-12,16-eicosadienyl-1-phosphocholine
608. (Z,Z)-13,17-eicosadienyl-1-phosphocholine
609. (Z,Z)-3,8-eicosadienyl-1-phosphocholine
610. (Z,Z)-4,9-eicosadienyl-1-phosphocholine
611. (Z,Z)-5,10-eicosadienyl-1-phosphocholine
612. (Z,Z)-6,11-eicosadienyl-1-phosphocholine
613. (Z,Z)-7,12-eicosadienyl-1-phosphocholine
614. (Z,Z)-8,13-eicosadienvl-1-phosphocholine
615. (Z,Z)-9,14-eicosadienyl-1-phosphocholine
616. (Z,Z)-10,15-eicosadienyl-1-phosphocholine
617. (Z,Z)-11,16-eicosadienyl-1-phosphocholine
618. (Z,Z)-12.17-eicosadienvl-1-phosphocholine
619. (Z,Z)-3,9-eicosadienyl-1-phosphocholine
620. (Z,Z)-4,10-eicosadienyl-1-phosphocholine
621. (Z,Z)-5,11-eicosadienyl-1-phosphocholine
622. (Z,Z)-6,12-eicosadienyl-1-phosphocholine
623. (Z,Z)-7,13-eicosadienyl-1-phosphocholine
624. (Z,Z)-8,14-eicosadienyl-1-phosphocholine
625. (Z,Z)-9,15-eicosadienyl-1-phosphocholine
626. (Z,Z)-10,16-eicosadienyl-1-phosphocholine
627. (Z,Z)-11,17-eicosadienyl-1-phosphocholine
```

628. (Z,Z)-3,10-eicosadienyl-1-phosphocholine

629. (Z,Z)-4,11-eicosadienyl-1-phosphocholine 630. (Z,Z)-5,12-eicosadienyl-1-phosphocholine 631. (Z,Z)-6,13-eicosadienyl-1-phosphocholine 632. (Z,Z)-7,14-eicosadienyl-1-phosphocholine 633. (Z,Z)-8,15-eicosadienyl-1-phosphocholine 634. (Z,Z)-9,16-eicosadienyl-1-phosphocholine 635. (Z,Z)-10,17-eicosadienyl-1-phosphocholine 636. (Z,Z)-3,11-eicosadienyl-1-phosphocholine 637. (Z,Z)-4,12-eicosadienyl-1-phosphocholine 638. (Z,Z)-5,13-eicosadienyl-1-phosphocholine 639. (Z,Z)-6,14-eicosadienyl-1-phosphocholine 640. (Z,Z)-7,15-eicosadienyl-1-phosphocholine 641. (Z,Z)-8,16-eicosadienvl-1-phosphocholine 642. (Z,Z)-9,17-eicosadienvl-1-phosphocholine 643. (Z,Z)-3,12-eicosadienyl-1-phosphocholine 644. (Z,Z)-4,13-eicosadienyl-1-phosphocholine 645. (Z,Z)-5,14-eicosadienyl-1-phosphocholine 646. (Z,Z)-6,15-eicosadienyl-1-phosphocholine 647. (Z,Z)-7,16-eicosadienyl-1-phosphocholine 648. (Z,Z)-8,17-eicosadienvl-1-phosphocholine 649. (Z,Z)-3,13-eicosadienyl-1-phosphocholine 650. (Z,Z)-4,14-eicosadienyl-1-phosphocholine 651. (Z,Z)-5,15-eicosadienyl-1-phosphocholine 652. (Z,Z)-6,16-eicosadienvl-1-phosphocholine 653. (Z,Z)-7,17-eicosadienvl-1-phosphocholine 654. (Z, Z)-3,14-eicosadienyl-1-phosphocholine 655. (Z,Z)-4,15-eicosadienyl-1-phosphocholine 656. (Z,Z)-5,16-eicosadienyl-1-phosphocholine 657. (Z,Z)-6,17-eicosadienyl-1-phosphocholine 658. (Z,Z)-3,15-eicosadienyl-1-phosphocholine 659. (Z,Z)-4,16-eicosadienyl-1-phosphocholine

660. (Z,Z)-5,17-eicosadienyl-1-phosphocholine

661. (Z,Z)-3,17-eicosadienyl-1-phosphocholine

21 chain carbon atoms

```
C26H52NO4P (473.68)
```

- 662. (Z,Z)-3,7-heneicosadienyl-1-phosphocholine
- 663. (Z,Z)-4,8-heneicosadienyl-1-phosphocholine
- 664. (Z,Z)-5,9-heneicosadienyl-1-phosphocholine
- 665. (Z,Z)-6,10-heneicosadienyl-1-phosphocholine
- 666. (Z,Z)-7,11-heneicosadienyl-1-phosphocholine
- 667. (Z,Z)-8,12-heneicosadienvl-1-phosphocholine
- 668. (Z,Z)-9,13-heneicosadienyl-1-phosphocholine
- 669. (Z,Z)-10.14-heneicosadienvl-1-phosphocholine
- 670. (Z,Z)-11.15-heneicosadienvl-1-phosphocholine
- 671. (Z,Z)-12,16-heneicosadienyl-1-phosphocholine
- 672. (Z,Z)-13,17-heneicosadienyl-1-phosphocholine
- 673. (Z,Z)-14,18-heneicosadienyl-1-phosphocholine
- 674. (Z,Z)-3,8-heneicosadienyl-1-phosphocholine
- 675. (Z,Z)-4,9-heneicosadienvl-1-phosphocholine
- 676. (Z,Z)-5,10-heneicosadienyl-1-phosphocholine
- 677. (Z,Z)-6,11-heneicosadienyl-1-phosphocholine
- 678. (Z,Z)-7,12-heneicosadienyl-1-phosphocholine
- 679. (Z,Z)-8,13-heneicosadienyl-1-phosphocholine
- 680. (Z,Z)-9,14-heneicosadienyl-1-phosphocholine
- 681. (Z,Z)-10,15-heneicosadienyl-1-phosphocholine
- 682. (Z,Z)-11,16-heneicosadienyl-1-phosphocholine
- 683. (Z,Z)-12,17-heneicosadienyl-1-phosphocholine
- 684. (Z,Z)-13,18-heneicosadienyl-1-phosphocholine
- 685. (Z,Z)-3,9-heneicosadienvl-1-phosphocholine
- 686. (Z,Z)-4,10-heneicosadienyl-1-phosphocholine
- 687. (Z,Z)-5,11-heneicosadienyl-1-phosphocholine
- 688. (Z,Z)-6,12-heneicosadienyl-1-phosphocholine
- 689. (Z,Z)-7,13-heneicosadieny1-1-phosphocholine
- 690. (Z,Z)-8,14-heneicosadienyl-1-phosphocholine
- 691. (Z,Z)-9,15-heneicosadienyl-1-phosphocholine

692. (Z,Z)-10,16-heneicosadienvl-1-phosphocholine 693. (Z,Z)-11,17-heneicosadienvl-1-phosphocholine 694. (Z,Z)-12,18-heneicosadienyl-1-phosphocholine 695. (Z,Z)-3,10-heneicosadienyl-1-phosphocholine 696. (Z,Z)-4.11-heneicosadienvl-1-phosphocholine 697. (Z,Z)-5,12-heneicosadienyl-1-phosphocholine 698. (Z,Z)-6,13-heneicosadienyl-1-phosphocholine 699. (Z,Z)-7,14-heneicosadienyl-1-phosphocholine 700. (Z,Z)-8,15-heneicosadienyl-1-phosphocholine 701. (Z,Z)-9.16-heneicosadienvl-1-phosphocholine 702. (Z,Z)-10,17-heneicosadienyl-1-phosphocholine 703. (Z,Z)-11,18-heneicosadienyl-1-phosphocholine 704. (Z,Z)-3,11-heneicosadienyl-1-phosphocholine 705. (Z,Z)-4,12-heneicosadienvl-1-phosphocholine 706. (Z,Z)-5,13-heneicosadienyl-1-phosphocholine 707. (Z,Z)-6,14-heneicosadienyl-1-phosphocholine 708. (Z,Z)-7,15-heneicosadienyl-1-phosphocholine 709. (Z,Z)-8,16-heneicosadienyl-1-phosphocholine 710. (Z,Z)-9,17-heneicosadienvl-1-phosphocholine 711. (Z,Z)-10,18-heneicosadienyl-1-phosphocholine 712. (Z,Z)-3,12-heneicosadienyl-1-phosphocholine 713. (Z,Z)-4,13-heneicosadienyl-1-phosphocholine 714. (Z,Z)-5,14-heneicosadienyl-1-phosphocholine 715. (Z,Z)-6,15-heneicosadienvl-1-phosphocholine 716. (Z,Z)-7,16-heneicosadienyl-1-phosphocholine 717. (Z,Z)-8,17-heneicosadienyl-1-phosphocholine 718. (Z,Z)-9,18-heneicosadienyl-1-phosphocholine 719. (Z,Z)-3,13-heneicosadienyl-1-phosphocholine 720. (Z,Z)-4,14-heneicosadienyl-1-phosphocholine 721. (Z,Z)-5,15-heneicosadienyl-1-phosphocholine 722. (Z,Z)-6,16-heneicosadienyl-1-phosphocholine 723. (Z,Z)-7,17-heneicosadienyl-1-phosphocholine 724. (Z,Z)-8,18-heneicosadienyl-1-phosphocholine

- 725. (Z,Z)-3,14-heneicosadienyl-1-phosphocholine
- 726. (Z,Z)-4,15-heneicosadienyl-1-phosphocholine
- 727. (Z,Z)-5,16-heneicosadienyl-1-phosphocholine
- 728. (Z,Z)-6,17-heneicosadienyl-1-phosphocholine
- 729. (Z,Z)-7,18-heneicosadienyl-1-phosphocholine
- 730. (Z,Z)-3,15-heneicosadienyl-1-phosphocholine
- 731. (Z,Z)-4,16-heneicosadienyl-1-phosphocholine
- 732. (Z,Z)-5,17-heneicosadienyl-1-phosphocholine
- 733. (Z,Z)-6,18-heneicosadienyl-1-phosphocholine
- 734. (Z,Z)-3,17-heneicosadienyl-1-phosphocholine
- 735. (Z,Z)-4,18-heneicosadienyl-1-phosphocholine

22 chain carbon atoms

C27H54NO4P (487.70)

- 736. (Z,Z)-3,7-docosadienyl-1-phosphocholine
- 737. (Z,Z)-4,8-docosadienyl-1-phosphocholine
- 738. (Z,Z)-5,9-docosadienyl-1-phosphocholine
- 739. (Z,Z)-6,10-docosadienyl-1-phosphocholine
- 740. (Z,Z)-7,11-docosadienyl-1-phosphocholine
- 741. (Z,Z)-8,12-docosadienyl-1-phosphocholine
- 742. (Z,Z)-9,13-docosadienyl-1-phosphocholine
- 743. (Z,Z)-10,14-docosadienyl-1-phosphocholine
- 744. (Z,Z)-11,15-docosadienyl-1-phosphocholine
- 745. (Z,Z)-12,16-docosadienyl-1-phosphocholine
- 746. (Z,Z)-13,17-docosadienyl-1-phosphocholine
- 747. (Z,Z)-14,18-docosadienyl-1-phosphocholine
- 748. (Z, Z)-15,19-docosadienyl-1-phosphocholine
- 749. (Z, Z) -3,8-docosadienyl-1-phosphocholine
- 750. (Z,Z)-4,9-docosadienyl-1-phosphocholine
- 751. (Z,Z)-5,10-docosadienyl-1-phosphocholine
- 752. (Z,Z)-6,11-docosadienyl-1-phosphocholine
- 753. (Z,Z)-7,12-docosadienyl-1-phosphocholine
- 754. (Z,Z)-8,13-docosadienyl-1-phosphocholine

755. (Z,Z)-9,14-docosadienyl-1-phosphocholine 756. (Z,Z)-10.15-docosadienvl-1-phosphocholine 757. (Z,Z)-11,16-docosadienyl-1-phosphocholine 758. (Z,Z)-12,17-docosadienyl-1-phosphocholine 759. (Z.Z)-13.18-docosadienvl-1-phosphocholine 760. (Z,Z)-14,19-docosadienyl-1-phosphocholine 761. (Z,Z)-3,9-docosadienyl-1-phosphocholine 762. (Z,Z)-4,10-docosadienyl-1-phosphocholine 763. (Z.Z)-5.11-docosadienvl-1-phosphocholine 764. (Z,Z)-6,12-docosadienyl-1-phosphocholine 765. (Z,Z)-7,13-docosadienyl-1-phosphocholine 766. (Z,Z)-8,14-docosadienyl-1-phosphocholine 767. (Z,Z)-9,15-docosadienyl-1-phosphocholine 768. (Z,Z)-10,16-docosadienyl-1-phosphocholine 769. (Z,Z)-11,17-docosadienyl-1-phosphocholine 770. (Z,Z)-12,18-docosadienyl-1-phosphocholine 771. (Z,Z)-13,19-docosadienyl-1-phosphocholine 772. (Z.Z)-3.10-docosadienyl-1-phosphocholine 773. (Z.Z)-4.11-docosadienvl-1-phosphocholine 774. (Z.Z)-5.12-docosadienvl-1-phosphocholine 775. (Z,Z)-6,13-docosadienyl-1-phosphocholine 776. (Z,Z)-7,14-docosadienyl-1-phosphocholine 777. (Z,Z)-8,15-docosadienyl-1-phosphocholine 778. (Z.Z)-9.16-docosadienvl-1-phosphocholine 779. (Z,Z)-10.17-docosadienvl-1-phosphocholine 780. (Z,Z)-11,18-docosadienyl-1-phosphocholine 781. (Z,Z)-12,19-docosadienyl-1-phosphocholine 782. (Z.Z)-3,11-docosadienyl-1-phosphocholine 783. (Z.Z)-4.12-docosadienvl-1-phosphocholine 784. (Z,Z)-5,13-docosadienyl-1-phosphocholine 785. (Z,Z)-6,14-docosadienyl-1-phosphocholine 786. (Z,Z)-7,15-docosadienyl-1-phosphocholine 787. (Z,Z)-8,16-docosadienyl-1-phosphocholine 788. (Z,Z)-9,17-docosadienyl-1-phosphocholine

789. (Z,Z)-10,18-docosadienyl-1-phosphocholine

- 790. (Z,Z)-11,19-docosadienyl-1-phosphocholine
- 791. (Z,Z)-3,12-docosadienyl-1-phosphocholine
- 792. (Z,Z)-4,13-docosadienyl-1-phosphocholine
- 793. (Z,Z)-5,14-docosadienyl-1-phosphocholine
- 794. (Z,Z)-6,15-docosadienyl-1-phosphocholine
- 795. (Z,Z)-7,16-docosadienyl-1-phosphocholine 796. (Z,Z)-8,17-docosadienyl-1-phosphocholine
- 797. (Z,Z)-9,18-docosadienyl-1-phosphocholine
- 798. (Z,Z)-10,19-docosadienyl-1-phosphocholine
- 799. (Z,Z)-3,13-docosadienyl-1-phosphocholine
- 800. (Z,Z)-4,14-docosadienyl-1-phosphocholine
- 801. (Z,Z)-5,15-docosadienyl-1-phosphocholine
- 802. (Z, Z) -6, 16-docosadienyl-1-phosphocholine
- 803. (Z,Z)-7,17-docosadienyl-1-phosphocholine
- 804. (Z,Z)-8,18-docosadienvl-1-phosphocholine
- 805. (Z,Z)-9,19-docosadienyl-1-phosphocholine
- 806. (Z,Z)-3,14-docosadienvl-1-phosphocholine
- 807. (Z,Z)-4,15-docosadienyl-1-phosphocholine
- 808. (Z,Z)-5,16-docosadienyl-1-phosphocholine
- 809. (Z,Z)-6,17-docosadienyl-1-phosphocholine
- 810. (Z,Z)-7,18-docosadienyl-1-phosphocholine
- 811. (Z,Z)-8,19-docosadienyl-1-phosphocholine
- 812. (Z,Z)-3,15-docosadienyl-1-phosphocholine
- 813. (Z,Z)-4,16-docosadienyl-1-phosphocholine
- 814. (Z,Z)-5,17-docosadienyl-1-phosphocholine 815. (Z,Z)-6,18-docosadienyl-1-phosphocholine
- 816. (Z,Z)-7,19-docosadienyl-1-phosphocholine
- 817. (Z,Z)-3,17-docosadienyl-1-phosphocholine
- 818. (Z,Z)-4,18-docosadienyl-1-phosphocholine
- 819. (Z,Z)-5,19-docosadienyl-1-phosphocholine
- 820. (Z,Z)-3,19-docosadienyl-1-phosphocholine

- 77 -

23 chain carbon atoms

C28H56NO4P (501.73)

```
821. (Z,Z)-3,7-tricosadienyl-1-phosphocholine
822. (Z,Z)-4,8-tricosadienyl-1-phosphocholine
823. (Z,Z)-5,9-tricosadienyl-1-phosphocholine
824. (Z,Z)-6,10-tricosadienyl-1-phosphocholine
825. (Z,Z)-7,11-tricosadienyl-1-phosphocholine
826. (Z,Z)-8,12-tricosadienyl-1-phosphocholine
827. (Z,Z)-9,13-tricosadienyl-1-phosphocholine
828. (Z,Z)-10,14-tricosadienyl-1-phosphocholine
829. (Z,Z)-11,15-tricosadienyl-1-phosphocholine
830. (Z,Z)-12,16-tricosadienyl-1-phosphocholine
831. (Z,Z)-13,17-tricosadienyl-1-phosphocholine
832. (Z,Z)-14,18-tricosadienyl-1-phosphocholine
833. (Z,Z)-15,19-tricosadienyl-1-phosphocholine
834. (Z,Z)-16,20-tricosadienyl-1-phosphocholine
835. (Z,Z)-3,8-tricosadienyl-1-phosphocholine
836. (Z,Z)-4,9-tricosadienyl-1-phosphocholine
837. (Z,Z)-5,10-tricosadienyl-1-phosphocholine
838. (Z,Z)-6,11-tricosadienyl-1-phosphocholine
839. (Z,Z)-7,12-tricosadienyl-1-phosphocholine
840. (Z,Z)-8,13-tricosadienyl-1-phosphocholine
841. (Z,Z)-9,14-tricosadienyl-1-phosphocholine
842. (Z,Z)-10.15-tricosadienyl-1-phosphocholine
843. (Z,Z)-11,16-tricosadienyl-1-phosphocholine
844. (Z,Z)-12,17-tricosadienyl-1-phosphocholine
845. (Z,Z)-13,18-tricosadienyl-1-phosphocholine
846. (Z,Z)-14,19-tricosadienyl-1-phosphocholine
847. (Z,Z)-15,20-tricosadienyl-1-phosphocholine
848. (Z,Z)-3,9-tricosadienyl-1-phosphocholine
849. (Z,Z)-4,10-tricosadienyl-1-phosphocholine
850. (Z,Z)-5,11-tricosadienyl-1-phosphocholine
851. (Z,Z)-6,12-tricosadienyl-1-phosphocholine
852. (Z,Z)-7,13-tricosadienyl-1-phosphocholine
```

853. (Z,Z)-8,14-tricosadienvl-1-phosphocholine 854. (Z,Z)-9,15-tricosadienyl-1-phosphocholine 855. (Z,Z)-10,16-tricosadienyl-1-phosphocholine 856. (Z,Z)-11,17-tricosadienyl-1-phosphocholine 857. (Z,Z)-12,18-tricosadienyl-1-phosphocholine 858. (Z,Z)-13,19-tricosadienvl-1-phosphocholine 859. (Z,Z)-14,20-tricosadienyl-1-phosphocholine 860. (Z,Z)-3,10-tricosadienyl-1-phosphocholine 861. (Z,Z)-4,11-tricosadienvl-1-phosphocholine 862. (Z,Z)-5,12-tricosadienyl-1-phosphocholine 863. (Z,Z)-6,13-tricosadienyl-1-phosphocholine 864. (Z,Z)-7,14-tricosadienyl-1-phosphocholine 865. (Z,Z)-8,15-tricosadienyl-1-phosphocholine 866. (Z,Z)-9,16-tricosadienyl-1-phosphocholine 867. (Z,Z)-10,17-tricosadienyl-1-phosphocholine 868. (Z,Z)-11,18-tricosadienvl-1-phosphocholine 869. (Z,Z)-12,19-tricosadienvl-1-phosphocholine 870. (Z,Z)-13,20-tricosadienyl-1-phosphocholine 871. (Z,Z)-3,11-tricosadienyl-1-phosphocholine 872. (Z,Z)-4,12-tricosadienyl-1-phosphocholine 873. (Z,Z)-5,13-tricosadienvl-1-phosphocholine 874. (Z,Z)-6,14-tricosadienyl-1-phosphocholine 875. (Z,Z)-7,15-tricosadienyl-1-phosphocholine 876. (Z,Z)-8,16-tricosadienyl-1-phosphocholine 877. (Z,Z)-9,17-tricosadienyl-1-phosphocholine 878. (Z,Z)-10,18-tricosadienyl-1-phosphocholine 879. (Z,Z)-11,19-tricosadienyl-1-phosphocholine 880. (Z,Z)-12,20-tricosadienyl-1-phosphocholine 881. (Z,Z)-3,12-tricosadienyl-1-phosphocholine 882. (Z,Z)-4,13-tricosadienyl-1-phosphocholine 883. (Z,Z)-5,14-tricosadienyl-1-phosphocholine 884. (Z,Z)-6,15-tricosadienyl-1-phosphocholine 885. (Z,Z)-7,16-tricosadienyl-1-phosphocholine 886. (Z,Z)-8,17-tricosadienyl-1-phosphocholine

887. (Z,Z)-9,18-tricosadienyl-1-phosphocholine

- 888. (Z,Z)-10,19-tricosadienyl-1-phosphocholine
- 889. (Z,Z)-11,20-tricosadienyl-1-phosphocholine
- 890. (Z,Z)-3,13-tricosadienyl-1-phosphocholine
- 891. (Z,Z)-4,14-tricosadienyl-1-phosphocholine
- 892. (Z,Z)-5,15-tricosadienyl-1-phosphocholine
- 893. (Z,Z)-6,16-tricosadienyl-1-phosphocholine
- 894. (Z,Z)-7,17-tricosadienyl-1-phosphocholine 895. (Z,Z)-8,18-tricosadienyl-1-phosphocholine
- --- (=,=, u,=u u=uuuunj= = phoopmoonorin
- 896. (Z,Z)-9,19-tricosadienyl-1-phosphocholine
- 897. (Z,Z)-10,20-tricosadienyl-1-phosphocholine
- 898. (Z,Z)-3,14-tricosadienvl-1-phosphocholine
- 899. (Z,Z)-4,15-tricosadienyl-1-phosphocholine
- 900. (Z,Z)-5,16-tricosadienyl-1-phosphocholine
- 901. (Z,Z)-6,17-tricosadienyl-1-phosphocholine
- 902. (Z,Z)-7,18-tricosadienyl-1-phosphocholine
- 903. (Z,Z)-8,19-tricosadienyl-1-phosphocholine
- 904. (Z,Z)-9,20-tricosadienyl-1-phosphocholine
- 905. (Z,Z)-3,15-tricosadienyl-1-phosphocholine
- 906. (Z,Z)-4,16-tricosadienyl-1-phosphocholine
- 907. (Z,Z)-5,17-tricosadienyl-1-phosphocholine
- 908. (Z,Z)-6,18-tricosadienyl-1-phosphocholine
- 909. (Z,Z)-7,19-tricosadienyl-1-phosphocholine
- 910. (Z,Z)-8,20-tricosadienyl-1-phosphocholine
- 911. (Z,Z)-3,17-tricosadienyl-1-phosphocholine
- 912. (Z,Z)-4,18-tricosadienyl-1-phosphocholine
- 913. (Z,Z)-5,19-tricosadienyl-1-phosphocholine
- 914. (Z,Z)-6,20-tricosadienyl-1-phosphocholine
- 915. (Z,Z)-3,19-tricosadienyl-1-phosphocholine
- 916. (Z,Z)-4,20-tricosadienyl-1-phosphocholine

24 chain carbon atoms

C29H58NO4P (515.76)

```
917.
         (Z,Z)-3,7-tetracosadienyl-1-phosphocholine
918.
         (Z,Z)-4,8-tetracosadienvl-1-phosphocholine
919.
         (Z,Z)-5,9-tetracosadienyl-1-phosphocholine
920.
         (Z,Z)-6,10-tetracosadienyl-1-phosphocholine
921.
         (Z,Z)-7,11-tetracosadienyl-1-phosphocholine
922.
         (Z,Z)-8,12-tetracosadienvl-1-phosphocholine
923.
         (Z,Z)-9,13-tetracosadienyl-1-phosphocholine
924.
         (Z,Z)-10,14-tetracosadienyl-1-phosphocholine
925.
         (Z,Z)-11,15-tetracosadienyl-1-phosphocholine
926.
         (Z,Z)-12,16-tetracosadienyl-1-phosphocholine
927.
         (Z,Z)-13,17-tetracosadienvl-1-phosphocholine
928
         (Z,Z)-14,18-tetracosadienyl-1-phosphocholine
929.
         (Z,Z)-15,19-tetracosadienyl-1-phosphocholine
930.
         (Z,Z)-16,20-tetracosadienyl-1-phosphocholine
931.
         (Z,Z)-17,21-tetracosadienyl-1-phosphocholine
932.
         (Z,Z)-3,8-tetracosadienvl-1-phosphocholine
933.
         (Z,Z)-4,9-tetracosadienyl-1-phosphocholine
934.
         (Z,Z)-5,10-tetracosadienyl-1-phosphocholine
935.
         (Z,Z)-6,11-tetracosadienyl-1-phosphocholine
936.
         (Z,Z)-7,12-tetracosadienyl-1-phosphocholine
937.
        (Z,Z)-8,13-tetracosadienvl-1-phosphocholine
938.
        (Z,Z)-9,14-tetracosadienyl-1-phosphocholine
939.
        (Z,Z)-10,15-tetracosadienyl-1-phosphocholine
940.
        (Z,Z)-11,16-tetracosadienyl-1-phosphocholine
941.
        (Z,Z)-12,17-tetracosadienyl-1-phosphocholine
942.
        (Z,Z)-13,18-tetracosadienvl-1-phosphocholine
943.
        (Z,Z)-14,19-tetracosadienyl-1-phosphocholine
944.
        (Z,Z)-15,20-tetracosadienyl-1-phosphocholine
945.
        (Z,Z)-16,21-tetracosadienyl-1-phosphocholine
946.
        (Z,Z)-3,9-tetracosadienyl-1-phosphocholine
947.
        (Z,Z)-4,10-tetracosadienyl-1-phosphocholine
948.
        (Z,Z)-5,11-tetracosadienyl-1-phosphocholine
```

949 (Z,Z)-6,12-tetracosadienyl-1-phosphocholine 950. (Z,Z)-7,13-tetracosadienyl-1-phosphocholine 951. (Z,Z)-8,14-tetracosadienvl-1-phosphocholine 952. (Z,Z)-9,15-tetracosadienyl-1-phosphocholine (Z,Z)-10,16-tetracosadienyl-1-phosphocholine 953. 954. (Z, Z) -11,17-tetracosadienyl-1-phosphocholine 955. (Z,Z)-12,18-tetracosadienyl-1-phosphocholine 956 (Z, Z) -13,19-tetracosadienyl-1-phosphocholine 957. (Z,Z)-14,20-tetracosadienyl-1-phosphocholine 958 (Z, Z) -15,21-tetracosadienyl-1-phosphocholine 959. (Z,Z)-3,10-tetracosadienvl-1-phosphocholine 960. (Z,Z)-4,11-tetracosadienyl-1-phosphocholine 961. (Z,Z)-5,12-tetracosadienyl-1-phosphocholine 962. (Z, Z) -6,13-tetracosadienyl-1-phosphocholine 963. (Z,Z)-7,14-tetracosadienyl-1-phosphocholine 964. (Z, Z) -8, 15-tetracosadienyl-1-phosphocholine 965. (Z,Z)-9,16-tetracosadienyl-1-phosphocholine 966. (Z,Z)-10,17-tetracosadienyl-1-phosphocholine 967. (Z,Z)-11,18-tetracosadienyl-1-phosphocholine 968. (Z,Z)-12,19-tetracosadienvl-1-phosphocholine 969. (Z,Z)-13,20-tetracosadienvl-1-phosphocholine 970. (Z,Z)-14,21-tetracosadienyl-1-phosphocholine 971. (Z,Z)-3,11-tetracosadienyl-1-phosphocholine 972. (Z,Z)-4,12-tetracosadienvl-1-phosphocholine 973. (Z, Z) -5, 13-tetracosadienyl-1-phosphocholine 974. (Z,Z)-6,14-tetracosadienyl-1-phosphocholine 975. (Z,Z)-7,15-tetracosadienyl-1-phosphocholine 976. (Z,Z)-8,16-tetracosadienyl-1-phosphocholine 977 (Z,Z)-9,17-tetracosadienyl-1-phosphocholine 978. (Z,Z)-10,18-tetracosadienvl-1-phosphocholine 979. (Z,Z)-11,19-tetracosadienyl-1-phosphocholine 980. (Z,Z)-12,20-tetracosadienyl-1-phosphocholine 981. (Z,Z)-13,21-tetracosadienyl-1-phosphocholine 982. (Z,Z)-3,12-tetracosadienvl-1-phosphocholine 983. (Z,Z)-4,13-tetracosadienvl-1-phosphocholine

984 (Z,Z)-5,14-tetracosadienvl-1-phosphocholine 985 (Z,Z)-6,15-tetracosadienyl-1-phosphocholine 986. (Z,Z)-7,16-tetracosadienyl-1-phosphocholine (Z,Z)-8,17-tetracosadienyl-1-phosphocholine 987. 988. (Z,Z)-9,18-tetracosadienyl-1-phosphocholine (Z,Z)-10,19-tetracosadienyl-1-phosphocholine 989 (Z,Z)-11,20-tetracosadienyl-1-phosphocholine 990. 991. (Z,Z)-12,21-tetracosadienyl-1-phosphocholine 992. (Z,Z)-3,13-tetracosadienyl-1-phosphocholine 993 (Z,Z)-4,14-tetracosadienyl-1-phosphocholine (Z,Z)-5,15-tetracosadienvl-1-phosphocholine 994. 995. (Z,Z)-6,16-tetracosadienyl-1-phosphocholine (Z,Z)-7,17-tetracosadienyl-1-phosphocholine 996. 997. (Z,Z)-8,18-tetracosadienyl-1-phosphocholine (Z,Z)-9,19-tetracosadienvl-1-phosphocholine 998. 999. (Z.Z)-10.20-tetracosadienvl-1-phosphocholine 1000. (Z,Z)-11,21-tetracosadienyl-1-phosphocholine (Z,Z)-3.14-tetracosadienvl-1-phosphocholine 1001. 1002. (Z,Z)-4,15-tetracosadienyl-1-phosphocholine 1003. (Z,Z)-5,16-tetracosadienyl-1-phosphocholine 1004. (Z,Z)-6.17-tetracosadienvl-1-phosphocholine 1005. (Z,Z)-7,18-tetracosadienyl-1-phosphocholine (Z,Z)-8,19-tetracosadienyl-1-phosphocholine 1006. 1007. (Z,Z)-9,20-tetracosadienyl-1-phosphocholine 1008. (Z,Z)-10,21-tetracosadienyl-1-phosphocholine 1009. (Z,Z)-3,15-tetracosadienyl-1-phosphocholine (Z,Z)-4,16-tetracosadienyl-1-phosphocholine 1010. 1011. (Z,Z)-5,17-tetracosadienyl-1-phosphocholine 1012. (Z,Z)-6,18-tetracosadienyl-1-phosphocholine 1013. (Z,Z)-7,19-tetracosadienyl-1-phosphocholine (Z,Z)-8,20-tetracosadienvl-1-phosphocholine 1014. 1015. (Z,Z)-9,21-tetracosadienyl-1-phosphocholine 1016. (Z,Z)-3,17-tetracosadienyl-1-phosphocholine 1017. (Z,Z)-4,18-tetracosadienyl-1-phosphocholine

1018. (Z,Z)-5,19-tetracosadienyl-1-phosphocholine

1019. (Z,Z)-6,20-tetracosadienyl-1-phosphocholine

1020. (Z,Z)-7,21-tetracosadienyl-1-phosphocholine

1021. (Z,Z)-3,19-tetracosadienyl-1-phosphocholine

1022. (Z,Z)-4,20-tetracosadienyl-1-phosphocholine

1023. (Z,Z)-5,21-tetracosadienyl-1-phosphocholine

25 chain carbon atoms

C30H60NO4P (529.78)

1024. (Z,Z)-6,12-pentacosadienyl-1-phosphocholine

1025. (Z,Z)-9,15-pentacosadienyl-1-phosphocholine

1026. (Z,Z)-6,16-pentacosadienyl-1-phosphocholine

1027. (Z,Z)-9,18-pentacosadienyl-1-phosphocholine

1028. (Z,Z)-10,20-pentacosadienyl-1-phosphocholine

1029. (Z,Z)-13,20-pentacosadienyl-1-phosphocholine

26 chain carbon atoms

C31H62NO4P (543.81)

1030. (Z,Z)-6,12-hexacosadienyl-1-phosphocholine

1031. (Z,Z)-9,15-hexacosadienyl-1-phosphocholine

1032. (Z,Z)-6,16-hexacosadienyl-1-phosphocholine

1033. (Z,Z)-9,18-hexacosadienvl-1-phosphocholine

1034. (Z,Z)-6,20-hexacosadienyl-1-phosphocholine

5. Examples of (Z,Z)-alkadienyl-1-phospho-N,N,Ntrimethylpropylammonium compounds

$$(A = IX; n = 3; R_3, CH_3; m = 1, x = 1; z = 0)$$

$$A - PO_3 - \left[(CH_2)_n - N^* \atop \mathring{R}_3 \right]_m - (CH_2)_X - \left[CH_2 - \left(\begin{matrix} CH \\ OH \end{matrix} \right)_y - CH_2 - O \right]_z - H$$

where A is a diunsaturated alkyl chain of the following structure (s,t,r \geq 0; 8 \leq s+t+r \leq 26):

- 84 -

 $A = O_{(CH_2)_5} (CH_2)_t (CH_2)_t H$

formula IX

1035.) (Z,Z)-5,11-hexadecadienyl-1-phospho-N,N,N-tri-methylpropylammonium

C₂₂H₄₄NO₄P (417.57)

1036.) (Z,Z)-5,11-heptadecadienyl-1-phospho-N,N,N-trimethylpropylammonium

C₂₃H₄₆NO₄P (431.60)

1037.) (Z,Z)-5,11-octadecadienyl-1-phospho-N,N,N-trimethylpropylammonium

 $C_{24}H_{48}NO_4P$ (445.62)

1038.) (Z,Z)-6,12-nonadecadienyl-1-phospho-N,N,N-trimethylpropylammonium
C25H60NO4P (459.65)

1039.) (Z,Z)-10,16-eicosadienyl-1-phospho-N,N,N-trimethylpropylammonium
C26H62NO4P (473.68)

1040.) (Z,Z)-10,16-heneicosadienyl-1-phospho-N,N,N-trimethylpropylammonium

C₂₇H₅₄NO₄P (487.70)

1041.) (Z,Z)-10,16-docosadienyl-1-phospho-N,N,N-trimethylpropylammonium
C20Hc6NO4P (501.73)

1042.) (Z,Z)-10,16-tricosadienyl-1-phospho-N,N,N-trimethylpropylammonium

C29H58NO4P (515.76)

1043.) (Z,Z)-6,18-tetracosadienyl-1-phospho-N,N,N-trimethylpropylammonium $C_{30}H_{60}NO_4P \end{tabular} (529.78)$

6. Examples of (Z,Z)-alkadienyl-1-phospho-N,N,N-trimethylbutylammonium compounds

 $(A = IX; n = 4; R_3; CH_3; m = 1, x = 1; z = 0)$

$$A - PO_3 = \begin{bmatrix} CH_2 \\ CH_2 \\ R_3 \end{bmatrix}_m - (CH_2)_X - \begin{bmatrix} CH_2 - \begin{pmatrix} CH \\ OH \end{pmatrix}_y - CH_2 - O \end{bmatrix}_z - H$$

where A is a diunsaturated alkyl chain of the following structure (s,t,r \geq 0; 8 \leq s+t+r \leq 26):

$$A = O(CH2)S (CH2)t (CH2)t H$$

formula IX

1044.) (Z,Z)-5,11-hexadecadienyl-1-phospho-N,N,N-tri-methylbutylammonium

 $C_{23}H_{46}NO_4P$ (431.60)

- 1045.) (Z,Z)-5,11-heptadecadienyl-1-phospho-N,N,N-trimethylbutylammonium C24H4RNO4P (445.62)
- 1046.) (Z,Z)-5,11-octadecadienyl-1-phospho-N,N,N-trimethylbutylammonium $C_{25}H_{50}NO_4P \end{tabular} \begin{tabular}{ll} (459.65) \end{tabular}$
- 1047.) (Z,Z)-6,12-nonadecadienyl-1-phospho-N,N,N-trimethylbutylammonium

C₂₆H₅₂NO₄P (473.68)

- 1048.) (Z,Z)-10,16-eicosadienyl-1-phospho-N,N,N-trimethylbutylammonium $C_{27}H_{54}NO_4P \end{tabular} \begin{tabular}{ll} (487.70) \end{tabular}$
- 1049.) (Z,Z)-10,16-heneicosadienyl-1-phospho-N,N,N-trimethylbutylammonium

C28H56NO4P (501.73)

- 1050.) (Z,Z)-10,16-docosadienyl-1-phospho-N,N,N-trimethylbutylammonium

 C29H48NO4P (515.76)
- 1051.) (Z,Z)-10,16-tricosadienyl-1-phospho-N,N,N-trimethylbutylammonium

 CnoHsoNOsP (529.78)

1052.) (Z,Z)-6,18-tetracosadienyl-1-phospho-N,N,N-trimethylbutylammonium $C_{31}H_{62}NO_4P \eqno(543.81)$

7. Examples of terminally unsaturated alkadienyl-phosphocholines

 $(A = IX; n = 2; R_3, CH_3; m = 1, x = 1; z = 0)$

$$A - PO_3 - \left[\underbrace{(CH_2)_n - N^2}_{R_3} \right]_m - (CH_2)_x - \left[\underbrace{CH_2 - \left(CH \atop OH \right)_y - CH_2 - O}_z \right]_z - H$$

where A is a diunsaturated alkyl chain of the following structure (s,t \geq 0; r = 0; 8 \leq s+t+r \leq 26):

$$A = O(CH2)5 (CH2)1 (CH2)1H$$

formula IX

- 1053.) (Z)-11,15-hexadecadienyl-1-phosphocholine C2,Ha2NO4P (403.54)
- 1054.) (Z)-11,16-heptadecadienyl-1-phosphocholine C₂₂H₄₄NO₄P (417.57)
- 1055.) (Z)-11,17-octadecadienyl-1-phosphocholine C21H46NO4P (431.60)
- 1056.) (Z)-11,18-nonadecadienyl-1-phosphocholine $C_{24}H_{48}NO_4P \hspace{1cm} (445.62)$
- 1057.) (Z)-11,19-eicosadienyl-1-phosphocholine C26H50NO4P (459.65)
- 1058.) (Z)-11,20-heneicosadienyl-1-phosphocholine CocHsoNO4P (473.68)
- 1059.) (Z)-11,21-docosadienyl-1-phosphocholine $C_{27}H_{54}NO_4P$ (487.70)
- 1060.) (Z)-11,22-tricosadienyl-1-phosphocholine C20H5cNO4P (501.73)
- 1061.) (Z)-11,23-tetracosadienyl-1-phosphocholine $C_{29}H_{58}NO_4P \eqno(515.76)$
- 1062.) (Z)-11,24-pentacosadienyl-1-phosphocholine $C_{30}H_{60}NO_4P \eqno(529.78)$

8. Examples of terminally unsaturated alkadienyl-1phospho-N,N,N-trimethylpropylammonium compounds

 $(A = IX; n = 3; R_3, CH_3; m = 1, x = 1; z = 0)$

$$A - PO_3 - \begin{bmatrix} CH_3 \\ (CH_2)_n - N^+ \\ R_3 \end{bmatrix}_m - (CH_2)_x - \begin{bmatrix} CH_2 - \begin{pmatrix} CH \\ OH \end{pmatrix}_y - CH_2 - O \\ OH \end{bmatrix}_z - H$$

where A is a diunsaturated alkyl chain of the following structure (s,t \geq 0; r = 0; 8 \leq s+t+r \leq 26):

$$A = O(CH2)5 (CH2)1 (CH2)1 + (C$$

formula IX

- 1063.) (Z)-11,15-hexadecadienyl-1-phospho-N,N,N-trimethylpropylammonium
 C22HakNO4P (417.57)
- 1064.) (Z)-11,16-heptadecadienyl-1-phospho-N,N,N-trimethylpropylammonium
 ColHacNOaP (431.60)
- 1065.) (Z)-11,17-octadecadienyl-1-phospho-N,N,N-trimethylpropylammonium C24H48NO4P (445.62)
- 1066.) (Z)-11,18-nonadecadienyl-1-phospho-N,N,N-trimethylpropylammonium
 CosHanNO4P (459.65)
- 1067.) (Z)-11,19-eicosadienyl-1-phospho-N,N,N-trimethylpropylammonium

 CosHapNOsP (473.68)
- 1068.) (Z)-11,20-heneicosadienyl-1-phospho-N,N,N-trimethylpropylammonium $C_{27}H_{54}NO_4P \eqno(487.70)$
- 1069.) (Z)-11,21-docosadienyl-1-phospho-N,N,N-trimethylpropylammonium CoaHacNOaP (501.73)
- 1070.) (Z)-11,22-tricosadienyl-1-phospho-N,N,N-trimethylpropylammonium C₂₉H₅₈NO₄P (515.76)

1071.) (Z)-11,23-tetracosadienyl-1-phospho-N,N,N-trimethylpropylammonium

> CanHanNO4P (529.78)

1072.) (Z)-11,24-pentacosadienyl-1-phospho-N,N,N-trimethylpropylammonium C31H52NO4P (543.81)

9. Examples of terminally unsaturated alkadienyl-1phospho-N,N,N-trimethylbutylammonium compounds

 $(A = IX; n = 4; R_3, CH_3; m = 1, x = 1; z = 0)$

$$A - PO_3 - \left[(CH_2)_n - N^* \atop R_3 \right]_m - (CH_2)_X - \left[CH_2 - \left(\begin{array}{c} CI1 \\ OI1 \end{array} \right)_y - CI1_2 - O \right]_z - H$$

where A is a diunsaturated alkyl chain of the following structure (s.t \geq 0: r = 0: 8 \leq s+t+r \leq 26):

$$A = O (CH2)S (CH2)t (CH2)t H$$

formula IX

1073.) (Z)-11,15-hexadecadienyl-1-phospho-N,N,N-trimethylbutylammonium

C23H46NO4P (431.60)

1074.) (Z)-11,16-heptadecadienyl-1-phospho-N,N,N-trimethylbutylammonium

C24H48NO4P (445.62)

1075.) (Z)-11,17-octadecadienyl-1-phospho-N,N,N-trimethylbutylammonium

> C25H50NO4P (459.65)

1076.) (Z)-11,18-nonadecadienyl-1-phospho-N,N,N-trimethylbutylammonium

(473.68)C26H52NO4P

1077.) (Z)-11,19-eicosadienyl-1-phospho-N,N,N-trimethylbutylammonium

C27H54NO4P (487.70)

1078.) (Z)-11,20-heneicosadienyl-1-phospho-N,N,N-trimethylbutylammonium C28H56NO4P (501.73)

1079.) (Z)-11,21-docosadienyl-1-phospho-N,N,N-tri-methylbutylammonium

C₂₉H₅₈NO₄P (515.76)

1080.) (Z)-11,22-tricosadienyl-1-phospho-N,N,N-tri-methylbutylammonium

 $C_{30}H_{60}NO_4P$ (529.78)

1081.) (Z)-11,23-tetracosadienyl-1-phospho-N,N,N-trimethylbutylammonium

C₃₁H₆₂NO₄P (543.81)

1082.) (Z)-11,24-pentacosadienyl-1-phospho-N,N,N-trimethylbutylammonium

C₃₂H₆₄NO₄P (557.84)

10. Active ingredients based on alkylated (ether)lyso-

<u>lecithins - monounsaturated compounds</u>

(A = III or A = IV; n = 2-6; R_3 , CH_3 ; m = 1, x = 1; z = 0)

$$A-PO_3 \stackrel{\longleftarrow}{-} \begin{bmatrix} CH_2)_n \stackrel{\longleftarrow}{N_1} \\ R_3 \end{bmatrix}_m - \begin{bmatrix} CH_2)_x - \begin{bmatrix} CH_2 - \begin{pmatrix} CH \\ OH \end{pmatrix}_y - CH_2 - O \end{bmatrix}_z - H$$

- 1083.) 1-0-(Z)-6-octadecenyl-2-0-methyl-sn-glycero-3-phosphocholine (n = 2) $C_{27}H_{56}NO_{5}P \qquad (521.72)$
- 1084.) 1-O-(Z)-10-octadecenyl-2-O-methyl-sn-glycero-3-phosphocholine (n = 2)
 C₂₂H₅₆NO₆P (521.72)
- 1085.) 1-O-(Z)-12-octadecenyl-2-O-methyl-sn-glycero-3-phosphocholine (n = 2) $C_{27}H_{56}NO_{6}P \qquad (521.72)$
- 1086.) 1-0-(Z)-6-nonadecenyl-2-0-methyl-sn-glycero-3phosphocholine (n = 2)
 C20H40NOAP (535.75)
- 1087.) 1-0-(Z)-10-nonadecenyl-2-0-methyl-sn-glycero-3phosphocholine (n = 2)
 C28Hs8NO6P (535.75)
- 1088.) 1-0-(Z)-12-nonadecenyl-2-0-methyl-sn-glycero-3-phosphocholine (n = 2)

```
- 90 -
        C_{28}H_{58}NO_{6}P
                          (535.75)
1089.) 1-0-(Z)-6-eicosenyl-2-0-methyl-sn-glycero-3-
        phosphocholine (n = 2)
        C_{29}H_{60}NO_{6}P
                          (549.77)
1090.) 1-0-(Z)-10-eicosenyl-2-0-methyl-sn-glycero-3-
        phosphocholine (n = 2)
        C29H60NO6P
                          (549.77)
        1-0-(Z)-12-eicosenvl-2-0-methyl-sn-glycero-3-
1091.)
        phosphocholine (n = 2)
        C29H60NO6P
                          (549.77)
1092.) 1-0-(Z)-6-heneicosenyl-2-0-methyl-sn-glycero-3-
        phosphocholine (n = 2)
        C30H62NO6P
                          (563.80)
        1-O-(Z)-10-heneicosenyl-2-O-methyl-sn-glycero-
1093.)
        3-phosphocholine (n = 2)
        C30H62NO6P
                          (563.80)
        1-0-(Z)-12-heneicosenvl-2-0-methyl-sn-glycero-
1094.)
        3-phosphocholine (n = 2)
                          (563.80)
        C30H62NO6P
1095.) 1-0-(Z)-6-docosenyl-2-0-methyl-sn-glycero-3-
        phosphocholine (n = 2)
        C31H64NO6P
                          (577.83)
        1-0-(Z)-10-docosenvl-2-0-methyl-sn-glycero-3-
1096.)
        phosphocholine (n = 2)
        C31H64NO6P
                          (577.83)
1097.) 1-0-(Z)-12-docosenyl-2-0-methyl-sn-glycero-3-
        phosphocholine (n = 2)
                          (577.83)
        C31H64NO6P
1098.) 1-0-(Z)-6-tricosenyl-2-0-methyl-sn-glycero-3-
        phosphocholine (n = 2)
        C_{32}H_{66}NO_{6}P
                          (591.86)
```

1099.) 1-O-(Z)-10-tricosenyl-2-O-methyl-sn-glycero-3phosphocholine (n = 2)C32HeeNOeP (591.86)

1100.) 1-0-(Z)-12-tricosenyl-2-0-methyl-sn-glycero-3phosphocholine (n = 2)C32H66NO6P (591.86)

- 1101.) 1-O-(Z)-6-tetracosenyl-2-O-methyl-sn-glycero-3-phosphocholine (n = 2) $C_{33}H_{58}NO_{6}P \qquad (605.89)$
 - C33116814O6F (605.65)
- 1102.) 1-0-(Z)-10-tetracosenyl-2-0-methyl-sn-glycero-3-phosphocholine (n = 2) C=>Hc=NOcP (605.89)
- 1103.) 1-0-(Z)-12-tetracosenyl-2-0-methyl-sn-glycero-3-phosphocholine (n = 2) C13HasNOsP (605.89)
- 1104.) 1-0-(Z)-6-octadecenyl-2-0-methyl-sn-glycero-3-phospho-N,N,N-trimethylpropylammonium (n = 3)

 CoaHeaNOaP (535.75)
- 1105.) 1-O-(Z)-10-octadecenyl-2-O-methyl-sn-glycero-3phospho-N,N,N-trimethylpropylammonium (n = 3)
 C>28HssNOsP (535.75)
- 1106.) 1-0-(Z)-12-octadecenyl-2-0-methyl-sn-glycero-3-phospho-N,N,N-trimethylpropylammonium (n = 3) $C_{28}H_{58}NO_6P$ (535.75)
- 1108.) 1-O-(Z)-10-nonadecenyl-2-O-methyl-sn-glycero-3-phospho-N,N,N-trimethylpropylammonium (n = 3) $C_{29}H_{60}NO_6P$ (549.77)
- 1109.) 1-O-(Z)-12-nonadecenyl-2-O-methyl-sn-glycero-3-phospho-N,N,N-trimethylpropylammonium (n = 3) $C_{29}H_{60}NO_6P \qquad (549.77)$
- 1110.) 1-O-(Z)-6-eicosenyl-2-O-methyl-sn-glycero-3-phospho-N,N,N-trimethylpropylammonium (n = 3) $C_{30}H_{62}NO_6P$ (563.80)
- 1111.) 1-O-(Z)-10-eicosenyl-2-O-methyl-sn-glycero-3-phospho-N,N,N-trimethylpropylammonium (n = 3) $C_{30}H_{62}NO_6P$ (563.80)
- 1112.) 1-0-(Z)-12-eicosenyl-2-0-methyl-sn-glycero-3-phospho-N,N,N-trimethylpropylammonium (n = 3) $C_{30}H_{62}NO_6P \qquad (563.80)$

į,

- 1113.) 1-0-(Z)-6-heneicosenyl-2-0-methyl-sn-glycero-3-phospho-N,N,N-trimethylpropylammonium (n = 3) $C_{31}H_{64}NO_6P \qquad (577.83)$
- 1114.) 1-O-(Z)-10-heneicosenyl-2-O-methyl-sn-glycero-3-phospho-N,N,N-trimethylpropylammonium (n = 3) C11Hc4NOcP (577.83)
- 1115.) 1-0-(Z)-12-heneicosenyl-2-0-methyl-sn-glycero-3-phospho-N,N,N-trimethylpropylammonium (n = 3) $C_{31}H_{64}NO_6P \qquad (577.83)$
- 1116.) 1-O-(Z)-6-docosenyl-2-O-methyl-sn-glycero-3-phospho-N,N,N-trimethylpropylammonium (n = 3) $C_{12}H_{66}NO_6P \hspace{1cm} (591.86)$
- 1117.) 1-O-(Z)-10-docosenyl-2-O-methyl-sn-glycero-3phospho-N,N,N-trimethylpropylammonium (n = 3)
 C₁₂H₆₆NO₆P (591.86)
- 1118.) 1-O-(Z)-12-docosenyl-2-O-methyl-sn-glycero-3-phospho-N,N,N-trimethylpropylammonium (n = 3)

 C12H66NO6P (591.86)
- 1119.) 1-O-(Z)-6-tricosenyl-2-O-methyl-sn-glycero-3-phospho-N,N,N-trimethylpropylammonium (n = 3) $C_{33}H_{68}NO_6P$ (605.89)
- 1120.) 1-0-(Z)-10-tricosenyl-2-0-methyl-sn-glycero-3-phospho-N,N,N-trimethylpropylammonium (n = 3) $C_{13}H_{68}NO_{5}P \qquad (605.89)$
- 1121.) 1-0-(Z)-12-tricosenyl-2-0-methyl-sn-glycero-3-phospho-N,N,N-trimethylpropylammonium (n = 3) $C_{33}H_{68}NO_{6}P \qquad (605.89)$
- 1122.) 1-O-(Z)-6-tetracosenyl-2-O-methyl-sn-glycero-3-phospho-N,N,N-trimethylpropylammonium (n = 3) $C_{34}H_{70}NO_5P \qquad (619.91)$
- 1123.) 1-0-(Z)-10-tetracosenyl-2-0-methyl-sn-glycero-3-phospho-N,N,N-trimethylpropylammonium (n = 3) $C_{34}H_{70}NO_5P$ (619.91)
- 1124.) 1-O-(Z)-12-tetracosenyl-2-O-methyl-sn-glycero-3-phospho-N,N,N-trimethylpropylammonium (n = 3) C₃₄H₇₀NO₄P (619.91)

- 1125.) 1-0-(Z)-6-octadecenyl-2-0-methyl-sn-glycero-3-phospho-N,N,N-trimethylbutylammonium (n = 4) $C_{20}H_{60}NO_6P$ (549.77)
- 1126.) 1-O-(Z)-10-octadecenyl-2-O-methyl-sn-glycero-3-phospho-N,N,N-trimethylbutylammonium (n = 4) $C_{20}H_{60}NO_6P$ (549.77)
- 1127.) 1-O-(Z)-12-octadecenyl-2-O-methyl-sn-glycero-3-phospho-N,N,N-trimethylbutylammonium (n = 4) $C_{29}H_{60}NO_{6}P \qquad (549.77)$
- 1128.) 1-0-(Z)-6-nonadecenyl-2-0-methyl-sn-glycero-3-phospho-N,N,N-trimethylbutylammonium (n = 4)

 C10H60NOcP (563.80)
- 1129.) 1-0-(Z)-10-nonadecenyl-2-0-methyl-sn-glycero-3-phospho-N,N,N-trimethylbutylammonium (n = 4) $C_{30H62}NO_6P$ (563.80)
- 1130.) 1-0-(Z)-12-nonadecenyl-2-0-methyl-sn-glycero-3phospho-N,N,N-trimethylbutylammonium (n = 4)
 C10He2NOeP (563.80)
- 1131.) 1-0-(Z)-6-eicosenyl-2-0-methyl-sn-glycero-3-phospho-N,N,N-trimethylbutylammonium (n = 4) $C_{31}H_{64}NO_{6}P$ (577.83)
- 1132.) 1-O-(Z)-10-eicosenyl-2-O-methyl-sn-glycero-3-phospho-N,N,N-trimethylbutylammonium (n = 4) $C_{31}H_{64}NO_6P$ (577.83)
- 1133.) 1-O-(Z)-12-eicosenyl-2-O-methyl-sn-glycero-3-phospho-N,N,N-trimethylbutylammonium (n = 4) $C_{31}H_{64}NO_6P$ (577.83)
- 1134.) 1-O-(Z)-6-heneicosenyl-2-O-methyl-sn-glycero-3-phospho-N,N,N-trimethylbutylammonium (n = 4) $C_{32}H_{56}NO_6P$ (591.86)
- 1135.) 1-0-(Z)-10-heneicosenyl-2-O-methyl-sn-glycero-3-phospho-N,N,N-trimethylbutylammonium (n = 4) CtyHckNOcP (591.86)
- 1136.) 1-0-(Z)-12-heneicosenyl-2-O-methyl-sn-glycero-3-phospho-N,N,N-trimethylbutylammonium (n = 4) $C_{12}H_{66}NO_6P$ (591.86)

C₃₃H₆₈NO₆P (605.89)

- 1138.) 1-O-(Z)-10-docosenyl-2-O-methyl-sn-glycero-3-phospho-N,N,N-trimethylbutylammonium (n = 4) $C_{33}H_{68}NO_6P \qquad (605.89)$
- 1139.) 1-O-(Z)-12-docosenyl-2-O-methyl-sn-glycero-3-phospho-N,N,N-trimethylbutylammonium (n = 4) $C_{33}H_{68}NO_6P$ (605.89)
- 1140.) 1-0-(Z)-6-tricosenyl-2-0-methyl-sn-glycero-3-phospho-N,N,N-trimethylbutylammonium (n = 4) $C_{34}H_{70}NO_6P$ (619.91)
- 1141.) 1-0-(Z)-10-tricosenyl-2-0-methyl-sn-glycero-3-phospho-N,N,N-trimethylbutylammonium (n = 4) $C_{34}H_{70}NO_6P$ (619.91)
- 1142.) 1-0-(Z)-12-tricosenyl-2-0-methyl-sn-glycero-3-phospho-N,N,N-trimethylbutylammonium (n = 4) $C_{14}H_{70}NO_{6}P \qquad (619.91)$
- 1143.) 1-O-(Z)-6-tetracosenyl-2-O-methyl-sn-glycero-3-phospho-N,N,N-trimethylbutylammonium (n = 4) $C_{35}H_{72}NO_6P$ (633.93)
- 1144.) 1-0-(Z)-10-tetracosenyl-2-0-methyl-sn-glycero-3-phospho-N,N,N-trimethylbutylammonium (n = 4) C35H72NO6P (633.93)
- 1145.) 1-0-(Z)-12-tetracosenyl-2-O-methyl-sn-glycero-3-phospho-N,N,N-trimethylbutylammonium (n = 4) $C_{15}H_{72}NO_{6}P$ (633.93)
- 1146.) 1-0-(Z)-10-octadecenyl-3-0-methyl-sn-glycero-2-phosphocholine (n = 2)

 C₂₇H₅₆NO₆P (521.72)
- 1147.) 1-0-(Z)-6-nonadecenyl-3-0-methyl-sn-glycero-2-phosphocholine (n = 2) $C_{28}H_{48}NO_6P$ (535.75)
- 1148.) 1-O-(Z)-12-eicosenyl-3-O-methyl-sn-glycero-2-phosphocholine (n = 2) $C_{29}H_{60}NO_6P \hspace{1cm} (549.77)$
- 1149.) 1-0-(Z)-10-heneicosenyl-3-0-methyl-sn-glycero-2-phosphocholine (n = 2) $C_{30}H_{62}NO_6P$ (563.80)

- 1150.) 1-0-(Z)-10-docosenyl-3-0-methyl-sn-glycero-2-phosphocholine (n = 2) $C_{33}H_{54}NO_{5}P$ (577.83)
- 1151.) 1-O-(Z)-12-docosenyl-3-O-methyl-sn-glycero-2-phosphocholine (n = 2) $C_{31}H_{64}NO_{6}P \qquad (577.83)$
- 1152.) 1-0-(Z)-10-tricosenyl-3-0-methyl-sn-glycero-2phosphocholine (n = 2)
 C12HacNOaP (591.86)
- 1153.) 1-0-(Z)-10-tetracosenyl-3-O-methyl-sn-glycero-2-phosphocholine (n = 2) $C_{33}H_{68}NO_6P \qquad (605.89)$
- 1154.) 1-O-(Z)-10-octadecenyl-3-O-methyl-sn-glycero-2-phospho-N,N,N-trimethylpropylammonium (n = 3) $C_{28}H_{58}NO_6P$ (535.75)
- 1155.) 1-0-(Z)-6-nonadecenyl-3-0-methyl-sn-glycero-2phospho-N,N,N-trimethylpropylammonium (n = 3)
 C:oHooNOoP (549.77)
- 1156.) 1-O-(Z)-12-eicosenyl-3-O-methyl-sn-glycero-2-phospho-N,N,N-trimethylpropylammonium (n = 3) $C_{30}H_{62}NO_6P$ (563.80)
- 1157.) 1-O-(Z)-10-heneicosenyl-3-O-methyl-sn-glycero-2-phospho-N,N,N-trimethylpropylammonium (n = 3) $C_{31}H_{64}NO_6P$ (577.83)
- 1158.) 1-0-(Z)-10-docosenyl-3-0-methyl-sn-glycero-2-phospho-N,N,N-trimethylpropylammonium (n = 3)

 C12HacNOaP (591.86)
- 1159.) 1-O-(Z)-12-docosenyl-3-O-methyl-sn-glycero-2phospho-N,N,N-trimethylpropylammonium (n = 3)
 C12HeeNOeP (591.86)
- 1160.) 1-0-(Z)-10-tricosenyl-3-0-methyl-sn-glycero-2phospho-N,N,N-trimethylpropylammonium (n = 3)
 C13Hc2NOcP (605.89)
- 1161.) 1-O-(Z)-10-tetracosenyl-3-O-methyl-sn-glycero-2-phospho-N,N,N-trimethylpropylammonium (n = 3) C₂₄H₇₀NO₆P (619.91)

```
1162.) 1-0-(Z)-10-octadecenvl-2-0-tert-butvl-sn-
        qlycero-3-phosphocholine (n = 2)
        C30H62NO6P
                         (563.80)
1163.) 1-0-(Z)-6-nonadecenvl-2-0-tert-butyl-sn-
        glycero-3-phosphocholine (n = 2)
        C31H64NO6P
                         (577.82)
1164.) 1-0-(Z)-12-eicosenvl-2-0-tert-butyl-sn-glycero-
        3-phosphocholine (n = 2)
        C32H66NO6P
                         (591.85)
1165.) 1-0-(Z)-10-heneicosenvl-2-0-tert-butyl-sn-
        glycero-3-phosphocholine (n = 2)
        C33H69NO6P
                         (605.88)
1166.) 1-0-(Z)-10-docosenyl-2-0-tert-butyl-sn-glycero-
        3-phosphocholine (n = 2)
        C34H70NO6P
                         (619.91)
1167.) 1-0-(Z)-12-docosenyl-2-0-tert-butyl-sn-glycero-
        3-phosphocholine (n = 2)
        C34H70NO6P
                         (619.91)
        1-0-(Z)-10-tricosenvl-2-0-tert-butvl-sn-
1168.)
        glycero-3-phosphocholine (n = 2)
        C35H72NO6P
                         (633.94)
1169.) 1-0-(Z)-10-tetracosenyl-2-0-tert-butyl-sn-
        glycero-3-phosphocholine (n = 2)
                         (647.97)
        C36H74NO6P
1170.) 1-0-(Z)-10-octadecenyl-2-0-tert-butyl-sn-
        glycero-3-phospho-N,N,N-trimethylpropylammonium
        (n = 3)
        C31H64NO6P
                         (577.82)
1171.) 1-0-(Z)-6-nonadecenvl-2-0-tert-butvl-sn-
        glycero-3-phospho-N,N,N-trimethylpropylammonium
        (n = 3)
        C32H66NO6P
                         (591.85)
1172.) 1-0-(Z)-12-eicosenyl-2-0-tert-butyl-sn-glycero-
```

3-phospho-N,N,N-trimethylpropylammonium (n = 3)

(605.88)

C33Hc8NOcP

- 1173.) 1-0-(Z)-10-heneicosenyl-2-0-tert-butyl-sn-glycero-3-phospho-N,N,N-trimethylpropylammonium (n = 3) $C_{34}H_{70}NO_6P \qquad (619.91)$
- 1174.) 1-O-(Z)-10-docosenyl-2-O-tert-butyl-sn-glycero-3-phospho-N,N,N-trimethylpropylammonium (n = 3) $C_{3}H_{72}NO_6P \qquad (633.94)$
- 1175.) 1-O-(Z)-12-docosenyl-2-O-tert-butyl-sn-glycero-3-phospho-N,N,N-trimethylpropylammonium (n = 3) CasHarNOeP (633.94)
- 1176.) 1-O-(Z)-10-tricosenyl-2-O-tert-butyl-sn-glycero-3-phospho-N,N,N-trimethylpropylammonium (n = 3) $C_{36}H_{74}NO_6P$ (647.97)

11. Active ingredients based on alkylated (ether) lysolecithins - diunsaturated compounds

(A = III or A = IV; n = 2-6; R_3 , CH_3 ; m = 1, x = 1; z = 0)

$$A - PO_3 - \begin{bmatrix} CH_2 \\ CCH_2 \\ R_3 \end{bmatrix}_m - (CH_2)_x - \begin{bmatrix} CH_2 \\ CH_2 - \begin{pmatrix} CH \\ OH \end{pmatrix}_y - CH_2 - O \end{bmatrix}_z - H_z - O = CH_2 - O = CH$$

$\underline{1\text{-O-}(Z,Z)}\text{-Alkadienyl-2-O-methyl-sn-glycero-3-phosphocholines}$

- 1178.) 1-O-(Z,Z)-6,12-hexadecadienyl-2-O-methyl-sn-glycero-3-phosphocholine (n = 2) $C_{25}H_{50}NO_6P$ (491.65)
- 1179.) 1-0-(Z,Z)-6,12-heptadecadienyl-2-0-methyl-sn-glycero-3-phosphocholine (n = 2) $C_{26}H_{52}NO_6P$ (505.68)

- 1180.) 1-0-(Z,Z)-6,12-octadecadienvl-2-0-methyl-snglycero-3-phosphocholine (n = 2)C27H54NO6P (519.71)
- 1181.) 1-0-(Z,Z)-6,12-nonadecadienvl-2-0-methyl-snglvcero-3-phosphocholine (n = 2)CasHseNOsP (533.74)
- 1182.) 1-O-(Z,Z)-9,15-eicosadienyl-2-O-methyl-snglycero-3-phosphocholine (n = 2)(547.77)C29H58NO6P
- 1183.) 1-0-(Z,Z)-9.15-heneicosadienvl-2-0-methyl-snglycero-3-phosphocholine (n = 2)C30H60NO6P (561.8)
- 1184.) 1-0-(Z,Z)-5,17-docosadienyl-2-0-methyl-snglycero-3-phosphocholine (n = 2)C31H62NO6P (575.83)
- 1185.) 1-0-(Z,Z)-6,18-tricosadienyl-2-0-methyl-snqlycero-3-phosphocholine (n = 2)C32H64NO6P (589.86)
- 1186.) 1-0-(Z,Z)-6,18-tetracosadienvl-2-0-methyl-snglvcero-3-phosphocholine (n = 2)C33H66NO6P (603.89)
- 1187.) 1-0-(Z,Z)-6,18-pentacosadienyl-2-0-methyl-snglycero-3-phosphocholine (n = 2)C34H68NO6P (617.92)

1-0-(Z,Z)-Alkadienyl-2-0-methyl-sn-glycero-3-phospho-N, N, N-trimethylpropylammonium compounds

1188.) 1-0-(Z,Z)-6,12-hexadecadienyl-2-0-methyl-snglycero-3-phospho-N, N, N-trimethylpropylammonium (n = 3)(505.68)

C26H52NO6P

C27H54NO6P

1189.) 1-0-(Z,Z)-6,12-heptadecadienyl-2-0-methyl-snglycero-3-phospho-N, N, N-trimethylpropylammonium (n = 3)(519.71)

C30H60NO6P

- 1-O-(Z,Z)-6,12-octadecadienyl-2-O-methyl-sn-1190.) glycero-3-phospho-N, N, N-trimethylpropylammonium (n = 3)C28H56NO6P (533.74)
- 1-O-(Z,Z)-6,12-nonadecadienyl-2-O-methyl-sn-1191.) glycero-3-phospho-N.N.N-trimethylpropylammonium (n = 3) $C_{29}H_{58}NO_{6}P$ (547.77)
- 1192.) 1-O-(Z,Z)-9,15-eicosadienyl-2-O-methyl-snglycero-3-phospho-N,N,N-trimethylpropylammonium (n = 3)(561.8)
- 1193.) 1-0-(Z,Z)-9,15-heneicosadienyl-2-0-methyl-snglycero-3-phospho-N, N, N-trimethylpropylammonium (n = 3)(575.83) C31H62NO6P
- 1194.) 1-0-(Z,Z)-5.17-docosadienvl-2-0-methyl-snglycero-3-phospho-N,N,N-trimethylpropylammonium (n = 3)C32H64NO6P (589.86)
- 1195.) 1-0-(Z,Z)-6.18-tricosadienyl-2-0-methyl-snglycero-3-phospho-N, N, N-trimethylpropylammonium (n = 3) $C_{33}H_{66}NO_6P$ (603.89)
- 1-O-(Z,Z)-6,18-tetracosadienyl-2-O-methyl-snglycero-3-phospho-N,N,N-trimethylpropylammonium (n = 3)C34H68NO6P (617.92)
- 1197.) 1-0-(Z,Z)-6,18-pentacosadienyl-2-0-methyl-snglycero-3-phospho-N,N,N-trimethylpropylammonium (n = 3)C35H70NO6P (631.95)

1-O-(Z,Z)-Alkadienyl-2-O-methyl-sn-glycero-3-phospho-N,N,N-trimethylbutylammonium compounds

- 1198.) 1-0-(Z,Z)-6,12-hexadecadienyl-2-0-methyl-snglycero-3-phospho-N,N,N-trimethylbutylammonium
 (n = 4)
 - C₂₇H₅₄NO₆P (519.71)
- 1199.) 1-0-(Z,Z)-6,12-heptadecadienyl-2-0-methyl-snglycero-3-phospho-N,N,N-trimethylbutylammonium
 (n = 4)
 C>0HecNOcP (533.74)
- 1200.) 1-0-(Z,Z)-6,12-octadecadienyl-2-0-methyl-sn-glycero-3-phospho-N,N,N-trimethylbutylammonium (n = 4) $C_{29}H_{58}NO_6P \hspace{1cm} (547.77)$
- 1201.) 1-0-(Z,Z)-6,12-nonadecadienyl-2-0-methyl-sn-glycero-3-phospho-N,N,N-trimethylbutylammonium (n = 4)

 CanHanNoaP (561.8)
- 1202.) 1-0-(Z,Z)-9,15-eicosadienyl-2-0-methyl-snglycero-3-phospho-N,N,N-trimethylbutylammonium
 (n = 4)
 C11Hc1NOcP (575.83)
- 1203.) 1-0-(Z,Z)-9,15-heneicosadienyl-2-O-methyl-sn-glycero-3-phospho-N,N,N-trimethylbutylammonium (n = 4)

 C12 $H_{64}NO_6P$ (589.86)
- 1204.) 1-0-(Z,Z)-5,17-docosadienyl-2-0-methyl-sn-glycero-3-phospho-N,N,N-trimethylbutylammonium (n = 4)
 - C33H66NO6P (603.89)
- 1205.) 1-0-(Z,Z)-6,18-tricosadienyl-2-0-methyl-snglycero-3-phospho-N,N,N-trimethylbutylammonium (n = 4) C14Hc0NOcP (617.92)
- 1206.) 1-0-(Z,Z)-6,18-tetracosadienyl-2-0-methyl-snglycero-3-phospho-N,N,N-trimethylbutylammonium
 (n = 4)

C35H70NO6P (631.95)

1207.) 1-0-(Z,Z)-6,18-pentacosadieny1-2-0-methy1-snglycero-3-phospho-N,N,N-trimethylbutylammonium
(n = 4)
C36H32NO6P (645.94)

1-O-(Z,Z)-Alkadienyl-3-O-methyl-sn-glycero-2-phosphocholine (n = 2)

- 1208.) 1-0-(Z,Z)-6,12-hexadecadienyl-3-0-methyl-sn-glycero-2-phosphocholine (n = 2)

 C₂₅H₅₀NO₆P (491.65)
- 1209.) 1-O-(Z,Z)-6,12-heptadecadienyl-3-O-methyl-sn-glycero-2-phosphocholine (n = 2) $C_{26}H_{52}NO_6P \hspace{1cm} (505.68)$
- 1210.) 1-0-(Z,Z)-6,12-octadecadienyl-3-0-methyl-sn-glycero-2-phosphocholine (n = 2)

 C27 $H_{54}NO_6P$ (519.71)
- 1211.) 1-0-(Z,Z)-6,12-nonadecadienyl-3-0-methyl-sn-glycero-2-phosphocholine (n = 2) $C_{28}H_{56}NO_6P \eqno(533.74)$
- 1212.) 1-O-(Z,Z)-9,15-eicosadienyl-3-O-methyl-sn-glycero-2-phosphocholine (n = 2) $C_{29}H_{58}NO_{6}P \hspace{1cm} (547.77)$
- 1213.) 1-O-(Z,Z)-9,15-heneicosadienyl-3-O-methyl-sn-glycero-2-phosphocholine (n = 2) $C_{30}H_{60}NO_6P$ (561.8)
- 1214.) 1-0- $\langle Z, Z \rangle$ -5,17-docosadienyl-3-0-methyl-sn-glycero-2-phosphocholine (n = 2) $C_{31}H_{62}NO_6P$ (575.83)
- 1215.) 1-0-(Z,Z)-6,18-tricosadienyl-3-0-methyl-snglycero-2-phosphocholine (n = 2) C₂₂H₆₄NO₆P (589.86)
- 1216.) 1-O-(Z,Z)-6,18-tetracosadienyl-3-O-methyl-sn-glycero-2-phosphocholine (n = 2) $C_{29}H_{58}NO_4P \hspace{1cm} (515.76)$
- 1217.) 1-0-(Z,Z)-6,18-pentacosadienyl-3-0-methyl-sn-glycero-2-phosphocholine (n = 2)

C₃₄H₆₈NO₆P (617.92)

1-O-(Z,Z)-Alkadienyl-3-O-methyl-sn-glycero-2-phospho-N,N,N-trimethylpropylammonium compounds

- 1218.) 1-O-(Z,Z)-6,12-hexadecadienyl-3-O-methyl-sn-glycero-2-phospho-N,N,N-trimethylpropylammonium (n=3) $C_{25}H_{52}NO_6P \qquad (505.68)$
- 1219.) 1-O-(Z,Z)-6,12-heptadecadienyl-3-O-methyl-sn-glycero-2-phospho-N,N,N-trimethylpropylammonium (n = 3)
 - $C_{27}H_{54}NO_6P$ (519.71)
- 1220.) 1-O-(Z,Z)-6,12-octadecadienyl-3-O-methyl-sn-glycero-2-phospho-N,N,N-trimethylpropylammonium (n = 3) $C_{28}H_{56}NO_6P$ (533.74)
- 1221.) 1-O-(Z,Z)-6,12-nonadecadienyl-3-O-methyl-sn-glycero-2-phospho-N,N,N-trimethylpropylammonium (n = 3) $C_{29}H_{5R}NO_6P \qquad (547.77)$
- 1222.) 1-O-(Z,Z)-9,15-eicosadienyl-3-O-methyl-sn-glycero-2-phospho-N,N,N-trimethylpropylammonium (n = 3) $C_{30}H_{50}NO_5P \qquad (561.8)$
- 1223.) 1-O-(Z,Z)-9,15-heneicosadienyl-3-O-methyl-sn-glycero-2-phospho-N,N,N-trimethylpropylammonium (n = 3) $C_{31}H_{52}NO_5P \hspace{1cm} (575.83)$
- 1224.) 1-O-(Z,Z)-5,17-docosadienyl-3-O-methyl-sn-glycero-2-phospho-N,N,N-trimethylpropylammonium (n = 3) $C_{32}H_{64}NO_6P$ (589.86)

- 103 -

- 1226.) 1-O-(Z,Z)-6,18-tetracosadienyl-3-O-methyl-sn-glycero-2-phospho-N,N,N-trimethylpropylammonium (n = 3) $C_{14}H_{46}NO_6P$ (617.92)
- 1227.) 1-O-(Z,Z)-6,18-pentacosadienyl-3-O-methyl-sn-glycero-2-phospho-N,N,N-trimethylpropylammonium (n = 3) $C_{35}H_{70}NO_{5}P \qquad (631.95)$

$\frac{1-O-(Z,Z)-Alkadienyl-2-O-tert-butyl-sn-glycero-3-phosphocholine~(n = 2)$

- 1228.) 1-0-(Z,Z)-6,12-hexadecadienyl-2-0-tert-butyl-sn-glycero-3-phosphocholine (n = 2) $C_{28}H_{56}NO_5P$ (533.73)
- 1230.) 1-0-(Z,Z)-6,12-octadecadienyl-2-0-tert-butyl-sn-glycero-3-phosphocholine (n = 2) $C_{30}H_{60}NO_6P \end{tabular} (561.78)$
- 1231.) 1-0-(Z,Z)-6,12-nonadecadienyl-2-0-tert-butyl-sn-glycero-3-phosphocholine (n = 2) $C_{13}H_{62}NO_6P$ (575.81)
- 1232.) 1-0-(Z, Z) -9,15-eicosadienyl-2-0-tert-butyl-sn-glycero-3-phosphocholine (n = 2) $C_{12}H_{64}NO_6P$ (589.84)
- 1233.) 1-0-(Z,Z)-9,15-heneicosadienyl-2-0-tert-butylsn-glycero-3-phosphocholine (n = 2)
 C13H6cNO6P (603.87)
- 1234.) 1-0-(Z,Z)-5,17-docosadienyl-2-0-tert-butyl-snglycero-3-phosphocholine (n = 2) C14H60NO6P (617.9)
- 1235.) 1-0-(Z,Z)-6,18-tricosadienyl-2-0-tert-butyl-snglycero-3-phosphocholine (n = 2)
 C3-H30NO6P (631.93)
- 1236.) 1-0-(Z,Z)-6,18-tetracosadienyl-2-0-tert-butyl-sn-glycero-3-phosphocholine (n = 2)

```
C36H72NO6P (645.96)
```

1237.) 1-0-(Z,Z)-6,18-pentacosadienyl-2-0-tert-butylsn-glycero-3-phosphocholine (n = 2) C₃₇H₇₄NO₆P (660.03)

1-O-(Z,Z)-Alkadienyl-2-O-tert-butyl-sn-glycero-3phospho-N,N,N-trimethylpropylammonium compounds

1238.) 1-O-(Z,Z)-6,12-hexadecadienyl-2-O-tert-butyl-sn-glycero-3-phospho-N,N,N-trimethylpropyl-ammonium (n = 3) $C_{29}H_{58}NO_{6}P \hspace{1cm} (547.76)$

1239.) 1-0-(Z,Z)-6,12-heptadecadienyl-2-0-tert-butyl-sn-glycero-3-phospho-N,N,N-trimethylpropyl-ammonium (n = 3)

CloHeoNOeP (561.78)

1240.) 1-0-(Z,Z)-6,12-octadecadienyl-2-0-tert-butylsn-glycero-3-phospho-N,N,N-trimethylpropylammonium (n = 3)
C1Hc2NOcP (575.81)

1241.) 1-O-(Z,Z)-6,12-nonadecadienyl-2-O-tert-butyl-sn-glycero-3-phospho-N,N,N-trimethylpropyl-ammonium (n = 3) $C_{12}H_{64}NO_6P \hspace{1cm} (589.84)$

1242.) 1-0-(Z,Z)-9,15-eicosadienyl-2-0-tert-butyl-snglycero-3-phospho-N,N,N-trimethylpropylammonium
(n = 3)
C13H66NO6P (603.87)

1243.) 1-0-(Z,Z)-9,15-heneicosadienyl-2-0-tert-butyl-sn-glycero-3-phospho-N,N,N-trimethylpropyl-ammonium (n = 3)

C14HcsNOcP (617.9)

1244.) 1-O-(Z,Z)-5,17-docosadienyl-2-O-tert-butyl-sn-glycero-3-phospho-N,N,N-trimethylpropylammonium (n = 3) C3-H70NO-P (631.93)

1245.) 1-0-(Z,Z)-6,18-tricosadienyl-2-0-tert-butyl-snglycero-3-phospho-N,N,N-trimethylpropylammonium (n = 3)

CasHaaNOsP (645.96)

1246.) 1-0-(Z,Z)-6,18-tetracosadienyl-2-0-tert-butylsn-qlycero-3-phospho-N,N,N-trimethylpropylammonium (n = 3)

C37H74NO6P (660.03)

1247.) 1-0-(Z,Z)-6,18-pentacosadienyl-2-0-tert-butylsn-glycero-3-phospho-N, N, N-trimethylpropylammonium (n = 3)C38H76NO6P (674.03)

12. Active ingredients based on alkanediol-phospho compounds - monounsaturated compounds

 $(A = VI \text{ or } VII; n = 2-6; R_3, CH_3; m = 1, x = 1; z = 0)$

$$A - PO_{3} - \left[(CH_{2})_{n} - \overset{CH_{3}}{\overset{N^{+}}{\stackrel{N}{R}_{3}}} \right]_{m} - (CH_{2})_{X} - \left[CH_{2} - \left(\overset{CH}{OH} \right)_{y} - CH_{2} - O \right]_{z} - H$$

1-0-(Z)-Alkenylpropanediol-(1,2)-phosphocholines

1248.) 1-0-(Z)-10-octadecenylpropanediol-(1,2)phosphocholine

> C26H54NO5P (491.68)

1249.) 1-0-(Z)-6-nonadecenylpropanediol-(1,2)phosphocholine

C27H56NO5P (505.71)

1-O-(Z)-12-eicosenylpropanediol-(1,2)-1250.) phosphocholine C28H58NO5P (519.74)

1251.) 1-0-(Z)-10-heneicosenylpropanediol-(1,2)phosphocholine

C29H60NO5P (533.77)

1252.) 1-0-(Z)-10-docosenylpropanediol-(1,2)phosphocholine C30H62NO5P (547.80)

- 106 -

1253.) 1-0-(Z)-12-docosenylpropanediol-(1,2)-phosphocholine

 $C_{30}H_{62}NO_5P$ (547.80)

1254.) 1-0-(Z)-10-tricosenylpropanediol-(1,2)-phosphocholine

C31H64NO5P (561.83)

1255.) 1-0-(Z)-10-tetracosenylpropanediol-(1,2)phosphocholine
C12HeeNOsP (575.86)

1-O-(Z)-Alkenylpropanediol-(1,2)-phospho-N,N,Ntrimethylpropylammonium compounds

1256.) 1-0-(Z)-10-octadecenylpropanediol-(1,2)phospho-N,N,N-trimethylpropylammonium $C_{27}H_{56}NO_5P \qquad (505.71)$

- 1257.) 1-0-(Z)-6-nonadecenylpropanediol-(1,2)-phospho-N,N,N-trimethylpropylammonium C28H56NO5P (519.74)
- 1258.) 1-O-(Z)-12-eicosenylpropanediol-(1,2)-phospho-N,N,N-trimethylpropylammonium $C_{29}H_{60}NO_5P \end{tabular} (533.77)$
- 1259.) 1-0-(Z)-10-heneicosenylpropanediol-(1,2)phospho-N,N,N-trimethylpropylammonium

 C30H62NO5P (547.80)
- 1260.) 1-0-(Z)-10-docosenylpropanediol-(1,2)-phospho-N,N,N-trimethylpropylammonium C1HaNOaP (561.83)
- 1261.) 1-0-(Z)-12-docosenylpropanediol-(1,2)-phospho-N,N,N-trimethylpropylammonium ColHa,NOaP (561.83)
- 1262.) 1-O-(Z)-10-tricosenylpropanediol-(1,2)-phosphoN,N,N-trimethylpropylammonium
 C12Hc6NOsP (575.86)
- 1263.) 1-0-(Z)-10-tetracosenylpropanediol-(1,2)-phospho-N,N,N-trimethylpropylammonium $C_{33}H_{58}NO_5P \eqno(589.89)$

2-O-(Z)-Alkenylpropanediol-(1,2)-phosphocholines

1264.) 2-0-(Z)-10-octadecenylpropanediol-(1,2)phosphocholine

> C26H54NO5P (491.68)

2-O-(Z)-6-nonadecenylpropanediol-(1,2)-1265.) phosphocholine (505.71)

C27H56NO5P

2-O-(Z)-12-eicosenylpropanediol-(1,2)phosphocholine CasHasNOsP (519.74)

1267.) 2-0-(Z)-10-heneicosenylpropanediol-(1,2)-

- phosphocholine C29H60NOsP (533.77)
- 1268.) 2-0-(Z)-10-docosenylpropanediol-(1,2)phosphocholine C30H62NO5P (547.80)
- 1269.) 2-0-(Z)-12-docosenylpropanediol-(1,2)phosphocholine $C_{30}H_{62}NO_5P$ (547.80)
- 1270.) 2-0-(Z)-10-tricosenylpropanediol-(1,2)phosphocholine
 - C31H64NO5P (561.83)
- 1271.) 2-0-(Z)-10-tetracosenylpropanediol-(1,2)phosphocholine C32HeeNOsP (575.86)

2-0-(Z)-Alkenylpropanediol-(1,2)-phospho-N,N,Ntrimethylpropylammonium compounds

- 1272.) 2-0-(Z)-10-octadecenylpropanediol-(1,2)phospho-N, N, N-trimethylpropylammonium C27H56NO5P (505.71)
- 1273.) 2-O-(Z)-6-nonadecenylpropanediol-(1,2)-phospho-N, N, N-trimethylpropylammonium C28H58NO5P (519.74)
- 1274.) 2-0-(Z)-12-eicosenylpropanediol-(1,2)-phospho-N, N, N-trimethylpropylammonium

- 108 -

C29H60NO5P (533.77)

- 1275.) 2-O-(Z)-10-heneicosenylproparediol-(1,2)phospho-N,N,N-trimethylpropylammonium
 C30Hg2NOsP (547.80)
- 1276.) 2-0-(Z)-10-docosenylpropanediol-(1,2)-phospho-N,N,N-trimethylpropylammonium $C_{11}H_{64}NO_5P$ (561.83)
- 1277.) 2-0-(Z)-12-docosenylpropanediol-(1,2)-phospho-N,N,N-trimethylpropylammonium C1H44N0sP (561.83)
- 1278.) 2-0-(Z)-10-tricosenylpropanediol-(1,2)-phospho-N,N,N-trimethylpropylammonium C12Ha6NOsP (575.86)
- 1279.) 2-0-(Z)-10-tetracosenylpropanediol-(1,2)phospho-N,N,N-trimethylpropylammonium $C_{33}H_{68}NO_5P \qquad (589.89)$

13. Active ingredients based on alkanediol-phospho compounds - diunsaturated compounds

 $(A = VI \text{ or } VII; n = 2-6; R_3, CH_3; m = 1, x = 1; z = 0)$

$$A - PO_3 - \left[(CH_2)_n - \overset{CH_3}{\overset{N}{R}_3} \right]_m - (CH_2)_x - \left[CH_2 - \left(\overset{CH}{\overset{OH}{\tilde{H}}} \right)_y - CH_2 - O \right]_z - H$$

1-0-(Z,Z)-Alkadienylpropanediol-(1,2)-phosphocholines

1280.) 1-0-(Z,Z)-6,12-hexadecadienylpropanediol-(1,2)-phosphocholine $\dot{}$

C₂₄H₄₈NO₅P (461.62)

- 1281.) 1-0-(Z,Z)-6,12-heptadecadienylpropanediol(1,2)-phosphocholine
 C25H50NO5P (475.65)
- 1282.) 1-0-(Z,Z)-6,12-octadecadienylpropanediol-(1,2)-phosphocholine

C₂₆H₅₂NO₅P (489.68)

1283.) 1-0-(Z,Z)-6,12-nonadecadienylpropanediol-(1,2)-phosphocholine

- 109 -

C₂₇H₅₄NO₅P (503.71)

1284.) 1-0-(Z,Z)-9,15-eicosadienylpropanediol-(1,2)-phosphocholine

 $C_{28}H_{56}NO_5P$ (517.74)

- 1285.) 1-O-(Z,Z)-9,15-heneicosadienylpropanediol-(1,2)-phosphocholine CosHeabNOsP (531.77)
- 1286.) 1-0-(Z,Z)-5,17-docosadienylpropanediol-(1,2)-phosphocholine $C_{30}H_{60}NO_{5}P$ (545.8)
- 1287.) 1-0-(Z,Z)-6,18-tricosadienylpropanediol-(1,2)-phosphocholine

 $C_{31}H_{62}NO_5P$ (559.83)

- 1288.) 1-0-(Z,Z)-6,18-tetracosadienylpropanediol-(1,2)-phosphocholine $C_{12}H_{64}NO_5P$ (573.86)
- 1289.) 1-0-(Z,Z)-6,18-pentacosadienylpropanediol-(1,2)-phosphocholine C33Ha6NOaP (587.89)

1-O-(Z,Z)-Alkadienylpropanediol-(1,2)-phospho-N,N,N-trimethylpropylammonium compounds

- 1290.) 1-0-(Z,Z)-6,12-hexadecadienylpropanediol-(1,2)phospho-N,N,N-trimethylpropylammonium

 C₂₅H₅₀NO₅P (475.65)
- 1292.) 1-0-(Z,Z)-6,12-octadecadienylpropanediol-(1,2)-phospho-N,N,N-trimethylpropylammonium $C_{27}H_{54}NO_5P$ (503.71)
- 1293.) 1-0-(Z,Z)-6,12-nonadecadienylpropanediol-(1,2)phospho-N,N,N-trimethylpropylammonium
 C>2HecNOcP (517.74)
- 1294.) 1-0-(Z,Z)-9,15-eicosadienylpropanediol-(1,2)phospho-N,N,N-trimethylpropylammonium

 C29Hs8NOsP (531.77)

	- 110 -
1295.)	1-O-(Z,Z)-9,15-heneicosadienylpropanediol-
	(1,2)-phospho-N,N,N-trimethylpropylammonium
	$C_{30}H_{60}NO_5P$ (545.8)
1296.)	1-O-(Z,Z)-5,17-docosadienylpropanediol-(1,2)
	phospho-N,N,N-trimethylpropylammonium
	$C_{31}H_{62}NO_5P$ (559.83)
1297.)	1-O-(Z,Z)-6,18-tricosadienylpropanediol-(1,2)
	phospho-N,N,N-trimethylpropylammonium
	$C_{32}H_{64}NO_5P$ (573.86)
1298.)	1-O-(Z,Z)-6,18-tetracosadienylpropanediol-

1298.) 1-0-(Z,Z)-6,18-tetracosadienylpropanediol(1,2)-phospho-N,N,N-trimethylpropylammonium
C33H66NO5P (587.89)

1299.) 1-0-(Z,Z)-6,18-pentacosadienylpropanediol-(1,2)-phospho-N,N,N-trimethylpropylammonium C34H66NO5P (601.92)

2-O-(Z,Z)-Alkadienylpropanediol-(1,2)-phosphocholines

1300.) 2-0-(Z,Z)-6,12-hexadecadienylpropanediol-(1,2)-phosphocholine $C_{24}H_{48}NO_5P \eqno(461.62)$

1301.) 2-0-(Z,Z)-6,12-heptadecadienylpropanediol-(1,2)-phosphocholine $C_{75}H_{50}NO_{5}P$ (475.65)

1302.) 2-O-(Z,Z)-6,12-octadecadienylpropanediol-(1,2)-phosphocholine

C26H52NO5P (489.68)

1303.) 2-O-(Z,Z)-6,12-nonadecadienylpropanediol-(1,2)-phosphocholine $C_{27}H_{54}NO_5P \qquad (503.71)$

1304.) 2-0-(Z,Z)-9,15-eicosadienylpropanediol-(1,2)phosphocholine
C78Hs6NOsP (517.74)

1305.) 2-O-(Z,Z)-9,15-heneicosadienylpropanediol-(1,2)-phosphocholine
C>0HsaNOsP (531.77)

1306.) 2-0-(Z,Z)-5,17-docosadienylpropanediol-(1,2)-phosphocholine

- 111 -

C30H60NO5P (545.8)

1307.) 2-0-(Z,Z)-6,18-tricosadienylpropanediol-(1,2)-phosphocholine

 $C_{31}H_{62}NO_5P$ (559.83)

- 1308.) 2-0-(Z,Z)-6,18-tetracosadienylpropanediol-(1,2)-phosphocholine C12Hc4NO5P (573.86)
- 1309.) 2-O-(Z,Z)-6,18-pentacosadienylpropanediol-(1,2)-phosphocholine $C_{23}H_{66}NO_5P$ (587.89)

2-O-(Z,Z)-Alkadienylpropanediol-(1,2)-phospho-N,N,N-trimethylpropylammonium compounds

- 1310.) 2-0-(Z,Z)-6,12-hexadecadienylpropanediol-(1,2)phospho-N,N,N-trimethylpropylammonium

 CosHsoNOsP (475.65)
- 1311.) 2-0-(Z,Z)-6,12-heptadecadienylpropanediol-(1,2)-phospho-N,N,N-trimethylpropylammonium $C_{26}H_{52}NO_5P$ (489.68)
- 1312.) 2-O-(Z,Z)-6,12-octadecadienylpropanediol-(1,2)phospho-N,N,N-trimethylpropylammonium

 C27H54NO5P (503.71)
- 1313.) 2-0-(Z,Z)-6,12-nonadecadienylpropanediol-(1,2)phospho-N,N,N-trimethylpropylammonium

 C28H56NO5P (517.74)
- 1314.) 2-0-(Z,Z)-9,15-eicosadienylpropanediol-(1,2)phospho-N,N,N-trimethylpropylammonium
 CoaHsaNOsP (531.77)
- 1315.) 2-O-(Z,Z)-9,15-heneicosadienylpropanediol-(1,2)-phospho-N,N,N-trimethylpropylammonium $C_{30}H_{50}NO_5P$ (545.8)
- 1316.) 2-0-(Z,Z)-5,17-docosadienylpropanediol-(1,2)phospho-N,N,N-trimethylpropylammonium

 C11H62NO4P (559.83)
- 1317.) 2-0-(Z,Z)-6,18-tricosadienylpropanediol-(1,2)-phospho-N,N,N-trimethylpropylammonium $C_{32}H_{64}NO_5P$ (573.86)

- 1318.) 2-0-(Z,Z)-6,18-tetracosadienylpropanediol-(1,2)-phospho-N,N,N-trimethylpropylammonium C33H66NO5P (587.89)
- 1319.) 2-0-(Z,Z)-6,18-pentacosadienylpropanediol-(1,2)-phospho-N, N, N-trimethylpropylammonium C34H68NO5P (601.92)

Solubilizers

Examples of single-chain glycero-phospho-N,Ndimethyl-N-dihydroxypropylalkylammonium compounds

 $(A = III \text{ or } IV; n = 2-6; R_3, CH_3; m = 1, x = 0; y = 1;$ z = 1

$$A - PO_3^{-} = \begin{bmatrix} CH_2 \\ N_3^{+} \end{bmatrix}_{m} - (CH_2)_x - \begin{bmatrix} CH_2 - \begin{pmatrix} CH \\ OH \end{pmatrix}_y - CH_2 - O \end{bmatrix}_{z} - H$$

n = 2

- 1320.) 1-(Z)-6-hexadecenoyl-sn-qlycero-3-phospho-N,Ndimethyl-N-dihydroxypropylethylammonium (n = 2)C26H52NO9P (553.67)
- 1321.) 1-(Z)-10-heptadecenoyl-sn-glycero-3-phospho-N, N-dimethyl-N-dihydroxypropylethylammonium (n = 2)C27H54NO9P

(567.70)

- 1322.) 1-(Z)-6-octadecenoyl-sn-glycero-3-phospho-N,Ndimethyl-N-dihydroxypropylethylammonium (n = 2)C28H56NO9P (581.73)
- 1323.) 1-(Z)-6-nonadecenoyl-sn-glycero-3-phospho-N,Ndimethyl-N-dihydroxypropylethylammonium (n = 2) $C_{29}H_{58}NO_9P$ (595.75)
- 1-(Z)-12-eicosenoyl-sn-glycero-3-phospho-N,N-1324.) dimethyl-N-dihydroxypropylethylammonium (n = 2)C30H60NO9P (609.78)
- 1325.) 1-(Z)-10-heneicosenoyl-sn-qlycero-3-phospho-N, N-dimethyl-N-dihydroxypropylethylammonium (n = 2)

- 113 -

```
C21H62NO0P (623.81)
```

- 1326.) 1-(Z)-10-docosenoyl-sn-glycero-3-phospho-N,N-dimethyl-N-dihydroxypropylethylammonium (n = 2)
 C19H64NOaP (637.84)
- 1327.) 1-(Z)-12-docosenoyl-sn-glycero-3-phospho-N,N-dimethyl-N-dihydroxypropylethylammonium (n = 2)

 C₃₂H₆₄NO₉P (637.84)
- 1328.) 1-(Z)-10-tricosenoyl-sn-glycero-3-phospho-N,N-dimethyl-N-dihydroxypropylethylammonium (n = 2)
 C3-H66NOoP (651.86)
- 1329.) 1-(Z)-10-tetracosenoyl-sn-glycero-3-phospho-N,N-dimethyl-N-dihydroxypropylethylammonium (n = 2) C12H66NOoP (665.89)
- 1330.) 1-(Z)-15-pentacosenoyl-sn-glycero-3-phospho-N,N-dimethyl-N-dihydroxypropylethylammonium (n = 2) $C_{35}H_{26}NO_9P \qquad (679.92)$
- 1331.) 1-(Z)-16-hexacosenoyl-sn-glycero-3-phospho-N,N-dimethyl-N-dihydroxypropylethylammonium (n = 2) $C_{36}H_{72}NO_{9}P \qquad (693.94)$
- 1332.) 1-(Z,Z)-5,11-hexadecadienoyl-sn-glycero-3-phospho-N,N-dimethyl-N-dihydroxypropylethyl-ammonium (n = 2)

 C2eHsoNOoP (551.66)
- 1333.) 1-(Z,Z)-5,11-heptadecadienoyl-sn-glycero-3-phospho-N,N-dimethyl-N-dihydroxypropylethyl-ammonium (n = 2) $C_{27}H_{52}NO_9P \qquad (565.68)$
- 1334.) 1-(Z,Z)-5,11-octadecadienoyl-sn-glycero-3-phospho-N,N-dimethyl-N-dihydroxypropylethyl-ammonium (n = 2)

(579.71)

1335.) 1-(Z,Z)-6,12-nonadecadienoyl-sn-glycero-3-phospho-N,N-dimethyl-N-dihydroxypropylethyl-ammonium (n = 2)
C>2H56NO9P (593.74)

C28H54NO9P

- 114 -

- 1336.) 1-(Z,Z)-10,16-eicosadienoyl-sn-glycero-3phospho-N.N-dimethyl-N-dihydroxypropylethylammonium (n = 2)(607.77)
- CanHanNOaP 1337.) 1-(Z,Z)-10,16-heneicosadienoyl-sn-glycero-3phospho-N, N-dimethyl-N-dihydroxypropylethyl-

ammonium (n = 2)C31H60NO9P (621.79)

1338.) 1-(Z,Z)-10,16-docosadienoyl-sn-glycero-3phospho-N, N-dimethyl-N-dihydroxypropylethylammonium (n = 2)(635.82) C32H62NO9P

- 1-(Z,Z)-10.16-tricosadienoyl-sn-glycero-3-1339.) phospho-N, N-dimethyl-N-dihydroxypropylethylammonium (n = 2)C33H64NO9P (649.85)
- 1340.) 1-(Z,Z)-6,18-tetracosadienoyl-sn-glycero-3phospho-N, N-dimethyl-N-dihydroxypropylethylammonium (n = 2)C34H66NO9P (663.87)
- 1-(Z,Z)-10,16-pentacosadienoyl-sn-glycero-3-1341.) phospho-N, N-dimethyl-N-dihydroxypropylethylammonium (n = 2)(677.90)CasHeeNOeP
- 1342.) 1-(Z,Z)-6,18-hexacosadienoyl-sn-glycero-3phospho-N.N-dimethyl-N-dihydroxypropylethylammonium (n = 2)(691.93) C36H70NO9P

Alkenyl

- 1343.) 1-0-(Z)-6-hexadecenyl-sn-glycero-3-phospho-N,Ndimethyl-N-dihydroxypropylethylammonium (n = 2)C26H54NO8P (539.69)
- 1-0-(Z)-6-octadecenyl-sn-glycero-3-phospho-N,Ndimethyl-N-dihydroxypropylethylammonium (n = 2)C28H58NO8P (567.74)
- 1-0-(Z)-12-eicosenvl-sn-glycero-3-phospho-N,N-1345.) dimethyl-N-dihydroxypropylethylammonium (n = 2)

C30H62NOaP (595.80)

- 1346.) 1-O-(Z)-10-docosenyl-sn-glycero-3-phospho-N,N-dimethyl-N-dihydroxypropylethylammonium (n = 2) $C_{32}H_{66}NO_8P$ (623.85)
- 1347.) 1-O-(Z)-10-tetracosenyl-sn-glycero-3-phospho-N,N-dimethyl-N-dihydroxypropylethylammonium (n = 2) $C_{34}H_{70}NO_{8}P \qquad (651.91)$

1348.) 1-0-(Z)-16-hexacosenyl-sn-glycero-3-phospho-N,N-dimethyl-N-dihydroxypropylethylammonium (n = 2)

C36H74NO8P (679.96)

- 1349.) 1-O-(Z,Z)-5,11-hexadecadienyl-sn-glycero-3-phospho-N,N-dimethyl-N-dihydroxypropylethyl-ammonium (n = 2)

 C26H62NOsP (537.67)
- 1350.) 1-0-(Z,Z)-5,11-octadecadienyl-sn-glycero-3-phospho-N,N-dimethyl-N-dihydroxypropylethyl-ammonium (n = 2)

 C28H56NO8P (565.73)
- 1351.) 1-0-(Z,Z)-10,16-eicosadienyl-sn-glycero-3-phospho-N,N-dimethyl-N-dihydroxypropylethyl-ammonium (n = 2) $C_{30}H_{50}NO_8P \qquad (593.78)$
- 1352.) 1-O-(Z,Z)-10,16-docosadienyl-sn-glycero-3-phospho-N,N-dimethyl-N-dihydroxypropylethyl-ammonium (n = 2)
 C12Hs6NOsP (621.84)
- 1353.) 1-0-(Z,Z)-6,18-tetracosadienyl-sn-glycero-3-phospho-N,N-dimethyl-N-dihydroxypropylethyl-ammonium (n = 2)

 C14HesNOsP (649.89)
- 1354.) 1-O-(Z,Z)-6,18-hexacosadienyl-sn-glycero-3-phospho-N,N-dimethyl-N-dihydroxypropylethyl-ammonium (n = 2) $C_{36}H_{72}NO_8P \qquad (677.94)$

```
n = 3
```

C₂₇H₅₄NO₉P (567.70)

1356.) 1-(Z)-10-heptadecenoyl-sn-glycero-3-phospho-N,N-dimethyl-N-dihydroxypropylpropylammonium (n = 3)

C28H56NO9P (581.73)

1357.) 1-(Z)-6-octadecenoyl-sn-glycero-3-phospho-N,Ndimethyl-N-dihydroxypropylpropylammonium
(n = 3)

 $C_{29}H_{58}NO_{9}P$ (595.75)

1358.) 1-(Z)-12-eicosenoyl-sn-glycero-3-phospho-N,Ndimethyl-N-dihydroxypropylpropylammonium
(n = 3)

C₃₁H₆₂NO₉P (623.81)

C33H66NO9P (651.86)

1360.) 1-(Z)-12-docosenoyl-sn-glycero-3-phospho-N,Ndimethyl-N-dihydroxypropylpropylammonium
(n = 3)

 $C_{33}H_{66}NO_9P$ (651.86)

1361.) 1-(Z)-10-tricosenoyl-sn-glycero-3-phospho-N,Ndimethyl-N-dihydroxypropylpropylammonium
(n = 3)

C34H68NO9P (665.89)

1362.) 1-(Z)-10-tetracosenoyl-sn-glycero-3-phospho-N,N-dimethyl-N-dihydroxypropylpropylammonium (n = 3) C3-H10NO-P (679.92)

1363.) 1-(Z,Z)-5,11-hexadecadienoyl-sn-glycero-3-phospho-N,N-dimethyl-N-dihydroxypropylpropyl-ammonium (n = 3)

C₂₂H₅₂NO₉P (565.68)

```
- 117 -
1364.)
        1-(Z,Z)-5,11-octadecadienoyl-sn-glycero-3-
        phospho-N, N-dimethyl-N-dihydroxypropylpropyl-
        ammonium (n = 3)
        C29H56NO9P
                          (593.74)
1365.)
        1-(Z,Z)-10,16-eicosadienoyl-sn-glycero-3-
        phospho-N, N-dimethyl-N-dihydroxypropylpropyl-
        ammonium (n = 3)
                          (621.79)
        C31H60NO9P
1366.)
        1-(Z,Z)-10,16-heneicosadienoyl-sn-glycero-3-
        phospho-N, N-dimethyl-N-dihydroxypropylpropyl-
        ammonium (n = 3)
        C22H62NOoP
                          (635.82)
1367.) 1-(Z,Z)-10,16-docosadienovl-sn-glycero-3-
        phospho-N, N-dimethyl-N-dihydroxypropylpropyl-
        ammonium (n = 3)
        C33H64NO9P
                          (649.85)
1368.) 1-(Z,Z)-6,18-tetracosadienovl-sn-glycero-3-
        phospho-N, N-dimethyl-N-dihydroxypropylpropyl-
        ammonium (n = 3)
        CasHeeNOoP
                          (677.90)
        1-(Z,Z)-6,18-hexacosadienoyl-sn-glycero-3-
1369.)
        phospho-N, N-dimethyl-N-dihydroxypropylpropyl-
        ammonium (n = 3)
        C37H72NO9P
                         (705.95)
1370.)
        1-0-(Z)-6-hexadecenyl-sn-glycero-3-phospho-N,N-
        dimethyl-N-dihydroxypropylpropylammonium
        (n = 3)
        C27H56NO8P
                          (553.72)
1371.)
        1-O-(Z)-6-octadecenyl-sn-glycero-3-phospho-N,N-
        dimethyl-N-dihydroxypropylpropylammonium
        (n = 3)
        C29H60NO8P
                         (581.77)
1372.)
        1-O-(Z)-12-eicosenyl-sn-glycero-3-phospho-N,N-
```

dimethyl-N-dihydroxypropylpropylammonium

(609.83)

(n = 3)C31H64NO8P 1373.) 1-0-(Z)-10-docosenyl-sn-glycero-3-phospho-N,N-dimethyl-N-dihydroxypropylpropylammonium (n = 3)

C33H68NO8P (637.88)

1374.) 1-O-(Z)-10-tetracosenyl-sn-glycero-3-phospho-N,N-dimethyl-N-dihydroxypropylpropylammonium (n = 3)

 $C_{35}H_{72}NO_8P$ (665.94)

1375.) 1-0-(Z,Z)-5,11-hexadecadienyl-sn-glycero-3-phospho-N,N-dimethyl-N-dihydroxypropylpropyl-ammonium (n = 3)

 $C_{27}H_{54}NO_8P$ (551.7)

1376.) 1-O-(Z,Z)-5,11-octadecadienyl-sn-glycero-3-phospho-N,N-dimethyl-N-dihydroxypropylpropyl-ammonium (n = 3)

ChaHeeNOeP (579.76)

1377.) 1-O-(Z,Z)-10,16-eicosadienyl-sn-glycero-3-phospho-N,N-dimethyl-N-dihydroxypropylpropyl-ammonium (n = 3) $C_{31}H_{52}NO_8P \qquad (607.81)$

1378.) 1-O-(Z,Z)-10,16-docosadienyl-sn-glycero-3phospho-N,N-dimethyl-N-dihydroxypropylpropylammonium (n = 3)
C13H66NOsP (635.87)

1379.) 1-O-(Z,Z)-6,18-tetracosadienyl-sn-glycero-3-phospho-N,N-dimethyl-N-dihydroxypropylpropyl-ammonium (n = 3)

C15H70NOsP (663.92)

1380.) 1-O-(Z,Z)-6,18-hexacosadienyl-sn-glycero-3-phospho-N,N-dimethyl-N-dihydroxypropylpropyl-ammonium (n = 3) $C_{17}H_{74}NO_8P \qquad (691.97)$

n = 4

1381.) 1-(Z)-6-octadecencyl-sn-glycero-3-phospho-N,Ndimethyl-N-dihydroxypropylbutylammonium (n = 4)
C10H60NO9P (609.78)

- 1382.) 1-(Z)-10-docosenoyl-sn-glycero-3-phospho-N,N-dimethyl-N-dihydroxypropylbutylammonium (n = 4) $C_{34}H_{58}NO_{9}P \qquad (665.89)$
- 1383.) 1-(Z,Z)-5,11-hexadecadienoyl-sn-glycero-3-phospho-N,N-dimethyl-N-dihydroxypropylbutyl-ammonium (n = 4)
 C28H64NOoP (579.71)
- 1384.) 1-(Z,Z)-10,16-docosadienoyl-sn-glycero-3phospho-N,N-dimethyl-N-dihydroxypropylbutylammonium (n = 4)
 C14Ha6NOoP (663.88)
- 1385.) 1-(Z,Z)-6,18-hexacosadienoyl-sn-glycero-3-phospho-N,N-dimethyl-N-dihydroxypropylbutyl-ammonium (n = 4) $C_{18}H_{74}NO_9P$ (719.98)
- 1386.) 1-O-(Z)-6-octadecenyl-sn-glycero-3-phospho-N,N-dimethyl-N-dihydroxypropylbutylammonium (n = 4) $C_{30}H_{62}No_8P \hspace{1cm} (595.80)$
- 1387.) 1-O-(Z)-10-docosenyl-sn-glycero-3-phospho-N,N-dimethyl-N-dihydroxypropylbutylammonium (n = 4) $C_{14}H_{70}NO_{8}P \qquad (651.91)$
- 1388.) 1-0-(Z,Z)-5,11-octadecadienyl-sn-glycero-3phospho-N,N-dimethyl-N-dihydroxypropylbutylammonium (n = 4)
 C30HsoNOsP (593.78)
- 1389.) 1-O-(Z)-12-eicosenyl-sn-glycero-3-phospho-N,N-dimethyl-N-dihydroxypropylbutylammonium (n = 4) $C_{32}H_{66}NO_8P \hspace{1.5cm} (623.85)$
- n = 6
- 1390.) 1-(Z)-6-octadecenoyl-sn-glycero-3-phospho-N,Ndimethyl-N-dihydroxypropylhexylammonium (n = 6)
 C₃₂H₆₄NO₉P (637.84)
- 1391.) 1-(Z)-10-docosenoyl-sn-glycero-3-phospho-N,Ndimethyl-N-dihydroxypropylhexylammonium (n = 6)
 C36H72NO9P (693.94)

(1)

- 1392.) 1-(Z,Z)-5-hexadecadienoyl-sn-glycero-3-phospho-N,N-dimethyl-N-dihydroxypropylhexylammonium (n = 6)
- 1393.) 1-(Z,Z)-10,16-docosadienoyl-sn-glycero-3-phospho-N,N-dimethyl-N-dihydroxypropylhexyl-ammonium (n = 6)

 $C_{36}H_{70}NO_9P$ (691.93)

- 1394.) 1-(Z,Z)-6,18-hexacosadienoyl-sn-glycero-3-phospho-N,N-dimethyl-N-dihydroxypropylhexyl-ammonium (n = 6) $C_{40}H_{78}NO_{9}P \qquad (748.03)$
- 1395.) 1-0-(Z)-6-octadecenyl-sn-glycero-3-phospho-N,N-dimethyl-N-dihydroxypropylhexylammonium (n = 6) C₁₂H₆₆NO₈P (623.85)
- 1396.) 1-O-(Z)-10-docosenyl-sn-glycero-3-phospho-N,Ndimethyl-N-dihydroxypropylhexylammonium (n = 6)
 C36H74NO8P (679.96)
- 1397.) 1-O-(Z,Z)-5,11-octadecadienyl-sn-glycero-3phospho-N,N-dimethyl-N-dihydroxypropylhexylammonium (n = 6)
 C22H64NOAP (621.84)
- 1398.) 1-O-(Z)-12-eicosenyl-sn-glycero-3-phospho-N,N-dimethyl-N-dihydroxypropylhexylammonium (n = 6)
 C14H10NOsP (651.91)
- 2. Examples of single-chain glycero-phospho-N,N-dimethyl-N-(2-hydroxypropyl-3,1-0,0-dihydroxy-propyl)alkylammonium compounds
- (A = III or IV; n = 2-6; R₃, CH₃; m = 1, x = 0; y = 1; z = 2)

$$A - PO_3 - \left[(CH_2)_m {\overset{CH_3}{\overset{N^+}{R_3}}} \right]_m - (CH_2)_x - \left[CH_2 - \left({\overset{CH}{OH}} \right)_y - CH_2 - O \right]_z - H$$

```
n = 2
```

- 1399.) 1-(Z)-6-hexadecenoyl-sn-glycero-3-phospho-N,Ndimethyl-N-(2-hydroxypropyl-3,1-0,0-dihydroxypropyl)ethylammonium (n = 2)
 CoaHeaNO1P (627.75)
- 1401.) 1-(Z)-10-docosenoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(2-hydroxypropyl-3,1-0,O-dihydroxy-propyl)ethylammonium (n = 2)

 C15HnNO11P (711.91)
- 1402.) 1-(Z)-12-docosenoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(2-hydroxypropyl-3,1-0,0-dihydroxy-propyl)ethylammonium (n = 2)

 C15H70NO11P (711.91)
- 1403.) 1-(Z)-10-tetracosenoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(2-hydroxypropyl-3,1-0,0dihydroxypropyl)ethylammonium (n = 2) C₃₇H₇₄NO₁₁P (739.97)
- 1404.) 1-(Z)-16-hexacosenoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(2-hydroxypropyl-3,1-0,0-dihydroxypropyl)ethylammonium (n = 2) $C_{39}H_{78}NO_{11}P$ (768.02)
- 1405.) 1-(Z,Z)-5,11-hexadecadienoyl-sn-glycero-3phospho-N,N-dimethyl-N-(2-hydroxypropyl-3,10,0-dihydroxypropyl)ethylammonium (n = 2)
 C29H36NO₁₁P (625.74)
- 1406.) 1-(Z,Z)-5,11-octadecadienoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(2-hydroxypropyl-3,1-0,O-dihydroxypropyl)ethylammonium (n = 2) $C_{31}H_{60}NO_{11}P \qquad (653.79)$
- 1407.) 1-(Z,Z)-10,16-heneicosadienoyl-sn-glycero-3phospho-N,N-dimethyl-N-(2-hydroxypropyl-3,10,O-dihydroxypropyl)ethylammonium (n = 2)
 C34H66NO11P (695.87)

- 1408.) 1-(Z,Z)-10,16-docosadienoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(2-hydroxypropyl-3,1-0,O-dihydroxypropyl)ethylammonium (n = 2)
 C35H68NO₁₁P (709.90)
- 1409.) 1-(Z,Z)-6,18-hexacosadienoyl-sn-glycero-3phospho-N,N-dimethyl-N-(2-hydroxypropyl-3,10,0-dihydroxypropyl)ethylammonium (n = 2)
 C₃₉H₇₆NO₁₁P (766.01)

Alkenvl

- 1410.) 1-0-(Z)-6-octadecenyl-sn-glycero-3-phospho-N,N-dimethyl-N-(2-hydroxypropyl-3,1-0,0-dihydroxy-propyl)ethylammonium (n = 2)

 C1H64NO10P (641.82)
- 1411.) 1-0-(Z)-12-eicosenyl-sn-glycero-3-phospho-N,N-dimethyl-N-(2-hydroxypropyl-3,1-0,0-dihydroxy-propyl)ethylammonium (n = 2)

 CniHcaNOnoP (669.88)
- 1412.) 1-0-(Z)-10-docosenyl-sn-glycero-3-phospho-N,N-dimethyl-N-(2-hydroxypropyl-3,1-0,0-dihydroxy-propyl)ethylammonium (n = 2)

 C15H72NO10P (697.93)
- 1413.) 1-0-(Z)-10-tetracosenyl-sn-glycero-3-phospho-N,N-dimethyl-N-(2-hydroxypropyl-3,1-0,0dihydroxypropyl)ethylammonium (n = 2) C12H7zNO10P (725.98)
- 1414.) 1-O-(Z)-16-hexacosenyl-sn-glycero-3-phospho-N,N-dimethyl-N-(2-hydroxypropyl-3,1-O,Odihydroxypropyl)ethylammonium (n = 2) C39HanNO1nP (754.04)
- 1415.) 1-O-(Z,Z)-5,11-octadecadienyl-sn-glycero-3-phospho-N,N-dimethyl-N-(2-hydroxypropyl-3,1-O,O-dihydroxypropyl)ethylammonium (n = 2) $C_{31}H_{62}NO_{10}P \qquad (639.81)$
- 1416.) 1-O-(Z,Z)-6,18-tetracosadienyl-sn-glycero-3-phospho-N,N-dimethyl-N-(2-hydroxypropyl-3,1-O,O-dihydroxypropyl)ethylammonium (n = 2) $C_{37}H_{74}NO_{10}P$ (723.97)

```
1417.) 1-0-(Z,Z)-6,18-hexacosadienyl-sn-glycero-3-phospho-N,N-dimethyl-N-(2-hydroxypropyl-3,1-0,0-dihydroxypropyl)ethylammonium (n = 2)

C:0HreNOnOP (752.04)
```

- 1418.) 1-(Z)-6-octadecenoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(2-hydroxypropyl-3,1-0,0-dihydroxy-propyl)propylammonium (n = 3)

 C₃₂H₆₄NO₁₁P (669.83)
- 1419.) 1-(Z)-12-eicosenoyl-sn-glycero-3-phospho-N,Ndimethyl-N-(2-hydroxypropyl-3,1-0,0-dihydroxypropyl)propylammonium (n = 3)
 CoaHeaNO1P (697.89)
- 1420.) 1-(Z)-10-docosenoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(2-hydroxypropyl-3,1-0,O-dihydroxy-propyl)propylammonium (n = 3)

 C₃₆H₇₂NO₁₁P (725.94)
- 1421.) 1-(Z)-12-docosenoyl-sn-glycero-3-phospho-N,Ndimethyl-N-(2-hydroxypropyl-3,1-0,O-dihydroxypropyl)propylammonium (n = 3)
 C₁₆H₇₂NO₁₁P (725.94)
- 1422.) 1-(Z)-10-tetracosenoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(2-hydroxypropyl-3,1-0,0dihydroxypropyl)propylammonium (n = 3) C₃₀H₇₆NO₁₁P (754.0)
- 1423.) 1-(Z,Z)-5,11-octadecadienoyl-sn-glycero-3phospho-N,N-dimethyl-N-(2-hydroxypropyl-3,10,0-dihydroxypropyl)propylammonium (n = 3)
 C₁₂H₆₂NO₁₁P (667.83)
- 1424.) 1-(Z,Z)-10,16-eicosadienoyl-sn-glycero-3phospho-N,N-dimethyl-N-(2-hydroxypropyl-3,10,O-dihydroxypropyl)propylammonium (n = 3)
 C34H66NO₁₁P (695.89)
- 1425.) 1-(Z,Z)-10,16-docosadienoyl-sn-glycero-3phospho-N,N-dimethyl-N-(2-hydroxypropyl-3,10,O-dihydroxypropyl)propylammonium (n = 3)

```
- 124 -
```

```
C<sub>36</sub>H<sub>70</sub>NO<sub>11</sub>P (723.94)
```

- 1426.) 1-(Z,Z)-6,18-tetracosadienoyl-sn-glycero-3phospho-N,N-dimethyl-N-(2-hydroxypropyl-3,10,O-dihydroxypropyl)propylammonium (n = 3)
 C38H74NO11P (751.98)
- 1427.) 1-(Z,Z)-6,18-hexacosadienoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(2-hydroxypropyl-3,1-O,O-dihydroxypropyl)propylammonium (n = 3)

 C40H78NO11P (780.03)
- 1428.) 1-O-(Z)-6-hexadecenyl-sn-glycero-3-phospho-N,N-dimethyl-N-(2-hydroxypropyl-3,1-O,O-dihydroxy-propyl)propylammonium (n = 3) $C_{30}H_{42}NO_{10}P \qquad (627.80)$
- 1429.) 1-0-(Z)-10-docosenyl-sn-glycero-3-phospho-N,Ndimethyl-N-(2-hydroxypropyl-3,1-0,0-dihydroxypropyl)propylammonium (n = 3)
 C₃₆H₇₄NO₁₀P (711.96)
- 1430.) 1-O-(Z)-10-tetracosenyl-sn-glycero-3-phospho-N,N-dimethyl-N-(2-hydroxypropyl-3,1-0,0dihydroxypropyl)propylammonium (n = 3) C18H18NO10P (740.01)
- 1431.) 1-O-(Z,Z)-5,11-hexadecadienyl-sn-glycero-3-phospho-N,N-dimethyl-N-(2-hydroxypropyl-3,1-O,O-dihydroxypropyl)propylammonium (n = 3)

 C_{30Hc0}NO₁₀P (625.78)
- 1432.) 1-O-(Z,Z)-5,11-octadecadienyl-sn-glycero-3-phospho-N,N-dimethyl-N-(2-hydroxypropyl-3,1-O,O-dihydroxypropyl)propylammonium (n = 3)

 C₁₂H₅₄NO₁₀P (653.83)
- 1433.) 1-O-(Z,Z)-10,16-eicosadienyl-sn-glycero-3-phospho-N,N-dimethyl-N-(2-hydroxypropyl-3,1-O,O-dihydroxypropyl)propylammonium (n = 3)

 C:4HssNO:0P (681.89)
- 1434.) 1-O-(Z,Z)-6,18-tetracosadienyl-sn-glycero-3-phospho-N,N-dimethyl-N-(2-hydroxypropyl-3,1-O,O-dihydroxypropyl)propylammonium (n = 3)

 C18H76NO10P (738.0)

1435.) 1-O-(Z,Z)-6,18-hexacosadienyl-sn-glycero-3phospho-N,N-dimethyl-N-(2-hydroxypropyl-3,1O,O-dihydroxypropyl)propylammonium (n = 3)
CanHanNOlnP (766.05)

- 1436.) 1-(Z)-6-octadecenoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(2-hydroxypropyl-3,1-0,0-dihydroxy-propyl)butylammonium (n = 4)

 CnHesNO11P (683.86)
- 1437.) 1-(Z)-6-docosenoyl-sn-glycero-3-phospho-N,Ndimethyl-N-(2-hydroxypropyl-3,1-0,0-dihydroxypropyl)butylammonium (n = 4)
 C12H14NO11P (739.97)
- 1438.) 1-(Z,Z)-5,11-hexadecadienoyl-sn-glycero-3phospho-N,N-dimethyl-N-(2-hydroxypropyl-3,10,0-dihydroxypropyl)butylammonium (n = 4)
 C_{31H60}NO₁₁P (653.79)
- 1439.) 1-(Z,Z)-10,16-docosadienoyl-sn-glycero-3phospho-N,N-dimethyl-N-(2-hydroxypropyl-3,10,O-dihydroxypropyl)butylammonium (n = 4)
 C37H32NO11P (737.95)
- 1440.) l-(Z,Z)-6,18-hexacosadienoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(2-hydroxypropyl-3,1-0,0-dihydroxypropyl)butylammonium (n = 4) $C_{41}H_{80}NO_{11}P \qquad (794.06)$
- 1441.) 1-O-(Z)-6-octadecenyl-sn-glycero-3-phospho-N,N-dimethyl-N-(2-hydroxypropyl-3,1-0,O-dihydroxy-propyl)butylammonium (n = 4)

 C33Hc6NO10P (669.88)
- 1442.) 1-0-(Z)-10-docosenyl-sn-glycero-3-phospho-N,N-dimethyl-N-(2-hydroxypropyl-3,1-0,O-dihydroxy-propyl)butylammonium (n = 4)

 C37H76NO10P (725.98)
- 1443.) 1-0-(Z,Z)-5,11-octadecadienyl-sn-glycero-3phospho-N,N-dimethyl-N-(2-hydroxypropyl-3,10,0-dihydroxypropyl)butylammonium (n = 4)

- 126 -

C22HccNO10P (667.86)

1444.) 1-0-(Z)-12-eicosenyl-sn-glycero-3-phospho-N,N-dimethyl-N-(2-hydroxypropyl-3,1-0,O-dihydroxy-propyl)butylammonium (n = 4)

C3:H-2NO10P (697.93)

- 1445.) 1-(Z)-6-octadecenoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(2-hydroxypropyl-3,1-0,O-dihydroxy-propyl)hexylammonium (n = 6) $C_{15}H_{70}NO_{11}P$ (711.91)
- 1446.) 1-(Z)-10-docosenoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(2-hydroxypropyl-3,1-0,O-dihydroxy-propyl)hexylammonium (n = 6)
 C19H7aNO11P (768.02)
- 1447.) 1-(Z,Z)-5,11-hexadecadienoyl-sn-glycero-3phospho-N,N-dimethyl-N-(2-hydroxypropyl-3,10,O-dihydroxypropyl)hexylammonium (n = 6)
 C₃₃H₆₄NO₁₁P (681.85)
- 1448.) 1-(Z,Z)-10,16-docosadienoyl-sn-glycero-3phospho-N,N-dimethyl-N-(2-hydroxypropyl-3,10,0-dihydroxypropyl)hexylammonium (n = 6)
 C36H36NO11P (766.01)
- 1449.) 1-(Z,Z)-6,18-hexacosadienoyl-sn-glycero-3phospho-N,N-dimethyl-N-(2-hydroxypropyl-3,10,0-dihydroxypropyl)hexylammonium (n = 6)
 Ca1Ha4NO11P (822.11)
- 1450.) 1-O-(Z)-6-octadecenyl-sn-glycero-3-phospho-N,Ndimethyl-N-(2-hydroxypropyl-3,1-0,O-dihydroxypropyl)hexylammonium (n = 6)
 C3:H72NO10P (697.93)
- 1451.) 1-0-(Z)-10-docosenyl-sn-glycero-3-phospho-N,Ndimethyl-N-(2-hydroxypropyl-3,1-0,O-dihydroxypropyl)hexylammonium (n = 6)
 C39H80NO10P (754.04)

- 1452.) 1-0-(Z,Z)-5,11-octadecadienyl-sn-glycero-3-phospho-N,N-dimethyl-N-(2-hydroxypropyl-3,1-0,0-dihydroxypropyl)hexylammonium (n = 6)

 C34H20NO10P (695.92)
- 1453.) 1-0-(Z)-12-eicosenyl-sn-glycero-3-phospho-N,Ndimethyl-N-(2-hydroxypropyl-3,1-0,O-dihydroxypropyl)hexylammonium (n = 6)
 C37H76NO10P (725.98)

3. Examples of single-chain glycero-phospho-N,Ndimethyl-N-(2-hydroxypropyl-3,1-0,0-2-hydroxypropyl-3,1-0,0-dihydroxypropyl)alkylammonium compounds

(A = III or IV; n = 2-6; R_3 , CH_3 ; m = 1, x = 0; y = 1; z = 3)

$$A-PO_3 = \begin{bmatrix} CH_{2h_1} & CH_{2h_2} \\ CH_{2h_1} & N^+ \\ R_3 \end{bmatrix}_m - \begin{bmatrix} CH_{2} - \begin{pmatrix} CH_{2} \\ OH \end{pmatrix}_y - CH_{2} - O \\ CH_{2} - \begin{pmatrix} CH_{2} \\ OH \end{pmatrix}_y - CH_{2} - O \\ CH_{2} - O \end{bmatrix}_z$$

In the following text, N-(2-hydroxypropyl-3,1-0,0-2-hydroxypropyl-3,1-0,0-dihydroxypropyl) is abbreviated to N-(HP₂-HP₂-diHP₂)

- 1454.) 1-(Z)-6-hexadecenoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(HP₁-HP₂-diHP₃) ethylammonium (n = 2) $C_{32}H_{54}NO_{13}P$ (701.83)
- 1455.) 1-(Z)-6-nonadecenoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(HP₁-HP₂-diHP₃)ethylammonium (n = 2) $C_{35}H_{70}NO_{13}P \qquad (743.91)$
- 1456.) 1-(Z)-10-docosenoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(HP₁-HP₂-diHP₃) ethylammonium (n = 2)

 C10H1zNO12P (785.99)
- 1457.) 1-(Z)-12-docosenoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(HP1-HP2-diHP3)ethylammonium (n = 2) $C_{38}H_{76}NO_{13}P \qquad (785.99)$
- 1458.) 1-(Z)-16-hexacosenoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(HP₁-HP₂-diHP₃) ethylammonium (n = 2) $C_{42}H_{84}NO_{13}P \qquad (842.10)$

```
1459.) 1-(Z,Z)-5,11-hexadecadienoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(HP<sub>1</sub>-HP<sub>2</sub>-diHP<sub>3</sub>)ethyl-ammonium (n = 2)
```

C32H62NO13P (699.82)

C38H74NO13P

1460.) 1-(Z,Z)-5,11-octadecadienoyl-sn-glycero-3-phospho-N,N-dimethyl-N- $(HP_1-HP_2-diHP_3)$ ethyl-ammonium (n=2) $C_{34}H_{66}NO_{13}P \qquad (727.87)$

1461.) 1-(Z,Z)-10,16-docosadienoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(HP_1-HP_2 -di HP_3)ethyl-ammonium (n = 2)

(783.98)

1462.) 1-(Z,Z)-6,18-hexacosadienoyl-sn-glycero-3-phospho-N,N-dimethyl-N- $(HP_1-HP_2-diHP_3)$ ethyl-ammonium (n=2) $C_{42}H_{42}NO_{12}P \qquad (840.09)$

Alkenyl

- 1463.) 1-O-(Z)-6-octadecenyl-sn-glycero-3-phospho-N,N-dimethyl-N-(HP₁-HP₂-diHP₃)ethylammonium (n = 2)
 C₂₄H₇₀NO₁₂P (715.90)
- 1464.) 1-0-(Z)-12-eicosenyl-sn-glycero-3-phospho-N,N-dimethyl-N-(HP₁-HP₂-diHP₃) ethylammonium (n = 2) C₃₆H₇₄NO₁₂P (743.96)
- 1465.) 1-0-(Z)-10-docosenyl-sn-glycero-3-phospho-N,N-dimethyl-N-(HP₁-HP₂-diHP₃)ethylammonium (n = 2) $C_{28}H_{-8}NO_{12}P \qquad (772.01)$
- 1466.) 1-0-(Z)-16-hexacosenyl-sn-glycero-3-phospho-N,N-dimethyl-N-(HP₁-HP₂-diHP₃) ethylammonium (n = 2)

C42H86NO12P (828.12)

1467.) 1-O-(Z,Z)-5,11-octadecadienyl-sn-glycero-3-phospho-N,N-dimethyl-N- $(HP_1-HP_2-diHP_3)$ ethyl-ammonium (n=2) $C_{14}H_{68}NO_{12}P \qquad (713.89)$

```
1468.) 1-0-(Z,Z)-6,18-hexacosadienyl-sn-glycero-3-phospho-N,N-dimethyl-N-(HP1-HP2-diHP3)ethyl-ammonium (n = 2)

C42Ha4NO12P (826.10)
```

- 1469.) 1-(Z)-6-octadecenoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(HP1-HP2-diHP3)propylammonium (n = 3)
 C3-H10NO13P (743.91)
- 1470.) 1-(Z)-10-docosenoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(HP₁-HP₂-diHP₃)propylammonium (n = 3)
 C₃₉H₇₈NO₁₃P (800.02)
- 1471.) 1-(Z)-10-tetracosenoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(HP1-HP2-diHP3) propylammonium (n = 3) C41H62NO13P (828.07)
- 1472.) 1-(Z,Z)-5,11-octadecadienoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(HP1-HP2-diHP3)propyl-ammonium (n = 3)

 C3:HesNO12P (741.90)
- 1473.) 1-(Z,Z)-10,16-eicosadienoyl-sn-glycero-3phospho-N,N-dimethyl-N-(HP1-HP2-diHP3)propylammonium (n = 3) C37H72NO13P (769.95)
- 1474.) 1-(Z,Z)-10,16-docosadienoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(HP₁-HP₂-diHP₃)propyl-ammonium (n = 3) $C_{33}H_{26}NO_{13}P$ (798.01)
- 1475.) 1-(Z,Z)-6,18-hexacosadienoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(HP₁-HP₂-diHP₃)propyl-ammonium (n = 3) $C_{43}H_{84}NO_{13}P \qquad (854.11)$
- 1476.) 1-O-(Z)-10-docosenyl-sn-glycero-3-phospho-N,N-dimethyl-N-(HP_1-HP_2 -diHP₃)propylammonium (n = 3) $C_{39}HanNO_{12}P$ (786.04)

```
1477.) 1-0-(Z)-10-tetracosenyl-sn-glycero-3-phospho-
        N, N-dimethyl-N-(HP1-HP2-diHP3) propylammonium
        (n = 3)
        C41H84NO12P
                          (814.09)
        1-O-(Z,Z)-10,16-eicosadienvl-sn-glycero-3-
1478.)
        phospho-N, N-dimethyl-N-(HP1-HP2-diHP3) propyl-
        ammonium (n = 3)
                          (812.08)
        C37H74NO12P
1479.)
        1-O-(Z,Z)-6,18-tetracosadienyl-sn-glycero-3-
        phospho-N, N-dimethyl-N-(HP1-HP2-diHP3) propyl-
        ammonium (n = 3)
        C41H82NO12P
                          (812.08)
1480.)
        1-0-(Z,Z)-6,18-hexacosadienyl-sn-glycero-3-
        phospho-N, N-dimethyl-N-(HP1-HP2-diHP3) propyl-
        ammonium (n = 3)
        C43H86NO12P
                          (840.13)
n = 4
        1-(Z)-10-docosenoyl-sn-glycero-3-phospho-N,N-
1481.)
        dimethyl-N-(HP_1-HP_2-diHP_3) butylammonium (n = 4)
        CanHanNO12P
                          (814.05)
1482.)
        1-(Z,Z)-10,16-docosadienoyl-sn-glycero-3-
        phospho-N, N-dimethyl-N- (HP1-HP2-diHP3) butyl-
        ammonium (n = 4)
                          (812.03)
        C40H78NO13P
1483.)
        1-(Z,Z)-6,18-hexacosadienoyl-sn-glycero-3-
        phospho-N, N-dimethyl-N-(HP1-HP2-diHP3) butyl-
        ammonium (n = 4)
        C44H86NO13P
                          (868.14)
       1-0-(Z)-6-octadecenyl-sn-glycero-3-phospho-N,N-
        dimethyl-N-(HP_1-HP_2-diHP_3) butylammonium (n = 4)
```

(743.96)1-0-(Z)-10-docosenyl-sn-glycero-3-phospho-N,N-

(800.06)

 $dimethyl-N-(HP_1-HP_2-diHP_3)$ butylammonium (n = 4)

C36H74NO12P

CanHanNO12P

1485.)

```
- 131 -
```

```
1486.) 1-O-(Z,Z)-5,11-octadecadienyl-sn-glycero-3-phospho-N,N-dimethyl-N-(HP<sub>1</sub>-HP<sub>2</sub>-diHP<sub>3</sub>)butyl-ammonium (n = 4)

C<sub>36</sub>H<sub>72</sub>NO<sub>12</sub>P (741.94)

1487.) 1-O-(Z)-12-eicosenyl-sn-glycero-3-phospho-N,N-dimethyl-N-(HP<sub>1</sub>-HP<sub>2</sub>-diHP<sub>3</sub>)butylammonium (n = 4)

C<sub>38</sub>H<sub>72</sub>NO<sub>12</sub>P (772.01)
```

- 1488.) 1-(Z)-6-octadecenoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(HP₁-HP₂-diHP₃) hexylammonium (n = 6) C₁₈H₇₆NO₁₃P (785.99)
- 1489.) 1-(Z)-10-docosenoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(HP₁-HP₂-diHP₃) hexylammonium (n = 6) $C_{\ell 2}H_{\theta 2}NO_{12}P \qquad (842.10)$
- 1490.) 1-(Z,Z)-5,11-hexadecadienoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(HP₁-HP₂-diHP₃)hexyl-ammonium (n = 6)
 C₂₆H₂₀NO₁₂P (755.92)
- 1491.) 1-(Z,Z)-10,16-docosadienoyl-sn-glycero-3-phospho-N,N-dimethyl-N- $(HP_1-HP_2-diHP_3)$ hexyl-ammonium (n = 6) $C_{42}H_{62}NO_{13}P \qquad (840.09)$
- 1492.) 1-(Z,Z)-6,18-hexacosadienoyl-sn-glycero-3-phospho-N,N-dimethyl-N- $(HP_1-HP_2-diHP_3)$ hexyl-ammonium (n=6) $C_{46}H_{90}NO_{13}P \qquad (896.19)$
- 1493.) 1-O-(Z)-6-octadecenyl-sn-glycero-3-phospho-N,N-dimethyl-N-(HP₁-HP₂-diHP₃) hexylammonium (n = 6) C₃₈H₂₆NO₂-P (772.01)
- 1494.) 1-0-(Z)-10-docosenyl-sn-glycero-3-phospho-N,N-dimethyl-N-(HP1-HP2-diHP3)hexylammonium (n = 6)
 C42Ha6NO12P (828.12)
- 1495.) 1-0-(Z,Z)-5,11-octadecadienyl-sn-glycero-3phospho-N,N-dimethyl-N-(HP₁-HP₂-diHP₃)hexylammonium (n = 6)

- 132 -

C38H76NO12P (769.99)

1496.) 1-0-(Z)-12-eicosenyl-sn-glycero-3-phospho-N,N-dimethyl-N-(HP1-HP2-diHP3)hexylammonium (n = 6) $C_{4n}H_{82}NO_{12}P \end{math} (800.06)$

4. Examples of single-chain glycero-phospho compounds not hydroxylated on the nitrogen

 $(A = III; n = 2-6; R_3, CH_3; m = 1, x = 1; z = 0)$

$$A - PO_3 - \left[(CH_2)_n - N^+ \atop \mathring{R}_3 \right]_m - (CH_2)_X - \left[CH_2 - \left(\begin{array}{c} CH \\ OH \end{array} \right)_y - CH_2 - O \right]_z - H_2 - O \right]_z$$

- 1497). 1-(Z)-6-octadecenoyl-sn-glycero-3-phospho-N,N,N-trimethylpropylammonium (n = 3) $C_{27}H_{54}NO_{7}P$ (535.70)
- 1498). 1-(Z)-10-docosenoyl-sn-glycero-3-phospho-N,N,Ntrimethylpropylammonium (n = 3)
 C1Hc2NO2P (591.81)
- 1499). 1-(Z)-10-tetracosenoyl-sn-glycero-3-phospho-N,N,N-trimethylpropylammonium (n = 3) $C_{33}H_{56}NO_7P \qquad (619.86)$
- 1500). 1-(Z,Z)-5,11-octadecadienoyl-sn-glycero-3-phospho-N,N,N-trimethylpropylammonium (n = 3) $C_{27}H_{52}NO_7P$ (533.69)
- 1501). 1-(Z,Z)-10,16-eicosadienoyl-sn-glycero-3-phospho-N,N,N-trimethylpropylammonium (n = 3) $<math>C_{2}H_{56}N0_{7}P$ (561.74)
- 1502). 1-(Z,Z)-10,16-docosadienoyl-sn-glycero-3-phospho-N,N,N-trimethylpropylammonium (n = 3) $C_{31}H_{60}NO_7P \end{tabular} (589.79)$
- 1503). 1-(Z,Z)-6,18-hexacosadienoyl-sn-glycero-3-phospho-N,N,N-trimethylpropylammonium (n = 3) $C_{35H_{68}NO_7P} \hspace{1.5cm} (645.90)$
- 1504.) 1-0-(Z)-10-docosenyl-sn-glycero-3-phospho-N,N,N-trimethylpropylammonium (n = 3)

- 133 -

C31H64NO6P (577.83)

- 1505.) 1-0-(Z)-10-tetracosenvl-sn-glycero-3-phospho-N, N, N-trimethylpropylammonium (n = 3) (605.88) C33H68NO6P
- 1-O-(Z,Z)-10.16-eicosadienvl-sn-glycero-3-1506.) phospho-N, N, N-trimethylpropylammonium (n = 3)C29H58NO6P (547.76)
- 1507.) 1-0-(Z,Z)-6,18-tetracosadienyl-sn-glycero-3phospho-N, N, N-trimethylpropylammonium (n = 3)(603.86) C33H66NO6P
- 1-O-(Z,Z)-6.18-hexacosadienvl-sn-glycero-3-1508.) phospho-N, N, N-trimethylpropylammonium (n = 3)C35H70NO6P (631.92)

Examples of ω,ω'-alkanediol-phospho-N,N-dimethyl-N-dihydroxypropylalkylammonium compounds

 $(A = V; n = 2-6; R_3, CH_3; m = 1, x = 0; y = 1; z = 1)$

$$A - PO_3 - \left[(CH_2)_n - \stackrel{CH_3}{N} \right]_m - (CH_2)_x - \left[\begin{array}{c} CH_2 - \left(\begin{array}{c} CH \\ OH \end{array} \right)_y - CH_2 - O \end{array} \right]_z - H$$

- 1509.) 1-(Z)-10-docosenoyl-ethyleneglycol-phospho-N,Ndimethyl-N-dihydroxypropylethylammonium (n = 2)(607.81)C31H62NO8P
- 1510.) 1-(Z)-6-octadecenoyl-propanediol-(1,3)-phospho-N.N-dimethyl-N-dihydroxypropylethylammonium (n = 2)C28H56NO8P (565.73)
- 1511.) 1-(Z)-10-docosenovl-propanediol-(1,3)-phospho-N, N-dimethyl-N-dihydroxypropylethylammonium (n = 2)

(621.84)

C32H64NO8P 1512.) 1-(Z)-10-tetracosenoyl-propanediol-(1,3)phospho-N, N-dimethyl-N-dihydroxypropylethylammonium (n = 2)

> C34H68NO8P (649.89)

1513.) 1-(Z,Z)-5,11-octadecadienoyl-propanediol-(1,3)-phospho-N,N-dimethyl-N-dihydroxypropylethyl-ammonium (n = 2)

C28H54NO8P (563.71)

- 1514.) 1-(Z,Z)-10,16-eicosadienoyl-propanediol-(1,3)phospho-N,N-dimethyl-N-dihydroxypropylethylammonium (n = 2)
 C10H6sNOsP (591.77)
- 1515.) 1-(Z,Z)-10,16-docosadienoyl-propanediol-(1,3)-phospho-N,N-dimethyl-N-dihydroxypropylethyl-ammonium (n = 2)

1516.) 1-(Z,Z)-6,18-hexacosadienoyl-propanediol-(1,3)-phospho-N,N-dimethyl-N-dihydroxypropylethyl-ammonium (n=2)

(619.82)

C₃₆H₇₀NO₈P (675.93)

C32H62NO8P

1517.) 1-(Z)-10-docosenoyl-propanediol-(1,3)-phospho-N,N-dimethyl-N-dihydroxypropylpropylammonium (n = 3)

 $C_{33}H_{66}NO_8P$ (635.86)

1518.) 1-(Z)-10-docosenoyl-propanediol-(1,3)-phospho-N,N-dimethyl-N-dihydroxypropylbutylammonium (n = 4) C14Hc4NO4P (649.89)

6. Examples of alkanediol-(1,2)-phospho-N,N-dimethylN-dihydroxypropylalkylammonium compounds

(A = VII; n = 2-6; R_3 , CH_3 ; m = 1, x = 0; y = 1; z = 1)

$$A - PO_3 - \begin{bmatrix} CH_3 \\ (CH_2)_n - N^- \\ R_3 \end{bmatrix}_m - (CH_2)_x - \begin{bmatrix} CH_2 - \begin{pmatrix} CH \\ OH \end{pmatrix}_y - CH_2 - O \\ \end{bmatrix}_z^{-H}$$

1519.) 2-(Z)-10-docosenoyl-propanediol-(1,2)-phospho-N,N-dimethyl-N-dihydroxypropylethylammonium (n = 2) - 135 -

C22H64NO8P (621.84)

1520.) 1-(Z)-10-docosenoyl-propanediol-(1,2)-phospho-N,N-dimethyl-N-dihydroxypropylethylammonium (n = 2)

 $C_{32}H_{64}NO_8P$ (621.84)

1521.) 2-(Z)-10-docosenoyl-propanediol-(1,2)-phospho-N,N-dimethyl-N-dihydroxypropylpropylammonium (n = 3)

C33H66NO8P (635.86)

- 1522.) 1-(Z)-10-docosenoyl-propanediol-(1,2)-phospho-N,N-dimethyl-N-dihydroxypropylbutylammonium (n = 4) $C_{14}H_{62}NO_3P$ (649.89)
- Examples of ω,ω'-alkanediol-phospho-N,N-dimethyl-N-(2-hydroxypropyl-3,1-0,0-dihydroxypropyl)alkylammonium compounds
- $(A = V; n = 2-6; R_3, CH_3; m = 1, x = 0; y = 1; z = 2)$

$$A - PO_3 - \begin{bmatrix} (CH_2)_0 - \overset{CH_3}{N^2} \\ \overset{R}{R_3} \end{bmatrix}_m - (CH_2)_X - \begin{bmatrix} CH_2 - \begin{pmatrix} CH \\ OH \end{pmatrix}_y - CH_2 - O \end{bmatrix}_z^{-H}$$

- 1523.) 1-(Z)-10-docosenoyl-ethyleneglycol-phospho-N,Ndimethyl-N-(2-hydroxypropyl-3,1-0,0-dihydroxypropyl)ethylammonium (n = 2)
 C14H68NO10P (681.89)
- 1524.) 1-(Z)-6-octadecenoyl-propanediol-(1,3)-phospho-N,N-dimethyl-N-(2-hydroxypropyl-3,1-0,0dihydroxypropyl)ethylammonium (n = 2) C11Hs2NO10P (639.81)
- 1525.) 1-(Z)-10-docosenoyl-propanediol-(1,3)-phospho-N,N-dimethyl-N-(2-hydroxypropyl-3,1-0,0dihydroxypropyl)ethylammonium (n = 2) C35H70NO10P (695.92)
- 1526.) 1-(Z)-10-tetracosenoyl-propanediol-(1,3)phospho-N,N-dimethyl-N-(2-hydroxypropyl-3,10,0-dihydroxypropyl)ethylammonium (n = 2)

- 136 -

C₃₇H₇₄NO₁₀P (723.97)

- 1527.) 1-(Z,Z)-5,11-octadecadienoyl-propanediol-(1,3)phospho-N,N-dimethyl-N-(2-hydroxypropyl-3,10,O-dihydroxypropyl)ethylammonium (n = 2)
 C2+HenNO10P (637.79)
- 1528.) 1-(Z,Z)-10,16-eicosadienoyl-propanediol-(1,3)-phospho-N,N-dimethyl-N-(2-hydroxypropyl-3,1-0,0-dihydroxypropyl)ethylammonium (n = 2) $C_{33}H_{54}NO_{10}P \qquad (665.85)$
- 1529.) 1-(Z,Z)-10,16-docosadienoyl-propanediol-(1,3)phospho-N,N-dimethyl-N-(2-hydroxypropyl-3,10,0-dihydroxypropyl)ethylammonium (n = 2)
 C15Hc2NO10P (693.90)
- 1530.) 1-(Z,Z)-6,18-hexacosadienoyl-propanediol-(1,3)-phospho-N,N-dimethyl-N-(2-hydroxypropyl-3,1-0,0-dihydroxypropyl)ethylammonium (n = 2) $C_{39}H_{76}NO_{10}P$ (750.01)
- 1531.) 1-(Z)-10-docosenoyl-propanediol-(1,3)-phospho-N,N-dimethyl-N-(2-hydroxypropyl-3,1-0,0dihydroxypropyl)propylammonium (n = 3) $C_{16}H_{72}NO_{10}P$ (709.94)
- 1532.) 1-(Z)-10-docosenoyl-propanediol-(1,3)-phospho-N,N-dimethyl-N-(2-hydroxypropyl-3,1-0,0dihydroxypropyl) butylammonium (n = 4) C17H14NO10P (723.96)
- 1533.) 1-(Z)-10-docosenoyl-butanediol-(1,4)-phospho-N,N-dimethyl-N-(2-hydroxypropyl-3,1-0,0dihydroxypropyl)propylammonium (n = 3) C₃₇H₇₄NO₁₀P (723.96)
- 1534.) 1-(Z)-10-docosenoyl-hexanediol-(1,6)-phosphoN,N-dimethyl-N-(2-hydroxypropyl-3,1-0,0dihydroxypropyl)propylammonium (n = 3)

 C19H78NO10P (752.02)
- 1535.) 1-(Z)-10-docosenoyl-octanediol-(1,8)-phospho-N,N-dimethyl-N-(2-hydroxypropyl-3,1-0,0dihydroxypropyl)propylammonium (n = 3)

- 137 -

CalHeaNO10P (780.07)

8. Examples of alkanediol-(1,2)-phospho-N,N-dimethylN-(2-hydroxypropyl-3,1-0,0-dihydroxypropyl)alkylammonium compounds

 $(A = VII; n = 2-6; R_3, CH_3; m = 1, x = 0; y = 1; z = 2)$

$$A - PO_3 - \left[\underbrace{(CH_2)_n - N^+}_{\hat{R}_3} \right]_m - (CH_2)_x - \left[\underbrace{CH_2 - \left(\begin{array}{c} CH \\ OH \end{array} \right)_y - CH_2 - O}_y \right]_2 - H$$

- 1536.) 2-(Z)-10-docosenoyl-propanediol-(1,2)-phospho-N,N-dimethyl-N-(2-hydroxypropyl-3,1-0,0dihydroxypropyl)ethylammonium (n = 2) CssHnoNOnP (695.91)
- 1537.) 1-(Z)-10-docosenoyl-propanediol-(1,2)-phospho-N,N-dimethyl-N-(2-hydroxypropyl-3,1-0,0dihydroxypropyl)ethylammonium (n = 2) C1=H₇₀NO₁₀P (695.91)
- 1538.) 2-(Z)-10-docosenoyl-propanediol-(1,2)-phospho-N,N-dimethyl-N-(2-hydroxypropyl-3,1-0,0dihydroxypropyl)propylammonium (n = 3) $C_{36}H_{72}NO_{10}P$ (709.94)
- 1539.) 1-(Z)-10-docosenoyl-propanediol-(1,2)-phosphoN,N-dimethyl-N-(2-hydroxypropyl-3,1-0,0dihydroxypropyl) butylammonium (n = 4)
 CoaHaaNOopP (723.97)
- 1540.) 1-(Z)-10-docosenoyl-butanediol-(1,2)-phospho-N,N-dimethyl-N-(2-hydroxypropyl-3,1-0,0dihydroxypropyl)propylammonium (n = 3) C₃₇H₂₄NO₁₀P (723.97)
- 1541.) 1-(Z)-10-docosenoyl-hexanediol-(1,2)-phosphoN,N-dimethyl-N-(2-hydroxypropyl-3,1-0,0dihydroxypropyl)propylammonium (n = 3)

 C10H78NO10P (752.02)
- 1542.) 1-(Z)-10-docosencyl-octanediol-(1,2)-phosphoN,N-dimethyl-N-(2-hydroxypropyl-3,1-0,0dihydroxypropyl)propylammonium (n = 3)

 C41H62NO10P (780.07)

9. Examples of ω,ω' -alkanediol-phospho-N,N-dimethyl-

N-(2-hydroxypropy1-3,1-0,0-2-hydroxypropy1-3,1-0,0-dihydroxypropy1)alkylammonium compounds

 $(A = V; n = 2-6; R_3, CH_3; m = 1, x = 0; y = 1; z = 3)$

$$A - PO_3 = \begin{bmatrix} CH_3 \\ (CH_2)_n - N^* \\ R_3 \end{bmatrix} - (CH_2)_x - \begin{bmatrix} CH_2 - \begin{pmatrix} CH_1 \\ OH \end{pmatrix}_y - CH_2 - O \end{bmatrix} - H$$

- 1543.) 1-(Z)-10-docosenoyl-ethyleneglycol-phospho-N,N-dimethyl-N-($HP_1-HP_2-diHP_3$) ethylammonium (n = 2) $C_{37}H_{74}NO_{12}P$ (755.97)
- 1544.) 1-(Z)-6-octadecenoyl-propanediol-(1,3)-phospho-N,N-dimethyl-N-(HP₁-HP₂-diHP₃) ethylammonium (n = 2)

C34H68NO12P (713.89)

1545.) 1-(Z)-10-docosenoyl-propanediol-(1,3)-phospho-N,N-dimethyl-N-(HP₁-HP₂-diHP₃)ethylammonium (n = 2)

C₃₈H₇₆NO₁₂P (769.99)

- 1546.) 1-(Z)-10-tetracosenoyl-propanediol-(1,3)- phospho-N,N-dimethyl-N-($HP_1-HP_2-diHP_3$)ethyl-ammonium (n = 2) $C_{40}H_{80}NO_{12}P \qquad (798.05)$
- 1547.) 1-(Z,Z)-5,11-octadecadienoyl-propanediol-(1,3)phospho-N,N-dimethyl-N-(HP1-HP2-diHP3)ethylammonium (n = 2)
 C34H66NO12P (711.89)
- 1548.) 1-(Z,Z)-10,16-eicosadienoyl-propanediol-(1,3)phospho-N,N-dimethyl-N-(HP1-HP2-diHP3)ethylammonium (n = 2)
 C16H00NO12P (739.93)
- 1549.) 1-(Z,Z)-10,16-docosadienoyl-propanediol-(1,3)-phospho-N,N-dimethyl-N- $(HP_1-HP_2-diHP_3)$ ethyl-ammonium (n=2) $C_{18}H_{24}NO_{12}P \qquad (767.98)$

100 PM 175 PM M fract their fact

- 1550.) 1-(Z,Z)-6,18-hexacosadienoyl-propanediol-(1,3)phospho-N, N-dimethyl-N-(HP1-HP2-diHP3)ethylammonium (n = 2)C42H82NO12P (824.09)
- 1551.) 1-(Z)-10-docosenoyl-propanediol-(1,3)-phospho-N.N-dimethyl-N-(HP1-HP2-diHP3) propylammonium (n = 3)(784.01)C39H78NO12P
- 1552.) 1-(Z)-10-docosenoyl-propanediol-(1,3)-phospho-N.N-dimethyl-N-(HP1-HP2-diHP3) butylammonium (n = 4)C40H80NO12P (798.04)
- 1553.) 1-(Z)-10-docosenoyl-butanediol-(1,4)-phospho-N.N-dimethyl-N-(HP1-HP2-diHP3) propylammonium (n = 3)C40H80NO12P (798.04)
- 1554.) 1-(Z)-10-docosenoyl-hexanediol-(1,6)-phospho-N, N-dimethyl-N-(HP1-HP2-diHP3) propylammonium (n = 3)(826.10)
- 1555.) 1-(Z)-10-docosenoyl-octanediol-(1,8)-phospho-N, N-dimethyl-N-(HP1-HP2-diHP3) propylammonium (n = 3)C44H88NO12P (854.16)

10. Examples of alkanediol-phospho compounds not hydroxylated on the nitrogen

 $(A = V; n = 2-6; R_3, CH_3; m = 1, x = 1; z = 0)$

C42H84NO12P

$$A - PO_3^{-} - \underbrace{ \begin{pmatrix} CH_2 \end{pmatrix}_n - \bigwedge^{CH_3} \\ R_3 \end{pmatrix}}_m - (CH_2)_X - \underbrace{ \begin{pmatrix} CH_2 - \begin{pmatrix} CH \\ OH \end{pmatrix}_y - CH_2 - O \end{pmatrix}}_z - H$$

1556.) 1-(Z)-10-docosenoyl-ethyleneglycol-phospho-N, N, N-trimethylpropylammonium (n = 3)

- 140 -

C30H60NO6P (561.78)

- 1557.) 1-(Z)-6-octadecenoyl-propanediol-(1,3)-phospho-N,N,N-trimethylethylammonium (n = 2) $C_{26}H_{52}NO_5P$ (505.68)
- 1558.) 1-(Z)-10-docosenoyl-propanediol-(1,3)-phospho-N,N,N-trimethylethylammonium (n = 2) $C_{30}H_{60}NO_{6}P$ (561.78)
- 1559.) 1-(Z)-10-tetracosenoyl-propanediol-(1,3)phospho-N,N,N-trimethylpropylammonium (n = 3) $C_{33}H_{66}NO_{6}P \qquad (603.86)$
- 1560.) 1-(Z,Z)-5,11-octadecadienoyl-propanediol-(1,3)phospho-N,N,N-trimethylpropylammonium (n = 3) $C_{27}H_{82}NO_6P$ (517.69)
- 1561.) 1-(Z,Z)-10,16-eicosadienoyl-propanediol-(1,3)-phospho-N,N,N-trimethylpropylammonium (n = 3) $C_{29}H_{56}NO_5P \hspace{1cm} (545.74)$
- 1562.) 1-(Z,Z)-10,16-docosadienoyl-propanediol-(1,3)phospho-N,N,N-trimethylpropylammonium (n = 3) $C_{31}H_{60}NO_6P \qquad (573.79)$
- 1563.) 1-(Z,Z)-6,18-hexacosadienoyl-propanediol-(1,3)phospho-N,N,N-trimethylpropylammonium (n = 3)
 C16HsgNO6P (629.90)
- 1564.) 1-(Z)-10-docosenoyl-propanediol-(1,3)-phospho-N,N,N-trimethylpropylammonium (n = 3) C₃₁H₆₂NO₆P (575.81)
- 1565.) 1-(Z)-10-docosenoyl-propanediol-(1,3)-phospho-N,N,N-trimethylbutylammonium (n = 4) $C_{32}H_{64}NO_5P \hspace{1cm} (589.84)$
- 1566.) 1-(Z)-10-docosenoyl-butanediol-(1,4)-phospho-N,N,N-trimethylpropylammonium (n = 3) C₁₂H₆₄NO₆P (589.84)
- 1567.) 1-(Z)-10-docosenoyl-hexanediol-(1,6)-phospho-N,N,N-trimethylpropylammonium (n = 3) C₃₄H₆₈NO₆P (617.89)

1568.) 1-(Z)-10-docosenoyl-octanediol-(1,8)-phospho-N,N,N-trimethylpropylammonium (n = 3) C16H12NO6P (645.94)

Liposome constituents

Neutral phospholipids

1. Examples of two-chain glycero-phospho-N,N-dimethyl-N-dihydroxypropylalkylammonium compounds

 $(A = III; n = 2-6; R_3, CH_3; m = 1, x = 0; y = 1; z = 1)$

$$A - PO_3 - \left[(CH_2)_n - N^* \atop R_3 \right]_m - (CH_2)_x - \left[CH_2 - \left(\begin{matrix} CH_1 \\ OH \end{matrix} \right)_y - CH_2 - O \right]_z - H$$

n = 2

1569.)
 1,2-di-(Z)-6-hexadecenoyl-sn-glycero-3-phospho-N,N-dimethyl-N-dihydroxypropylethylammonium (n = 2)

C₄₂H₈₀NO₁₀P (790.07)

- 1570.) 1,2-di-(Z)-10-heptadecenoyl-sn-glycero-3phospho-N,N-dimethyl-N-dihydroxypropylethylammonium (n = 2)
 C44H84NO10P (818.13)
- 1571.) 1,2-di-(Z)-6-octadecenoyl-sn-glycero-3-phospho-N,N-dimethyl-N-dihydroxypropylethylammonium (n = 2)

C46H88NO10P (846.18)

- 1572.) 1,2-di-(Z)-6-nonadecenoyl-sn-glycero-3-phospho-N,N-dimethyl-N-dihydroxypropylethylammonium (n = 2) $C_{48}H_{92}NO_{10}P \qquad (874.23)$
- 1573.) 1,2-di-(Z)-12-eicosenoyl-sn-glycero-3-phospho-N,N-dimethyl-N-dihydroxypropylethylammonium (n = 2)

- 1574.) 1,2-di-(Z)-10-heneicosenoyl-sn-glycero-3phospho-N,N-dimethyl-N-dihydroxypropylethylammonium (n = 2)
 C₅₂H₁₉₀NO₁₉P (930.34)
- 1575.) 1,2-di-(Z)-10-docosenoyl-sn-glycero-3-phospho-N,N-dimethyl-N-dihydroxypropylethylammonium (n = 2) CsaHtanNOnaP (958.39)
- 1576.) 1,2-di-(Z)-12-docosenoyl-sn-glycero-3-phospho-N,N-dimethyl-N-dihydroxypropylethylammonium (n = 2)

C54H104NO10P (958.39)

1577.) 1,2-di-(Z)-10-tricosenoyl-sn-glycero-3-phospho-N,N-dimethyl-N-dihydroxypropylethylammonium (n = 2)

C₅₆H₁₀₈NO₁₀P (986.45)

- 1578.) 1,2-di-(Z)-10-tetracosenoyl-sn-glycero-3phospho-N,N-dimethyl-N-dihydroxypropylethylammonium (n = 2)
 C₅₈H₁₁₂NO₁₀P (1014.50)
- 1579.) 1,2-di-(Z)-15-pentacosenoyl-sn-glycero-3-phospho-N,N-dimethyl-N-dihydroxypropylethyl-ammonium (n = 2) $C_{50}H_{115}NO_{10}P \qquad (1042.56)$
- 1580.) 1,2-di-(Z)-16-hexacosenoyl-sn-glycero-3phospho-N,N-dimethyl-N-dihydroxypropylethylammonium (n = 2)
 C62H120NO10P (1070.61)
- 1581.) 1,2-di-(Z,Z)-5,11-hexadecadienoyl-sn-glycero-3-phospho-N,N-dimethyl-N-dihydroxypropylethyl-ammonium (n = 2) $C_{42}H_{76}NO_{10}P \qquad (786.04)$
- 1582.) 1,2-di-(Z,Z)-5,11-heptadecadienoyl-sn-glycero-3-phospho-N,N-dimethyl-N-dihydroxypropylethyl-ammonium (n = 2) $C_{44H_{80}NO_{10}P} \tag{814.09}$

```
1583.) 1,2-di-(Z,Z)-5,11-octadecadienoyl-sn-glycero-3-phospho-N,N-dimethyl-N-dihydroxypropylethyl-ammonium (n = 2)

C_{46}He_4NO_{10}P (842.15)
```

1584.) 1,2-di-(Z,Z)-6,12-nonadecadienoyl-sn-glycero-3-phospho-N,N-dimethyl-N-dihydroxypropylethyl-ammonium (n = 2)

C45H45RNO10P (870.20)

1585.) 1,2-di-(Z,Z)-10,16-eicosadienoyl-sn-glycero-3-phospho-N,N-dimethyl-N-dihydroxypropylethyl-ammonium (n = 2)

 $C_{50}H_{92}NO_{10}P$ (898.25)

1586.) 1,2-di-(Z,Z)-10,16-heneicosadienoyl-sn-glycero-3-phospho-N,N-dimethyl-N-dihydroxypropylethylammonium (n = 2)

Cs-HashNCroP (926.31)

1587.) 1,2-di-(Z,Z)-10,16-docosadienoyl-sn-glycero-3-phospho-N,N-dimethyl-N-dihydroxypropylethyl-ammonium (n = 2) $C_{54}H_{100}NO_{10}P$ (955.36)

1588.) 1,2-di-(Z,Z)-10,16-tricosadienoyl-sn-glycero-3phospho-N,N-dimethyl-N-dihydroxypropylethylammonium (n = 2)
C=6H:04NO:0P (982.42)

1589.) 1,2-di-(Z,Z)-6,18-tetracosadienoyl-sn-glycero-3-phospho-N,N-dimethyl-N-dihydroxypropylethylammonium (n = 2) CsaHinaNOioP (1010.47)

1590.) 1,2-di-(Z,Z)-10,16-pentacosadienoyl-sn-glycero-3-phospho-N,N-dimethyl-N-dihydroxypropylethyl-ammonium (n = 2) $C_{50}H_{112}NO_{10}P \qquad (1038.52)$

1591.) 1,2-di-(Z,Z)-6,18-hexacosadienoyl-sn-glycero-3-phospho-N,N-dimethyl-N-dihydroxypropylethyl-ammonium (n = 2)

Cs2HukNOnP (1066.58)

```
1592.)
        2-(Z)-6-hexadecenoyl-1-stearoyl-sn-glycero-3-
        phospho-N, N-dimethyl-N-dihydroxypropylethyl-
        ammonium (n = 2)
        C44H86NO10P
```

(820.14)

2-(Z)-10-octadecenoyl-1-stearoyl-sn-glycero-3-1593.) phospho-N, N-dimethyl-N-dihydroxypropylethylammonium (n = 2)C44H90NO10P (848,20)

2-(Z)-10-eicosenoyl-1-stearoyl-sn-glycero-3-1594.) phospho-N, N-dimethyl-N-dihydroxypropylethylammonium (n = 2)C48H94NO10P (876.25)

1595.) 1-behenyl-2-(Z)-10-docosenoyl-sn-glycero-3phospho-N, N-dimethyl-N-dihydroxypropylethylammonium (n = 2)C52H102NO10P (932.36)

1596.) 2-(Z,Z)-6,12-hexadecadienovl-1-stearovl-snglycero-3-phospho-N, N-dimethyl-N-dihydroxypropylethylammonium (n = 2)C44H84NO10P (818.13)

1597.) 2-(Z,Z)-10,16-docosadienovl-1-stearovl-snglycero-3-phospho-N,N-dimethyl-N-dihydroxypropylethylammonium (n = 2)CsoHosNO10P (902.29)

1-stearov1-2-(Z,Z)-6,18-tetracosadienov1-snglycero-3-phospho-N, N-dimethyl-N-dihydroxypropylethylammonium (n = 2)C52H100NO10P (930.34)

1-(Z)-10-octadecenoyl-2-stearoyl-sn-glycero-3phospho-N, N-dimethyl-N-dihydroxypropylethylammonium (n = 2)C46H90NO10P (848.20)

1600.) 1-(Z,Z)-6,18-hexacosadienovl-2-stearovl-snglycero-3-phospho-N, N-dimethyl-Ndihydroxypropylethylammonium (n = 2)C54H104NO10P (958.39)

- 1601.) 1-(Z,Z)-6,18-hexacosadienoyl-2-(Z)-6-hexadecenoyl-sn-glycero-3-phospho-N,N-dimethyl-N-dihydroxypropylethylammonium (n = 2) $C_{52}H_{98}NO_{10}P$ (928.32)
- 1602.) 2-(Z,Z)-6,18-hexacosadienoyl-1-(Z)-6-hexadecenoyl-sn-glycero-3-phospho-N,N-dimethyl-N-dihydroxypropylethylammonium (n = 2) $C_{52}H_{98}NO_{10}P \qquad (928.32)$

n = 3

- 1603.) 1,2-di-(Z)-6-hexadecenoyl-sn-glycero-3-phospho-N,N-dimethyl-N-dihydroxypropylpropylammonium (n = 3) $C_{43}H_{82}NO_{10}P \qquad (804.10)$
- 1604.) 1,2-di-(Z)-10-heptadecenoyl-sn-glycero-3-phospho-N,N-dimethyl-N-dihydroxypropylpropyl-ammonium (n = 3) $C_{45}H_{86}NO_{10}P \qquad (832.15)$
- 1605.) 1,2-di-(Z)-6-octadecenoyl-sn-glycero-3-phospho-N,N-dimethyl-N-dihydroxypropylpropylammonium (n = 3) Ca-HanNO10P (860.21)
- 1606.) 1,2-di-(Z)-12-eicosenoyl-sn-glycero-3-phospho-N,N-dimethyl-N-dihydroxypropylpropylammonium (n = 3) C=1H98NO1nP (916.31)
- 1607.) 1,2-di-(Z)-10-docosenoyl-sn-glycero-3-phospho-N,N-dimethyl-N-dihydroxypropylpropylammonium (n = 3)

C₅₅H₁₀₆NO₁₀P (972.42)

1608.) 1,2-di-(Z)-12-docosenoyl-sn-glycero-3-phospho-N,N-dimethyl-N-dihydroxypropylpropylammonium (n = 3)

C₅₅H₁₀₆NO₁₀P (972.42)

1609.) 1,2-di-(Z)-10-tricosenoyl-sn-glycero-3-phospho-N,N-dimethyl-N-dihydroxypropylpropylammonium (n = 3) C₅₇H₁₁₀NO₁₀P (1000.47)

```
- 146 -
1610.) 1,2-di-(Z)-10-tetracosenoyl-sn-glycero-3-
        phospho-N, N-dimethyl-N-dihydroxypropylpropyl-
        ammonium (n = 3)
        C59H114NO10P
                         (1028.53)
1611.) 1,2-di-(Z,Z)-5,11-octadecadienovl-sn-glycero-3-
        phospho-N, N-dimethyl-N-dihydroxypropylpropyl-
        ammonium (n = 3)
        C47H86NO10P
                         (856.17)
        1.2-di-(Z,Z)-10,16-eicosadienoyl-sn-glycero-3-
1612.)
        phospho-N, N-dimethyl-N-dihydroxypropylpropyl-
        ammonium (n = 3)
        Cs1H94NO10P
                          (912.28)
        1, 2-di-(Z, Z)-10, 16-docosadienoyl-sn-glycero-3-
1613.)
        phospho-N, N-dimethyl-N-dihydroxypropylpropyl-
        ammonium (n = 3)
        C55H102NO10P
                         (968.39)
        1,2-di-(Z,Z)-6,18-hexacosadienovl-sn-glycero-3-
1614.)
        phospho-N, N-dimethyl-N-dihydroxypropylpropyl-
        ammonium (n = 3)
        C63H118NO10P
                         (1080.60)
1615.)
        2-(Z)-6-hexadecenovl-1-stearovl-sn-glycero-3-
        phospho-N, N-dimethyl-N-dihydroxypropylpropyl-
        ammonium (n = 3)
        CasHooNOnoP
                         (834.17)
1616.)
        2-(Z)-10-octadecenovl-1-stearovl-sn-glycero-3-
        phospho-N,N-dimethyl-N-dihydroxypropylpropyl-
        ammonium (n = 3)
        C47H92NO10P
                         (862.22)
1617.)
       2-(Z)-10-docosenoyl-1-behenyl-sn-glycero-3-
        phospho-N, N-dimethyl-N-dihydroxypropylpropyl-
        ammonium (n = 3)
```

 $C_{53}H_{104}NO_{10}P$ (946.38) 1618.) 2-(Z,Z)-6,12-hexadecadienoyl-1-stearoyl-sn-glycero-3-phospho-N,N-dimethyl-N-dihydroxypropylpropylammonium (n = 3) $C_{45}H_{45}NO_{10}P$ (832.15)

```
1619.) 1-(Z)-10-octadecenoyl-2-stearoyl-sn-glycero-3-phospho-N,N-dimethyl-N-dihydroxypropylpropyl-ammonium (n = 3)

CtrHo-NO10P (862.22)
```

1620.) 1-(Z,Z)-6,18-hexacosadienoyl-2-stearoyl-snglycero-3-phospho-N,N-dimethyl-Ndihydroxypropylpropylammonium (n = 3)
CssHageNO10P (972.42)

n = 4

1621.) 1,2-di-(Z)-6-octadecenoyl-sn-glycero-3-phospho-N,N-dimethyl-N-dihydroxypropylbutylammonium (n = 4)
C48He2NO10P (874.23)

1622.) 1,2-di-(Z)-10-docosenoyl-sn-glycero-3-phospho-N,N-dimethyl-N-dihydroxypropylbutylammonium

> (n = 4) $C_{56}H_{108}NO_{10}P$ (986.45)

1623.) 1,2-di-(Z,Z)-5,11-hexadecadienoyl-sn-glycero-3-phospho-N,N-dimethyl-N-dihydroxypropylbutyl-ammonium (n = 4) $C_{44}H_{80}NO_{10}F \qquad (814.09)$

1624.) 1,2-di-(Z,Z)-10,16-docosadienoyl-sn-glycero-3-phospho-N,N-dimethyl-N-dihydroxypropylbutyl-ammonium (n = 4)

C₅₆H₁₀₄NO₁₀P (982.42)

1625.) 1,2-di-(Z,Z)-6,18-hexacosadienoyl-sn-glycero-3-phospho-N,N-dimethyl-N-dihydroxypropylbutyl-ammonium (n = 4) $C_{64}H_{120}NO_{10}P \qquad (1094.63)$

n = 6

1626.) 1,2-di-(Z)-6-octadecenoyl-sn-glycero-3-phosphoN,N-dimethyl-N-dihydroxypropylhexylammonium
(n = 6)
CsnHegNOtoP (902.29)

- 1627.) 1,2-di-(Z)-10-docosenoyl-sn-glycero-3-phospho-N,N-dimethyl-N-dihydroxypropylhexylammonium (n = 6)
 - C₅₈H₁₁₂NO₁₀P (1014.50)
- 1628.) 1,2-di-(Z,Z)-10,16-docosadienoyl-sn-glycero-3-phospho-N,N-dimethyl-N-dihydroxypropylhexyl-ammonium (n = 6) $C_{saH_{108}NO_{10}P}$ (1010.47)
- 1629.) 1,2-di-(Z,Z)-6,18-hexacosadienoyl-sn-glycero-3-phospho-N,N-dimethyl-N-dihydroxypropylhexyl-ammonium (n = 6)

 CssH₁₂₄NO₁₀P (1122.69)

2. Examples of two-chain glycero-phospho-N,Ndimethyl-N-(2-hydroxypropyl-3,1-0,0-dihydroxypropyl)alkylammonium compounds

 $(A = III; n = 2-6; R_3, CH_3; m = 1, x = 0; y = 1; z = 2)$

$$A - PO_3 = \begin{bmatrix} CH_3 \\ CH_2 \\ n \end{bmatrix}_{m} - \begin{bmatrix} CH_2 \\ CH_2 - \begin{pmatrix} CH \\ OH \end{pmatrix}_y - CH_2 - O \end{bmatrix}_{-H}$$

- 1630.) 1,2-di-(Z)-6-hexadecenoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(2-hydroxypropyl-3,1-0,0dihydroxypropyl)ethylammonium (n = 2) CatHagNO12P (864.15)
- 1631.) 1,2-di-(Z)-10-heptadecenoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(2-hydroxypropyl-3,1-0,O-dihydroxypropyl)ethylammonium (n = 2) $C_{4}H_{90}NO_{12}P \qquad (892.20)$
- 1632.) 1,2-di-(Z)-6-octadecenoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(2-hydroxypropyl-3,1-0,0-dihydroxypropyl)ethylammonium (n = 2) $C_{49}H_{94}NO_{12}P \qquad (920.26)$
- 1633.) 1,2-di-(Z)-6-nonadecenoyl-sn-glycero-3-phosphoN,N-dimethyl-N-(2-hydroxypropyl-3,1-0,0dihydroxypropyl)ethylammonium (n = 2)
 Cs:HaaNO12P (948.31)

- 1634.) 1,2-di-(Z)-12-eicosenoyl-sn-glycero-3-phosphoN,N-dimethyl-N-(2-hydroxypropyl-3,1-0,0dihydroxypropyl)ethylammonium (n = 2)
 C53H₁₀₂NO₁₂P (976,37)
- 1635.) 1,2-di-(Z)-10-heneicosenoyl-sn-glycero-3phospho-N,N-dimethyl-N-(2-hydroxypropyl-3,10,O-dihydroxypropyl)ethylammonium (n = 2)
 C₅₅H₁₀₆NO₁₂P (1004.42)
- 1636.) 1,2-di-(Z)-10-docosenoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(2-hydroxypropyl-3,1-0,0dihydroxypropyl) ethylammonium (n = 2) C₅₇H₁₁₀NO₁₂P (1032.47)
- 1637.) 1,2-di-(Z)-12-docosenoyl-sn-glycero-3-phosphoN,N-dimethyl-N-(2-hydroxypropyl-3,1-0,0dihydroxypropyl)ethylammonium (n = 2)
 C57H110NO12P (1032.47)
- 1638.) 1,2-di-(Z)-10-tricosenoyl-sn-glycero-3-phosphoN,N-dimethyl-N-(2-hydroxypropyl-3,1-0,0dihydroxypropyl)ethylammonium (n = 2)
 C₅₉H₁₁₄NO₁₂P (1060.53)
- 1639.) 1,2-di-(Z)-10-tetracosenoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(2-hydroxypropyl-3,1-0,0-dihydroxypropyl)ethylammonium (n = 2) $C_{61}H_{118}NO_{12}P \qquad (1088.58)$
- 1640.) 1,2-di-(Z)-15-pentacosenoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(2-hydroxypropyl-3,1-0,O-dihydroxypropyl)ethylammonium (n = 2) $C_{53}H_{122}NO_{12}P$ (1116.63)
- 1641.) 1,2-di-(Z)-16-hexacosenoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(2-hydroxypropyl-3,1-0,0-dihydroxypropyl)ethylammonium (n = 2) $C_{65}H_{126}NO_{12}P \hspace{1cm} (1144.69)$
- 1642.) 1,2-di-(Z,Z)-5,11-hexadecadienoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(2-hydroxypropyl-3,1-0,0-dihydroxypropyl)ethylammonium (n=2) $C_{45}H_{82}NO_{12}P \qquad (860.12)$

- 1643.) 1,2-di-(Z,Z)-5,11-heptadecadienoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(2-hydroxypropyl-3,1-0,O-dihydroxypropyl)ethylammonium (n = 2) $C_{47}H_{86}NO_{12}P \qquad (888.17)$
- 1644.) 1,2-di-(Z,Z)-5,11-octadecadienoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(2-hydroxypropyl-3,1-0,0-dihydroxypropyl)ethylammonium (n = 2) $C_{49}H_{90}NO_{12}P \qquad (916.23)$
- 1645.) 1,2-di-(Z,Z)-6,12-nonadecadienoyl-sn-glycero-3phospho-N,N-dimethyl-N-(2-hydroxypropyl-3,10,0-dihydroxypropyl)ethylammonium (n = 2)
 C₅₁H₉₄NO₁₂P (944.28)
- 1646.) 1,2-di-(Z,Z)-10,16-eicosadienoyl-sn-glycero-3phospho-N,N-dimethyl-N-(2-hydroxypropyl-3,10,0-dihydroxypropyl)ethylammonium (n = 2)
 CtiHanNO12P (972.33)
- 1647.) 1,2-di-(Z,Z)-10,16-heneicosadienoyl-sn-glycero3-phospho-N,N-dimethyl-N-(2-hydroxypropyl-3,10,0-dihydroxypropyl)ethylammonium (n = 2)
 Cs-H102NO12P (1000.39)
- 1648.) 1,2-di-(Z,Z)-10,16-docosadienoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(2-hydroxypropyl-3,1-0,0-dihydroxypropyl)ethylammonium (n = 2) $C_{57}H_{106}NO_{12}P \qquad (1028.44)$
- 1649.) 1,2-di-(Z,Z)-10,16-tricosadienoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(2-hydroxypropyl-3,1-0,0-dihydroxypropyl) ethylammonium (n = 2) $C_{59}H_{110}NO_{12}P \qquad (1056.50)$
- 1650.) 1,2-di-(Z,Z)-6,18-tetracosadienoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(2-hydroxypropyl-3,1-0,0-dihydroxypropyl)ethylammonium (n = 2) $C_{61}H_{14}NO_{12}P \qquad (1084.55)$
- 1651.) 1,2-di-(Z,Z)-10,16-pentacosadienoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(2-hydroxypropyl-3,1-0,0-dihydroxypropyl)ethylammonium (n = 2) $C_{63}H_{118}NO_{12}P \qquad (1112.60)$

```
1652.) 1,2-di-(Z,Z)-6,18-hexacosadienoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(2-hydroxypropyl-3,1-0,0-dihydroxypropyl)ethylammonium (n = 2) C_{65}H_{122}NO_{12}P \hspace{1cm} (1140.66)
```

- 1653.) 2-(Z)-6-hexadecenoyl-1-stearoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(2-hydroxypropyl-3,1-0,0-dihydroxypropyl)ethylammonium (n = 2) $C_{47}H_{92}NO_{12}P \qquad (894.22)$
- 1654.) 2-(Z)-10-octadecenoyl-1-stearoyl-sn-glycero-3phospho-N,N-dimethyl-N-(2-hydroxypropyl-3,10,0-dihydroxypropyl)ethylammonium (n = 2)
 C49HocNO12P (922.27)
- 1655.) 2-(Z)-10-eicosenoyl-1-stearoyl-sn-glycero-3phospho-N,N-dimethyl-N-(2-hydroxypropyl-3,10,0-dihydroxypropyl)ethylammonium (n = 2)
 C51H100NO12P (950.33)
- 1656.) 1-behenyl-2-(Z)-10-docosenoyl-sn-glycero-3phospho-N,N-dimethyl-N-(2-hydroxypropyl-3,10,O-dihydroxypropyl)ethylammonium (n = 2)
 C₅H₁₀₈NO₁₂P (1006.44)
- 1657.) 2-(Z,Z)-6,12-hexadecadienoyl-1-stearoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(2-hydroxy-propyl-3,1-0,0-dihydroxypropyl)ethylammonium (n = 2)

 C4-HexNOxP (892.20)
- 1658.) 2-(Z,Z)-10,16-docosadienoyl-1-stearoyl-snglycero-3-phospho-N,N-dimethyl-N-(2-hydroxypropyl-3,1-0,0-dihydroxypropyl)ethylammonium
 (n = 2)
 Cs1H102NO12P (976.37)
- 1659.) 1-stearoyl-2-(Z,Z)-6,18-tetracosadienoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(2-hydroxy-propyl-3,1-0,0-dihydroxypropyl)ethylammonium (n = 2) $C_{55}H_{106}NO_{12}P$ (1004.42)

```
1-(Z)-10-octadecenovl-2-stearovl-sn-glycero-3-
1660.)
        phospho-N.N-dimethyl-N-(2-hydroxypropyl-3,1-
        O, O-dihydroxypropyl) ethylammonium (n = 2)
        C49H96NO12P
                          (922.27)
```

1661.) 1-(Z,Z)-6,18-hexacosadienovl-2-stearovl-snglycero-3-phospho-N, N-dimethyl-N-(2-hydroxypropyl-3,1-0,0-dihydroxypropyl)ethylammonium (n = 2)

C57H110NO12P (1032.47)

- 1-(Z,Z)-6,18-hexacosadienovl-2-(Z)-6-1662) hexadecenovl-sn-glycero-3-phospho-N, N-dimethyl-N-(2-hydroxypropyl-3,1-0,0-dihydroxypropyl)ethylammonium (n = 2)C55H104NO12P (1002.40)
- 2-(Z,Z)-6,18-hexacosadienovl-1-(Z)-6hexadecenoyl-sn-glycero-3-phospho-N, N-dimethyl-N-(2-hydroxypropyl-3,1-0,0-dihydroxypropyl)ethvlammonium (n = 2)C55H104NO12P (1002.40)

n = 3

- 1664.) 1,2-di-(Z)-6-hexadecenoyl-sn-glycero-3-phospho-N, N-dimethyl-N-(2-hydroxypropyl-3,1-0,0dihydroxypropyl)propylammonium (n = 3)CacHeeNO12P (878.18)
- 1,2-di-(Z)-10-heptadecenovl-sn-glycero-3-1665.) phospho-N, N-dimethyl-N-(2-hydroxypropyl-3,1-O, O-dihydroxypropyl) propylammonium (n = 3) C48H92NO12P (906.23)
- 1,2-di-(Z)-6-octadecenoyl-sn-glycero-3-phospho-N, N-dimethyl-N-(2-hydroxypropyl-3,1-0,0dihydroxypropyl) propylammonium (n = 3) C50H96NO12P (934.29)
- 1667.) 1,2-di-(Z)-12-eicosenoyl-sn-glycero-3-phospho-N, N-dimethyl-N-(2-hydroxypropyl-3,1-0,0dihydroxypropyl) propylammonium (n = 3) C54H104NO12P (990.39)

```
1668.) 1,2-di-(Z)-10-docosenoyl-sn-glycero-3-phospho-
N,N-dimethyl-N-(2-hydroxypropyl-3,1-0,0-
dihydroxypropyl)propylammonium (n = 3)
C<sub>58</sub>H<sub>112</sub>NO<sub>12</sub>P (1046.50)
```

- 1669.) 1,2-di-(Z)-12-docosenoyl-sn-glycero-3-phosphoN,N-dimethyl-N-(2-hydroxypropyl-3,1-0,0dihydroxypropyl)propylammonium (n = 3)
 C_{5e}H₁₁₂NO₁₂P (1046.50)
- 1670.) 1,2-di-(Z)-10-tricosenoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(2-hydroxypropyl-3,1-0,0dihydroxypropyl)propylammonium (n = 3) CsoH116NO12P (1074.55)
- 1671.)
 1,2-di-(Z)-10-tetracosenoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(2-hydroxypropyl-3,1-0,O-dihydroxypropyl)propylammonium (n = 3) $C_{62}H_{120}NO_{12}P$ (1102.61)
- 1672.) 1,2-di-(Z,Z)-5,11-octadecadienoyl-sn-glycero-3phospho-N,N-dimethyl-N-(2-hydroxypropyl-3,10,0-dihydroxypropyl)propylammonium (n = 3)
 C50H02NO10P (930.25)
- 1673.) 1,2-di-(Z,Z)-10,16-eicosadienoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(2-hydroxypropyl-3,1-0,0-dihydroxypropyl)propylammonium (n = 3) $C_{54}H_{100}NO_{12}P$ (986,36)
- 1674.) 1,2-di-(Z,Z)-10,16-docosadienoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(2-hydroxypropyl-3,1-0,0-dihydroxypropyl)propylammonium (n = 3) $C_{58}H_{108}NO_{12}P \qquad (1042.47)$
- 1675.) 1,2-di-(Z,Z)-6,18-hexacosadienoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(2-hydroxypropyl-3,1-0,O-dihydroxypropyl)propylammonium (n = 3) $C_{66}H_{124}NO_{12}P$ (1154.68)
- 1676.) 2-(Z)-6-hexadecenoyl-1-stearoyl-sn-glycero-3phospho-N,N-dimethyl-N-(2-hydroxypropyl-3,10,O-dihydroxypropyl)propylammonium (n = 3)
 C48H94NO12P (908.25)

- 1677.) 2-(Z)-10-octadecenoyl-1-stearoyl-sn-glycero-3phospho-N,N-dimethyl-N-(2-hydroxypropyl-3,1O,O-dihydroxypropyl)propylammonium (n = 3)
 CsnHosNO12P (936.30)
- 1678.) 2-(Z)-10-docosenoyl-1-behenyl-sn-glycero-3phospho-N,N-dimethyl-N-(2-hydroxypropyl-3,10,0-dihydroxypropyl)propylammonium (n = 3)
 CseH110NO12P (1020.46)
- 1679.) 2-(Z,Z)-6,12-hexadecadienoyl-1-stearoyl-snglycero-3-phospho-N,N-dimethyl-N-(2-hydroxypropyl-3,1-0,0-dihydroxypropyl)propylammonium
 (n = 3)

C48H92NO12P (906.23)

- 1680.) 1-(Z)-10-octadecenoyl-2-stearoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(2-hydroxypropyl-3,1-0,0-dihydroxypropyl)propylammonium (n = 3) $C_{50}H_{98}NO_{12}P \qquad (936.30)$
- 1681.) 2-(Z,Z)-6,18-hexacosadienoyl-2-stearoyl-snglycero-3-phospho-N,N-dimethyl-N-(2-hydroxypropyl-3,1-0,O-dihydroxypropyl)propylammonium
 (n = 3)
 CssH.12NO12P (1046.50)

n = 4

- 1682.) 1,2-di-(Z)-6-octadecenoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(2-hydroxypropyl-3,1-0,0-dihydroxypropyl)butylammonium (n = 4) $C_{51}H_{98}NO_{12}P \qquad (948.31)$
- 1683.) 1,2-di-(Z)-10-docosenoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(2-hydroxypropyl-3,1-0,0dihydroxypropyl) butylammonium (n = 4) CcoH:14NO:2P (1060.53)
- 1684.) 1,2-di-(Z,Z)-5,11-hexadecadienoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(2-hydroxypropyl-3,1-0,0-dihydroxypropyl)butylammonium (n = 4) C_{4} -HagNO₁₂F (888.17)

- 1685.) 1,2-di-(Z,Z)-10,16-docosadienoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(2-hydroxypropyl-3,1-0,O-dihydroxypropyl)butylammonium (n = 4)

 Cs-H110NO12P (1056.50)
- 1686.) 1,2-di-(Z,Z)-6,18-hexacosadienoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(2-hydroxypropyl-3,1-0,0-dihydroxypropyl) butylammonium (n = 4) $C_{67}H_{126}NO_{12}P$ (1168.71)

n = 6

- 1687.) 1,2-di-(Z)-6-octadecenoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(2-hydroxypropyl-3,1-0,0dihydroxypropyl)hexylammonium (n = 6)
- 1688.) 1,2-di-(Z)-10-docosenoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(2-hydroxypropyl-3,1-0,0dihydroxypropyl)hexylammonium (n = 6) C₆₁H₁₁₈NO₁₂P (1088.58)
- 1689.) 1,2-di-(Z,Z)-10,16-docosadienoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(2-hydroxypropyl-3,1-0,0-dihydroxypropyl)hexylammonium (n = 6) $C_{61}H_{114}NO_{12}P \qquad (1084.55)$
- 1690.) 1,2-di-(Z,Z)-6,18-hexacosadienoyl-sn-glycero-3phospho-N,N-dimethyl-N-(2-hydroxypropyl-3,10,O-dihydroxypropyl)hexylammonium (n = 6)
 C₅₉H₁₃₀NO₁₂P (1196.76)
- 3. Examples of two-chain glycero-phospho-N,Ndimethyl-N-(2-hydroxypropyl-3,1-0,0-2-hydroxypropyl-3,1-0,0-dihydroxypropyl)alkylammonium
 compounds
- (A = III; n = 2-6; R_3 , CH_3 ; m = 1, x = 0; y = 1; z = 3)

$$A - PO_3 - \begin{bmatrix} CH_3 \\ R_3 \end{bmatrix}_m - (CH_2)_x - \begin{bmatrix} CH_2 - \begin{pmatrix} CH \\ OH \end{pmatrix}_y - CH_2 - O \\ \end{bmatrix}_z^{-H}$$

1691.) 1,2-di-(Z)-6-hexadecenoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(HP1-HP2-diHP3) ethylammonium (n = 2)

 $C_{48}H_{92}NO_{14}P$ (938.23)

1692.) 1,2-di-(Z)-10-heptadecenoyl-sn-glycero-3phospho-N,N-dimethyl-N-(HP₁-HP₂diHP₃)ethylammonium (n = 2)
C₅₀H₉₆NO₁₄P (966.28)

1693.) 1,2-di-(Z)-6-octadecenoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(HP₁-HP₂-diHP₃)ethylammonium
(n = 2)
C₂-H₁₀₀NO₁₄P (994.34)

1694.) 1,2-di-(Z)-6-nonadecenoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(HP1-HP2-diHP3) ethylammonium (n = 2)

 $C_{54}H_{104}NO_{14}P$ (1022.39)

1695.) 1,2-di-(Z)-12-eicosenoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(HP1-HP2-diHP3) ethylammonium (n = 2) CssH.osNO-aP (1050.45)

1696.) 1,2-di-(Z)-10-heneicosenoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(HP₁-HP₂-diHP₃)ethyl-ammonium (n = 2)

C₅₈H₁₁₂NO₁₄P (1078.50)

1697.) 1,2-di-(Z)-10-docosenoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(HP₁-HP₂-diHP₃) ethylammonium (n = 2) CssH₁₁₅NO₁₄P (1106.55)

1698.) 1,2-di-(Z)-12-docosenoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(HP₁-HP₂-diHP₃) ethylammonium

C₆₀H₁₁₆NO₁₄P (1106.55)

(n = 2)

1699.) 1,2-di-(Z)-10-tricosenoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(HP1-HP2-diHP3)ethylammonium (n = 2) C63H120NO14P (1134.61)

(3)

```
1700.) 1,2-di-(Z)-10-tetracosenoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(HP<sub>1</sub>-HP<sub>2</sub>-diHP<sub>3</sub>)ethyl-ammonium (n = 2)
```

 $C_{64}H_{124}NO_{14}P$ (1134.61)

1701.) 1,2-di-(Z)-15-pentacosenoyl-sn-glycero-3phospho-N,N-dimethyl-N-(HP1-HP2-diHP3)ethylammonium (n = 2)
Cc6H128NO14P (1190.71)

1702.) 1,2-di-(Z)-16-hexacosenoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(HP₁-HP₂-diHP₃)ethyl-ammonium (n = 2) $C_{68}H_{132}NO_{14}P \qquad (1218.77)$

1703.) 1,2-di-(Z,Z)-5,11-hexadecadienoyl-sn-glycero-3-phospho-N,N-dimethyl-N- $(HP_1-HP_2-diHP_3)$ ethyl-ammonium (n = 2) $C_{48}H_{88}NO_{14}P$ (934.20)

1704.) 1,2-di-(Z,Z)-5,11-heptadecadienoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(HP₁-HP₂-diHP₃) ethyl-ammonium (n = 2)

CsoHo:NO1 $_4$ P (962.25)

1705.) 1,2-di-(Z,Z)-5,11-octadecadienoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(HP₁-HP₂-diHP₃)ethyl-ammonium (n = 2) $C_{52}H_{96}NO_{14}P \qquad (990.31)$

1706.) 1,2-di-(Z,Z)-6,12-nonadecadienoyl-sn-glycero-3-phospho-N,N-dimethyl-N- $(HP_1-HP_2-diHP_3)$ ethyl-ammonium (n=2) $C_{54}H_{100}NO_{14}P \qquad (1018.36)$

1707.) 1,2-di-(Z,Z)-10,16-eicosadienoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(HP1-HP2-diHP3)ethyl-ammonium (n = 2)

C56H104NO14P (1046.41)

1708.) 1,2-di-(Z,Z)-10,16-heneicosadienoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(HP₁-HP₂-diHP₃)ethyl-ammonium (n = 2) $C_{58}H_{108}NO_{14}P \hspace{1cm} (1074.47)$

```
1709.) 1,2-di-(Z,Z)-10,16-docosadienoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(HP1-HP2-diHP3) ethyl-ammonium (n = 2)
```

C₆₀H₁₁₂NO₁₄P (1102.52)

1710.) 1,2-di-(Z,Z)-10,16-tricosadienoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(HP1-HP2-diHP3)ethyl-ammonium (n = 2)

 $C_{62}H_{116}NO_{14}P$ (1130.58)

1711.) 1,2-di-(Z,Z)-6,18-tetracosadienoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(HP₁-HP₂-diHP₃)ethyl-ammonium (n = 2)

 $C_{64}H_{120}NO_{14}P$ (1158.63)

1712.) 1,2-di-(Z,Z)-10,16-pentacosadienoyl-sn-glycero-3-phospho-N,N-dimethyl-N- $(HP_1-HP_2-diHP_3)$ ethyl-ammonium (n = 2) $C_{66}H_{124}NO_{14}P \qquad (1186.68)$

1714.) 2-(Z)-6-hexadecenoyl-1-stearoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(HP1-HP2-diHP3)ethyl-ammonium (n = 2) $C_{50}H_{98}NO_{14}P$ (968.30)

1715.) 2-(Z)-10-octadecenoyl-1-stearoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(HP₁-HP₂-diHP₃)ethyl-ammonium (n = 2) $C_{52}H_{102}NO_{14}P$ (996.35)

1716.) 2-(Z)-10-eicosenoyl-1-stearoyl-sn-glycero-3phospho-N,N-dimethyl-N-(HP₁-HP₂-diHP₃)ethylammonium (n = 2)
C54H106NO14P (1024.41)

1717.) 1-behenyl-2-(Z)-10-docosenoyl-sn-glycero-3phospho-N,N-dimethyl-N-(HP₁-HP₂-diHP₃)ethylammonium (n = 2)

C₅₈H_{1.4}NO₁₄P (1080.52)

```
1718.) 2-(Z,Z)-6,12-hexadecadienoyl-1-stearoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(HP<sub>1</sub>-HP<sub>2</sub>-diHP<sub>3</sub>)ethylammonium (n = 2)

C_{50}H_{96}NO_{14}P (966.28)
```

- 1719.) 2-(Z,Z)-10,16-docosadienoyl-1-stearoyl-snglycero-3-phospho-N,N-dimethyl-N-(HP₁-HP₂diHP₃)ethylammonium (n = 2)
 C₅cH₁₀aNO₁₄P (1050,45)
- 1720.) 1-stearoyl-2-(Z,Z)-6,18-tetracosadienoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(HP₁-HP₂-diHP₃)ethylammonium (n = 2) $C_{58}H_{112}NO_{14}P \hspace{1cm} (1078.50)$
- 1721.) 1-(Z)-10-octadecenoyl-2-stearoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(HP1-HP2-diHP3)ethyl-ammonium (n = 2)

 C=2H-02NO14P (996.35)
- 1722.) 1-(Z,Z)-6,18-hexacosadienoyl-2-stearoyl-snglycero-3-phospho-N,N-dimethyl-N-(HP1-HP2diHP3)ethylammonium (n = 2)
 C66H116NO14P (1106.55)
- 1723.) 1-(Z,Z)-6,18-hexacosadienoyl-2-(Z)-6-hexadecenoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(HP₁-HP₂-diHP₃)ethylammonium (n = 2)

 CsaH1uNO1 $_4$ P (1076.48)
- 1724.) 2-(Z,Z)-6,18-hexacosadienoyl-1-(Z)-6hexadecenoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(HP1-HP2-diHP3)ethylammonium (n = 2) C58H110NO14P (1076.48)
- n = 3
- 1725.) 1,2-di-(Z)-6-hexadecenoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(HP₁-HP₂-diHP₃)propylammonium
 (n = 3) $C_{4}H_{24}NO_{14}P$ (952.26)
- 1726.) 1,2-di-(Z)-10-heptadecenoyl-sn-glycero-3phospho-N,N-dimethyl-N-(HP₁-HP₂-diHP₃)propylammonium (n = 3)

```
C<sub>51</sub>H<sub>98</sub>NO<sub>14</sub>P (980.31)
```

1727.)
1,2-di-(Z)-6-octadecenoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(HP₁-HP₂-diHP₃) propylammonium (n = 3)

C53H102NO14P (1008.36)

1728.) 1,2-di-(Z)-12-eicosenoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(HP₁-HP₂-diHP₃)propylammonium (n = 3)

 $C_{57}H_{110}NO_{14}P$ (1064.47)

1729.)
1,2-di-(Z)-10-docosenoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(HP1-HP2-diHP3) propylammonium (n = 3)

 $C_{61}H_{118}NO_{14}P$ (1120.58)

1730.) 1,2-di-(Z)-12-docosenoyl-sn-glycero-s-phospho-s-N,N-dimethyl-N-(HP $_1$ -HP $_2$ -diHP $_3$)propylammonium (n = 3)

C₆₁H₁₁₈NO₁₄P (1120.58)

1731.)
1,2-di-(Z)-10-tricosenoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(HP1-HP2-diHP3) propylammonium (n = 3)

C₅₃H₁₂₂NO₁₄P (1148.63)

1732.) 1,2-di-(Z)-10-tetracosenoyl-sn-glycero-3phospho-N,N-dimethyl-N-(HP₁-HP₂-diHP₃)propylammonium (n = 3)

C₆₅H₁₂₆NO₁₆P (1176.69)

1733.)
1,2-di(Z,Z)-5,11-octadecadienoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(HP1-HP2-diHP3)propyl-ammonium (n = 3)

 $C_{53}H_{98}NO_{14}P$ (1004.33)

1734.) 1,2-di(Z,Z)-10,16-eicosadienoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(HP1-HP2-diHP3)propyl-ammonium (n = 3)

C57H106NO14P (1060.44)

1735.) 1,2-di(Z,Z)-10,16-docosadienoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(HP1-HP2-diHP3)propyl-ammonium (n = 3)

C51H114NO14P (1116.55)

```
1736.) 1,2-di(Z,Z)-6,18-hexacosadienoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(HP<sub>1</sub>-HP<sub>2</sub>-diHP<sub>3</sub>)propyl-ammonium (n = 3)
C_{69}H_{130}NO_{14}P (1228.76)
```

1737.) 2-(Z)-6-hexadecenoyl-1-stearoyl-sn-glycero-3phospho-N,N-dimethyl-N-(HP1-HP2-diHP3)propylammonium (n = 3)
C51H100NO14P (982.33)

1738.) 2-(Z)-10-octadecenoyl-1-stearoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(HP₁-HP₂-diHP₃)propyl-ammonium (n = 3)

C₅₃H₁₀₄NO₁₄P (1010.38)

1739.) 2-(Z)-10-docosenoyl-1-behenyl-sn-glycero-3phospho-N,N-dimethyl-N-(HP1-HP2-diHP3)propylammonium (n = 3)
CsaH116NO16P (1094.54)

1740.) 2-(Z,Z)-6,12-hexadecadienoyl-1-stearoyl-sn-glycero-3-phospho-N,N-dimethyl-N- $(HP_1-HP_2-diHP_3)$ propylammonium (n=3) $C_{51}H_{98}NO_{14}P$ (980.31)

1741.) 1-(Z)-10-octadecenoyl-2-stearoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(HP₁-HP₂-diHP₃)propyl-ammonium (n = 3) $C_{53}H_{104}NO_{14}P$ (1010.38)

1742.) 1-(Z,Z)-6,18-hexacosadienoyl-2-stearoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(HP1-HP2-diHP3)propylammonium (n = 3) $C_{61}H_{118}NO_{14}P \qquad (1120.58)$

n = 4

1743.) 1,2-di-(Z)-6-octadecenoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(HP₁-HP₂-diHP₃)butylammonium
(n = 4) $C_{54}H_{104}NO_{14}P$ (1022.39)

1744.) 1,2-di-(Z)-10-docosenoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(HP₁-HP₂-diHP₃) butylammonium (n = 4) C₆₂H₁₂₀NO₁₄P (1134.61)

- 1745.) 1,2-di-(Z,Z)-5,11-hexadecadienoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(HP1-HP2-diHP3)butyl-ammonium (n = 4)

 C50H02NO14P (962.25)
- 1746.) 1,2-di-(Z,Z)-10,16-docosadienoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(HP₁-HP₂-diHP₃)butyl-ammonium (n = 4)

 C₆₂H₁₁₆NO₁₄P (1130.58)
- 1747.) 1,2-di-(Z,Z)-6,18-hexacosadienoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(HP1-HP2-diHP3)butyl-ammonium (n = 4)

 C70H133NO14P (1242.79)

n = 6

1748.) 1,2-di-(Z)-6-octadecenoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(HP1-HP2-diHP3)hexylammonium (n = 6)

 $C_{56}H_{108}NO_{14}P$ (1050.45)

- 1749.) 1,2-di-(Z)-10-docosenoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(HP₁-HP₂-diHP₃)hexylammonium (n = 6) C₆₄H₁₂₄NO₁₄P (1162.66)
- 1750.) 1,2-di-(Z,Z)-10,16-docosadienoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(HP1-HP2-diHP3)hexyl-ammonium (n = 6) $C_{64}H_{120}NO_{14}P$ (1158.63)
- 1751.) 1,2-di-(Z,Z)-6,18-hexacosadienoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(HP1-HP2-diHP3)hexyl-ammonium (n = 6)
 C72H13cNO14P (1270.84)

4. Examples of two-chain glycero-phospho-N,Ndimethyl-N-(2-hydroxypropyl-3,1-0,0-2-hydroxypropyl-3,1-0,0-2-hydroxypropyl-3,1-0,0-dihydroxypropyl)alkylammonium compounds

 $(A = III; n = 2-6; R_3, CH_3; m = 1, x = 0; y = 1; z = 4)$

$$A - PO_3 - \left[(CH_2)_n - N^2 \atop R_3 \right]_m - (CH_2)_x - \left[CH_2 - \left(\begin{matrix} CH \\ OH \end{matrix} \right)_y - CH_2 - O \right]_{z} - H$$

In the following text, N-(2-hydroxypropyl-3,1-0,0-2-hydroxypropyl-3,1-0,0-2-hydroxypropyl-3,1-0,0-di-hydroxypropyl) is abbreviated to N-(HP1-HP2-HP3-diHP4).

1752.) 1,2-di-(Z)-6-hexadecenoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(HP1-HP2-HP3-diHP4) ethylammonium (n = 2)

(1012.31)

1753.) 1,2-di-(Z)-10-heptadecenoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(HP₁-HP₂-HP₃-diHP₄)ethyl-ammonium (n = 2)

C₅₁H₁₀NO₁₆P (1040.36)

Cs1HoaNO16P

C55H105NO16P

1754.) 1,2-di-(Z)-6-octadecenoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(HP1-HP2-HP3-diHP4) ethylammonium (n = 2)

(1068.42)

- 1755.) 1,2-di-(Z)-6-nonadecenoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(HP₁-HP₂-HP₃-diHP₄)ethylammonium (n = 2) $C_{57}H_{110}NO_{16}P$ (1096.47)
- 1756.) 1,2-di-(Z)-12-eicosenoyl-sn-glycero-3-phosphoN,N-dimethyl-N-(HP1-HP2-HP3-diHP4)ethylammonium
 (n = 2)
 Cs9H14NO16P (1124.53)
- 1757.) 1,2-di-(Z)-10-heneicosenoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(HP₁-HP₂-HP₃-diHP₄)ethyl-ammonium (n = 2) $C_{51}H_{118}NO_{15}P$ (1152.58)

1758.)
1,2-di-(Z)-10-docosenoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(HP₁-HP₂-HP₃-diHP₄) ethylammonium (n = 2)

 $C_{63}H_{122}NO_{16}P$ (1180.63)

1759.) 1,2-di-(Z)-12-docosenoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(HP₁-HP₂-HP₃-diHP₄) ethylammonium (n = 2) $C_{63}H_{122}NO_{16}P$ (1180.63)

1760.) 1,2-di-(Z)-10-tricosenoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(HP1-HP2-HP3-diHP4)ethylammonium (n = 2)

 $C_{65}H_{126}NO_{16}P$ (1208.69)

- 1761.) 1,2-di-(Z)-10-tetracosenoyl-sn-glycero-3phospho-N,N-dimethyl-N-(HP₁-HP₂-HP₃-diHP₄)ethylammonium (n = 2)
 Cs7H₁₃₀NO₁₆P (1236.74)
- 1762.) 1,2-di-(Z)-15-pentacosenoyl-sn-glycero-3phospho-N,N-dimethyl-N-(HP1-HP2-HP3-diHP4)ethylammonium (n = 2)
 CsoH134NO16P (1264.79)
- 1763.) 1,2-di-(Z)-16-hexacosenoyl-sn-glycero-3phospho-N,N-dimethyl-N-(HP1-HP2-HP3-diHP4)ethylammonium (n = 2)
 C71H138NO16P (1292.85)
- 1764.) 1,2-di-(Z,Z)-5,11-hexadecadienoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(HP₁-HP₂-HP₃-diHP₄)ethyl-ammonium (n = 2) $C_{51}H_{94}NO_{16}P \qquad (1008.28)$
- 1765.) 1,2-di-(Z,Z)-5,11-heptadecadienoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(HP1-HP2-HP3-diHP4)ethylammonium (n = 2) $C_{52}H_{58}NO_{16}P$ (1036.33)
- 1766.) 1,2-di-(Z,Z)-5,11-octadecadienoyl-sn-glycero-3-phospho-N,N-dimethyl-N- $(HP_1-HP_2-HP_3-diHP_4)$ ethyl-ammonium (n = 2)

 CssH102NO16P (1064.39)

- 1767.) 1,2-di-(Z,Z)-6,12-nonadecadienoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(HP1-HP2-HP3-diHP4) ethyl-ammonium (n = 2)
 - C₅₇H₁₀₆NO₁₆P (1092.44)
- 1768.) 1,2-di-(Z,Z)-10,16-eicosadienoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(HP₁-HP₂-HP₃-diHP₄)ethyl-ammonium (n = 2) $C_{59}H_{110}NO_{16}P$ (1120.49)
- 1769.) 1,2-di-(Z,Z)-10,16-heneicosadienoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(HP₁-HP₂-HP₃-diHP₄)ethylammonium (n = 2) $C_{61}H_{114}NO_{16}P$ (1148.55)
- 1770.) 1,2-di-(Z,Z)-10,16-docosadienoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(HP₁-HP₂-HP₃-diHP₄)ethyl-ammonium (n = 2)

 Cs1H11sNO1sP (1176.60)
- 1771.) 1,2-di-(Z,Z)-10,16-tricosadienoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(HP₁-HP₂-HP₃-diHP₄)ethyl-ammonium (n = 2) $C_{65}H_{12}$ 3NO₁₆P (1204.65)
- 1772.) 1,2-di-(Z,Z)-6,18-tetracosadienoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(HP₁-HP₂-HP₃-diHP₄)ethylammonium (n = 2) $C_{67}H_{126}NO_{14}P$ (1232.71)
- 1773.) 1,2-di-(Z,Z)-10,6-pentacosadienoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(HP₁-HP₂-HP₃-diHP₄)ethylammonium (n = 2) $C_{69}H_{13}oNO_{16}P \qquad (1260.76)$
- 1774.) 1,2-di-(Z,Z)-6,18-hexacosadienoyl-sn-glycero-3-phospho-N,N-dimethyl-N- $(HP_1-HP_2-HP_3-diHP_4)$ ethyl-ammonium (n=2) $C_{71}H_{134}NO_{16}P$ (1288.82)
- 1775.) 2-(Z)-6-hexadecenoyl-1-stearoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(HP₁-HP₂-HP₃-diHP₄)ethyl-ammonium (n = 2) $C_{53}H_{104}NO_{16}P \qquad (1042.38)$

```
1776.) 2-(Z)-10-octadecenoyl-1-stearoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(HP<sub>1</sub>-HP<sub>2</sub>-HP<sub>3</sub>-diHP<sub>4</sub>)ethyl-ammonium (n = 2)

CssH<sub>108</sub>NO<sub>16</sub>P (1070.43)
```

1777.) 2-(Z)-10-eicosenoyl-1-stearoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(HP₁-HP₂-HP₃-diHP₄)ethyl-ammonium (n = 2) $C_{57}H_{112}NO_{16}P$ (1098.49)

1778.) 1-behenyl-2-(Z)-10-docosenoyl-sn-glycero-3phospho-N,N-dimethyl-N-(HP1-HP2-HP3-diHP4)ethylammonium (n = 2)
C61H120NO16P (1154.59)

1779.) 2-(Z,Z)-6,12-hexadecadienoyl-1-stearoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(HP1-HP2-HP3-diHP4)ethylammonium (n = 2)

C₅₃H₁₀₂NO₁₆P (1040.36)

- 1780.) 2-(Z,Z)-10,16-docosadienoyl-1-stearoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(HP₁-HP₂-HP₃-diHP₄)ethylammonium (n = 2) $C_{59}H_{114}NO_{16}P$ (1124.53)
- 1781.) 1-stearoyl-2-(Z,Z)-6,18-tetracosadienoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(HP₁-HP₂-HP₃-diHP₄)ethylammonium (n = 2) $C_{61}H_{118}NO_{16}P \hspace{1cm} (1152.58)$
- 1782.) 1-(Z)-10-octadecenoyl-2-stearoyl-sn-glycero-3-phospho-N,N-dimethyl-N-(HP₁-HP₂-HP₃-diHP₄)ethyl-ammonium (n = 2)

 C₅₅H₁₀₈NO₁₆P (1070.43)
- 1783.) 1-(Z,Z)-6,18-hexacosadienoyl-2-stearoyl-sn-glycero-3-phospho-N,N-dimethyl-N- $(HP_1-HP_2-HP_3-diHP_4)$ ethylammonium (n=2) $C_{63}H_{122}NO_{16}P$ (1180.63)
- 1784.) 1-(Z,Z)-6,18-hexacosadienoy1-2-(Z)-6-hexadecenoy1-sn-glycero-3-phospho-N,N-dimethyl-N-(HP1-HP2-HP3-diHP4)ethylammonium (n = 2) $C_{61}H_{116}NO_{16}P$ (1150.56)

```
- 167 -
        2-(Z,Z)-6,18-hexacosadienovl-1-(Z)-6-
         hexadecenoyl-sn-glycero-3-phospho-N, N-dimethyl-
         N-(HP_1-HP_2-HP_3-diHP_4) ethylammonium (n = 2)
         C61H116NO16P
                          (1150.56)
n = 3
        1,2-di-(Z)-6-hexadecenoyl-sn-glycero-3-phospho-
1786.)
        N, N-dimethyl-N-(HP1-HP2-HP3-diHP4) propylammonium
         (n = 3)
        C52H100NO16P
                           (1026.34)
        1,2-di-(Z)-10-heptadecenoyl-sn-glycero-3-
1787.)
        phospho-N, N-dimethyl-N-(HP1-HP2-HP3-diHP4)-
        propylammonium (n = 3)
        C54H104NO16P
                          (1054.39)
1788.) 1,2-di-(Z)-6-octadecenoyl-sn-glycero-3-phospho-
        N, N-dimethyl-N-(HP1-HP2-HP3-diHP4) propylammonium
         (n = 3)
        C56H108NO16P
                          (1082.44)
1789.) 1,2-di-(Z)-12-eicosenoyl-sn-glycero-3-phospho-
        N, N-dimethyl-N-(HP1-HP2-HP3-diHP4) propylammonium
        (n = 3)
        C60H116NO16P
                         (1138.55)
1790.)
        1,2-di-(Z)-10-docosenoyl-sn-glycero-3-phospho-
        N, N-dimethyl-N-(HP1-HP2-HP3-diHP4) propylammonium
        (n = 3)
        C64H124NO16P
                          (1194.66)
1791.)
        1,2-di-(Z)-12-docosenoyl-sn-glycero-3-phospho-
        N, N-dimethyl-N-(HP1-HP2-HP3-diHP4) propylammonium
        (n = 3)
        C64H124NO16P
                          (1194.66)
        1,2-di-(Z)-10-tricosenoyl-sn-glycero-3-phospho-
1792.)
        N, N-dimethyl-N-(HP1-HP2-HP3-diHP4) propylammonium
        (n = 3)
        C66H128NO16P
                          (1222.71)
1793.) 1,2-di-(Z)-10-tetracosenoyl-sn-glycero-3-
        phospho-N, N-dimethyl-N-(HP1-HP2-HP3-diHP4) -
        propylammonium (n = 3)
```

(1250.77)

C68H132NO16P

```
1794.) 1,2-di-(Z,Z)-5,11-octadecadienoyl-sn-glycero-3-
         phospho-N, N-dimethyl-N-(HP1-HP2-HP3-diHP4) -
         propylammonium (n = 3)
        CseH104NO16P
                          (1078.41)
        1,2-di-(Z,Z)-10,16-eicosadienoyl-sn-glycero-3-
1795.)
        phospho-N, N-dimethyl-N-(HP1-HP2-HP3-diHP4) -
        propylammonium (n = 3)
        C60H112NO16P
                          (1134.52)
1796.)
        1,2-di-(Z,Z)-10,16-docosadienoyl-sn-glycero-3-
        phospho-N, N-dimethyl-N-(HP1-HP2-HP3-diHP4)-
        propylammonium (n = 3)
        C64H120NO16P
                          (1190.63)
1797.)
        1,2-di-(Z,Z)-6,18-hexacosadienoyl-sn-glycero-3-
        phospho-N, N-dimethyl-N-(HP1-HP2-HP3-diHP4) -
        propylammonium (n = 3)
        C72H136NO16P
                          (1302.84)
1798.) 2-(Z)-6-hexadecenoyl-1-stearoyl-sn-glycero-3-
        phospho-N, N-dimethyl-N-(HP1-HP2-HP3-diHP4) -
        propylammonium (n = 3)
        C54H106NO16P
                          (1056.41)
1799.)
        2-(Z)-10-octadecenoyl-1-stearoyl-sn-qlycero-3-
        phospho-N, N-dimethyl-N-(HP1-HP2-HP3-diHP4) -
        propylammonium (n = 3)
        CseH110NO16P
                          (1084.46)
1800.)
        2-(Z)-10-docosenovl-1-behenvl-sn-glycero-3-
        phospho-N, N-dimethyl-N-(HP1-HP2-HP3-diHP4) -
        propylammonium (n = 3)
        C62H122NO16P
                          (1168.62)
1801.)
        2-(Z,Z)-6,12-hexadecadienoyl-1-stearoyl-sn-
        glycero-3-phospho-N, N-dimethyl-N-(HP1-HP2-HP3-
        diHP_4) propylammonium (n = 3)
        C54H104NO16P
                          (1054.39)
1802.)
        1-(Z)-10-octadecenoyl-2-stearoyl-sn-glycero-3-
        phospho-N, N-dimethyl-N-(HP1-HP2-HP3-diHP4) -
        propylammonium (n = 3)
```

(1084.46)

C56H110NO16P

```
- 169 -
1803.) 1-(Z,Z)-6,18-hexacosadienoyl-2-stearoyl-sn-
         diHP_4) propylammonium (n = 3)
         C64H124NO16P
                          (1194.66)
n = 4
1804.) 1,2-di-(Z)-6-octadecenoyl-sn-glycero-3-phospho-
        N, N-dimethyl-N-(HP_1-HP_2-HP_3-diHP_4) butylammonium
         (n = 4)
        C57H110NO16P
                          (1096.47)
1805.)
        1,2-di-(Z)-10-docosenoyl-sn-glycero-3-phospho-
        N, N-dimethyl-N-(HP1-HP2-HP3-diHP4) butylammonium
         (n = 4)
        C65H126NO16P
                          (1208.69)
1806.) 1,2-di-(Z,Z)-5,11-hexadecadienoyl-sn-glycero-3-
        phospho-N, N-dimethyl-N-(HP1-HP2-HP3-diHP4) butyl-
        ammonium (n = 4)
        C53H98NO16P
                          (1036.33)
1807.) 1,2-di-(Z,Z)-10,16-docosadienoyl-sn-glycero-3-
        phospho-N, N-dimethyl-N-(HP1-HP2-HP3-diHP4) butyl-
        ammonium (n = 4)
        C65H122NO16P
                          (1204.65)
1808.)
        1,2-di-(Z,Z)-6,18-hexacosadienoyl-sn-glycero-3-
        phospho-N, N-dimethyl-N-(HP1-HP2-HP3-diHP4) butyl-
        ammonium (n = 4)
        C73H138NO16P
                         (1316.87)
n = 6
       1,2-di-(Z)-6-octadecenoyl-sn-glycero-3-phospho-
1809.)
        {\tt N,N-dimethyl-N-(HP_1-HP_2-HP_3-diHP_4)}\ hexylammonium
        (n = 6)
        C59H114NO16P
                        (1124.53)
       1,2-di-(Z)-10-docosenoyl-sn-glycero-3-phospho-
1810.)
       N, N-dimethyl-N-(HP1-HP2-HP3-diHP4) hexylammonium
        (n = 6)
```

(1236.74)

C67H130NO16P

1811.) 1,2-di-(Z,Z)-10,16-docosadienovl-sn-glycero-3phospho-N, N-dimethyl-N-(HP1-HP2-HP3-diHP4) hexylammonium (n = 6)C67H126NO16P

(1232.71)

1812.) 1,2-di-(Z,Z)-6,18-hexacosadienovl-sn-glycero-3phospho-N, N-dimethyl-N-(HP1-HP2-HP3-diHP4) hexylammonium (n = 6)C75H142NO16P (1344.92)

5. Examples of two-chain glycero-phospho compounds not hydroxylated on the nitrogen

 $(A = III; n = 2-6; R_3, CH_3; m = 1, x = 1; z = 0)$

$$A - PO_3 - \left[(CH_2)_n - N^* \atop R_3 \right]_m - (CH_2)_X - \left[CH_2 - \left(\begin{matrix} CH \\ OH \end{matrix} \right)_y - CH_2 - O \right]_z - H$$

- 1813.) 1,2-di-(Z)-6-hexadecenovl-sn-glycero-3-phospho-N, N, N-trimethylpropylammonium (n = 3) C41H78NO8P (744.05)
- 1814.) 1,2-di-(Z)-10-heptadecenoyl-sn-glycero-3phospho-N,N,N-trimethylpropylammonium (n = 3)(772.10)C43H82NO8P
- 1815.) 1,2-di-(Z)-6-octadecenoyl-sn-glycero-3-phospho-N, N, N-trimethylpropylammonium (n = 3) C45H86NO8P (800.15)
- 1816.) 1,2-di-(Z)-12-eicosenoyl-sn-glycero-3-phospho-N, N, N-trimethylpropylammonium (n = 3) C49H94NO8P (856.26)
- 1817.) 1,2-di-(Z)-10-docosenoyl-sn-glycero-3-phospho-N, N, N-trimethylpropylammonium (n = 3)C53H102NO8P (912.37)
- 1818.) 1,2-di-(Z)-12-docosenoyl-sn-qlycero-3-phospho-N, N, N-trimethylpropylammonium (n = 3) C53H102NO8P (912.37)
- 1819.) 1,2-di-(Z)-10-tricosenoyl-sn-glycero-3-phospho-N, N, N-trimethylpropylammonium (n = 3) C55H106NO8P (940.42)

- 1820.) 1,2-di-(Z)-10-tetracosenoyl-sn-glycero-3-phospho-N,N,N-trimethylpropylammonium (n = 3) $C_{57}H_{110}NO_{8}P$ (968.48)
- 1821.) 1,2-di-(Z,Z)-5,11-octadecadienoyl-sn-glycero-3-phospho-N,N,N-trimethylpropylammonium (n = 3) $C_{45}H_{82}NO_8P \qquad (796.12)$
- 1822.) 1,2-di-(Z,Z)-10,16-eicosadienoyl-sn-glycero-3-phospho-N,N,N-trimethylpropylammonium (n = 3) $C_{49}H_{90}NO_{8}P$ (852.23)
- 1823.) 1,2-di-(Z,Z)-10,16-docosadienoyl-sn-glycero-3-phospho-N,N,N-trimethylpropylammonium (n = 3)
 Cc:HoaNOaP (908.34)
- 1824.) 1,2-di-(Z,Z)-6,18-hexacosadienoyl-sn-glycero-3-phospho-N,N,N-trimethylpropylammonium (n = 3) $C_{61}H_{114}NO_8P \hspace{1cm} (1020.55)$
- 1825.) 2-(Z)-6-hexadecenoyl-1-stearoyl-sn-glycero-3-phospho-N,N,N-trimethylpropylammonium (n = 3) $C_{43}H_{84}NO_8P$ (774.12)
- 1826.) 2-(Z)-10-octadecenoyl-1-stearoyl-sn-glycero-3-phospho-N,N,N-trimethylpropylammonium (n = 3) $C_{45}H_{88}NO_8P \qquad (802.17)$
- 1827.) 2-(Z)-10-docosenoyl-1-behenyl-sn-glycero-3-phospho-N,N,N-trimethylpropylammonium (n = 3) $C_{51}H_{100}NO_8P \qquad (886.33)$
- 1828.) 2-(Z,Z)-6,12-hexadecadienoyl-1-stearoyl-sn-glycero-3-phospho-N,N,N-trimethylpropylammonium (n = 3) $C_{43}H_{82}NO_8P \hspace{1cm} (772.10)$
- 1829.) 1-(Z)-10-octadecenoyl-2-stearoyl-sn-glycero-3-phospho-N,N,N-trimethylpropylammonium (n = 3) $C_{45}H_{98}NO_8P$ (802.17)
- 1830.) 1-(Z,Z)-6,18-hexacosadienoyl-2-stearoyl-sn-glycero-3-phospho-N,N,N-trimethylpropylammonium (n = 3) $C_{53}H_{102}NO_8P$ (912.37)

n = 4

- 1831.) 1,2-di-(Z)-6-octadecenoyl-sn-glycero-3-phospho-N,N,N-trimethylbutylammonium (n = 4) $C_{46}H_{88}NO_8P$ (814.18)
- 1832.) 1,2-di-(Z)-10-docosenoyl-sn-glycero-3-phospho-N,N,N-trimethylbutylammonium (n = 4) $C_{54}H_{104}NO_8P \qquad (926.40)$
- 1833.) 1,2-di-(Z,Z)-5,11-hexadecadienoyl-sn-glycero-3-phospho-N,N,N-trimethylbutylammonium (n = 4) $C_{42}H_{76}N0_8P$ (796.12)
- 1834.) 1,2-di-(Z,Z)-10,16-docosadienoyl-sn-glycero-3-phospho-N,N,N-trimethylbutylammonium (n=4) $C_{54}H_{100}NO_8P$ (922.36)
- 1835.) 1,2-di-(Z,Z)-6,18-hexacosadienoyl-sn-glycero-3-phospho-N,N,N-trimethylbutylammonium (n = 4) $C_{62}H_{116}NO_8P$ (1034.58)

n = 6

- 1836.) 1,2-di-(Z)-6-octadecenoyl-sn-glycero-3-phospho-N,N,N-trimethylhexylammonium (n = 6) $C_{48}H_{92}NO_8P$ (842.23)
- 1837.) 1,2-di-(Z)-10-docosenoyl-sn-glycero-3-phospho-N,N,N-trimethylhexylammonium (n = 6) $C_{56}H_{108}NO_8P \qquad (954.45)$
- 1838.) 1,2-di-(Z,Z)-10,16-docosadienoyl-sn-glycero-3-phospho-N,N,N-trimethylhexylammonium (n=6) $C_{56}H_{104}NO_8P \qquad (950.42)$
- 1839.) 1,2-di-(Z,Z)-6,18-hexacosadienoyl-sn-glycero-3-phospho-N,N,N-trimethylhexylammonium (n = 6) $C_{64}H_{120}NO_8P$ (1062.63)

Negatively charged phospholipids: Phosphatidyloligoglycerols

6. Examples of glycero-glycerols (Na salts of phospho-G1-G2 compounds)

(A = III; m = 0; y = 1; z = 2)

$$A - PO_3 - \begin{bmatrix} CH_2 \\ CH_2 \end{pmatrix}_m - N^* \\ R_3 \end{bmatrix}_m - (CH_2)_x - \begin{bmatrix} CH_2 - \begin{pmatrix} CH \\ OH \end{pmatrix}_y - CH_2 - O \\ OH \end{bmatrix}_z - H$$

- 1840.) 1,2-di-(Z)-6-hexadecenoyl-sn-glycero-3-phospho-glycero-glycerol; Na salt $C_{41}H_{76}NaO_{12}P$ (815.01)
- 1841.) 1,2-di-(Z)-10-heptadecenoyl-sn-glycero-3-phospho-glycero-glycero1; Na salt $C_{43}H_{80}NaO_{12}P \eqno(843.06)$
- 1842.) 1,2-di-(Z)-6-octadecenoyl-sn-glycero-3-phospho-glycero-glycerol; Na salt $C_{45}H_{84}NaO_{12}P$ (871.12)
- 1843.) 1,2-di-(Z)-6-nonadecenoyl-sn-glycero-3-phosphoglycero-glycerol; Na salt
 Ca7HasNaO22P (899.17)
- 1844.) 1,2-di-(Z)-12-eicosenoyl-sn-glycero-3-phosphoglycero-glycerol; Na salt C49H32NaO12P (927.23)
- 1845.) 1,2-di-(Z)-10-heneicosenoyl-sn-glycero-3-phospho-glycero-glycero1; Na salt

 C₅₁H₉₆NaO₁₂P (955.28)
- 1846.) 1,2-di-(Z)-10-docosenoyl-sn-glycero-3-phosphoglycero-glycerol; Na salt C52H100N2O12P (983.33)
- 1847.) 1,2-di-(Z)-12-docosenoyl-sn-glycero-3-phosphoglycero-glycerol; Na salt C₅₃H₁₀₀NaO₁₂P (983.33)
- 1848.) 1,2-di-(Z)-10-tricosenoyl-sn-glycero-3-phosphoglycero-glycerol; Na salt C₅₅H₁₀₄NaO₁₂P (1011.39)
- 1849.) 1,2-di-(Z)-10-tetracosenoy1-sn-glycero-3-phospho-glycero-glycerol; Na salt

C₅₇H₁₀₈NaO₁₂P (1039.44)

- 1850.) 1,2-di-(Z)-15-pentacosenoyl-sn-glycero-3-phospho-glycero-glycerol; Na salt
 Cs4H112NaO12P (1067.49)
- 1851.) 1,2-di-(Z)-16-hexacosenoyl-sn-glycero-3-phospho-glycero-glycerol; Na salt $C_{61}H_{116}NaO_{12}P$ (1095.55)
- 1852.) 1,2-di-(Z,Z)-5,11-hexadecadienoyl-sn-glycero-3-phospho-glycero-glycerol; Na salt $C_{41}H_{72}NaO_{12}P$ (810.98)
- 1853.) 1,2-di-(Z,Z)-5,11-octadecadienoyl-sn-glycero-3phospho-glycero-glycero1; Na salt
 C₄₅H₈₀NaO₁₂P (867.09)
- 1854.) 1,2-di-(Z,Z)-6,12-nonadecadienoyl-sn-glycero-3phospho-glycero-glycerol; Na salt
 C47H84NaO12P (895.14)
- 1855.) 1,2-di-(Z,Z)-10,16-eicosadienoyl-sn-glycero-3-phospho-glycero-glycerol; Na salt

 C49HssNaO12P (923.19)
- 1856.) 1,2-di-(Z,Z)-10,16-docosadienoyl-sn-glycero-3-phospho-glycero-glycerol; Na salt

 C53HscNaO12P (979,30)
- 1857.) 1,2-di-(Z,Z)-6,18-tetracosadienoyl-sn-glycero-3-phospho-glycero-glycerol; Na salt $C_{57}H_{104}NaO_{12}P$ (1035.41)
- 1858.) 1,2-di-(Z,Z)-10,16-pentacosadienoyl-sn-glycero3-phospho-glycero-glycerol; Na salt
 Cs9H10ANAO12P (1063.46)
- 1859.) 1,2-di-(Z,Z)-6,18-hexacosadienoyl-sn-glycero-3-phospho-glycero-glycerol; Na salt $C_{61}H_{112}NaO_{12}P \eqno(1091.52)$
- 1860.) 2-(Z)-6-hexadecenoyl-1-stearoyl-sn-glycero-3-phospho-glycero-glycerol; Na salt $C_{43}H_{92}NaO_{12}P$ (845.08)
- 1861.) 2-(Z)-10-octadecenoyl-1-stearoyl-sn-glycero-3phospho-glycero-glycerol; Na salt

- 175 -

C₄₅H₈₆NaO₁₂P (873.13)

- 1862.) 2-(Z)-10-eicosenoyl-1-stearoyl-sn-glycero-3-phospho-glycero-glycerol; Na salt

 C47H9nNaOloP (901.19)
- 1863.) 2-(Z,Z)-6,12-hexadecadienoyl-1-stearoyl-sn-glycero-3-phospho-glycero-glycerol; Na salt $C_{43}H_{80}NaO_{12}P$ (843.06)
- 1864.) 2-(Z,Z)-10,16-docosadienoyl-1-stearoyl-sn-glycero-3-phospho-glycero-glycerol; Na salt $C_{49}H_{92}NaO_{12}P$ (927.23)
- 1865.) 1-stearoyl-2-(Z,Z)-6,18-tetracosadienoyl-sn-glycero-3-phospho-glycero-glycerol; Na salt $C_{51}H_{96}NaO_{12}P$ (955.28)
- 1866.) 1-(Z)-10-octadecenoyl-2-stearoyl-sn-glycero-3-phospho-glycero-glycerol; Na salt $C_{45}H_{86}NaO_{12}P \eqno(873.13)$
- 1867.) 1-(Z,Z)-6,18-hexacosadienoyl-2-stearoyl-snglycero-3-phospho-glycero-glycerol; Na salt
 Cs2HooNaO22P (983.33)
- 1868.) 1-(Z,Z)-6,18-hexacosadienoyl-2-(Z)-6hexadecenoyl-sn-glycero-3-phospho-glyceroglycerol; Na salt
 Cs1HauNaOc2P (953,26)
- 1869.) 2-(Z,Z)-6,18-hexacosadienoyl-1-(Z)-6hexadecenoyl-sn-glycero-3-phospho-glyceroglycerol; Na salt C₅₁H₉₄NaO₁₂P (953.26)

Examples of phosphatidyl-glycero-glycero-glycerols (Na salts of phospho-G₁-G₂-G₃ compounds)

(A = III; m = 0, x = 0; y = 1; z = 3)

$$A - PO_{3} - \left[(CH_{2})_{n} - \overset{CH_{3}}{\overset{N}{\overset{}{=}}} \right]_{m} - (CH_{2})_{X} - \left[\begin{array}{c} CH_{2} - \left(\begin{array}{c} CH \\ OH \end{array} \right)_{y} - CH_{2} - O \end{array} \right]_{T} - \left[\begin{array}{c} CH_{2} - \left(\begin{array}{c} CH \\ OH \end{array} \right)_{y} - CH_{2} - O \end{array} \right]_{T} - \left[\begin{array}{c} CH_{2} - \left(\begin{array}{c} CH \\ OH \end{array} \right)_{y} - CH_{2} - O \end{array} \right]_{T} - \left[\begin{array}{c} CH_{2} - \left(\begin{array}{c} CH \\ OH \end{array} \right)_{y} - CH_{2} - O \end{array} \right]_{T} - \left[\begin{array}{c} CH_{2} - \left(\begin{array}{c} CH \\ OH \end{array} \right)_{y} - CH_{2} - O \end{array} \right]_{T} - \left[\begin{array}{c} CH_{2} - \left(\begin{array}{c} CH \\ OH \end{array} \right)_{y} - CH_{2} - O \end{array} \right]_{T} - \left[\begin{array}{c} CH_{2} - \left(\begin{array}{c} CH \\ OH \end{array} \right)_{y} - CH_{2} - O \end{array} \right]_{T} - \left[\begin{array}{c} CH_{2} - \left(\begin{array}{c} CH \\ OH \end{array} \right)_{y} - CH_{2} - O \end{array} \right]_{T} - \left[\begin{array}{c} CH_{2} - \left(\begin{array}{c} CH \\ OH \end{array} \right)_{y} - CH_{2} - O \end{array} \right]_{T} - \left[\begin{array}{c} CH_{2} - \left(\begin{array}{c} CH \\ OH \end{array} \right)_{y} - CH_{2} - O \end{array} \right]_{T} - \left[\begin{array}{c} CH_{2} - \left(\begin{array}{c} CH \\ OH \end{array} \right)_{y} - CH_{2} - O \end{array} \right]_{T} - \left[\begin{array}{c} CH_{2} - \left(\begin{array}{c} CH \\ OH \end{array} \right)_{y} - CH_{2} - O \end{array} \right]_{T} - \left[\begin{array}{c} CH_{2} - \left(\begin{array}{c} CH \\ OH \end{array} \right)_{y} - CH_{2} - O \end{array} \right]_{T} - \left[\begin{array}{c} CH_{2} - \left(\begin{array}{c} CH \\ OH \end{array} \right)_{y} - CH_{2} - O \end{array} \right]_{T} - \left[\begin{array}{c} CH_{2} - \left(\begin{array}{c} CH \\ OH \end{array} \right)_{y} - CH_{2} - O \end{array} \right]_{T} - \left[\begin{array}{c} CH_{2} - \left(\begin{array}{c} CH \\ OH \end{array} \right)_{y} - CH_{2} - O \end{array} \right]_{T} - \left[\begin{array}{c} CH_{2} - \left(\begin{array}{c} CH \\ OH \end{array} \right)_{y} - CH_{2} - O \end{array} \right]_{T} - \left[\begin{array}{c} CH_{2} - \left(\begin{array}{c} CH \\ OH \end{array} \right)_{y} - CH_{2} - O \end{array} \right]_{T} - \left[\begin{array}{c} CH_{2} - \left(\begin{array}{c} CH \\ OH \end{array} \right)_{y} - CH_{2} - O \end{array} \right]_{T} - \left[\begin{array}{c} CH_{2} - \left(\begin{array}{c} CH \\ OH \end{array} \right)_{y} - CH_{2} - O \end{array} \right]_{T} - \left[\begin{array}{c} CH_{2} - \left(\begin{array}{c} CH \\ OH \end{array} \right)_{y} - CH_{2} - O \end{array} \right]_{T} - \left[\begin{array}{c} CH_{2} - \left(\begin{array}{c} CH \\ OH \end{array} \right)_{y} - CH_{2} - O \end{array} \right]_{T} - \left[\begin{array}{c} CH_{2} - \left(\begin{array}{c} CH \\ OH \end{array} \right)_{y} - CH_{2} - O \end{array} \right]_{T} - \left[\begin{array}{c} CH_{2} - \left(\begin{array}{c} CH \\ OH \end{array} \right]_{T} - CH_{2} - O \end{array} \right]_{T} - CH_{2} - O - CH_{$$

- 1870.) 1,2-di-(Z)-6-hexadecenoyl-sn-glycero-3-phosphoglycero-glycero-glycerol; Na salt C44H82NaO14P (889.09)
- 1871.) 1,2-di-(Z)-10-heptadecenoyl-sn-glycero-3-phospho-glycero-glycero-glycerol; Na salt C46H86NaO14P (917.14)
- 1872.) 1,2-di-(Z)-6-octadecenoyl-sn-glycero-3-phosphoglycero-glycero-glycerol; Na salt C₄₈H₉₀NaO₁₄P (945.20)
- 1873.) 1,2-di-(Z)-6-nonadecenoyl-sn-glycero-3-phosphoglycero-glycero-glycerol; Na salt C₅₀H₉₄NaO₁₄P (973.25)
- 1874.) 1,2-di-(Z)-12-eicosenoyl-sn-glycero-3-phosphoglycero-glycero-glycerol; Na salt C₅₂H₉₈NaO₁₄P (1001.31)
- 1875.) 1,2-di-(Z)-10-heneicosenoyl-sn-glycero-3-phospho-glycero-glycero-glycerol; Na salt C54H102NaO14P (1029.36)
- 1876.) 1,2-di-(Z)-10-docosenoyl-sn-glycero-3-phosphoglycero-glycero-glycerol; Na salt Cs6H106NaO14P (1057.41)
- 1877.) 1,2-di-(Z)-12-docosenoyl-sn-glycero-3-phosphoglycero-glycero-glycerol; Na salt C₅₆H₁₀₆NaO₁₄P (1057.41)
- 1878.) 1,2-di-(Z)-10-tricosenoyl-sn-glycero-3-phosphoglycero-glycero-glycerol; Na salt C₅₈H₁₁₀NaO₁₄P (1085.47)
- 1879.) 1,2-di-(Z)-10-tetracosenoyl-sn-glycero-3phospho-glycero-glycero-glycerol; Na salt
 C60H114NaO14P (1113.52)
- 1880.) 1,2-di-(Z)-15-pentacosenoyl-sn-glycero-3phospho-glycero-glycero-glycerol; Na salt
 C₆₂H₁₁₈NaO₁₄P (1141.57)
- 1881.) 1,2-di-(Z)-16-hexacosenoyl-sn-glycero-3-phospho-glycero-glycero-glycerol; Na salt C₆₄H₁₂₂NaO₁₄P (1169.63)

- 1882.) 1,2-di-(Z,Z)-5,11-hexadecadienoyl-sn-glycero-3-phospho-glycero-glycero-glycero1; Na salt C44H78NaO14P (885.06)
- 1883.) 1,2-di-(Z,Z)-5,11-octadecadienoyl-sn-glycero-3-phospho-glycero-glycero-glycero1; Na salt C48H86NaOl4P (941.17)
- 1884.) 1,2-di-(Z,Z)-6,12-nonadecadienoyl-sn-glycero-3-phospho-glycero-glycero-glycerol; Na salt
 C50H30NaOl4P (969.22)
- 1885.) 1,2-di-(Z,Z)-10,16-eicosadienoyl-sn-glycero-3phospho-glycero-glycero-glycero1; Na salt
 C₅₂H₉₄NaO₁₄P (997.27)
- 1886.) 1,2-di-(Z,Z)-10,16-docosadienoyl-sn-glycero-3phospho-glycero-glycero-glycerol; Na salt
 C56H102NAO14P (1053.38)
- 1887.) 1,2-di-(Z,Z)-6,18-tetracosadienoyl-sn-glycero-3-phospho-glycero-glycero-glycerol; Na salt $C_{60}H_{110}NaO_{14}P$ (1109.49)
- 1888.) 1,2-di-(Z,Z)-10,16-pentacosadienoyl-sn-glycero-3-phospho-glycero-glycero-glycerol; Na salt C₆₂H₁₁₄NaO₁₄P (1137.54)
- 1889.) 1,2-di-(Z,Z)-6,18-hexacosadienoyl-sn-glycero-3-phospho-glycero-glycero-glycerol; Na salt $C_{64}H_{116}NaO_{14}P$ (1165.60)
- 1890.) 2-(Z)-6-hexadecenoyl-1-stearoyl-sn-glycero-3phospho-glycero-glycero-glycerol; Na salt
 C46H89NaO14P (919.16)
- 1891.) 2-(Z)-10-octadecenoyl-1-stearoyl-sn-glycero-3phospho-glycero-glycero-glycerol; Na salt
 C48H99NaO14P (947.21)
- 1892.) 2-(Z)-10-eicosenoyl-1-stearoyl-sn-glycero-3phospho-glycero-glycero-glycerol; Na salt
 C50H36NaO14P (975.27)
- 1893.) 2-(Z,Z)-6,12-hexadecadienoyl-1-stearoyl-sn-glycero-3-phospho-glycero-glycero-glycerol;
 Na salt $C_{46}H_{86}NaO_{14}P$ (917.14)

1894.) 2-(Z,Z)-10,16-docosadienoyl-1-stearoyl-sn-glycero-3-phospho-glycero-glycero-glycerol; Na salt

C₅₂H₉₈NaO₁₄P (1001.31)

- 1895.) 1-stearoyl-2-(Z,Z)-6,18-tetracosadienoyl-snglycero-3-phospho-glycero-glycero-glycero1;
 Na salt
 C54H102NaO14P (1029.36)
- 1896.) 1-(Z)-10-octadecenoy1-2-stearoy1-sn-glycero-3phospho-glycero-glycero-glycero1; Na salt
 C48H92NaO14P (947.21)
- 1897.) 1-(Z,Z)-6,18-hexacosadienoyl-2-stearoyl-snglycero-3-phospho-glycero-glycero-glycerol;
 Na salt
 Cs6H106NaO14P (1057.41)
- 1898.) 1-(Z,Z)-6,18-hexacosadienoy1-2-(Z)-6-hexadecenoy1-sn-glycero-3-phospho-glycero-glycero-glycero1; Na salt
 C54H100NaO14P (1027.34)
- 1899.) 2-(Z,Z)-6,18-hexacosadienoy1-1-(Z)-6-hexadecenoy1-sn-glycero-3-phospho-glycero-glycero-glycerol; Na salt $C_{54}H_{100}NaO_{14}P \hspace{1cm} (1027.34)$
- (A = III; m = 0, x = 0; y = 1; z = 4)

$$A - PO_{3}^{-} - \left[(CH_{2})_{n} - N^{+} \atop R_{3} \right]_{m}^{-} - (CH_{2})_{X} - \left[CH_{2} - \left(CH \atop OH \right)_{y} - CH_{2} - O \right]_{z}^{-} + H_{z}^{-} + H_{$$

1900.) 1,2-di-(Z)-6-hexadecenoyl-sn-glycero-3-phosphoglycero-glycero-glycero-glycerol; Na salt C₄-H₈₈NaO₁₆P (963.17)

- 1901.) 1,2-di-(Z)-10-heptadecenoyl-sn-glycero-3phospho-glycero-glycero-glycero-glycerol;
 Na salt
 - C49H92NaO16P (991.22)
- 1902.) 1,2-di-(Z)-6-octadecenoyl-sn-glycero-3-phosphoglycero-glycero-glycero-glycerol; Na salt C₅₁H₉₆NaO₁₆P (1019.28)
- 1903.) 1,2-di-(Z)-6-nonadecenoyl-sn-glycero-3-phosphoglycero-glycero-glycero-glycerol; Na salt C53H100NaO16P (1047.33)
- 1904.) 1,2-di-(Z)-12-eicosenoyl-sn-glycero-3-phosphoglycero-glycero-glycero-glycero1; Na salt C55H104NaO16P (1075.38)
- 1905.) 1,2-di-(Z)-10-heneicosenoyl-sn-glycero-3-phospho-glycero-glycero-glycero-glycerol;
 Na salt
 Cs7H10aNaO16P (1103.44)
- 1906.) 1,2-di-(Z)-10-docosenoyl-sn-glycero-3-phosphoglycero-glycero-glycero-glycerol; Na salt C59H112NaO16P (1131.49)
- 1907.) 1,2-di-(Z)-12-docosenoyl-sn-glycero-3-phosphoglycero-glycero-glycero-glycero1; Na salt C55H112NaO16P (1131.49)
- 1908.) 1,2-di-(Z)-10-tricosenoyl-sn-glycero-3-phospho-glycero-glycero-glycero-glycerol; Na salt $C_{61}H_{116}NaO_{16}P$ (1159.55)
- 1909.) 1,2-di-(Z)-10-tetracosenoyl-sn-glycero-3phospho-glycero-glycero-glycero-glycerol;
 Na salt
- $C_{63}H_{120}NaO_{16}P$ (1187.60)
- 1910.) 1,2-di-(Z)-15-pentacosenoyl-sn-glycero-3phospho-glycero-glycero-glycero-glycerol;
 Na salt
 - C₆₅H₁₂₄NaO₁₆P (1215.65)
- 1911.) 1,2-di-(Z)-16-hexacosenoyl-sn-glycero-3phospho-glycero-glycero-glycero-glycerol;
 Na salt
 C67H128NAO16P (1243.71)

Na salt C49H94NaO16P

```
1912.) 1,2-di-(Z,Z)-5,11-hexadecadienoyl-sn-glycero-3-
        phospho-glycero-glycero-glycerol;
        Na salt
        C47He4NaO16P
                         (959.14)
1913.)
        1,2-di-(Z,Z)-5,11-octadecadienoyl-sn-glycero-3-
        phospho-glycero-glycero-glycero-glycerol:
        Na salt
        C51H92NaO16P
                         (1015.25)
        1,2-di-(Z,Z)-6,12-nonadecadienoyl-sn-glycero-3-
        phospho-glycero-glycero-glycero-glycerol;
        Na salt
        Cs3HocNaO1cP
                         (1043.30)
1915.) 1,2-di-(Z,Z)-10,16-eicosadienoyl-sn-glycero-3-
        phospho-glycero-glycero-glycerol;
        Na salt
        CssH100NaO16P
                        (1071.35)
1916.) 1,2-di-(Z,Z)-10,16-docosadienoyl-sn-qlycero-3-
        phospho-glycero-glycero-glycerol;
        Na salt
        C<sub>59</sub>H<sub>108</sub>NaO<sub>16</sub>P (1127.46)
1917.)
        1,2-di-(Z,Z)-6,18-tetracosadienoyl-sn-glycero-
        3-phospho-glycero-glycero-glycero];
        Na salt
        C63H116NaO16P
                         (1183.57)
        1,2-di-(Z,Z)-10,16-pentacosadienoyl-sn-glycero-
        3-phospho-glycero-glycero-glycerol;
        Na salt
        C_{65}H_{120}NaO_{16}P
                        (1211.62)
1919.)
        1,2-di-(Z,Z)-6,18-hexacosadienoyl-sn-glycero-3-
        phospho-glycero-glycero-glycero-glycerol;
        Na salt
        C67H124NaO16P
                        (1239.68)
1920.) 2-(Z)-6-hexadecenoyl-1-stearoyl-sn-glycero-3-
       phospho-glycero-glycero-glycerol;
```

(993.24)

- 1921.) 2-(Z)-10-octadecenoyl-1-stearoyl-sn-glycero-3phospho-glycero-glycero-glycero-glycerol;
 Na salt
 - $C_{51}H_{98}NaO_{16}P$ (1021.29)
- 1922.) 2-(Z)-10-eicosenoyl-1-stearoyl-sn-glycero-3phospho-glycero-glycero-glycero-glycerol;
 Na salt
 - $C_{53}H_{102}NaO_{16}P$ (1049.35)
- 1923.) 2-(Z,Z)-6,12-hexadecadienoyl-1-stearoyl-sn-glycero-3-phospho-glycero-glycero-glycero-glyceroglycerol; Na salt

 C49H32NaO16P (991.22)
- 1924.) 2-(Z,Z)-10,16-docosadienoyl-1-stearoyl-sn-glycero-3-phospho-glycero-glycero-glycero-glyceroglycerol; Na salt

 C55H104NaO16P (1075.38)
- 1925.) 1-stearoyl-2-(Z,Z)-6,18-tetracosadienoyl-snglycero-3-phospho-glycero-glyceroglycerol; Na salt C₅₇H₁₀₈NaO₁₆P (1103.44)
- 1926.) 1-(Z)-10-octadecenoyl-2-stearoyl-sn-glycero-3-phospho-glycero-glycero-glycero-glycerol;
 Na salt
 C51HanNaO.6P (1021.29)
- 1927.) 1-(Z,Z)-6,18-hexacosadienoyl-2-stearoyl-snglycero-3-phospho-glycero-glycero-glyceroglycerol; Na salt
 - C₅₉H₁₁₂NaO₁₆P (1131.49)
- 1928.) 1-(Z,Z)-6,18-hexacosadienoyl-2-(Z)-6-hexadecenoyl-sn-glycero-3-phospho-glycero-glycero-glycero-glycero-(Z)-101,42) $C_{57}H_{106}NaO_{16}P$ (1101,42)
- 1929.) 1-(Z,Z)-6,18-hexacosadienoyl-1-(Z)-6-hexadecenoyl-sn-glycero-3-phospho-glycero-glycero-glycero-glycero-glycero-glycero-(1101.42)

9. Examples of phospho-sn-G1 linkages

sn-1-G1-G2 compounds

- 1930.) 1,2-di-(Z)-6-octadecenoyl-sn-glycero-3-phosphosn-1-glycero-glycerol; Na salt C4-H44N3O12P (871.12)
- 1931.) 1,2-di-(Z)-6-nonadecenoyl-sn-glycero-3-phosphosn-1-glycero-glycerol; Na salt C4-HasNaO12P (899.17)
- 1932.) 1,2-di-(Z)-10-docosenoyl-sn-glycero-3-phosphosn-1-glycero-glycerol; Na salt CsHnoNaOloP (983.33)
- 1933.) 1,2-di-(Z)-12-docosenoyl-sn-glycero-3-phosphosn-1-glycero-glycerol; Na salt C₅₃H₁₀₀NaO₁₂P (983.33)
- 1934.) 1,2-di-(Z)-10-tetracosenoyl-sn-glycero-3-phospho-sn-1-glycero-glycerol; Na salt C₅₇H₁₀₆NaO₁₂P (1039.44)
- 1935.) 1,2-di-(Z)-16-hexacosenoyl-sn-glycero-3-phospho-sn-1-glycero-glycerol; Na salt $C_{61}H_{116}NaO_{12}P$ (1095.55)
- 1936.) 1,2-di-(Z,Z)-5,11-octadecadienoyl-sn-glycero-3-phospho-sn-1-glycero-glycerol; Na salt $C_{49}H_{60}NaO_{12}P$ (867.09)
- 1937.) 1,2-di-(Z,Z)-10,16-docosadienoyl-sn-glycero-3-phospho-sn-1-glycero-glycerol; Na salt $C_{53}H_{96}NaO_{12}P$ (979,30)
- 1938.) 1,2-di-(Z,Z)-6,18-tetracosadienoyl-sn-glycero-3-phospho-sn-1-glycero-glycerol; Na salt $C_{57}H_{104}NaO_{12}P$ (1035.41)
- 1939.) 1,2-di-(Z,Z)-6,18-hexacosadienoyl-sn-glycero-3-phospho-sn-1-glycero-glycerol; Na salt $C_{61}H_{112}NaO_{12}P$ (1091.52)
- 1940.) 2-(Z)-10-octadecenoyl-1-stearoyl-sn-glycero-3-phospho-sn-1-glycero-glycerol; Na salt

```
- 183 -
```

```
C<sub>45</sub>H<sub>86</sub>NaO<sub>12</sub>P (873.13)
```

- 1941.) 2-(Z)-10-eicosenoyl-1-stearoyl-sn-glycero-3-phospho-sn-1-glycero-glycerol; Na salt C_4 - H_{90} NaO₁₂P (901.19)
- 1942.) 2-(Z,Z)-6,12-hexadecadienoyl-1-stearoyl-snglycero-3-phospho-sn-1-glycero-glycerol;
 Na salt

C₄₃H₈₀NaO₁₂P (843.06)

1943.) 2-(Z,Z)-10,16-docosadienoyl-1-stearoyl-sn-glycero-3-phospho-sn-1-glycero-glycerol; Na salt

 $C_{49}H_{92}NaO_{12}P$ (927.23)

1944.) 1-(Z,Z)-6,18-hexacosadienoyl-2-stearoyl-sn-glycero-3-phospho-sn-1-glycero-glycerol; Na salt $C_{53}H_{100}NaO_{12}P \qquad (983.33)$

sn-1-G1-G2-G3 compounds

- 1945.) 1,2-di-(Z)-6-octadecenoyl-sn-glycero-3-phosphosn-1-glycero-glycero-glycerol; Na salt C48H30NaO14P (945.20)
- 1946.) 1,2-di-(Z)-6-nonadecenoyl-sn-glycero-3-phosphosn-1-glycero-glycero-glycerol; Na salt C₅₀H₉₄NaO₁₄P (973.25)
- 1947.) 1,2-di-(Z)-10-docosenoyl-sn-glycero-3-phosphosn-1-glycero-glycero-glycerol; Na salt C₅₆H₁₀₆NaO₁₄P (1057.41)
- 1948.) 1,2-di-(Z)-12-docosenoyl-sn-glycero-3-phosphosn-1-glycero-glycero-glycerol; Na salt C₅₆H₁₀₆NaO₁₄P (1057.41)
- 1949.) 1,2-di-(Z)-10-tetracosenoyl-sn-glycero-3-phospho-sn-1-glycero-glycero-glycerol; Na salt $C_{60}H_{114}NaO_{14}P$ (1113.52)
- 1950.) 1,2-di-(Z)-16-hexacosenoyl-sn-glycero-3-phospho-sn-1-glycero-glycero-glycero1; Na salt $C_{64}H_{122}NaO_{14}P$ (1169.63)

- 1951.) 1,2-di-(Z,Z)-5,11-octadecadienoyl-sn-glycero-3-phospho-sn-1-glycero-glycero-glycerol; Na salt
 CasHacNaO12P (941.17)
- 1952.) 1,2-di-(Z,Z)-10,16-docosadienoyl-sn-glycero-3-phospho-sn-1-glycero-glycero-glycerol; Na salt

 Cs_H102NaO14P (1053.38)
- 1953.) 1,2-di-(Z,Z)-6,18-tetracosadienoy1-sn-glycero-3-phospho-sn-1-glycero-glycero-glycerol; Na salt
 - $C_{60}H_{110}NaO_{14}P$ (1109.49)
- 1954.) 1,2-di-(Z,Z)-6,18-hexacosadienoyl-sn-glycero-3-phospho-sn-1-glycero-glycero-glycerol; Na salt $C_{64}H_{118}NaO_{14}P$ (1165.60)
- 1955.) 2-(Z)-10-octadecenoyl-1-stearoyl-sn-glycero-3-phospho-sn-1-glycero-glycero-glycerol; Na salt C4sH4:NaO14P (947.21)
- 1956.) 2-(Z)-10-eicosenoyl-1-stearoyl-sn-glycero-3-phospho-sn-1-glycero-glycero-glycerol; Na salt C50H3cNaO14P (975.27)
- 1957.) 2-(Z,Z)-6,12-hexadecadienoyl-1-stearoyl-sn-glycero-3-phospho-sn-1-glycero-glycero-glycerol; Na salt

 C46He6NaO14P (917.14)
- 1958.) 2-(Z,Z)-10,16-docosadienoyl-1-stearoyl-sn-glycero-3-phospho-sn-1-glycero-glycero-glycero-
- C₅₂H₉₈NaO₁₄P (1001.31) 1959.) 1-(Z,Z)-6,18-hexacosadienoyl-2-stearoyl-*sn*-
- glycero-3-phospho-sn-1-glycero-glyceroglycerol; Na salt C₅₆H₁₀₆NaO₁₄P (1057.41)

$sn-1-G_1-G_2-G_3-G_4$ compounds

1960.) 1,2-di-(Z)-6-octadecenoyl-sn-glycero-3-phosphosn-1-glycero-glycero-glycero-glycerol; Na salt Ct.HazNaOteP (1019.28)

```
1961.) 1,2-di-(Z)-6-nonadecenoyl-sn-glycero-3-phospho-
sn-1-glycero-glycero-glycero-glycerol; Na salt
C<sub>53</sub>H<sub>100</sub>NaO<sub>16</sub>P (1047.33)
```

- 1962.) 1,2-di-(Z)-10-docosenoyl-sn-glycero-3-phosphosn-1-glycero-glycero-glycero-glycerol; Na salt C₅₅H₁₁₂NaO₁₆P (1131.49)
- 1963.) 1,2-di-(Z)-12-docosenoyl-sn-glycero-3-phosphosn-1-glycero-glycero-glycero-glycerol; Na salt C59H112NaO16P (1131.49)
- 1964.) 1,2-di-(Z)-10-tetracosenoyl-sn-glycero-3phospho-sn-1-glycero-glycero-glycero-glycerol;
 Na salt

 $C_{63}H_{120}NaO_{16}P$ (1187.60)

- 1965.) 1,2-di-(Z)-16-hexacosenoyl-sn-glycero-3 phospho-sn-1-glycero-glycero-glycero-glycerol;
 Na salt
 C₅₇H₁₂₈NaO₁₆P (1243.71)
- 1966.) 1,2-di-(Z,Z)-5,11-octadecadienoyl-sn-glycero-3-phospho-sn-1-glycero-glycero-glycero-glycerol; Na salt $C_{51}H_{92}NaO_{16}P$ (1015.25)
- 1967.) 1,2-di-(Z,Z)-10,16-docosadienoyl-sn-glycero-3phospho-sn-1-glycero-glycero-glycero-glycerol;
 Na salt
 C5:H108NaO16P (1127.46)
- 1968.) 1,2-di-(Z,Z)-6,18-tetracosadienoyl-sn-glycero3-phospho-sn-1-glycero-glycero-glyceroglycerol; Na salt
 C₅₁H₁₁₆NaO₁₆P (1183.57)
- 1969.) 1,2-di-(Z,Z)-6,18-hexacosadienoyl-sn-glycero-3-phospho-sn-1-glycero-glycero-glycero-glycerol;
 Na salt

 C₆₇H₁₂₄NaO₁₆P (1239.68)
- 1970.) 2-(Z)-10-octadecenoyl-1-stearoyl-sn-glycero-3-phospho-sn-1-glycero-glycero-glycero-glycerol;
 Na salt
 C51H98NaO76P (1021.29)

- 1971.) 2-(Z)-10-eicosenoyl-1-stearoyl-sn-glycero-3phospho-sn-1-glycero-glycero-glycero-glycerol;
 Na salt
 - C₅₃H₁₀₂NaO₁₆P (1049.35)
- 1972.) 2-(Z,Z)-6,12-hexadecadienoyl-1-stearoyl-sn-glycero-3-phospho-sn-1-glycero-glycero-glycero-glycerol; Na salt

 C49H92NaO16P (991.22)
- 1973.) 2-(Z,Z)-10,16-docosadienoyl-1-stearoyl-sn-glycero-3-phospho-sn-1-glycero-glycero-glycero-glycerol; Na salt

 CssH104NaO16P (1075.38)
- 1974.) 1-(Z,Z)-6,18-hexacosadienoy1-2-stearoy1-sn-glycero-3-phospho-sn-1-glycero-glycero-glycero-glycerol; Na salt $C_{59}H_{112}NaO_{16}P$ (1131.49)

Linkages with sugar alcohols

10. Phospho-D-mannitol compounds

$$(A = III; m = 0, x = 0; y = 4; z = 1)$$

$$A - PO_3 - \left[(CH_2)_n - \stackrel{CH_3}{N^*} \right]_m - (CH_2)_x - \left[\begin{array}{c} CH_2 - \left(\begin{array}{c} CH_1 \\ OH \end{array} \right)_y - CH_2 - O \\ \end{array} \right]_z - \left[\begin{array}{c} CH_2 - \left(\begin{array}{c} CH_2 - CH_2 - O \\ OH \end{array} \right)_y - CH_2 - O \\ \end{array} \right]_z - \left[\begin{array}{c} CH_2 - CH_2 - O \\ OH \end{array} \right]_z - \left[\begin{array}{c} CH_2 - CH_2 - O \\ OH \end{array} \right]_z - \left[\begin{array}{c} CH_2 - CH_2 - O \\ OH \end{array} \right]_z - \left[\begin{array}{c} CH_2 - CH_2 - O \\ OH \end{array} \right]_z - \left[\begin{array}{c} CH_2 - CH_2 - O \\ OH \end{array} \right]_z - \left[\begin{array}{c} CH_2 - CH_2 - O \\ OH \end{array} \right]_z - \left[\begin{array}{c} CH_2 - CH_2 - O \\ OH \end{array} \right]_z - \left[\begin{array}{c} CH_2 - CH_2 - O \\ OH \end{array} \right]_z - \left[\begin{array}{c} CH_2 - CH_2 - O \\ OH \end{array} \right]_z - \left[\begin{array}{c} CH_2 - CH_2 - O \\ OH \end{array} \right]_z - \left[\begin{array}{c} CH_2 - CH_2 - O \\ OH \end{array} \right]_z - \left[\begin{array}{c} CH_2 - CH_2 - O \\ OH \end{array} \right]_z - \left[\begin{array}{c} CH_2 - CH_2 - O \\ OH \end{array} \right]_z - \left[\begin{array}{c} CH_2 - CH_2 - O \\ OH \end{array} \right]_z - \left[\begin{array}{c} CH_2 - CH_2 - O \\ OH \end{array} \right]_z - \left[\begin{array}{c} CH_2 - CH_2 - O \\ OH \end{array} \right]_z - \left[\begin{array}{c} CH_2 - CH_2 - O \\ OH \end{array} \right]_z - \left[\begin{array}{c} CH_2 - CH_2 - O \\ OH \end{array} \right]_z - \left[\begin{array}{c} CH_2 - CH_2 - O \\ OH \end{array} \right]_z - \left[\begin{array}{c} CH_2 - CH_2 - O \\ OH \end{array} \right]_z - \left[\begin{array}{c} CH_2 - CH_2 - O \\ OH \end{array} \right]_z - \left[\begin{array}{c} CH_2 - CH_2 - O \\ OH \end{array} \right]_z - \left[\begin{array}{c} CH_2 - CH_2 - O \\ OH \end{array} \right]_z - \left[\begin{array}{c} CH_2 - CH_2 - O \\ OH \end{array} \right]_z - \left[\begin{array}{c} CH_2 - CH_2 - O \\ OH \end{array} \right]_z - \left[\begin{array}{c} CH_2 - CH_2 - O \\ OH \end{array} \right]_z - \left[\begin{array}{c} CH_2 - CH_2 - O \\ OH \end{array} \right]_z - \left[\begin{array}{c} CH_2 - CH_2 - O \\ OH \end{array} \right]_z - \left[\begin{array}{c} CH_2 - CH_2 - O \\ OH \end{array} \right]_z - \left[\begin{array}{c} CH_2 - CH_2 - O \\ OH \end{array} \right]_z - \left[\begin{array}{c} CH_2 - CH_2 - O \\ OH \end{array} \right]_z - \left[\begin{array}{c} CH_2 - CH_2 - O \\ OH \end{array} \right]_z - \left[\begin{array}{c} CH_2 - CH_2 - O \\ OH \end{array} \right]_z - \left[\begin{array}{c} CH_2 - CH_2 - CH_2 - O \\ OH \end{array} \right]_z - \left[\begin{array}{c} CH_2 - CH_2 - CH_2 - O \\ OH \end{array} \right]_z - \left[\begin{array}{c} CH_2 - CH_2 - CH_2 - O \\ OH \end{array} \right]_z - \left[\begin{array}{c} CH_2 - CH_2 - CH_2 - CH_2 - O \\ OH \end{array} \right]_z - \left[\begin{array}{c} CH_2 - CH_2$$

- 1975.) 1,2-di-(Z)-6-hexadecenoyl-sn-glycero-3-phospho-D-mannitol; Na salt C₄₁H₇₆NaO₁₃P (831.01)
- 1976.) 1,2-di-(Z)-6-nonadecenoyl-sn-glycero-3-phospho-D-mannitol; Na salt C₄₇H₈₈NaO₁₃P (915.17)
- 1977.) 1,2-di-(Z)-12-eicosenoyl-sn-glycero-3-phospho-D-mannitol; Na salt
 C4-H-2NAO11P (943 23)
- 1978.) 1,2-di-(Z)-10-docosenoyl-sn-glycero-3-phospho-D-mannitol; Na salt $C_{53}H_{100}NaO_{13}P$ (999.33)

- 1979.) 1,2-di-(Z)-12-docosenoyl-sn-glycero-3-phospho-D-mannitol; Na salt

 C53H100NaO11P (999.33)
- C₅₃H₁₀₀NaO₁₃P (999.33)
- 1980.) 1,2-di-(Z)-10-tetracosenoyl-sn-glycero-3-phospho-D-mannitol; Na salt $C_{57}H_{108}NaO_{13}P$ (1055.44)
- 1981.) 1,2-di-(Z)-16-hexacosenoyl-sn-glycero-3-phospho-D-mannitol; Na salt

 C₅₁H₁₁₆NaO₁₃P (1111.55)
- 1982.) 1,2-di-(Z,Z)-5,11-hexadecadienoyl-sn-glycero-3-phospho-D-mannitol; Na salt $C_{41}H_{72}NaO_{13}P$ (826.98)
- 1983.) 1,2-di-(Z,Z)-5,11-octadecadienoyl-sn-glycero-3-phospho-D-mannitol; Na salt $C_{45}H_{80}NaO_{12}P$ (883.09)
- 1984.) 1,2-di-(Z,Z)-6,12-nonadecadienoyl-sn-glycero-3-phospho-D-mannitol; Na salt C_4 - H_{64} Na O_{12} P (911.14)
- 1985.) 1,2-di-(Z,Z)-10,16-docosadienoyl-sn-glycero-3-phospho-D-mannitol; Na salt $C_{53}H_{96}NaO_{13}P$ (995.30)
- 1986.) 1,2-di-(Z,Z)-6,18-hexacosadienoyl-sn-glycero-3-phospho-D-mannitol; Na salt $C_{61}H_{112}NaO_{12}P$ (1107.52)
- 1987.) 2-(Z)-6-hexadecenoyl-1-stearoyl-sn-glycero-3phospho-D-mannitol; Na salt
 C₄₃H₈₂NaO₁₃P (861.08)
- 1988.) 2-(Z)-10-octadecenoyl-1-stearoyl-sn-glycero-3phospho-D-mannitol; Na salt
 C45H86NaO13P (889.13)
- 1989.) 2-(Z,Z)-6,12-hexadecadienoyl-1-stearoyl-sn-glycero-3-phospho-D-mannitol; Na salt $C_{43}H_{80}NaO_{13}P \eqno(859.06)$
- 1990.) 2-(Z,Z)-10,16-docosadienoyl-1-stearoyl-snglycero-3-phospho-D-mannitol; Na salt C49Ha2NaO13P (943.23)

1991.) 1-stearoyl-2-(Z,Z)-6,18-tetracosadienoyl-sn-glycero-3-phospho-D-mannitol; Na salt
C51HosNaO13P (971.28)

- 188 -

- 1992.) 1-(Z)-10-octadecenoyl-2-stearoyl-sn-glycero-3-phospho-D-mannitol; Na salt

 C65HacNaO13P (889.13)
- 1993.) 1-(Z,Z)-6,18-hexacosadienoyl-2-stearoyl-sn-glycero-3-phospho-D-mannitol; Na salt $C_{53}H_{100}NaO_{13}P \hspace{0.5cm} (999.33)$
- 1994.) 1-(Z,Z)-6,18-hexacosadienoyl-2-(Z)-6-hexadecenoyl-sn-glycero-3-phospho-D-mannitol; Na salt

 $C_{51}H_{94}NaO_{13}P$ (969.26)

- 1995.) 2-(Z,Z)-6,18-hexacosadienoyl-1-(Z)-6hexadecenoyl-sn-glycero-3-phospho-D-mannitol;
 Na salt
 C=1Ha4NaO12P (969.26)
- 1996.) 1-(Z)-12-docosenoyl-sn-glycero-3-phospho-D-mannitol; Na salt
- $C_{31}H_{50}NaO_{12}P$ (678.77) 1997.) 1-(Z,Z)-10,16-docosadienoyl-sn-glycero-3-phospho-D-mannitol; Na salt
 - C₃₁H₅₈NaO₁₂P (676.76)
- 1998.) 1-(Z)-12-docosenyl-phospho-D-mannitol; Na salt $C_{29}H_{56}NaO_{9}P$ (590.71)
- 1999.) 1-(Z.Z)-10,16-docosadienyl-phospho-D-mannitol; Na salt

 $C_{28}H_{54}NaO_9P$ (588.69)

- 2000.) 1-0-(Z)-10-docoseny1-2-0-methy1-sn-glycero-3phospho-D-mannitol; Na salt C₁₂H₆₄NaO₁₁P (678.82)
- 2001.) 1-0-(Z,Z)-10,16-docosadienyl-2-0-methyl-snglycero-3-phospho-D-mannitol; Na salt C₃₂H₆₂NaO₃₁P (676.80)

11. Phospho-D-lyxitol compounds

(A = III; m = 0, x = 0; y = 3; z = 1)

$$A - PO_3^{-1} = \begin{bmatrix} CH_3 \\ CH_2 \\ R_3 \end{bmatrix}_m - \begin{bmatrix} CH_2 \\ CH_2 - \begin{pmatrix} CH \\ OH \end{pmatrix}_y - CH_2 - O \\ Z \end{bmatrix}_z - H$$

- 2002.) 1,2-di-(Z)-6-hexadecenoyl-sn-glycero-3-phospho-D-lyxitol; Na salt $C_{40}H_{74}NaO_{12}P$ (800.98)
- 2003.) 1,2-di-(Z)-6-nonadecenoyl-sn-glycero-3-phospho-D-lyxitol; Na salt C₄₆H₈₆NaO₁₂P (885.15)
- 2004.) 1,2-di-(Z)-10-docosenoyl-sn-glycero-3-phospho-D-lyxitol; Na salt $C_{52}H_{96}NaO_{12}P$ (969.31)
- 2005.) 1,2-di-(Z)-10-tetracosenoyl-sn-glycero-3-phospho-D-lyxitol; Na salt
 C56H106NaO12P (1025.41)
- 2006.) 1,2-di-(Z)-16-hexacosenoyl-sn-glycero-3-phospho-D-lyxitol; Na salt $C_{60}H_{114}NaO_{12}P$ (1081.52)
- 2007.) 1,2-di-(Z,Z)-5,11-hexadecadienoyl-sn-glycero-3-phospho-D-lyxitol; Na salt $C_{40}H_{70}NaO_{12}P$ (796.95)
- 2008.) 1,2-di-(Z,Z)-5,11-octadecadienoyl-sn-glycero-3-phospho-D-lyxitol; Na salt $C_{44}H_{78}NaO_{12}P$ (853.06)
- 2009.) 1,2-di-(Z,Z)-10,16-docosadienoyl-sn-glycero-3-phospho-D-lyxitol; Na salt

 C52H94NaO12P (965.27)
- 2010.) 1,2-di-(Z,Z)-6,18-hexacosadienoyl-sn-glycero-3-phospho-D-lyxitol; Na salt $C_{60}H_{110}NaO_{12}P$ (1077,49)

- 2011.) 2-(Z)-6-hexadecenoyl-1-stearoyl-sn-glycero-3-phospho-D-lyxitol; Na salt

 CarHanNaO12P (831.05)
- 2012.) 2-(Z)-10-octadecenoyl-1-stearoyl-sn-glycero-3-phospho-D-lyxitol; Na salt

 C44Ha4NaO12P (859.11)
- 2013.) 2-(Z,Z)-6,12-hexadecadienoyl-1-stearoyl-snglycero-3-phospho-D-lyxitol; Na salt C₄₂H₇₈NaO₁₂P (829.04)
- 2014.) 2-(Z,Z)-10,16-docosadienoyl-1-stearoyl-snglycero-3-phospho-D-lyxitol; Na salt C48H90NaO12P (913.20)
- 2015.) 1-stearoyl-2-(Z,Z)-6,18-tetracosadienoyl-sn-glycero-3-phospho-D-lyxitol; Na salt
 C50H94NaOl2P (941.25)
- 2016.) 1-(Z)-10-octadecenoyl-2-stearoyl-sn-glycero-3-phospho-D-lyxitol; Na salt $C_{44}H_{94}NaO_{12}P$ (859.11)
- 2017.) 1-(Z,Z)-6,18-hexacosadienoyl-2-stearoyl-sn-glycero-3-phospho-D-lyxitol; Na salt
 C52HasNaO12P (969.31)
- 2018.) 1-(Z,Z)-6,18-hexacosadienoyl-2-(Z)-6hexadecenoyl-sn-glycero-3-phospho-D-lyxitol;
 Na salt

C₅₀H₉₂NaO₁₂P (939.24)

- 2019.) 2-(Z,Z)-6,18-hexacosadienoyl-1-(Z)-6hexadecenoyl-sn-glycero-3-phospho-D-lyxitol; Na salt C₅₀H₉₂NaO₁₂P (939.24)
- 12. Phospho-D-threitol compounds

$$(A = III; m = 0, x = 0; y = 2; z = 1)$$

$$A - PO_3 - \left[(CH_2)_n \stackrel{CH_3}{\stackrel{N}{\stackrel{C}{\longrightarrow}}} \right]_m - (CH_2)_X - \left[CH_2 - \left(\stackrel{CH}{\stackrel{OH}{\longrightarrow}} \right)_y - CH_2 - O \right]_z - H$$

```
2020.) 1,2-di-(Z)-6-hexadecenoyl-sn-glycero-3-phospho-D-threitol; Na salt C39H72NaO11P (770.96)
```

2021.) 1,2-di-(Z)-6-nonadecenoyl-sn-glycero-3-phospho-D-threitol; Na salt

 $C_{45}H_{84}NaO_{11}P$ (855.12)

2022.) 1,2-di-(Z)-10-docosenoyl-sn-glycero-3-phospho-D-threitol; Na salt C₅₁H_{9¢}NaO₁₁P (939.28)

2023.) 1,2-di-(Z)-10-tetracosenoyl-sn-glycero-3phospho-D-threitol; Na salt
C₅₅H₁₀₄NaO₁₁P (995.39)

2024.) 1,2-di-(Z)-16-hexacosenoyl-sn-glycero-3-phospho-D-threitol; Na salt

C59H112NaO11P (1051.50)

2025.) 1,2-di-(Z,Z)-5,11-hexadecadienoyl-sn-glycero-3-phospho-D-threitol; Na salt

C39H68NaO11P (766.93)

2026.) 1,2-di-(Z,Z)-5,11-octadecadienoyl-sn-glycero-3-phospho-D-threitol; Na salt $C_{43}H_{76}NaO_{11}P \eqno(823.03)$

2028.) 1,2-di-(Z,Z)-6,18-hexacosadienoyl-sn-glycero-3-phospho-D-threitol; Na salt $C_{59}H_{108}NaO_{11}P \eqno(1047.46)$

2029). 2-(Z)-6-hexadecenoyl-1-stearoyl-sn-glycero-3-phospho-D-threitol; Na salt $C_{41}H_{78}NaO_{11}P \eqno(801.03)$

2030). 2-(Z)-10-octadecenoy1-1-stearoy1-sn-glycero-3phospho-D-threitol; Na salt
C43H82NaO11P (829.08)

2031). 2-(Z,Z)-6,12-hexadecadienoyl-1-stearoyl-sn-glycero-3-phospho-D-threitol; Na salt
C41H76NaO11P (799.01)

- 2032). 2-(Z,Z)-10,16-docosadienoyl-1-stearoyl-snglycero-3-phospho-D-threitol; Na salt C47Ha8NaO11P (883.17)
- 2033). 1-stearoyl-2-(Z,Z)-6,18-tetracosadienoyl-sn-glycero-3-phospho-D-threitol; Na salt $C_{49}H_{92}NaO_{11}P$ (911.23)
- 2034.) 1-(Z)-10-octadecenoy1-2-stearoy1-sn-glycero-3-phospho-D-threitol; Na salt $C_{43}H_{62}NaO_{31}P \eqno(829.08)$
- 2035.) 1-(Z,Z)-6,18-hexacosadienoyl-2-stearoyl-sn-glycero-3-phospho-D-threitol; Na salt C₅₁H₉₆NaO₁₁P (939.28)

Sources:

[1] Kaufmann-Kolle, P., Berger M.R., Unger, C. and H. Eibl

Systemic administration of alkylphosphocholines: Erucylphosphocholine and liposomal hexadecylphosphocholine

Adv. Exp. Med. Bio. 416, 165-168 (1996)

WINDERS SEELS

15

20

Patent Claims

1. A compound of the general formula (I)

I) A - PO3 - B

5 in which B is a radical of the general formula (II)

(II)
$$\begin{bmatrix} CH_{2} \\ CH_{2} \\ R_{3} \end{bmatrix}_{m} - (CH_{2})_{x} - \begin{bmatrix} CH_{2} - \begin{pmatrix} CH \\ OH \end{pmatrix}_{y} - CH_{2} - O \end{bmatrix}_{z} - H_{z} - O$$

10 in which

n is an integer from 2 to 8;

m is 0, 1 or 2;

x is an integer from 0 to 8;

y is an integer from 1 to 4;

z is an integer from 0 to 5;

R₃ is an alkyl radical having 1 to 3 C atoms, which may be substituted by one or more hydroxyl groups;

and in which A is a radical selected from one of the formulae (III) to (IX):

(III)
$$CH_2-O-R_1 \ CH-O-R_2 \ CH_2-O-R_2 \ CH_2-O-R_2$$

(IX) O (CH₂)
$$r$$
 (CH₂) r (CH

in which

g is an integer from 0 to 8;

p, q, r, s, $t \ge 0$;

 $12 \le p + q \le 30$ and

25

10

 $8 \le s + t + r \le 26$;

where R_1 and R_2 are each independently hydrogen, a saturated or unsaturated acyl or alkyl radical or a radical selected from one of the formulae (X), (XI), (XII) and (XIII), and at least one of R_1 and R_2 is a radical selected from one of the formulae (X), (XI), (XII) and (XIII):

(X)
$$(CH_2)_p$$
 $(CH_2)_qH$
(XI) $(CH_2)_s$ $(CH_2)_rH$
(XII) $(CH_2)_p$ $(CH_2)_qH$

where $q \neq 8$ for p + q = 14, 16, 18 or 20, if neither of the radicals R_1 and R_2 is a radical of the formula (XI) or (XIII), or if A is a radical of the formula (VIII).

- 15 2. A compound as claimed in claim 1, in which the following applies to B: $m \, = \, 1 \, .$
- A compound as claimed in claim 2, in which the following applies to B:

m = 1;

(XIII)

x = 1 to 3;

z = 0.

25 4. A compound as claimed in claim 3, in which the following applies to B:

m = 1;

x = 1;

z = 0.

- 5. A compound as claimed in claim 1, in which the following applies to B:
- 5 m = 1;
 - x = 0;
 - y = 1;
 - z = 1 to 5.
- 10 6. A compound as claimed in claim 5, in which the following applies to B:
 - m = 1;
 - x = 0;
 - y = 1;
- 15 z = 1 to 3.
 - A compound as claimed in claim 1, in which the following applies to B:
 - m = 1;
 - x = 0;
 - y = 2 to 4;
 - z = 1.
- 8. A compound as claimed in claim 1, in which the following applies to B:
 - m = 0;
 - x = 0;
 - y = 1;
 - z = 1 to 5.
- 30

20

- - m = 0:
 - x = 0:
- y = 2 to 4;
 - z = 1.

20

- 10. A compound as claimed in any of the preceding claims, in which the following applies to B: $R_3 = CH_3$.
- 5 11. A compound as claimed in any of claims 1 to 9, in which the following applies to B:
 R₃ = 1,2-dihydroxypropyl.
- 12. A compound as claimed in any of the preceding claims, in which the following applies to B: n = 2 to 6.
 - 13. A compound as claimed in any of the preceding claims, in which the following applies to B: $n = 3. \label{eq:n}$
 - 14. A compound as claimed in any of the preceding claims, in which A is a radical of the formula (VIII) or (IX).
 - 15. A compound as claimed in claim 14, in which A is a radical of the formula (VIII) and has 16 to 23 carbon atoms.
- 25 $\,$ 16. A compound as claimed in claim 14, in which A is a radical of the formula (IX) and has 19 to 26 carbon atoms.
- 17. A compound as claimed in claim 16, in which A is a radical of the formula (IX) and has 19 to 26 carbon atoms, and r = 0.
- 18. A compound as claimed in any of claims 1 to 13, in which A is a radical selected from one of the formulae (III) to (VII), and R₁ and R₂ are each independently a radical selected from one of the formulae (X) to (XIII).

- 19. A compound as claimed in claim 18, in which the following applies to B: $x = 1 \text{ and } z = 0 \, .$
- 5 20. A compound as claimed in claim 18 or 19, in which A is a radical of the formula (III) or (IV), and R_1 and R_2 are each independently a radical selected from one of the formulae (X) to (XIII), where one of R_1 and R_2 has 16 to 32 carbon atoms and one of R_1 and R_2 has 16 to 26 carbon atoms.
- 21. A compound as claimed in claim 18 or 19, in which A is a radical of the formula (III) or (IV), and R_1 and R_2 are both a radical selected from one of the formulae (X) to (XIII) and have 16 to 26 carbon atoms.
- 22. A compound as claimed in claim 18 or 19, in which A is a radical of the formula (III) or (IV), and $R_1 \ \ \text{and} \ \ R_2 \ \ \text{are each independently a radical of the formulae (X) to (XIII) and have 16 to 24 carbon atoms.}$
- 23. A compound as claimed in any of claims 18 to 22, in which R_1 and R_2 are each independently a radical of the formula (X) or (XI).
- 24. A compound as claimed in any of claims 18 to 22, in which R_1 and R_2 are each independently a radical of the formula (XII) or (XIII).
 - 25. A compound as claimed in claim 18, 19, 21 or 23, in which R_1 and R_2 are both a radical of the formula (XI).

26. A compound as claimed in claim 18, 19, 21 or 24, in which R_1 and R_2 are both a radical of the formula (XIII).

10

1.5

20

25

30

- 27. A compound as claimed in claim 18 or 19, in which A is a radical of the formula (III) or (IV), and one of R_1 and R_2 is an alkyl radical having 1 to 4 carbon atoms.
- 28. A compound as claimed in claim 18 or 19, in which A is a radical selected from one of the formulae (III) or (IV), and one of R_1 and R_2 is a hydrogen radical.
 - 29. Liposomes which comprise as liposome shell constituents phospholipids and/or alkylphospholipids, where appropriate cholesterol and 1 to 50 mol% of a compound as claimed in any of claims 1, 18 to 26 or salt thereof, where the cholesterol, the phospholipids, the alkylphospholipids and the compound together result in 100 mol% of the liposome shell constituents.
- 30. Liposomes as claimed in claim 29, which additionally comprise an active ingredient, where appropriate together with pharmaceutically acceptable diluents, excipients, carriers and fillers.
- 31. Liposomes as claimed in claim 30, wherein the active ingredient is a compound as claimed in any of claims 1, 14 to 17 and 27 to 28.
- 32. Liposomes as claimed in any of claims 29 to 31, which additionally comprise a nucleic acid.
- 33. A pharmaceutical composition, which comprises an
 active ingredient as claimed in any of claims 1,
 14 to 17 and 27 to 29, where appropriate together
 with pharmaceutically acceptable diluents,
 excipients, carriers and fillers.

10

15

20

25

30

34. A process for preparing unsaturated (Z)-fatty acids or (Z)-alkenols corresponding to a radical as set forth in any of the formulae (VIII), (IX), (X) and (XI) having 16 to 34 carbon atoms, supplemented by the missing H, which comprises using as starting material a lactone of the formula (XIV):

(XIV)

where a = 10 to 16, and which comprises the steps:

- 1) cleavage of the lactone ring with a trimethylsilyl halide to give the corresponding trimethylsilyl halo-carboxylate,
- simultaneous or subsequent alcoholysis of the trimethylsilyl halo-carboxylate to give the corresponding halo-carboxylic ester,
- reaction of the halo-carboxylic ester with triphenylphosphane to give the corresponding phosphonium salt,
- 4) reaction of the phosphonium salt with an aldehyde using a base and subsequent hydrolysis to give a corresponding (Z)-fatty acid salt,
- 5) liberation of the (Z)-fatty acid from the (Z)-fatty acid salt, and
- 6) where appropriate conversion of the (Z)-fatty acid into the corresponding (Z)-alkenol using lithium aluminum hydride.
- 35. The process as claimed in claim 34, wherein the (Z)-fatty acid is 15-(Z)-tetracosenoic acid, in which case cyclopentadecanolide is used as

25

starting lactone, and pelargonaldehyde is used as the aldehyde in step 4.

- 36. The use of a compound of the general formula (I) s as claimed in any of claims 1 to 17, 27 and 28 as cytostatic active ingredient.
- 37. The use of a compound of the general formula (I) as claimed in any of claims 1 to 17, 27 and 28 as 10 active ingredient against protozoal infections such as, for example, leishmaniosis and trypanosomiasis.
- 38. The use of a compound of the general formula (I)

 as claimed in any of claims 1 to 13 and 18 to 26
 as liposome shell constituent.
 - 39. The use of a compound of the general formula (I) as claimed in any of claims 1 to 13 and 22 to 26 as solubilizer for active ingredients insoluble in water.
 - 40. The use of liposomes as claimed in claim 32 as gene transport vehicles.
 - 41. The use of liposomes as claimed in claim 30 as antitumor compositions, where the active ingredient is doxorubicin.
- 30 42. The use of liposomes as claimed in claim 30 as compositions for influencing the proliferation of cells, where the active ingredient is a cytokine.

PTO/SB/01 (4-96) Approved for use through 9/30/98 OMB 0651-0032 Type a plus sign (+) inside this box → 2. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Attorney Docket Number HUBR 1177 **DECLARATION FOR** First Named Inventor Eibl, et al UTILITY OR DESIGN COMPLETE IF KNOWN PATENT APPLICATION Application Number Filing Date Declaration OR Declaration Group Art Unit Submitted Submitted after with Initial Filing Initial Filing Examiner Name As a below named inventor, I hereby declare that: My residence, post office address, and officenship are as stated below next to my name. ieve I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention emitted : Phospholipids with unsaturated alkyl and acyl chains (Title of the Invention) the specification of which is attached hereto OR |X | was filed on (MM/DD/YYYY) as United States Application Number or PCT International August 06, 1999 Application Number PCT/EP99/05710 and was amended on (MM/DD/YYY) I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any endment specifically referred to above. I addrowledge the duty to disclose information which is material to patentalistify as defined in Title 37 Code of Federal Regulations, §1.56, I hereby claim foreign priornly benefits under Tible 35, United States Code §119 (a)-(d) or \$585(b) of any foreign application(a) for parent or inventor's sometimes or \$505 (a) of any PCT immensional application which designated at least one occupy other time the funded States of Annora, tasted application and application of the parent or inventor's certificate, or of any PCT immensional sections of the parent or inventor's certificate, or of any PCT immensional sections of the parent or inventor's certificate, or of any PCT immensional sections of the parent or inventor's certificate, or of any PCT immensional sections of the parent or inventor's certificate, or of any PCT immensional sections or of the parent or inventor's certificate, or of any PCT immensional sections or of the parent or inventor's certificate, or of any PCT immensional sections or of the parent or inventor's certificate, or of any PCT immensional sections or of the parent or inventor's certificate, or of any PCT immensional section of the parent or inventor's certificate, or of any PCT immensional section of the parent or inventor's certificate, or of any PCT immensional sections or parent or inventor's certificate, or of any PCT immensional section of the parent or inventor's certificate, or of any PCT immensional section or parent or inventor's certificate, or of any PCT immensional section or inventor application having a filing date before that of the application on which priority is claimed. Prior Foreign Application Number(s) Foreign Filing Date (MM/COYYYY) Certified Copy Attached? Country Not Claimed YES ю 198 35 611.0 Germany Aug.06,98

Additional foreign application numbers are listed on a supplemental pointy sheet stauched heretic.

I hereby dawn the benefit under Title 33, United States Goods \$119(e) of any United States provisional application numbers.

Application Number(s)

Filling Date (MM/DD/YYYY)

Additional provisional application numbers are listed on a supplemental principly sheet attached hereto.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information series at ducklys a valid GMB control number.

Under the Proprietor's Reduction Act of 1995, no persons are required to respond to a collection of information stress it disclays a valid CMB control resultance.

Burden Floor Stressment This form a seamment to take 4.0 hours to compress. There will very depoyancy quite in the need of the information and the second of the resultance of the resultance

hease type a	plus sign (+) inside this box 🗝				Approved	for usa t	through 9	аала см	3/01 (12-97) 8 0651-0032		
	Under the Paperwork Reduction a valid OMB control number.	on Act of 1995, no perso	Pater onsameneo	nt and Tra puired to r	espond to a	100 (U.S. 100 (MCC)	on of into	MENT OF C	COMMERCE ss & contains		
DEC	CLARATION -	Litility	- Dos	ian	Date	nt /	1 22	licati	22		
	the benefit under 35 U.S.C. 120 of America, listed below and, inside PCT international application in lich is material to patientabliky as all or PCT international filing date.		pacation(s) ther of eac y the first 6 which be	n of the samagraph scame av	c) or any mu claims of the or 35 U.S. alkable between	intom is applic C. 112, I con the	abonal ap abon is r acionowi Ging dat	opikation de not disclosed adge the dut a of the pric	signating the in the prior y to disclose r application		
	S. Parent Application or Number		Parent Filing Date Par (MM/DD/YYYY)				ent Patent Number (If applicable)				
Additional	U.S. or PCT international applica	tion numbers are found	m 1 sim	lomental r	conty com	sheet or	TOWN	9 attached			
a named in	rentor. I hereby appoint the follow	not marstment acactifica									
Trademark	Office connected therewith:	Customer Number OR Registered practitioner	2.4 (s) rame/	972	n morniser S	ted belo		Place Cust Number Bau Label he	Code		
	Name		Hame					Registration Number			
		Number				, NG			and e		
1											
	recistered practitioner(s) named o	on supplemental Peoiste	red Practi	tioner info	ormation she	et PTO/	S8/02C a	ttached her	eto.		
rect all con		ner Number Code Label			CA		rrespon	dence ado	ress below		
ame	Fulbright & 3	Jaworski L.	L.P.								
ddress	666 Fifth Ave	enue									
ddress	New York, N.	7. 10103									
•	New York		St	Starte NY			ZIP 10103				
my		* · + • · · · · · · · · · · · · · · · · ·		-212-3183000 Fax 001					-212-7525958		
A-1-	USA	Telephone 0	07-577	-3183							
ountry hereby decla seved to be nishable by	USA we that all statements made here true; and further that these stat fine or imprisonment, or both, or any patient issued thereon.	sin of my own knowled	ge are true	and the	at within to	se state	ments an	nd the Ske s	o made are		
nereby decta nereby decta nereby decta nereby decta nereby decta nereby decta nereby decta nereby decta nereby decta nereby decta	tre that all statements made here true; and further that these stat fine or imprisonment, or both, or	sin of my own knowled	ge are true in the know and that st	and tha wiedge th sch willful	t all stament at without to take stame	ise state ments n	ments ar	nd the Ske s	o made are sacity of the		
nereby declar served to be inishable by plication or a ame of Se	are that all statements made here true; and further that these stat fine or imprisonment, or both, u any patient issued thereon.	ein of my own knowled ements were made wit nder 18 U.S.C. 1001 a	ge are true in the know and that st	and tha wiedge th sch willful	at all statement at willful fall falls state state has been	se state ments n	ments ar	nd the like s under the vi	o made are sacity of the		
ame of So	re that all statements made hen true; and further that these stat fine or imprisonment, or both, or any patient issued thereon.	ein of my own knowled ements were made wit nder 18 U.S.C. 1001 a	ge are true in the know and that st	e and that wiedge the sch willful petition	at all statement at willful fall falls state state has been	se state ments n filed for Name	ments ar lay jeopa r this un	nd the like s under the vi	o made are sadity of the entor		
country hereby decla fieved to be nishable by plication or a ame of So	re that all statements made hen true; and further that these stat fine or imprisonment, or both, or any patient issued thereon.	ein of my own knowled ements were made wit nder 18 U.S.C. 1001 a	ge are true in the know and that st	e and that wiedge the sch willful petition	at all statement at within the table statement that the statement that	se state ments n filed for Name	ments ar lay jeopa r this un	nd the like s under the vi	o made are sacity of the		
ountry ereby decla feved to be nistable by plication or : ame of So G EIBL nventor's	re that all statements made here true and herber hat these statements and herber hat these statements and herber hat these statements are statements as a statement of the herber harms (first and middle five Name (first and mid	oin of my own knowled emerts were made will note 18 U.S.C. 1001 a	ge are true th the knownd that a	e and that wiedge the sch willful petition	at all statement at within the table statement that the statement that	se statements in	r this un	nd the like is vicing the vicing	o made are active of the enter		

Post Office Address same as above

Additional inventors are being named on the

supplemental Additional inventor(s) sheet(s) PTO/SE/02A attached hereto

gibble, derthe ferren, gipte steine, geben, geste, geten, geben, genen, geste, geben, bei i ben i

Type a plus sign (+) inside this box --

DECLARATION									ADDITIONAL INVENTOR(S) Supplemental Sheet						
									attion has been filed for this unsigned inventor						
Name Thomas Middle							Family Name	HOTTKOWITZ Suntx							
inventor's Signature	\ \	Thom	. -	1	zt	~	1/2			Date	X	27:0	1, 2001		
Residence: City	Neu	ıstadt			State		Country	Germ	any	2	X	Citizenship	DE		
Post Office Address Kleingasse 8, 67435 Neustadt an der Weinstraße, German															
Post Office	Address	same as	abo												
City			State	T	ZΙρ			Country							
	f Additio	onal Joint Inver	itor, if				□ A	etition has	been filed	for this u	nsıgn	ed inventor			
Given Name				Midd			Family					Suf	fix Jr		
inventor's Signature										Date					
Residence: City					State		Country					Cittzenship			
Post Office	Address														
Post Office	Address														
City			Starte	1	ZIp	T		Country							
	Additio	nai Joint Inver	itor, if	any:			A	etition has	been tiled	for this ur	ısıgıı	ed inventor			
Giv-ri Name					diddle nttial		Family Name					Suffix e.g. J			
Inventor's Signature										Date			1		
Residence: City		_		T	State		Country					Citizenship			
Post Office A	Address														
Post Office A	ddress														
City			State		ΖΙp			Country							
	Addition	nai Joint Inven	or, if			_		ettion has	been filed	for this un	nsign				
Given Name					Middle	1_	Family Name					Suffi	r.		
Inventor's Signature										Date					
Residence: City				s	tate		Country					Citizenship			
Post Office A	ddress														
Post Office A	ddress	•													
City			State		ZΙρ			Country							
Addit	onal inv	entors are being	g name	ed on	supp	leme	ntal shee	t(s attac	ned heret	0					